[
	{
		"fields": {
			"corresp_author_email": "xyxzyxzh@163.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. Have any known disease that seriously affects the immune system, such as a history of infection with the human immunodeficiency virus (HIV), or malignant tumors of the blood system or solid organs, or splenectomy;\r\u003cbr\u003e2. Other circu",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: On January 27, 2020, the general office of the national health commission and the office of the state administration of traditional Chinese medicine issued the pneumonia diagnosis and treatment plan for new coronavirus infection (trial",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "control group:Conventional treatment;experimental group:conventional treatment combined with umbilical cord blood mononuclear cells group;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "PSI;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "parallel",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000029572",
			"start_date": "2020-02-05",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically novel coronavirus pneumonia(COVID-19): a randomized controlled clinical trial                                                                          ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=41760",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "tangjianyuan163@163.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: No",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: cured patients of 2019 novel coronavirus.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Experimental group:Health Guidance + Guixi Regulating Lung Gong Method + Shenling Baizhu Powder + Moxibustion Treatment;Control group:Health Guidance + Guixi Regulating Lung Gong Method ;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Quality of life;Anxiety assessment;Depression assessment;Major symptoms improved;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "parallel",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000029956",
			"start_date": "2020-02-18",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Chinese Medicine Promotes Rehabilitation Recommendations after 2019 Novel Coronavirus Infection (COVID-19)                                                                                                                                                     ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=49618",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "zhaochunhua@vip.163.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. Malignant disease in the past five years;\r\u003cbr\u003e2. The clinical prediction is that there is no hope for survival, only cases of hospice care, or cases of deep coma that do not respond to supportive treatment measures within three hour",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. Male or female, 18-95 years old;\r\u003cbr\u003e2. 2019 new coronavirus nucleic acid test positive;\r\u003cbr\u003e3. Diagnosed as moderate to severe cases of new coronavirus pneumonia in 2019, which meets the following clinical manifestations:\r\u003cbr\u003e4. Wi",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "experimental group:mesenchymal stem cells;control group:saline;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Improved respiratory system function (blood oxygen saturation) recovery time;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "parallel",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000029990",
			"start_date": "2020-01-30",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus (COVID-19)                                                                                                                                              ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=49674",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "w.w.puijk-2@umcutrecht.nl",
			"corresp_author_email_certainty": "prefilled",
			"country": "Portugal;Greece;Spain;Ireland;United Kingdom;Czech Republic;Hungary;Belgium;Romania;Croatia;Australia;Denmark;Netherlands;Germany;New Zealand",
			"country_certainty": "generated",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e                General REMAP-CAP Exclusion Criteria:\u003cbr\u003e                1. Healthcare-associated pneumonia:\u003cbr\u003e                a. Prior to this illness, is known to have been an inpatient in any healthcare facility within the last 30 days\u003cbr\u003e                b. Resident of a nursing home or long-term care facility.\u003cbr\u003e                2. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment.\u003cbr\u003e                3. Previous participation in this REMAP within the last 90 days\u003cbr\u003e\u003cbr\u003e                AB Domain Specific Exclusion Criteria\u003cbr\u003e\u003cbr\u003e                Received more than 48 hours of IV antibiotic treatment for this index illness\u003cbr\u003e                • More than 24 hours has elapsed since ICU admission\u003cbr\u003e                • Known hypersensitivity to all of the study drugs in the site randomization schedule\u003cbr\u003e                • A specific antibiotic choice is indicated, for example:\u003cbr\u003e                o Suspected or proven concomitant infection such as meningitis\u003cbr\u003e                o Suspected or proven infection with resistant bacteria where agents being trialed would not be expected to be active. This includes cystic fibrosis, bronchiectasis or other chronic suppurative lung disease where infection with Pseudomonas may be suspected but does not include patients with suspected methicillin-resistant staphylococcus aureus (MRSA) infection (see MRSA below).\u003cbr\u003e                o Febrile neutropenia or significant immunosuppression (including organ or bone marrow transplantation, human immunodeficiency virus (HIV) Infection with CD4 cell count \u003c200 cells/µL, systemic immunosuppressive, systemic corticosteroids comprising prednisolone, or equivalent, =20mg/day for \u003e 4 preceding weeks).\u003cbr\u003e                o Suspected melioidosis (tropical sites during melioidosis season – see melioidosis below)\u003cbr\u003e                o There is sufficient microbiological information to guide specific antibacterial therapy\u003cbr\u003e                • The treating clinician believes that participation in the domain would not be in the best interests of the patient\u003cbr\u003e\u003cbr\u003e                AB Specific Intervention Exclusion Criteria\u003cbr\u003e                1.\tKnown non-serious hypersensitivity to penicillins will result in exclusion from receiving interventions that include piperacillin and amoxicillin\u003cbr\u003e                2.\tKnown non-serious hypersensitivity to cephalosporins will result in exclusion from receiving interventions that include ceftriaxone and ceftaroline\u003cbr\u003e                3.\tKnown serious hypersensitivity to beta-lactams, including penicillins or cephalosporins, will result in exclusion from interventions that include piperacillin, amoxicillin, ceftriaxone, and ceftaroline.\u003cbr\u003e                4.\tKnown hypersensitivity to moxifloxacin or levofloxacin will result in exclusion from moxifloxacin or levofloxacin intervention\u003cbr\u003e                5.\tKnown serious hypersensitivity to the macrolide will result in exclusion from interventions that include piperacillin, amoxicillin, ceftriaxone, and ceftaroline.\u003cbr\u003e                6.\tKnown or suspected pregnancy will result in exclusion from moxifloxacin or levofloxacin and ceftaroline interventions.\u003cbr\u003e\u003cbr\u003e                Corticisteroid domain Specific Exclusion Criteria\u003cbr\u003e                • Known hypersensitivity to hydrocortisone\u003cbr\u003e                • Intention to prescribe systemic corticosteroids for a reason that is unrelated to the current episode of CAP (or direct compli",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e                General REMAP-CAP Inclusion Criteria:\u003cbr\u003e                1. Adult patient admitted to an ICU for acute severe CAP within 48 hours of hospital admission with\u003cbr\u003e                a. symptoms or signs or both that are consistent with lower respiratory tract infection (for example, acute onset of dyspnea, cough, pleuritic chest pain) AND\u003cbr\u003e                b. Radiological evidence of new onset infiltrate of infective origin (in patients with pre-existing radiological changes, evidence of new infiltrate)\u003cbr\u003e                2. Up to 48 hours after ICU admission, receiving organ support with one or more of:\u003cbr\u003e                a. Non-invasive or invasive ventilatory support;\u003cbr\u003e                b. Receiving infusion of vasopressor or inotropes or both\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e                Are the trial subjects under 18? no\u003cbr\u003e                Number of subjects for this age range:\u003cbr\u003e                F.1.2 Adults (18-64 years) yes\u003cbr\u003e                F.1.2.1 Number of subjects for this age range 2000\u003cbr\u003e                F.1.3 Elderly (\u003e=65 years) yes\u003cbr\u003e                F.1.3.1 Number of subjects for this age range 2000\u003cbr\u003e            ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003e                Product Name: LEVOFLOXACIN\u003cbr\u003e                Pharmaceutical Form:\u003cbr\u003e                INN or Proposed INN: LEVOFLOXACIN\u003cbr\u003e                CAS Number: CAS 138199-7\u003cbr\u003e\u003cbr\u003e                Product Name: HYDROCORTISONE\u003cbr\u003e                Pharmaceutical Form:\u003cbr\u003e                INN or Proposed INN: HYDROCORTISONE\u003cbr\u003e                CAS Number: 50-23-7\u003cbr\u003e\u003cbr\u003e                Product Name: CEFTRIAXONE\u003cbr\u003e                Pharmaceutical Form:\u003cbr\u003e                INN or Proposed INN: CEFTRIAXONE\u003cbr\u003e                CAS Number: 73384-59-5\u003cbr\u003e\u003cbr\u003e                Product Name: AZITHROMYCIN\u003cbr\u003e                Pharmaceutical Form:\u003cbr\u003e                INN or Proposed INN: AZITHROMYCIN\u003cbr\u003e                CAS Number: 83905-01-5\u003cbr\u003e\u003cbr\u003e                Product Name: CLARITHROMYCIN\u003cbr\u003e                Pharmaceutical Form:\u003cbr\u003e                INN or Proposed INN: CLARITHROMYCIN\u003cbr\u003e                CAS Number: 81103-11-9\u003cbr\u003e                Other descriptive name: CLARITHROMYCIN LACTOBIONATE\u003cbr\u003e\u003cbr\u003e                Product Name: ERYTHROMYCIN\u003cbr\u003e                Pharmaceutical Form:\u003cbr\u003e                INN or Proposed INN: ERYTHROMYCIN\u003cbr\u003e                CAS Number: 3847-29-8\u003cbr\u003e\u003cbr\u003e                Product Name: AMOXICILLINE-CLAVULANTE\u003cbr\u003e                Pharmaceutical Form:\u003cbr\u003e                INN or Proposed INN: AMOXICILLIN\u003cbr\u003e                CAS Number: 34642-77-8\u003cbr\u003e                INN or Proposed INN: POTASSIUM CLAVULANATE\u003cbr\u003e                CAS Number: 61177-45-5\u003cbr\u003e\u003cbr\u003e                Product Name: AZITHROMYCIN\u003cbr\u003e                Pharmaceutical Form:\u003cbr\u003e                INN or Proposed INN: AZITHROMYCIN MONOHYDRATE\u003cbr\u003e                CAS Number: 121470-24-4\u003cbr\u003e\u003cbr\u003e                Product Name: CLARITHROMYCIN\u003cbr\u003e                Pharmaceutical Form:\u003cbr\u003e                INN or Proposed INN: CLARITHROMYCIN\u003cbr\u003e                CAS Number: 81103-11-9\u003cbr\u003e\u003cbr\u003e                Product Name: PIPERACILLIN-TAZOBACTAM\u003cbr\u003e                Ph",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Timepoint(s) of evaluation of this end point: 90 Days from the date of enrolment.;Primary end point(s): The primary objective of this REMAP is, for adult patients with severe CAP who are admitted to an ICU, to identify the effect of a range of interventions to improve outcome as defined by all-cause mortality at 90 days.;\u003cbr\u003e                Main Objective: The primary objective of this REMAP is, for adult patients with severe CAP who are admitted to an ICU, to identify the effect of a range of interventions to improve outcome as defined by the occurrence of death during the index hospital admission censored 90 days from the date of enrolment.\u003cbr\u003e            ;Secondary Objective: The secondary objectives are to determine, for adult patients with severe CAP who are admitted to an ICU, the effect of interventions on ICU mortality, ICU length of stay (LOS), hospital LOS, ventilator free days (VFDs) censored at 28 days, organ failure free days (OFFDs) censored at 28 days, other endpoints as indicated for specific domains, and, where feasible or specified in a DSA, survival at 6 months, health related quality of life (HRQoL) assessed after 6 months using the EQ5D and disability assessed after 6 months using the World Health Organization Disability Assessment Schedule (WHODAS).",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "\u003cbr\u003e                controlled: yes\u003cbr\u003e                randomised: yes\u003cbr\u003e                open: yes\u003cbr\u003e                single blind: no\u003cbr\u003e                double blind: no\u003cbr\u003e                parallel group: no\u003cbr\u003e                cross over: no\u003cbr\u003e                other: no\u003cbr\u003e                if controlled, specify comparator, other medicinial product: yes\u003cbr\u003e                placebo: no\u003cbr\u003e                other: no\u003cbr\u003e                number of treatment arms in the trial: 20\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2015-002340-14-NL",
			"start_date": "16/09/2015",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) - REMAP-CAP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-002340-14",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "455957898@qq.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: (1) younger than 12 years old;\r\u003cbr\u003e(2) refuse to sign informed consent.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: (1) Outpatient and emergency patients of PLA General Hospital;\r\u003cbr\u003e(2) The body temperature higher than 37.3 degree C.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Case series:no;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "temperature;novel coronavirus;Influenza virus;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031366",
			"start_date": "2020-04-01",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Causes of fever in outpatient outside Wuhan during novel coronavirus pneumonia pandemic: a medical records based retrospective analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51692",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";dicastel@ngi.it;",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Augusto Di Castelnuovo, MSc, PhD;Augusto Di Castelnuovo, MSc, PhD;Augusto Di Castelnuovo",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Italy",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        Patients hospitalized for COVID-19\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        none\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "Severe COVID-19",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04318418",
			"start_date": "2020-03-23",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04318418",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "fwl@hust.edu.cn",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1) POSITIVE;\r\u003cbr\u003e2) Those who cannot cooperate to complete the magnetic resonance examination.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1) About one month after the recovery of COVID-19;\r\u003cbr\u003e2) No other neurological diseases.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "mild recovery:none;severe recovery:none;control:none;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "brain volume;white matter;brain function;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "factorial",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031356",
			"start_date": "2020-04-12",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Altered brain structure and function in patients with COVID-19 after rehabilitation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51499",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "sunnyabs1215@163.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: Incomplete case data. ",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: Including maternal cases who performed emergency cesarean section in our hospital from January 24, 2020 to March 10, 2020",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Cesarean section:Case Series;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "fever;Chest CT;cough;;Anesthesia during cesarean section;Adverse reactions;Apgar score for neonates; Intraoperative blood loss;diagnosis of COVID-19 during perioperative;the medical observations of anesthesiologists participating in anesthesia management;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031361",
			"start_date": "2020-03-31",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Retrospective analysis of anesthesia management of emergency cesarean section in non-pneumonia hospital of Wuhan during pandemic of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51385",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "lilibestever@126.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: History of eye surgery,trauma,other eye diseases,family history of glaucoma,etc.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. Myopia teenagers who were first fitted with or re-examined orthokeratology lens in our hospital from November 2019 to January 2020 were invited to review the progression of myopia by telephone and text messages;\r\u003cbr\u003e2.The cornea is transparent;no history of eye disease,eye trauma or surgery.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Case series:orthokeratology lens;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Axle length;Visual acuity;corneal diopter;Tear film rupture time;Visual fatigue;habits of using eyes;Accommodative Amplitude;Adjustment sensitivity;Adjustment lag;Negative relative adjustment;Positive relative adjustment;Fusion function;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031330",
			"start_date": "2020-03-18",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Analysis for prevention and control effects of orthokeratology lens on myopia adolescents during the novel coronavirus pneumonia (COVID-19) pandemic situation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51504",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "litian-wang@163.com",
			"corresp_author_email_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. Pregnant or breast-fed women;\r\u003cbr\u003e2. age \u003c 18 years;\r\u003cbr\u003e3. Participating in any clinical trail in 12 weeks before signing informed consent form;\r\u003cbr\u003e4. refuse to sign the informed consent form;\r\u003cbr\u003e5. individuals who suffer from severe diseases, or serious complications which affect disease and/ or psychological assessment;\r\u003cbr\u003e6. patients cannot finish questionnaires;\r\u003cbr\u003e7. employees and related people of investigators and research center;\r\u003cbr\u003e8. Individuals who are unsuitable to take part in this study due to consideration of researchers.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: Patients should fulfill the diagnosis criteria of rheumatoid arthritis in 2009, systemic lupus erythematosus in 2009, axial spondyloarthritis in 2009 or gout in 2015.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Case series:None.;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "medication possession ratio;selfrating anxiety scale;selfrating depression scale;Disease activity score-28;Systemic lupus erythematosus disease activity index;Ankylosing spondylits disease activity score;Visual analogue scale;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031329",
			"start_date": "2020-03-11",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Influence of COVID-19 on disease activity, medical and mental condition of patients with rheumatic diseases                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51667",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "chenhx@enzemed.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: Death was excluded. Cases with BMI mismatch were excluded",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: We anticipate collecting 200 COVID-19 serum samples (40 severe patients, 130 non-severe patients and 30 influza patients) in 2-4 hospitals. At present, there are two cooperate unit, Taizhou Hospital of Zhejiang Province and the First Hospital of Jiangxing. Severe patients include three categories: good prognosis, poor prognosis under cytokine storm and poor prognosis without cytokine storm. We will collect serum, urine and feces samples at multiple time points during the course of the disease to conduct multi-omics analysis.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Gold Standard:Clinical outcome, novel coronavirus nucleic acid test, clinical symptoms, lung CT;Index test:Proteomics,\u0026#32;metabolomics\u0026#32;and\u0026#32;other\u0026#32;markers,\u0026#32;mass\u0026#32;spectrometer;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "proteomics;metabonomics;SEN, SPE, ACC, AUC of ROC;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031365",
			"start_date": "2020-01-17",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Serum and urine proteins and metabolomic markers in patients with COVID-19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51694",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "20215851@qq.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: (1) Receive any clinical trial drug treatment for COVID-2019 within 30 days before the screening assessment;\r\u003cbr\u003e(2) Severe liver disease (e.g., Child Pugh score \u003e=C or AST\u003e 5 times of the upper limit);\r\u003cbr\u003e(3) Patients with known severe renal insufficiency (estimated glomerular filtration rate \u003c=30mL / min/1.73 m2) or patients receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis;\r\u003cbr\u003e(4) Co-infection of HIV, hepatitis B, tuberculosis, influenza virus, adenovirus or other respiratory infection viruses;\r\u003cbr\u003e(5) Female patients who have no sexual protection in the last 30 days prior to the screening assessment;\r\u003cbr\u003e(6) Pregnant or lactating women or women using estrogen contraception;\r\u003cbr\u003e(7) Patients who are planning to become pregnant during the study period or within 6 months after the end of the study period;\r\u003cbr\u003e(8) Other conditions that the researchers consider inappropriate for participating in this clinical trial.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: (1) Aged 18-65 years;\r\u003cbr\u003e(2) Voluntarily participate in this clinical trial and sign off \"informed consent form\";\r\u003cbr\u003e(3) Diagnosed with severe pneumonia of COVID: respiratory distress, RR \u003e30 times / min; resting oxygen saturation of 93% or less; arterial partial pressure of oxygen / oxygen concentration 300mmHg; SARS-CoV-2 nucleic acid test was positive.\r\u003cbr\u003e(4) Chest imaging confirm COVID-19 featured changes in lung.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "hDPSCs group:Routine treatment + Intravenous injection of human dental pulp stem cells;Control group:Routine treatment + Placebo;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "TTCI;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "parallel",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031319",
			"start_date": "2020-04-01",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe Pneumonia of COVID-19:a Single-center, Prospective, Randomised Clinical Trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51647",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "fyang@vip.163.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1) Those with poor CT image quality;\r\u003cbr\u003e2) Patients who are unwilling to participate in the study.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1) Positive;\r\u003cbr\u003e2) There is a CT examination in our hospital.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Gold Standard:Clinical outcome by diagnosis results of imaging doctors and clinicians;Index test:new\u0026#32;artificial\u0026#32;intelligence-based\u0026#32;prognosis\u0026#32;assessment\u0026#32;system;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "sensitivity;accuracy;specificity;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031336",
			"start_date": "2020-04-12",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "AI based prognostic evaluation of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51517",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "824647903@qq.com",
			"corresp_author_email_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: No",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: (1) the medical staff on the frontline of the clinical fight against COVID - 19 epidemic should wear protective equipment such as N95 / KN95 respirator, goggles or mask, protective clothing or isolation clothing when they go to hubei province or fight in the local frontline [5];\r\u003cbr\u003e(2) there is no limitation on the gender and age of the participants, and they are willing to participate",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Case series:none;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Incidence of medical adhensive-related injury;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031324",
			"start_date": "2020-04-10",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "The investigation on medical adhesive-related skin injury caused by protective dressings of medical staffs during the period of COVID-19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51668",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "doctor.wuyh@gmail.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. Combining patients with severe primary respiratory diseases, or with other pathogenic microbial pneumonia that needs to be identified in relation to COVID-19;\r\u003cbr\u003e2. Combining systems such as heart, brain, lung, liver and kidney syllading with severe primary diseases, as well as mental illness;\r\u003cbr\u003e3. Those who are unconscious and unable to cooperate;\r\u003cbr\u003e4. People who cannot accept music because of hearing impairment;\r\u003cbr\u003e5. Combining patients with other serious diseases such as uremia and severe heart failure;\r\u003cbr\u003e6. The researchers did not consider it appropriate for patients to participate in the study.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. Mild or moderate cases who meet the \"Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia\" issued by the National Health And Health Council are trialled in the fifth and sixth editions of clinical diagnosis and diagnostic criteria;\r\u003cbr\u003e2. Aged \u003e=18 years;\r\u003cbr\u003e3. Patient informed consent.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Group M:Play sleep-aid music on the cell phone at the same time as basic therapy, listen to it once every night at 22 o'clock, and the patient falls asleep with the music. A total of 2 weeks of treatment.;Group C:No music, the use of basic treatment, in accordance with the \"new coronavirus infection pneumonia diagnosis and treatment program\" trial fifth, sixth, seventh version of the provisions of the implementation.;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Self-assessment of sleep quality;Efficient of sleep improvement;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "parallel",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031328",
			"start_date": "2020-03-13",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "The protective effect of sleep psychology and music therapy in patients with new coronary pneumonia (mild and moderate type)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51425",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "tjqiuhong@163.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. Suspected patients;\r\u003cbr\u003e2. Pregnancy and lactation.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. Diagnosed as COVID-19 confirmed patient with a throat swab test;\r\u003cbr\u003e2. Aged \u003e=18 years;\r\u003cbr\u003e3. Diagnosed as critical ill patients according to the New Coronavirus Pneumonia Diagnosis and Treatment Plan (the seventh edition);\r\u003cbr\u003e4. Complete medical records;\r\u003cbr\u003e5. The time from admission to death was 3 days or more.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Case series:Nil;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Time of death;The hospitalization time;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031327",
			"start_date": "2020-04-01",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Clinical characteristics and death risk factors in COVID-19 patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51669",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "lilibestever@126.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: History of eye surgery,trauma,other eye diseases,family history of glaucoma,etc.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. Myopia teenagers who have optometry in our hospital from November 2019 to January 2020 were invited to review the progression of myopia by telephone and text messages,including those newly diagnosed patients who have been fitted with orthokeratology lens during this period;\r\u003cbr\u003e2.The cornea is transparent;no history of eye disease,eye trauma or surgery.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Case series:Nil;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "eye axial length;corneal diopter;Tear film rupture time;Visual acuity;Visual fatigue;habits of using eyes;Accommodative Amplitude;Adjustment sensitivity;Adjustment lag;Negative relative adjustment;Positive relative adjustment;Fusion function;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031337",
			"start_date": "2020-03-18",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "The relationship between habits of using eyes, degree of visual fatigue and myopia progression in students during the novel coronavirus pneumonia (COVID-19) pandemic                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51170",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "zhengxue.academic@gmail.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: Participants who were not located in Wuhan when we conducted the study and those who did not practice mindfulness or mind-wandering exercise over the next 10 days.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: Eligible participants are residents who were located in Wuhan during the lockdown starting from 23 January 2020 due to the Coronavirus breakout. The study was conducted for 12 days between 20 Feb to 2 March",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "mindfulness intervention group:Mindfulness practice;control group:mind-wandering practice;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Anxiety level;Sleep;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "quasi-randomized controlled",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031272",
			"start_date": "2020-02-18",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "The effectiveness of mindfulness intervention in improving people's psychological and physical well-being during novel coronavirus pneumonia (COVID-19) outbreak                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51455",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "qshi@cqmu.edu.cn",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: (1) Patients have clinical symptoms or CT positive changes;\r\u003cbr\u003e(2) Patients have no willingness to participate in the study;\r\u003cbr\u003e(3) Patients with unconsciousness.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: (1) Have a clear history of contact with confirmed cases;\r\u003cbr\u003e(2) Two consecutive positive nucleic acid tests;\r\u003cbr\u003e(3) No clinically relevant symptoms;\r\u003cbr\u003e(4) Patient voluntary.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Case series:Nil;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Demographic data;Epidemiological characteristics;Routine laboratory testing;Viral nucleic acid test;Patient reports symptoms daily;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "cohort study",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031252",
			"start_date": "2020-02-10",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Outcomes and infectivity of patients with asymptomatic novel coronavirus (COVID-19) infection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51559",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "chenzhuanggui@126.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: (1) Basic diseases: Patients with severe diabetes, cardiopulmonary insufficiency, chronic kidney disease, chronic liver failure, cirrhosis, etc. before onset; tumor patients; patients with azotemia;\r\u003cbr\u003e(2) Not willing to participate in the experiment;",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: Novel coronavirus pneumonia diagnosis and treatment plan (trial version seventh) was revised to meet the diagnostic criteria of the 18-65 year old patients",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Control group:regular treatment;Experimental group:Compound amino acid combined with routine treatment;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Hospital stay or death ratio of experimental group / death ratio of control group;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "parallel",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031271",
			"start_date": "2020-04-01",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Metabolic abnormalities and rearrangement reversal treatment of patient with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51194",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "wanzimili@sina.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: not in this period",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: We did a retrospective review of medical records from surgical patients with COVID-19 pneumonia admitted to Renmin Hospital of Wuhan University from January 13 to March 12, 2020.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Case series:Nil;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Rate of COVID-19, distribution, time of onset and outcome;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031245",
			"start_date": "2020-01-25",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Epidemiologic and Clinical Characteristics of novel coronavirus pneumonia (COVID-19) in surgical patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51518",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "sidaoyuan1984@sina.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: Patients not suitable for study judged by researchers",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: Confirmed Covid-19 pneumonia patients (Covid-19 pneumonia treatment plan (Seventh Edition) who were admitted from February 2020 to March, and combined with cTnI elevation.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Case series:Nil;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "ECG;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031301",
			"start_date": "2020-02-01",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "A retrospective study of clinical characteristics and prognosis of novel coronavirus pneumonia (COVID-19) patients with myocardial injury                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51603",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "wchmhcmxd@163.com",
			"corresp_author_email_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: Medical staff without informed consent.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: Medical staff involved in COVID-19 prevention and control.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Case series:Nil;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "mental state;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031247",
			"start_date": "2020-03-01",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Study on the mental state of medical staff  during the epidemic period of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51540",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "13972046539@163.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: other viral pneumonia and COVID-19 in children.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: All adult COVID-19 patients cofirmed PCR or CT scan.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Survival and D:none;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "clinical features of COVID-19 patients and risk factors of death;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031296",
			"start_date": "2020-01-14",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "A medical records based study for clinical features of novel coronavirus pneumonia (COVID-19) patients and risk factors of death                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51584",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "haoyaner@163.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. Patients at h high risk of SARS-CoV-2 infection;\r\u003cbr\u003e2. The guardian does not agree to sign the informed consent or the guardian does not agree to collect information.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: Children at medium/low risk aged 0-18 years who were admitted to the department of pediatrics during the study period",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Case series:Nil;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Epidemiological characteristics;clinical features;Treatment outcome;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031293",
			"start_date": "2020-03-16",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Epidemiological study of novel coronavirus infection (COVID-19) in children at medium/low risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51629",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "tangxiaoj0726@qq.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. Have clinical symptoms or CT positive changes;\r\u003cbr\u003e2. Patients no willingness to participate in the study;\r\u003cbr\u003e3. Patients with consciousness disorders.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. History of contact with confirmed cases;\r\u003cbr\u003e2. During the 14-day clinical observation period after contact with the confirmed case;\r\u003cbr\u003e3. Nucleic acid test positive twice in a row;\r\u003cbr\u003e4. Without any clinically relevant symptoms;\r\u003cbr\u003e5. No positive change in chest CT;\r\u003cbr\u003e6. Patients willing to participate in study.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Case series:NO;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "IgG antibody;IgM antibody;Throat swab virus nucleic acid test;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031246",
			"start_date": "2020-02-01",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Epidemiological survey of close contacts of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51535",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "wwang@vip.126.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: Pregnant women; less than 18 years old; serious diseases (cardiovascular diseases, respiratory diseases, digestive diseases, etc); patients with tumor; patients who can not cooperate",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: Patients with Covid-19 discharged from the hospital meet the following criteria:\r\u003cbr\u003e(1) clinical and inpatient data are completely available;\r\u003cbr\u003eMust include: blood routine on admission and discharge; chest CT; antibody test results on admission and discharge. Non essential data: inflammatory factors test results;\r\u003cbr\u003e(2) confirmed patients. At least once nucleic acid test was positive;\r\u003cbr\u003e(3) Up to discharge standard ?, within 3 months after onset;\r\u003cbr\u003e(4) Sign informed consent.\r\u003cbr\u003eNote: The nucleic acid test must be performed twice and the interval of more than 12 hours is negative, and the corresponding results must be presented.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Case series:Nil;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "RT-PCR test for Covid-19;CT image;Covid-19 antibody test;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031244",
			"start_date": "2020-03-25",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Shedding virus and functional prognosis in patients with novel coronavirus pneumonia (COVID-19): a cohort study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51486",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "jin_eagle@sina.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. severe vomiting and difficulty in taking oral medication or in taking oral medication;\r\u003cbr\u003e2. pregnant and nursing women;\r\u003cbr\u003e3. subjects received lopinavir/ridonavir, ribavirin, monoclonal antibodies and other specific antiviral drugs in the week prior to admission;\r\u003cbr\u003e4. cases of respiratory failure requiring mechanical ventilation;\r\u003cbr\u003e5. cases of shock;\r\u003cbr\u003e6. combined with other organ failure requires intensive care unit;\r\u003cbr\u003e7. patients with no clinical expectation of survival and only end-of-life care, or those in a deep coma who did not respond to supportive treatment within three hours of admission.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. male and female aged 18-70 years;\r\u003cbr\u003e2. positive result of test for 2019 novel coronavirus nucleic acid;\r\u003cbr\u003e3. Clinical diagnosed with pneumonia;\r\u003cbr\u003e4. onset within 7 days (severe cases can be delayed to 14 days);\r\u003cbr\u003e5. the informed consent shall be signed by me or the authorized agent;\r\u003cbr\u003e6. subjects who can take oral medication or who receive oral medication;\r\u003cbr\u003e7. agree to collect clinical samples;\r\u003cbr\u003e8. female subjects of child-bearing age are not pregnant and agree to take effective contraceptive measures within 7 days of the last oral medication to ensure that they are not pregnant;\r\u003cbr\u003e9. men agree not to have sex with women for seven days after their last oral medication.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Experimental treatment group:Oral chloroquine phosphate tablets (treatment group);control group:Oral placebo group (control group);",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": " Clearance time of virus RNA;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "parallel",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031204",
			"start_date": "2020-01-30",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "A multicenter, single-blind, randomized controlled clinical trial for chloroquine phosphate in the treatment of 2019 novel coronavirus-infected pneumonia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=49420",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "pluo@whu.edu.cn",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: (1) Patients who are negative for multiple PT-PCR tests and cannot be diagnosed;\r\u003cbr\u003e(2) Patients with incomplete medical records;\r\u003cbr\u003e(3) There are patients who other researchers believe are not suitable for inclusion in this study.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: (1) Inpatients in our hospital;\r\u003cbr\u003e(2) Age and gender are not limited;\r\u003cbr\u003e(3) The PT-PCR test is positive or suspected;\r\u003cbr\u003e(4) There is a complete medical record in our hospital medical record system.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Case series:?;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "PT-PCR test;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "case-control study",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031187",
			"start_date": "2020-03-23",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "A medical records based retrospective study for novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51442",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "fuliran@126.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. Cases of clinical treatment of pneumonia;\r\u003cbr\u003e2. Those who cannot understand the content of the scale and cannot evaluate the curative effect;\r\u003cbr\u003e3. Suicide-prone by the doctor;\r\u003cbr\u003e4. pregnant women, those with severe cardiovascular and cerebrovascular, liver, kidney, hematopoietic system and other diseases;\r\u003cbr\u003e5. Those who do not cooperate with the treatment plan;\r\u003cbr\u003e6. The researcher thinks that others are not suitable for enrollment.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. Those who meet the above-mentioned diagnostic criteria and have reached the standards of separation and discharge after clinical treatment;\r\u003cbr\u003e2. The patient was conscious, without aphasia, mental retardation, literacy, volunteered to participate in the trial, agreed to sign the informed consent and cooperated with the treatment.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "1:Blank;2:Moxibustion treatment;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "TCM Syndrome Scale;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "parallel",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031203",
			"start_date": "2020-03-16",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Study for the effect of Moxibustion Guidance and Intervention based on internet for the discharged patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51030",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "nicole8611@163.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: Patients in hospital, complicated with other acute and severe diseases, etc",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: Homeopathic patient",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Homeopathic patient:The popular science education;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Patient satisfaction;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031176",
			"start_date": "2020-02-20",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Study on home pharmaceutical care for chronic patients over the new coronavirus pneumonia epidemic                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51443",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "mengqt2013@hotmail.com",
			"corresp_author_email_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. Patients with cardiac arrest before endotracheal intubation;\r\u003cbr\u003e2. Patients with severe medical record information registration defects;\r\u003cbr\u003e3. Patients whose condition is not stable and whose prognosis cannot be determined.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. The diagnosis of COVID-19 was confirmed;\r\u003cbr\u003e2. Patients with invasive mechanical ventilation.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Case series:Nil;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Clinical features and prognosis;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "case-control study",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031227",
			"start_date": "2020-03-26",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Clinical features and prognosis of  invasive mechanicalventilation patients  with novel coronavirus pneumonia (COVID-19) in Wuhan, China: a single-centered, retrospective, observational study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51473",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "2235658154@qq.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: (1) patients with severe basic diseases and intolerance such as cardiopulmonary function;\r\u003cbr\u003e(2) patients combined with diseases affecting the assessment; with communication and cognitive impairment, unclear consciousness and unable to cooperate with the experiment.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: (1) a patient who meets the diagnostic criteria of novel coronavirus pneumonia and is confirmed by lung CT or nucleic acid examination;\r\u003cbr\u003e(2) stable condition, normal cognitive function, able to understand tests and requirements;\r\u003cbr\u003e(3) willing to sign the informed consent.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Case series:Nil;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Modified dyspnea index scale;St.George's Respiratory Questionnaire;Self-Rating Depression Scale;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031214",
			"start_date": "2020-03-31",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Clinical study on the correlation between novel coronavirus pneumonia (COVID-19) clinical rehabilitation assessment and prognosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51509",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "sjun1982@163.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: Age \u003c 18 years old, clinical data missing.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: This retrospective cohort study included a cohorts of adult inpatients (\u003e=18 years old) from Department of Respiratory and Critical Care, The First People's Hospital of Jiangxia District, Wuhan(China) between January 29, 2020 to February 29, 2020. All adult patients who were diagnosed with COVID-19 according to WHO interim guidance were screened.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Case series:none;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "mortality;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031198",
			"start_date": "2020-04-01",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Clinical characteristics and risk factors of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51488",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "xuzhe302@139.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. Pregnant or lactating women;\r\u003cbr\u003e2. patients with malignant tumor, other serious systemic diseases and psychosis; \r\u003cbr\u003e3. patients with severe liver dysfunction; \r\u003cbr\u003e4. recent or participating in other clinical trials; \r\u003cbr\u003e5. evidence of drug addiction within one year before joining the trial;\r\u003cbr\u003e6. unable or unwilling to provide informed consent or comply with the trial requirements;\r\u003cbr\u003e7. Combined with other infectious diseases.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. patients aged 16-85 male or female; \r\u003cbr\u003e2. they were willing to sign the informed consent;\r\u003cbr\u003e3. The novel coronavirus nucleic acid was detected by real-time fluorescence RT-PCR in sputum, throat swabs, and lower respiratory tract secretions based on the novel coronavirus infection suspected case standard; Sequencing of viral genes is highly homologous to Known novel coronavirus.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "treatment group:combination of  Lopinavir/ritonavir (Kaletra) Tablets and interferon;control group:Routine medical treatment,;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "time till the SARS-CoV-2 clearance;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "non randomized control",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031196",
			"start_date": "2020-01-10",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Clinical efficacy of novel coronavirus infection treated by combination of interferon regimen and Ritonavir Tablets                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51112",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "laurens.liesenborghs@uzleuven.be",
			"corresp_author_email_certainty": "prefilled",
			"country": "Belgium",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e1. ALT/AST \u003e 5 times the upper limit of normal. \r\u003cbr\u003e2. Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR \u003c 30)  \r\u003cbr\u003e3. Pregnancy or breast feeding. \r\u003cbr\u003e4. Allergy to any study medication\r\u003cbr\u003e5. Any medical condition which would impose an unacceptable safety hazard by participation to the study.\r\u003cbr\u003e6. Study drug specific exclusion criteria:\r\u003cbr\u003e\t- for itraconazole: heart failure ,  concomitant treatment with lopinavir/ritonavir, and potent CYP450 inducers such as rifampicin, rifabutin, carbamazepine, phenobarbital, phenytoin.\r\u003cbr\u003e\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e1.\tSubject (=18 years old) or legally authorized representative provides informed consent prior to initiation of any study procedures. When signed informed consent is not possible (e.g. due to restrictions to prevent viral transmission), verbal informed consent in the presence of a witness not related to the investigational research study will be obtained.\r\u003cbr\u003e2.\tSubject (or legally authorized representative) understands and agrees to comply with planned study procedures. \r\u003cbr\u003e3.\tMale or non-pregnant female adult =18 years of age at time of enrolment. \r\u003cbr\u003e4.\tHas laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen as diagnosed within 72 hours prior to randomization.\r\u003cbr\u003e5.\tIllness of any duration, and at least one of the following:\r\u003cbr\u003ea.\tRadiographic infiltrates by imaging (chest x-ray, CT scan, etc.), or \r\u003cbr\u003eb.\tClinical assessment (evidence of rales/crackles on exam) AND SpO2 = 94% on room air, or \r\u003cbr\u003ec.\tRequiring mechanical ventilation and/or supplemental oxygen. \r\u003cbr\u003e\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range 100\u003cbr\u003eF.1.3 Elderly (\u003e=65 years) yes\u003cbr\u003eF.1.3.1 Number of subjects for this age range 100\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eProduct Name: itraconazole\u003cbr\u003ePharmaceutical Form: Capsule, hard\u003cbr\u003eINN or Proposed INN: ITRACONAZOLE\u003cbr\u003eCAS Number: 84625-61-6\u003cbr\u003e\u003cbr\u003eProduct Name: itraconazole\u003cbr\u003ePharmaceutical Form: Oral solution\u003cbr\u003eINN or Proposed INN: ITRACONAZOLE\u003cbr\u003eCAS Number: 84625-61-6\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Timepoint(s) of evaluation of this end point: Day 15;Primary end point(s): Clinical status of subject at day 15 (on a 7-point ordinal scale): \u003cbr\u003e1.\tNot hospitalized, no limitations on activities \u003cbr\u003e2.\tNot hospitalized, limitation on activities; \u003cbr\u003e3.\tHospitalized, not requiring supplemental oxygen; \u003cbr\u003e4.\tHospitalized, requiring supplemental oxygen; \u003cbr\u003e5.\tHospitalized, on non-invasive ventilation or high flow oxygen devices; \u003cbr\u003e6.\tHospitalized, on invasive mechanical ventilation or ECMO; \u003cbr\u003e7.\tDeath.;Secondary Objective: To evaluate clinical efficacy of different investigational therapeutics as compared to the control arm as assessed by Clinical Severity, Oxygenation, Ventilation, Hospitalisation.;Main Objective: The overall objective of the study is to evaluate the clinical efficacy and safety of different investigational therapeutics relative to the standard of care in patients hospitalized with COVID-19.",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: yes\nrandomised: yes\nopen: yes\nsingle blind: no\ndouble blind: no\nparallel group: no\ncross over: no\nother: no\nif controlled, specify comparator, other medicinial product: no\nplacebo: no\nother: yes\nother specify the comparator: best clinical practice\nnumber of treatment arms in the trial: 2\n",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001243-15-BE",
			"start_date": "26/03/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "Covid-19: A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2. - Antivirals for COVID-19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001243-15",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "Public-Registry-MA-France@sanofi.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "France;Canada;Spain;Russian Federation;Israel;Germany;Japan;Italy",
			"country_certainty": "generated",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003eUnlikely to survive for \u003e48 hours from screening\u003cbr\u003ePresence of neutropenia less than 2000/mmˆ3, AST or ALT greater than 5 X ULN, platelets less than 50,000/mmˆ3\u003cbr\u003ePrior immunosuppressive therapies\u003cbr\u003eUse of chronic oral corticosteroids for non-COVID-19 related condition\u003cbr\u003ePast or current history of autoimmune or inflammatory disease(s)\u003cbr\u003eKnown or suspected history of tuberculosis\u003cbr\u003eSuspected or known active systemic bacterial or fungal infections\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003eParticipants must have severe disease, multi-system organ dysfunction or critical disease\u003cbr\u003eLaboratory-confirmed SARS-CoV-2 infection\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range 184\u003cbr\u003eF.1.3 Elderly (\u003e=65 years) yes\u003cbr\u003eF.1.3.1 Number of subjects for this age range 276\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eTrade Name: Kevzara®\u003cbr\u003ePharmaceutical Form: Solution for injection in pre-filled syringe\u003cbr\u003eINN or Proposed INN: SARILUMAB\u003cbr\u003eCurrent Sponsor code: SAR153191\u003cbr\u003eConcentration unit: mg milligram(s)\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 200-\u003cbr\u003ePharmaceutical form of the placebo: Solution for injection\u003cbr\u003eRoute of administration of the placebo: Intravenous use\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Timepoint(s) of evaluation of this end point: Baseline to Day 29;Primary end point(s): Phase 2: time to resolution of fever for at least 48 hours without antipyretics or until discharge, whichever is sooner\u003cbr\u003ePhase 3: The percentage of patients reporting each severity rating on the 7-point ordinal scale;Secondary Objective: Evaluate the clinical efficacy of sarilumab compared to the control arm by clinical severity, changes in the National Early Warning Score 2, duration of predefined symptoms and signs, duration of supplemental oxygen dependency, incidence of new mechanical ventilation use, the duration of new mechanical ventilation use, need for admission into ICU, duration of hospitalization,  28-day mortality rate.\u003cbr\u003eSecondary safety objectives are to evaluate the safety of sarilumab compared to the control arm as assessed by incidence of: SAEs, Grade 4 neutropenia (ANC\u003c500/mm3) with concurrent severe or life-threatening bacterial, invasive fungal, or opportunistic infection, Grade =2 infusion related reactions, Grade =2 hypersensitivity reactions, Increase in ALT =3X ULN (for patients with normal baseline) or \u003e3X ULN and at least 2-fold increase from baseline value (for patients with abnormal baseline), Invasive bacterial or fungal infections of clinical significance with confirmed diagnosis ;Main Objective: Phase 2: To evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with severe COVID-19\u003cbr\u003ePhase 3: To evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with severe or critical COVID-19  \u003cbr\u003e",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: yes\nrandomised: yes\nopen: no\nsingle blind: no\ndouble blind: yes\nparallel group: yes\ncross over: no\nother: no\nif controlled, specify comparator, other medicinial product: no\nplacebo: yes\nother: no\nnumber of treatment arms in the trial: 3\n",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001162-12-FR",
			"start_date": "26/03/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "An adaptive phase 2/3, randomized, double-blind, placebo-controlled, study assessing efficacy and safety of sarilumab for hospitalized patients with COVID19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001162-12",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "M.J.M.Bonten@umcutrecht.nl",
			"corresp_author_email_certainty": "prefilled",
			"country": "Netherlands",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003eA potential subject who meets any of the following criteria will be excluded from participation in this study:\u003cbr\u003e•\tKnown allergy to (components of) the BCG vaccine or serious adverse events to prior BCG administration  \u003cbr\u003e•\tKnown active or latent Mycobacterium tuberculosis or with another mycobacterial species.  A history with- or a suspicion of M. tuberculosis infection. \u003cbr\u003e•\tFever (\u003e38 C) within the past 24 hours \u003cbr\u003e•\tPregnancy \u003cbr\u003e•\tSuspicion of active viral or bacterial infection \u003cbr\u003e•\tVaccination in the past 4 weeks or expected vaccination during the study period, independent of the type of vaccination.\u003cbr\u003e•\tSeverely immunocompromised subjects. This exclusion category comprises: a) subjects with known infection by the human immunodeficiency virus (HIV-1); b) neutropenic subjects with less than 500 neutrophils/mm3; c) subjects with solid organ transplantation; d) subjects with bone marrow transplantation; e) subjects under chemotherapy; f) subjects with primary immunodeficiency; g) severe lymphopenia with less than 400 lymphocytes/mm3; h) treatment with any anti-cytokine therapies. i) treatment with oral or intravenous steroids defined as daily doses of 10mg prednisone or equivalent for longer than 3 months, or probable use of oral or intravenous steroids in the following four weeks \u003cbr\u003e•\tActive solid or non-solid malignancy or lymphoma within the prior two years\u003cbr\u003e•\tDirect involvement in the design or the execution of the BCG-CORONA study\u003cbr\u003e•\tExpected absence from work of =4 of the following 12 weeks due to any reason (holidays, maternity leave, retirement, planned surgery etc)  \u003cbr\u003e•\tEmployed to the hospital \u003c 22 hours per week\u003cbr\u003e•\tNot in possession of a smartphone \u003cbr\u003e\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003eIn order to be eligible to participate in this study, a subject must meet the following criteria:\u003cbr\u003e•\tAdult (=18 years) \u003cbr\u003e•\tMale or female\u003cbr\u003e•\tHospital personnel (expected to) taking care for patients with SARS-CoV-2 infection\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range 1000\u003cbr\u003eF.1.3 Elderly (\u003e=65 years) yes\u003cbr\u003eF.1.3.1 Number of subjects for this age range 40\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eTrade Name: BCG vaccine (BCG-Vaccin SSI [Nederlands VaccinStatens Serum Instituut]) Danish strain 1331.\u003cbr\u003ePharmaceutical Form: Concentrate and solvent for solution for injection\u003cbr\u003ePharmaceutical form of the placebo: Concentrate and solvent for solution for injection\u003cbr\u003eRoute of administration of the placebo: Intradermal use\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Timepoint(s) of evaluation of this end point: Between day 0 up to day 180 after inclusion;Primary end point(s): Number of days of unplanned absenteeism for any reason ;Secondary Objective: To reduce hospital admission, ICU admission or death in HCW with direct patient contacts during the epidemic phase of SARS-CoV-2.;Main Objective: To reduce absenteeism among HCW with direct patient contacts during the epidemic phase of SARS-CoV-2.",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: yes\nrandomised: yes\nopen: no\nsingle blind: no\ndouble blind: yes\nparallel group: no\ncross over: no\nother: no\nif controlled, specify comparator, other medicinial product: no\nplacebo: yes\nother: no\nnumber of treatment arms in the trial: 2\n",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-000919-69-NL",
			"start_date": "17/03/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "Reducing health care workers absenteeism in SARS-CoV-2 pandemic by enhanced trained immune responses through Bacillus Calmette-Guérin vaccination, a randomized controlled trial (COVID-19). - BCG-CORONA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000919-69",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "diane.egger-adam@uni-tuebingen.de",
			"corresp_author_email_certainty": "prefilled",
			"country": "Germany",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e•\tRespiratory rate \u003e24/min\u003cbr\u003e•\tPregnancy or lactation\u003cbr\u003e•\tWeight \u003c50 kg\u003cbr\u003e•\tHemodynamic/rhythm instability\u003cbr\u003e•\tAcute myocardial infarction Type 1\u003cbr\u003e•\tUse of concomitant medications that prolong the QT/QTc interval.\u003cbr\u003e•\tAny other significant disease, disorder or finding which, in the opinion of the investigator, may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data\u003cbr\u003e\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e•\tWritten informed consent\u003cbr\u003e•\tAge above 18 years\u003cbr\u003e•\tWomen of childbearing age only: Must agree to practice continuous effective contraception for the duration of the study (a method which results in a failure rate less than 1% per year)\u003cbr\u003e•\tDisease severe enough to require hospitalization\u003cbr\u003e\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) no\u003cbr\u003eF.1.2.1 Number of subjects for this age range \u003cbr\u003eF.1.3 Elderly (\u003e=65 years) yes\u003cbr\u003eF.1.3.1 Number of subjects for this age range 25\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eTrade Name: Quensyl\u003cbr\u003ePharmaceutical Form: Capsule\u003cbr\u003ePharmaceutical form of the placebo: Capsule\u003cbr\u003eRoute of administration of the placebo: Oral use\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Timepoint(s) of evaluation of this end point: One interim analysis for evaluating the primary efficacy endpoint is planned for this study. The interim analysis will be done when 40% of events have accrued.  In case the interim analysis shows a HR \u003e 1.93 (nominal p \u003c 0.0018), efficacy is shown and the trial may be stopped.  Final analysis upon completion of the trial and final database lock.;Primary end point(s): Primary efficacy endpoint: Viral clearance defined as time to sustained SARS-CoV-2-specific RNA copy number =100, measured by real time reverse-transcription polymerase chain reaction in throat swabs\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e;Secondary Objective: Exploratory objectives are to assess the effect of infection and HCQ treatment on clinical outcome, cardiac function, mucosal, humoral and cellular immune response including single cell phenotype and RNA expression, effect on anti-viral defense, assessment of chronic symptoms and quality of life. ;Main Objective: Primary objective: Effect of HCQ on in vivo viral clearance. ",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: yes\nrandomised: yes\nopen: no\nsingle blind: no\ndouble blind: yes\nparallel group: yes\ncross over: no\nother: no\nif controlled, specify comparator, other medicinial product: no\nplacebo: yes\nother: no\nnumber of treatment arms in the trial: 2\n",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001224-33-DE",
			"start_date": "25/03/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "Randomized controlled trial of hydroxychloroquine versus placebo for the treatment of adult patients with acute coronavirus disease 2019 – COVID-19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001224-33",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "andreas.barrattdue@gmail.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "Norway",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e1.\tSevere co-morbidity with life expectancy \u003c3 months according to investigators assessment\r\u003cbr\u003e2.\tASAT/ALAT \u003e 5 times the upper limit of normal\r\u003cbr\u003e3.\tAcute co-morbidity within 7 days before inclusion such as myocardial infarction\r\u003cbr\u003e4.\tKnown intolerance to the available study drugs\r\u003cbr\u003e5.\tPregnancy, possible pregnancy or breast feeding\r\u003cbr\u003e6.\tAny reason why, in the opinion of the investigators, the patient should not participate\r\u003cbr\u003e7.\tSubject participates in a potentially confounding drug or device trial during the course of the study \r\u003cbr\u003e8.\tProlonged QT interval (\u003e450 ms)\r\u003cbr\u003e\r\u003cbr\u003e9.\tAlready receiving any of the study drugs\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e1.\tAdult patients, 18 years and above\r\u003cbr\u003e2.\tConfirmed SARS-2-CoV-2 infection by PCR\r\u003cbr\u003e3.\tAdmitted to the hospital ward or the ICU\r\u003cbr\u003e4.\tSubjects (or legally authorized representative) provides written informed consent prior to initiation of the study\r\u003cbr\u003e5.\tNo anticipated transfer within 72 hours to a non-study hospital\r\u003cbr\u003e\r\u003cbr\u003e\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range 221\u003cbr\u003eF.1.3 Elderly (\u003e=65 years) yes\u003cbr\u003eF.1.3.1 Number of subjects for this age range 222\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eTrade Name: Plaquenil\u003cbr\u003eProduct Name: Plaquenil\u003cbr\u003ePharmaceutical Form: Film-coated tablet\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Timepoint(s) of evaluation of this end point: Please see above;Primary end point(s):  The primary endpoint will be in-hospital mortality. The primary endpoint will be the same as the primary endpoint in the core WHO protocol.;Secondary Objective: Not applicable;Main Objective: 1.\tTo investigate the effect of Remdesivir and Hydroxychloroquine in COVID 19 infection in relation to the defined primary and secondary endpoints.\u003cbr\u003e2.\tTo compare the effect of early versus late intervention with Remdesivir and Hydroxychloroquine in relation to time from symptom debut and in relation to disease severity when included.\u003cbr\u003e3.\tTo analyse markers that can give prognostic information and information on pathogenic mechanisms in COVID 19 infection with particular focus on ICU patient characteristics compared with patientstreated at the hospital ward. \u003cbr\u003e4.\tTo establish the safety of the study drugs.\u003cbr\u003e",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: yes\nrandomised: yes\nopen: no\nsingle blind: no\ndouble blind: no\nparallel group: no\ncross over: no\nother: no\nif controlled, specify comparator, other medicinial product: yes\nplacebo: no\nother: yes\nother specify the comparator: standard of care\nnumber of treatment arms in the trial: 2\n",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-000982-18-NO",
			"start_date": "26/03/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "The NOR Solidarity multicenter trial on the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19) - N-ReCOVID 19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000982-18",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "shuminwang7000@163.com;shuminwang7000@163.com",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Shumin Wang, Phd.;Shumin Wang, Phd.",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Male and female, 18-75 years old\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients previously diagnosed with novel coronavirus pneumonia: the course of illness\r\u003cbr\u003e             is no more than 14 days; if the course of the disease was more than 14 days, patient\r\u003cbr\u003e             meets one of the following conditions can also be included in the group: (1) No\r\u003cbr\u003e             apparent absorption or progression of chest radiograph was observed within 7 days; (2)\r\u003cbr\u003e             respiratory symptoms (chest tightness, or cough, or breathing difficulties); (3) Test\r\u003cbr\u003e             for viral nucleic acid positive within 3 days.\r\u003cbr\u003e\r\u003cbr\u003e          -  informed consent should be signed by the participate or an authorized agent\r\u003cbr\u003e\r\u003cbr\u003e          -  Agree to clinical samples collection\r\u003cbr\u003e\r\u003cbr\u003e          -  Female or male subjects of childbearing age agree to take effective contraceptive\r\u003cbr\u003e             measures within 3 months of the last oral medication to ensure that female or male\r\u003cbr\u003e             partners of childbearing age do not become pregnant\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Severe vomiting or difficulty ingesting medication\r\u003cbr\u003e\r\u003cbr\u003e          -  Woman who are pregnant or during lactation\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients received lopinavir/ridonavir, ribavirin, interferon and monoclonal antibody\r\u003cbr\u003e             specific antiviral drugs three days before enrollment\r\u003cbr\u003e\r\u003cbr\u003e          -  Cases of respiratory failure requiring mechanical ventilation\r\u003cbr\u003e\r\u003cbr\u003e          -  Shock\r\u003cbr\u003e\r\u003cbr\u003e          -  Combined with other organ failure and requires ICU care\r\u003cbr\u003e\r\u003cbr\u003e          -  Clinical prognostic non-survival, palliative care, or in deep coma and no have\r\u003cbr\u003e             response to supportive treatment within three hours of admission\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Drug: favipiravir tablets+chloroquine phosphatetablets tablets;Drug: Favipiravir tablets;Drug: Placebo",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Time of Improvement or recovery of respiratory symptoms;Number of days virus nucleic acid shedding;Frequency of Improvement or recovery of respiratory symptoms",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "allocation: randomized. intervention model: parallel assignment. primary purpose: treatment. masking: double (participant, care provider). ",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04319900",
			"start_date": "2020-03-05",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04319900",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  We identify individuals aged 18 years or older and registered in the current primary\r\u003cbr\u003e             care practice for at least one year.\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  We exclude individuals with a prior history of influenza and viral pneumonia before\r\u003cbr\u003e             study entry.\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Drug: ACE inhibitor",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Incidence of influenza",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04322786",
			"start_date": "1998-01-01",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective? An Analysis Using UK Based Electronic Health Records of 5.6 Million Individuals.",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04322786",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";;;;;;;bartshealth.covid-hcw@nhs.net;",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "James C Moon;Gabriella Captur;Charlotte Manisty;Ben O'Brien;Hugh Montgomery;Steffen Petersen;Thomas Treibel;James C Moon, MD MBBS MRCP;James Moon",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "United Kingdom",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  healthy asymptomatic healthcare workers attending hospital (place of work)\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  SARS-CoV-2 positive or symptomatic healthcare workers\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Diagnostic Test: COPAN swabbing and blood sample collection",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Seroconversion to SARS-CoV-2 positivity",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04318314",
			"start_date": "2020-03-18",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04318314",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "joe-elie.salem@aphp.fr;joe-elie.salem@aphp.fr",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Joe-Elie Salem, MD-PhD;Joe-Elie Salem, MD-PhD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "France",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        - COVID-19 positive patients admitted in a ward identified by positive PCR on nasal swab\r\u003cbr\u003e        samples\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        - Patients for which electrocardiogram or transthoracic echocardiography is not technically\r\u003cbr\u003e        feasible\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Diagnostic Test: Electrocardiogram and transthoracic echocardiography",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Incidence of acute myocardial events in COVID-19 population at baseline and during hospital stay",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04320017",
			"start_date": "2020-03-20",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Joint Use of Electrocardiogram and Transthoracic Echocardiography in an Observational Study to Monitor Cardio-vascular Events in Patients Diagnosed With COVID-19",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04320017",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";erenavcil@gmail.com;erenavcil@gmail.com",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Ipek Yeldan, Prof.;Eren Avcil, M.Sc,Pt;Eren Avcil, M.Sc,Pt",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Turkey",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Being between the ages of 18-55\r\u003cbr\u003e\r\u003cbr\u003e          -  To continue their active education or business life before the social isolation\r\u003cbr\u003e             period.\r\u003cbr\u003e\r\u003cbr\u003e          -  Spending time at home differently from routine life recently\r\u003cbr\u003e\r\u003cbr\u003e          -  Having a smart phone\r\u003cbr\u003e\r\u003cbr\u003e          -  Not having visual impairment\r\u003cbr\u003e\r\u003cbr\u003e          -  Being literate in Turkish\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Mental disability or diagnosed severe psychological discomfort\r\u003cbr\u003e\r\u003cbr\u003e          -  Being diagnosed with serious systemic disease (cardiovascular, metabolic, pulmonary…)\r\u003cbr\u003e\r\u003cbr\u003e          -  Changing the living conditions in the last 3 months (moving, changing jobs ...)\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: Determination of physical activity, quality of life, stress levels of isolated people at home with the danger of coronavirus.",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Beck Depression Scale;Health-Related Quality of Life SF-12 Scale;International Physical Activity Questionnaire (IPAQ)",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04319211",
			"start_date": "2020-03-25",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Investigation of Physical Activity, Quality of Life and Stress Levels of Individuals Who Live in Their Homes Isolated Because of Coronavirus (COVID-19) Disease",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04319211",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "A.A.Bhangu@bham.ac.uk",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Aneel Bhangu",
			"corresp_author_lastname_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients undergoing ANY type of surgery in an operating theatre, this includes\r\u003cbr\u003e             obstetrics\r\u003cbr\u003e\r\u003cbr\u003e        AND\r\u003cbr\u003e\r\u003cbr\u003e        - The patient had COVID-19 infection either at the time of surgery or within 30 days of\r\u003cbr\u003e        surgery, based on\r\u003cbr\u003e\r\u003cbr\u003e        (i) positive COVID-19 lab test or computed tomography (CT) chest scan\r\u003cbr\u003e\r\u003cbr\u003e        OR\r\u003cbr\u003e\r\u003cbr\u003e        (ii) clinical diagnosis (no COVID-19 lab test or CT chest performed)\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  If COVID-19 infection is diagnosed \u003e30 days after discharge, the patient should not be\r\u003cbr\u003e             included.\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Procedure: Surgery",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "30-day mortality",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04323644",
			"start_date": "2020-03-31",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Outcomes of Surgery in COVID-19 Infection: International Cohort Study (CovidSurg)",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04323644",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "winsonhong@126.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. Have a clear history of celecoxib allergy;\r\u003cbr\u003e2. Serious nausea, vomiting, diarrhea and other clinical manifestations affect the oral or absorption of the drug;\r\u003cbr\u003e3. Taking drugs that may interact with celecoxib at the same time;\r\u003cbr\u003e4. Patients with serious basic diseases, such as heart disease (including history of angina pectoris or coronary heart disease of myocardial infarction, atrioventricular block), lung, kidney, liver, etc., or mental diseases that cannot be treated together;\r\u003cbr\u003e5. History of peptic ulcer;\r\u003cbr\u003e6. Pregnant and lactating women;\r\u003cbr\u003e7. Suspected or confirmed that there is still a history of alcohol, drug abuse or drug abuse;\r\u003cbr\u003e8. Participated in other drug trials in the past month.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. The nucleic acid of novel coronavirus 2019 was positive or the virus gene was highly homologous to the known new coronavirus. \r\u003cbr\u003e2. The patient has fever or / and pneumonia;\r\u003cbr\u003e3. Aged \u003e=18 years old.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Experimental group:Celebrex capsules 200mg / time twice a day for 7 days;control group:routine treatment;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Prostaglandin E2;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "non randomized control",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031630",
			"start_date": "2020-02-17",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Clinical study for Celebrex in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=50474",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";;;;libertario.demi@unitn.it",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Riccardo Inchingolo, MD, PhD;Andrea Smargiassi, MD, PhD;Libertario Demi, PhD;Gino Soldati, MD;Libertario Demi, PhD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Italy",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  suspected COVID-19 patients,\r\u003cbr\u003e\r\u003cbr\u003e          -  known COVID-19 patients.\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  confirmed disease different from COVID-19.\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Diagnostic Test: Lung ultrasound",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Lung ultrasound grading system for COVID-19 pneumonia",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04322487",
			"start_date": "2020-04-01",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Proposal for International Standardization of the Use of Lung Ultrasound for COVID-19 Patients; a Simple, Quantitative, Reproducible Method",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04322487",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "wenqin-1987@163.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. a history of neurologic and psychiatric deficits \r\u003cbr\u003e2. medical-care worker",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. People aged between 18 and 65 years old;\r\u003cbr\u003e2. People have electronic social software such as WeChat, QQ and Email.  ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "cross-sectional study:no;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "PSQI;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031589",
			"start_date": "2020-03-06",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "What happens to non-health care workers' sleep of China during the pandemic of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51969",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "xmguo@tjh.tjmu.edu.cn",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: No",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: included in \"Diagnosis and treatment scheme of pneumonia infected by novel coronavirus (trial version 5 or later version)\"",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "ordinary group versus severe group versus critical group versus deceased patients group:no;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Chest computed tomography (CT);",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "factorial",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031587",
			"start_date": "2020-01-27",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "A paired clinical study of novel coronavirus pneumonia (COVID-19) patients with ordinary, severe, critical, and deceased patients in Tongji Hospital                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51952",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "f.w.asselbergs@umcutrecht.nl;m.p.m.linschoten@umcutrecht.nl",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Folkert W. Asselbergs, MD, PhD;Marijke Linschoten, MD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Netherlands",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Highly suspected/confirmed infection with SARS-CoV-2\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        - Patients that opt-out\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "The incidence of cardiovascular complications in patients with COVID-19",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04325412",
			"start_date": "2020-03-23",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Cardiac complicAtions in Patients With SARS Corona vIrus 2 regisTrY",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04325412",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Daniel R Karlin, MD, MA;Daniel R Karlin, MD, MA",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "United States",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        Cohort 1:\r\u003cbr\u003e\r\u003cbr\u003e          -  Females and males over 18 years old\r\u003cbr\u003e\r\u003cbr\u003e          -  Willing to share demographic data with the sponsor of the study\r\u003cbr\u003e\r\u003cbr\u003e          -  Willing to follow app use instructions during the course of the study\r\u003cbr\u003e\r\u003cbr\u003e          -  Willing to complete survey instruments as described in study procedures\r\u003cbr\u003e\r\u003cbr\u003e          -  Willing to provide electronic informed consent\r\u003cbr\u003e\r\u003cbr\u003e          -  Able to read and understand the English language well enough to complete electronic\r\u003cbr\u003e             informed consent\r\u003cbr\u003e\r\u003cbr\u003e        Cohort 2:\r\u003cbr\u003e\r\u003cbr\u003e        Any person present in the vicinity of a HealthMode Cough Monitoring Device\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        No exclusion criteria\r\u003cbr\u003e\r\u003cbr\u003e        -\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "Dataset size",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04326309",
			"start_date": "2020-03-25",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Audio Data Collection for Identification and Classification of Coughing",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04326309",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "lxy7111@126.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: Uninfected group: with severe disease of heart, liver, lung, kidney or other organs; \r\u003cbr\u003enormal group: those who refused to join this trial;\r\u003cbr\u003esevere group: those who refused to join this trial. ",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: Healthy group: healthy, without serious disease; \r\u003cbr\u003enormal group: diagnosed patients with common NCP; \r\u003cbr\u003esevere group: diagnosed patients with severe NCP.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Control group :Isolate PBMC to extract tRNA ;normal group:Isolate PBMC to extract tRNA;severe group:Isolate PBMC to extract tRNA;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "CRP;SAA;IL-6;PCT;tRNA;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "factorial",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031627",
			"start_date": "2020-04-20",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Study for the Mechanism of the Relationship between Infection of novel coronavirus pneumonia (COVID-19) and Host Innate Immune                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51865",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "yxzpumch@126.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. Have been diagnosed with psychologic illness;\r\u003cbr\u003e2. Taking antipsychotic drugs;\r\u003cbr\u003e3. Participating in clinical trials of other drugs.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. Chinese emergency medical staff on duty from November 2019 to June 2020;\r\u003cbr\u003e2. Aged \u003e= 18 years;\r\u003cbr\u003e3. Meet ethical standards and be able to sign informed consent.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Case series:N/A;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "The score of PHQ-9;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031533",
			"start_date": "2020-04-10",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Survey of psychological status and related factors of emergency medical staff in the country during the COVID-19 pandemic                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51835",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "paulkschan@cuhk.edu.hk;",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Paul CHAN;",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Hong Kong",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Case are adults age = 18 years old admitted to hospital with laboratory confirmed\r\u003cbr\u003e             COVID-19\r\u003cbr\u003e\r\u003cbr\u003e          -  Controls are patients admitted for community-acquired pneumonia\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients who refuse to consent for study\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: No intervention",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Microbiological;Virological;Clinical",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04325919",
			"start_date": "2020-02-24",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Comprehensive Clinical, Virological, Microbiological, Immunological and Laboratory Monitoring of Patients Hospitalized With Coronavirus Disease 2019 (COVID-19)",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04325919",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";joost.wauters@uzleuven.com",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Joost Wauters, MD PhD;Joost Wauters, MD PhD",
			"corresp_author_lastname_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients \u003e/= 18 years old AND\r\u003cbr\u003e\r\u003cbr\u003e          -  Hospitalised with PCR-confirmed and/or CT-confirmed SARS-CoV-2 disease\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Age \u003c 18 years old\r\u003cbr\u003e\r\u003cbr\u003e          -  No informed consent\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients on cyclosporine/tacrolimus/sirolimus/everolimus therapy*\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: Patient sampling",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Host genetic variation;Immune host response at local level;Immune host response at systemic level;Clinical Features",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04327570",
			"start_date": "2020-03-27",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "In-depth Characterisation of the Dynamic Host Immune Response to Coronavirus SARS-CoV-2",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04327570",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "whet_ctr@163.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. Missing or incomplete medical records;\r\u003cbr\u003e2. 28 day follow-up is incompleted;\r\u003cbr\u003e3. Co-infection with influenza or other viruses;\r\u003cbr\u003e4. Discontinuation of antihypertensive or chronic kidney disease treatment is more than 48 hours;\r\u003cbr\u003e5. ACEIs were used during the treatment.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. Patients meet Diagnosis and treatment of novel coronavirus pneumonia (Seventh Edition);\r\u003cbr\u003e2. Over 18 years old;\r\u003cbr\u003e3. Patients with hypertension,diabetes and chronic kidney disease were treated with ARBs or other drugs;\r\u003cbr\u003e4. Complete data;\r\u003cbr\u003e5. Agree to participate in the study and cooperate with the follow-up.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "ARBs Group:Treatment of ARBs;non-ARBs Group:other treatments;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Incidence of ARDS;Mortality within 28 days;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "factorial",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031539",
			"start_date": "2020-03-15",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "A Medical Records Based Study for the Correlation between Angiotensin II Type 1 Receptor Blockers (ARBs) and  the Progression and Outcome of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51893",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "jzxhl@126.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. Heart rate\u003e 120 beats / min or \u003c40 beats / min;\r\u003cbr\u003e2. Blood pressure \u003c90/60 mmHg or\u003e 140/90 mmHg;\r\u003cbr\u003e3. Blood oxygen saturation is \u003c=90% or the change from baseline value is decreased by\u003e 4%;\r\u003cbr\u003e4. Respiratory frequency\u003e 40 times / minute;\r\u003cbr\u003e5. Pregnant women or other special groups.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. Patients with new crowns who meet the criteria for the removal and discharge of \"Pneumonitis Diagnosis and Treatment Program for New Coronavirus Infection (Trial Version 7)\".\r\u003cbr\u003e2. Aged \u003e=18 years;\r\u003cbr\u003e3. The limbs function is sound;\r\u003cbr\u003e4. No serious dysfunction of vital organs such as lung, liver and kidney;\r\u003cbr\u003e5. The patient is clearly conscious, willing and signed the informed consent.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Experimental group:Rehabilitation Nursing Program;Control group:Routine rehabilitation care;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "6minu tewalkingtest,6MWT;mMRC;Rating of Perceived Exertion Scale;SAS;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "case-control study",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031540",
			"start_date": "2020-02-05",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Study for clinical effect of rehabilitation nursing program for patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51684",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "zyq1590@163.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. Never worked on first-line clinical duty in the dental emergency department;\r\u003cbr\u003e2. Having a history of mental illness;\r\u003cbr\u003e3. Drug abusers.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. Informed consent;\r\u003cbr\u003e2. Aged 20-65 years;\r\u003cbr\u003e3. Dental emergency medical staff.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Medical personnel group:N/A;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "ASDS;PSS;PHQ;GAD;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031538",
			"start_date": "2020-04-03",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Assessment of mental health status of first-line dental emergency medical personnel during novel coronavirus pneumonia (COVID-19) pandemic                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51938",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "paolo.gisondi@univr.it",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Paolo Gisondi",
			"corresp_author_lastname_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Group 1\r\u003cbr\u003e\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Aged 18 to 75 years old\r\u003cbr\u003e\r\u003cbr\u003e          -  Individuals with a clinical diagnosis of moderate-to-severe chronic plaque psoriasis\r\u003cbr\u003e             confirmed by the Investigator\r\u003cbr\u003e\r\u003cbr\u003e          -  Continuous immunosuppressive therapy (etanercept, adalimumab, infliximab, ustekinumab,\r\u003cbr\u003e             secukinumab, ixekizumab, brodalumab, guselkumab, apremilast, methotrexate,\r\u003cbr\u003e             ciclsoporin, acitretin) for the past 3 months\r\u003cbr\u003e\r\u003cbr\u003e          -  Is willing and able to sign informed consent to participate\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients unwilling to undergo noasopharyngeal swab\r\u003cbr\u003e\r\u003cbr\u003e          -  Inability to give informed consent\r\u003cbr\u003e\r\u003cbr\u003e        Group 2\r\u003cbr\u003e\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Aged 18 to 75 years old\r\u003cbr\u003e\r\u003cbr\u003e          -  Partner of a patient with psoriasis enrolled in the study\r\u003cbr\u003e\r\u003cbr\u003e          -  Is willing and able to sign informed consent to participate\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Personal history of psoriasis\r\u003cbr\u003e\r\u003cbr\u003e          -  Ongoing immunosuppressive therapy\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients unwilling to undergo noasopharyngeal swab\r\u003cbr\u003e\r\u003cbr\u003e          -  Inability to give informed consent\r\u003cbr\u003e\r\u003cbr\u003e        Group 3\r\u003cbr\u003e\r\u003cbr\u003e          -  Aged 18 to 75 years old\r\u003cbr\u003e\r\u003cbr\u003e          -  Individuals with a clinical diagnosis of moderate-to-severe atopic dermatitis\r\u003cbr\u003e             confirmed by the Investigator\r\u003cbr\u003e\r\u003cbr\u003e          -  Continuous therapy with dupilumab for the past 3 months\r\u003cbr\u003e\r\u003cbr\u003e          -  Is willing and able to sign informed consent to participate\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients unwilling to undergo noasopharyngeal swab\r\u003cbr\u003e\r\u003cbr\u003e          -  Inability to give informed consent\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Diagnostic Test: Nasopharyngeal swab",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Point prevalence of COVID-19 infection",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04324866",
			"start_date": "2020-04-01",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04324866",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "393176736@qq.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. unclear diagnosis;\r\u003cbr\u003e2. participants are not able to understand or cooperate;\r\u003cbr\u003e3. malignancy;\r\u003cbr\u003e4. pregnancy or abortion;\r\u003cbr\u003e5. breast-feeding.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. Rheumatic disease;\r\u003cbr\u003e2. Residents in Hubei province;\r\u003cbr\u003e3. \u003e 18 years old.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Rheumatic disease with COVID-19:N/A;Rheumatic disease without COVID-19:N/A;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Infection;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "factorial",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031504",
			"start_date": "2019-12-01",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "A multi-center telephone follow-up study of disease management and infection in rheumatic patients during novel coronavirus pneumonia (COVID-19) pandemic in Hubei province                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51781",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "leetangbaba@163.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: Patients refusing to participate in the experiment",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: novel coronavirus pneumonia patients who admitted into the Wuhan mobile cabin Hospital between 10th February 2020 and 25th February 2020",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "eye patch and earplugs:Nil;eye patch:Nil;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Quality of sleep;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "factorial",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031499",
			"start_date": "2020-02-10",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Sleep quality of patients with novel coronavirus pneumonia (COVID-19) treated in mobile cabin hospital: a retrospective study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51915",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "zhu1635253@163.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. With any autoimmune disease;\r\u003cbr\u003e2. with malignant tumors;\r\u003cbr\u003e3. Participated in other clinical studies within three months before entering the group;\r\u003cbr\u003e4. Severe allergic history, allergic to T cell therapy products or other biological agents;\r\u003cbr\u003e5. Pregnant, planning to become pregnant or lactating women;\r\u003cbr\u003e6. Patients with severe systemic diseases who are not suitable for entering the study, including but not limited to severe liver dysfunction, severe coagulation disorders, severe mental diseases, etc.;\r\u003cbr\u003e7. Previously received other stem cell therapy, had received CIK cell therapy within two months;\r\u003cbr\u003e8. Researchers believe that other conditions should not be included in this trial.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: (1) Aged 18 to 90 years old, male or female;\r\u003cbr\u003e(2) Patients with a definite diagnosis of new type of coronavirus pneumonia;\r\u003cbr\u003e(3) Expected survival time \u003e 10 days;\r\u003cbr\u003e(4) Serology: HIV antibody negative; hepatitis B surface antigen, e antigen negative; hepatitis C antibody negative; female patients with negative pregnancy test; ALT, AST \u003c=2.5 ULN; for patients with liver metastases, ALT, AST \u003c=5 ULN; ALP \u003c=2.5 ULN; serum urea nitrogen and creatinine \u003c=1.5 ULN; serum total bilirubin \u003c1.5 times the upper limit of normal;\r\u003cbr\u003e(6) Patients or their legal representatives can understand and voluntarily sign informed consent.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Experimental group:Conventional medication + Infusion of mesenchymal stem cells;Control group:Conventional medication;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Chest Imaging;lung function;ADL;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "single arm",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031494",
			"start_date": "2020-02-01",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Clinical study for stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51904",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "18971327286@163.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: (1) The time of sample collection or case information is not clear;\r\u003cbr\u003e(2) Sample size less than 200 uL;\r\u003cbr\u003e(3) Samples with severe hemolysis, lipemia and jaundice;\r\u003cbr\u003e(4) The researchers believe that the sample does not meet the test requirements.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: Novel coronavirus 2019-nCoV suspected cases, confirmed cases, excluded cases and clinical cases with negative detection of nucleic acid",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Gold Standard:PCR Nucleic acid detection;Index test:2019-nCov IgG;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "2019-nCov IgG;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031465",
			"start_date": "2020-03-25",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Novel coronavirus (2019-nCOV) IgG detection kit (magnetic particle chemiluminescence) clinical trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51538",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "yuanxianglin@hust.edu.cn",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1) Previous history of chronic bronchitis, emphysema, interstitial lung disease or pulmonary heart disease;\r\u003cbr\u003e2) Combining with other serious diseases: such as those who have suffered myocardial infarction and uncontrollable diabetes within 6 months, and are considered unsuitable to participate in the trial;\r\u003cbr\u003e3) People with active peptic ulcer;\r\u003cbr\u003e4) Patients during pregnancy and lactation;\r\u003cbr\u003e5) Patients with mental illness or others who cannot cooperate effectively;\r\u003cbr\u003e6) Researcher judged unsuitable to participate.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1) Aged 18 to 70 years old;\r\u003cbr\u003e2) Infection with new coronavirus pneumonia was confirmed by throat swab nucleic acid test. Patients with severe and critical illness were clinically judged. The symptoms of acute infection have been alleviated after treatment (at least 14 days after onset, no fever for more than 3 days), and the disease is recovering Within three months;\r\u003cbr\u003e3) CT examination of patients with multiple fibrotic shadows in both lungs;\r\u003cbr\u003e4) Blood routine, liver, and kidney functions are within the controllable range: such as the normal upper limit of plasma total bilirubin and creatinine \u003c=1.5 NUL; AST, ALT, LDH \u003c=2 NUL; sufficient hematopoietic function: such as white blood cells \u003e=4.0x10^9/L, platelets \u003e=100x10^9/L;\r\u003cbr\u003e5) Signed informed consent.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Nintedanib group:Nintedanib;Control group:Placebo;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "FVC;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "parallel",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031453",
			"start_date": "2020-04-01",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Efficacy and safety of Nintedanib esilate soft capsules in the treatment of pulmonary fibrosis in healed moderate to severe patients of novel coronavirus pneumonia (COVID-19): a single-center, randomized, placebo-controlled trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51859",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "oucehua@swmu.edu.cn",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: (1) Patients with mental, cognitive, expression and basic writing disorders;\r\u003cbr\u003e(2) Patients with severe heart, lung and blood vessels who need to stay in bed for a long time;\r\u003cbr\u003e(3) Patients who are not willing to participate by themselves or their families;\r\u003cbr\u003e(4) Patients or family members cannot cooperate with the implementer;\r\u003cbr\u003e(5) Those who cannot obtain complete data;\r\u003cbr\u003e(6) Suspected personnel and confirmed isolated patients",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: (1) Aged 18-70-year-old patients with clear intelligence;\r\u003cbr\u003e(2) Non-medical staff and staff who need to participate in epidemic prevention and control;\r\u003cbr\u003e(3) Patients with non-new coronary pneumonia infection and treatment and rehabilitation;\r\u003cbr\u003e(4) Those who are willing to cooperate with the investigation or after explanation, are willing to cooperate with the investigation and sign the informed consent.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Case series:Questionnaire survey without intervention;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Phone time before and during the outbreak;Physical exercise time before and during the outbreak;Symptoms worsened in patients with previous cervical spondylosis since the outbreak;Symptoms in people with no previous symptoms of cervical spondylosis since the outbreak;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031438",
			"start_date": "2020-04-01",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Analysis of changes in high risk factors of cervical spondylosis during novel coronavirus pneumonia (COVID-19) pandemic                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51815",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "xiaof35@sysu.edu.cn",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. in pregnancy, breast-feeding female patients;\r\u003cbr\u003e2. to determine the history of chloroquine phosphate, rabeprazole drug allergy patients;\r\u003cbr\u003ePatients suffering from diseases of the blood system;\r\u003cbr\u003e3. patients suffering from chronic liver and kidney diseases and reaching the terminal stage;\r\u003cbr\u003e4. Serious heart, lung dysfunction and mental illness;\r\u003cbr\u003e5. Patients with known retinal diseases, hearing loss or hearing loss;\r\u003cbr\u003e6. Patients who have to take digitalis drugs for existing underlying diseases;\r\u003cbr\u003e7. Merger of other digestive tract diseases;\r\u003cbr\u003e8. Combine ribavirin;\r\u003cbr\u003e9. Involved in other processing clinical drug trials.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. Aged 18 to 75 years old;\r\u003cbr\u003e2. mild or normal patients;\r\u003cbr\u003e3. not using chloroquine phosphate, lopinavir other than other antiviral drugs;\r\u003cbr\u003e4. under the gastroscope, there was mucosal damage and pathological biopsy of 2019-ncov nucleic acid positive;\r\u003cbr\u003e5. confirmed cases meeting all the following criteria (the 5th edition of the medical guidelines):\r\u003cbr\u003e(1) epidemiological history;\r\u003cbr\u003e(2) Clinical manifestations (in accordance with any 2 of the following): fever; In the early stage of the disease, the total number of white blood cells was normal or decreased, or the lymphocyte count was decreased. In the early stage of chest imaging, multiple small plaques and stromal changes were observed, especially in the lung. Then, it developed into multiple ground-glass shadows and infiltrating shadows in both lungs. In severe cases, lung consolidation may occur, and pleural effusion is rare;\r\u003cbr\u003e(3) Confirmed: the suspected case has one of the following etiological evidence: respiratory or blood specimens were tested positive for novel coronavirus nucleic acid by real-time fluorescent rt-pcr; Respiratory or blood specimen virus gene sequencing, and known novel coronavirus highly homologous.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "experimental group:Rabeprazole plus chloroquine;control group :Lopinavir + rabeprazole;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": " 2019-ncov nucleic acid yin rate;Blood 2019-ncov nucleic acid positive;Positive 2019-ncov nucleic acid in feces;Nasopharyngeal swab positive for 2019-ncov nucleic acid;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "parallel",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031454",
			"start_date": "2020-01-25",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Clinical study for prevention and treatment of digestive tract lesions caused by novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51693",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "wanli0604@163.com",
			"corresp_author_email_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: ?????????\r\u003cbr\u003eIncomplete medical history",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: From February 4, 2020 to March 12, 2020 novel coronavirus pneumonia patients undergoing emergency endotracheal intubation in the severe isolation ward of the Sino French new town hospital in Tongji Hospital",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "Success rate of intubation;Exposure classification of glottis;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031439",
			"start_date": "2020-03-20",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Clinical experience of 59 novel coronavirus pneumonia patients with intensive endotracheal intubation: a single center, retrospective, descriptive study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51837",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";matthias.totzeck@uk-essen.de;amir-abbas.mahabadi@uk-essen.de",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Tienush Rassaf, MD;Matthias Totzeck, MD;Amir A Mahabadi, MD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Germany",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients with suspected SARS-CoV2/Covid-19 infection\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Unwillingness to participate\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Diagnostic Test: Assessment of cardiovascular diseases and cardiovascular risk factors",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "All-cause mortality",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04327479",
			"start_date": "2020-03-26",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04327479",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";dgebow@gmail.com;TBD@TBD.com",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Daniel Mollura, MD;Dan Gebow, PhD;TBD TBD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "United States",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  18 years or older\r\u003cbr\u003e\r\u003cbr\u003e          -  Suspected or known Covid-19 infection (currently or previously)\r\u003cbr\u003e\r\u003cbr\u003e          -  Image procedure performed as part of a Covid-19 exam with the images available in\r\u003cbr\u003e             DICOM format\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        • Under age 18\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: No intervention",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "CT or Xray images from COVID-19 patients",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04331860",
			"start_date": "2020-03-30",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "COVID-19 Public Image Registry",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04331860",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "393176736@qq.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. Missing critical clinical data;\r\u003cbr\u003e2. \u003c 12 years old.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. Hospitalized between December 2019 and March 2020;\r\u003cbr\u003e2. Diagnosed with COVID-19.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "COVID-19 with risk factors:N/A;COVID-19 without risk factors:N/A;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Blood cell number;Biochemical markers;Metabolic markers;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "factorial",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031429",
			"start_date": "2020-04-01",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "The Effects of novel coronavirus pneumonia (COVID-19) Risk Factors on Dynamic Changes of  Immunological, biochemical, and Metabolic Parameters: a Retrospective Observational Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51816",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "18971327286@163.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: (1) The time of sample collection or case information is not clear;\r\u003cbr\u003e(2) Sample size less than 200 uL;\r\u003cbr\u003e(3) Samples with severe hemolysis, lipemia and jaundice;\r\u003cbr\u003e(4) The researchers believe that the sample does not meet the test requirements.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: Novel coronavirus 2019-nCoV suspected cases, confirmed cases, excluded cases and clinical cases with negative detection of nucleic acid",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Gold Standard:PCR Nucleic acid detection;Index test:2019-nCov IgM;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "SPE, SEN, ACC, AUC of ROC;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031427",
			"start_date": "2020-03-25",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Novel coronavirus infection (COVID-19) IgM detection kit (magnetic particle chemiluminescence) clinical trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51809",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "fanrong3463@163.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: NO",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: According to the clinical diagnostic criteria of the seventh or latest edition  \"diagnosis and treatment of pneumonia with novel coronavirus infection\", severe COVID-19 pneumonia was clinically diagnosed.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Case series:Nil;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Cure rate;improvement rate;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031199",
			"start_date": "2020-02-04",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "A Medical Records Based Retrospective Study for Clinical Characteristics of severe Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51478",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "sunhq@bjmu.edu.cn",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. Another mental disorder meets the DSM-5 criteria, including substance use disorders (except for nicotine dependence);\r\u003cbr\u003e2. Another sleep disorder meets the DSM-5 criteria;\r\u003cbr\u003e3. Current using hypnotic drugs;\r\u003cbr\u003e4. Individuals who are pregnant or lactating; Individuals who are plan to become pregnant within 3 months;\r\u003cbr\u003e5. Individuals with organ failures such as heart, liver, lung, and kidney, and organic diseases of the brain;\r\u003cbr\u003e6. Accept cognitive-behavioral therapy or taking antidepressants, antipsychotics in the past two weeks;\r\u003cbr\u003e7. Traveling across 2 time zones in the past 2 months or planning travel in the next 3 months; Shift workers.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. Insomnia diagnosed by DSM-5, but reported a duration of less than 3 months for the current episode;\r\u003cbr\u003e2. Insomnia happened after the COVID-19 public health first-level response (after January 25, 2020); Patients with insomnia before, the interval between two episodes must be 3 months or more;\r\u003cbr\u003e3. Aged 18-60 years;\r\u003cbr\u003e4. ISI \u003e 7;\r\u003cbr\u003e5. Educational background is high school and above.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Group 1:single-shot CBT-I;Group 2:Sleep Hygiene;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Sleep diary;The insomnia severity index;Sleep visual analogue scale;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "parallel",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031639",
			"start_date": "2020-03-27",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Effects of a single session internet-delivered cognitive behavioral therapy for Acute Insomnia during the pandemic of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51119",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "shencx@sjtu.edu.cn",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: (1) patients without definite diagnosis of novel coronavirus pneumonia;\r\u003cbr\u003e(2) combined with a end-stage disease with a life expectancy of less than 1 year;\r\u003cbr\u003e(3) intolerance to cardiopulmonary monitoring recorder;\r\u003cbr\u003e(4) regular follow-up is not possible.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: (1) patients with definite diagnosis of novel coronavirus pneumonia and hospitalized at Leishenshan hospital;\r\u003cbr\u003e(2) patients aged 18-80 years old;\r\u003cbr\u003e(3) patients who signed informed consents, voluntarily and persistently participated in the study and follow-up.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Control:NA;Noninvasive cardiopulmonary monitoring group:Wear non-invasive multi-channel cardiopulmonary monitor;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Exposure time in the medical cabin;Hospitalization period;Detection rate of arrhythmia;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "parallel",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031503",
			"start_date": "2020-04-01",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Application of non-invasive multichannel cardiopulmonary monitoring cloud management platform in patients with Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51911",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "zejinliu@163.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: lack of NAT or serologically specific antibody detection",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. Clinical manifestations of suspected Covid-19 such as fever and dry cough; \r\u003cbr\u003e2. Pulmonary CT results indicate suspected Covid-19; \r\u003cbr\u003e3. Apparently healthy physical examination subjects with a history of exposure to confirmed Covid-19 patients",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Gold Standard:Viral nucleic acid detection;Index test:specific\u0026#32;serological\u0026#32;detection;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "SARS-CoV-2 antibody;SEN, SPE, ACC, AUC of ROC;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031428",
			"start_date": "2020-02-05",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Clinical application value of multiple tests for novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51813",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "liudongyang@vip.sina.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. Patients with server diseases of the blood system;\r\u003cbr\u003ePatients with identified severe liver disease, underlying cirrhosis or alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevation more than 3 times the normal upper limit;\r\u003cbr\u003ePatients with renal impairment (estimated glomerular filtration rate [eGFR]\u003c 30 mL/min/1.73m2, using the MDRD method);\r\u003cbr\u003e2. History of acute myocardial infarction, unstable angina pectoris, severe arrhythmia (frequent ventricular, ventricular tachycardia, ventricular fibrillation) in recent 6 months; New York Heart Association (NYHA) level III-IV;\r\u003cbr\u003e 3. QTc \u003e= 480ms;\r\u003cbr\u003e 4. Uncorrected patients with hypokalemia or hypokalemia;\r\u003cbr\u003e 5. Patients with psychiatric disorders;\r\u003cbr\u003e 6. Patients with pancreatitis;\r\u003cbr\u003e 7. Pregnant or breastfeeding women or female with positive pregnancy test at child-bearing age.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. Aged 18 to 75 years;\r\u003cbr\u003e2. Patients with confirmed cases meeting the following criteria:\r\u003cbr\u003e(1) Epidemiology history;\r\u003cbr\u003e(2) Clinical manifestations (epidemiological history and in accordance with any of the following 2 items; no clear epidemiology history, conforms to 3 items in clinical manifestations):\r\u003cbr\u003eFever and / or respiratory symptoms;\r\u003cbr\u003eIn the early stage of the disease, the total leukocyte count was normal or decreased, or the lymphocyte count decreased;\r\u003cbr\u003eEarly chest imaging showed multiple small plaques and interstitial changes, which were evident in the extraneous lung. Further, multiple ground-glass shadows and infiltration shadows were found in both lungs, and lung consolidation and pleural effusion were rare in severe cases;\r\u003cbr\u003e(3) Having one of the following etiological evidence:\r\u003cbr\u003eRespiratory tract, blood or fecal samples RT-PCR confirmed infection with 2019-nCoV;\r\u003cbr\u003eThe virus genes of the above samples were sequenced and highly homologous to the 2019-nCoV;\r\u003cbr\u003e3. Patients who meet the following mild and normal criteria;\r\u003cbr\u003eMild: mild clinical symptoms, no signs of pneumonia on imaging;\r\u003cbr\u003eNormal: fever, respiratory symptoms, imaging manifestations of pneumonia;\r\u003cbr\u003e4.Patients who meet the following criteria of severe and critical severity (one of 3 and 4 is enough):\r\u003cbr\u003e(1) Criteria for severe patients (if any of them meet the criteria, they will be involved): Respiratory distress, RR \u003e=30 times/min;            \r\u003cbr\u003e(2) In the resting state, the oxygen saturation \u003c=93%;            \r\u003cbr\u003e(3) PaO2 / FiO2 \u003c=300 mmHg;           \r\u003cbr\u003e(4) Lung imaging showed that the lesions progressed more than 50% in 24-48 hours, which was managed according to heavy duty;            \r\u003cbr\u003eCriteria for critical patients (only those who meet the conditions in Article 1 can be selected):            \r\u003cbr\u003e(1) respiratory failure and mechanical ventilation is required;           \r\u003cbr\u003e(2) shock;           \r\u003cbr\u003e(3) Other organ failure should be monitored and treated by ICU.\r\u003cbr\u003e5. The antimalarial drugs of chloroquine phosphate and hydroxychloroquine sulfate were not used within 3 months;            \r\u003cbr\u003e6. From February 19, 2020, hospitalized patients in Wuhan Tongji Hospital, the First Affiliated Hospital of Nanchang University, the Third Hospital of Beijing Medical University (Wuhan Center), the first hospital of Peking University, the people's Hospital of Peking University, and Haidian Hospital of the Third Hospital of Beijing Medical University.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Mild:No;severe:No;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Safety;Effectiveness;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "factorial",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031376",
			"start_date": "2020-03-28",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Safety and effectiveness analysis of data from novel coronavirus pneumonia (COVID-19) patients with conventional therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51724",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "liweiqindr@vip.163.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: (1) Patients who are participating in clinical trials of other drugs;\r\u003cbr\u003e(2) Pregnant or lactating women;\r\u003cbr\u003e(3) ALT / AST \u003e 5-fold ULN, neutrophil \u003c 0.5x10^9/L, platelet \u003c 50x10^9/L;\r\u003cbr\u003e(4) The diagnosis of rheumatic immune related diseases was clear;\r\u003cbr\u003e(5) Long term oral anti rejection drugs or immunomodulatory drugs;\r\u003cbr\u003e(6) Hypersensitive reaction to mAb or any adjuvant;\r\u003cbr\u003e(7) Active tuberculosis patients with definite bacterial and fungal infection;\r\u003cbr\u003e(8) Patients with organ transplantation history within three months;\r\u003cbr\u003e(9) There was a history of PCI in the past 60 days;\r\u003cbr\u003e(10) COPD with end-stage chronic diseases, including NYHA heart failure above grade III, chronic kidney disease with CCR \u003c 40 ml / min or requiring family oxygen therapy.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: (1) severe or critical patients with covid-19 pneumonia confirmed by novel coronavirus novel coronavirus diagnosis and treatment plan (seventh Edition);\r\u003cbr\u003e(2) 18-85 years old;\r\u003cbr\u003e(3) Obtaining informed consent;",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Group 1:Routine treatment + Infusion of convalescent plasma;Group 2:Routine treatment;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "hospital mortality;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "non randomized control",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031501",
			"start_date": "2020-03-17",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "The efficacy  of convalescent plasma in patients with critical novel coronavirus pneumonia (COVID-19): a pragmatic, prospective cohort study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=50254",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "drlihang@126.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: Druring pregnancy or breastfeeding.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. aged between 20 to 30 years old;\r\u003cbr\u003e2. generally well;\r\u003cbr\u003e3. able to understand and sign an informed consent.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "experiment group:Cold outdoor environment;experiment group :temperature measuring distance;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "body surface temperature;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "diagnostic test for accuracy",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031500",
			"start_date": "2020-03-05",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Impact of measuring distance and cold outdoor environment on the screening of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51897",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "cyzhang@nju.edu.cn",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. Patients with allergic constitution or known allergy to study drug / similar drug;\r\u003cbr\u003e2. Patients who often use sedatives, sleeping pills or other addictive drugs; patients who have a history of drug abuse or positive drug abuse screening within 12 months before the first administration;\r\u003cbr\u003e3. Alcoholics or patients who drink more than 14 units of alcohol per week (1 unit = 360ml of beer or 45ml of spirits or 150ml of wine with 40% of alcohol), patients who are addicted to smoking or quit smoking for less than 3 months, patients who are positive in alcohol breath test and nicotine test, and can not be banned from smoking or alcohol during the test period;\r\u003cbr\u003e4. Patients who used any prescription medicine or Chinese herbal medicine supplement within one month before the first administration; patients who used any over-the-counter medicine (OTC), food supplement (including vitamins, calcium tablets, etc.) within two weeks before the first administration; patients who used contraceptive within two weeks before the first administration;\r\u003cbr\u003e5. Patients who participated in other clinical trials and took the study drug within 3 months before the first administration;\r\u003cbr\u003e6. The patients who participated in blood donation (including component blood donation) or lost 400ml blood within 3 months before the first administration, and the patients who participated in blood donation (including component blood donation) or lost 200ml blood within 1 month before screening, or received blood transfusion;\r\u003cbr\u003e7. There was a history of autonomic nervous dysfunction and / or current history (such as recurrent syncope, palpitation, etc.) within 3 years before the first administration;\r\u003cbr\u003e8. Patients with previous history of cardiovascular, liver, kidney, lung, digestive tract, nervous system diseases, and any history or condition that may significantly affect drug absorption, distribution, metabolism and excretion. Any medical history or condition that may be hazardous to the subjects participating in the trial. Researchers should consider the following medical history or conditions: inflammatory gastroenteritis, gastroesophageal reflux, gastrointestinal or rectal bleeding; history of pancreatic injury or pancreatitis; major surgical history such as gastrectomy, gastroenterostomy, or enterotomy; history of acute and chronic renal insufficiency, history of kidney transplantation;\r\u003cbr\u003e9. Screening the patients with severe vomiting and diarrhea in the previous week;\r\u003cbr\u003e10. Pregnant and lactating female subjects and those of childbearing age who could not use contraception as required;\r\u003cbr\u003e11. Hepatitis B surface antigen positive, hepatitis C antibody positive, syphilis antibody positive, HIV antibody positive;\r\u003cbr\u003e12. Patients who have special requirements for diet and fail to comply with the provided diet and corresponding regulations;\r\u003cbr\u003e13. Subjects who refused to stop using any drink or food containing methylxanthine, such as coffee, tea, cola, chocolate, etc., 48 hours before the first administration until the end of the study;\r\u003cbr\u003e14. Subjects who refused to discontinue any drink or food containing grapefruit 7 days before the first administration until the end of the study;\r\u003cbr\u003e15. Subjects with difficulty in venous blood collection or intolerability to venipuncture;\r\u003cbr\u003e16. Subjects with other unsuitable factors (including but not limited to the inability to understand the research requirements, poor compliance, weakness, etc.) judged by the researcher.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. Healthy male or female subjects \u003e=18 years old at the date of signing the informed consent;\r\u003cbr\u003e2. Male body weight 50kg, female body weight \u003e=45kg, body mass index (BMI) in the range of 19-28kg / m2 (including 19 and 28) (BMI = weight (kg) / height 2 (M2));\r\u003cbr\u003e3. The results of physical examination, vital signs, blood routine, urine routine, blood biochemistry, blood coagulation, abdominal B-ultrasound, chest X-ray and other examinations in the screening period must be within the normal range consistent with age and gender, or meet the requirements of the program, or be judged as \"NCS\" if they are beyond the normal range;\r\u003cbr\u003e4. 12 lead ECG was normal, QTCF was less than 430ms in men and 450 ms in women; QTc interval was corrected by friderica formula (QTCF = QT / (RR ^ 0.33), RR was the standardized heart rate value, which was obtained by dividing 60 by heart rate);\r\u003cbr\u003e5. Pregnancy test is negative in women of childbearing age;\r\u003cbr\u003e6. Agree to abstain or take effective non drug contraceptive measures within at least 3 months from screening to the last study drug administration (female subjects also require to start abstinence or take effective non drug contraceptive measures two weeks before entering the study);\r\u003cbr\u003e7. Subjects who can communicate well with researchers, understand and comply with the requirements of this study, and understand and sign the informed consent.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Different dose groups:Injection dose;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Safety and tolerance;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "dose comparison",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031432",
			"start_date": "2020-05-01",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "A clinical study evaluating the safety and tolerability of microRNA2911 plasmids in healthy adults                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51646",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "fswang302@163.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1) Pregnant or lactating women;\r\u003cbr\u003e2) High-resolution CT before the onset of the disease suggests the presence of interstitial injures in lungs;\r\u003cbr\u003e3) Acute interstitial lung injures caused by other reasons (within two weeks);\r\u003cbr\u003e4) Invasive ventilator assisted ventilation;\r\u003cbr\u003e5) Multiple organ dysfunction syndrome.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1) Male or female patients aged form 18 to 80 years;\r\u003cbr\u003e2) Willing to sign informed consent;\r\u003cbr\u003e3) Confirmed cases who meet \"Novel Coronavirus Pneumonia Diagnosis and Treatment Protocol\" revised by the National Health Commission of the Peoples Republic of China.\r\u003cbr\u003e4) High-resolution CT indicates interstitial injures in the lungs (honeycomb shadows or grid shadows).",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Experimental group:Conventional treatment regimen + MSC treatment;Control group:Conventional treatment regimen;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Electrocardiogram;St George's Respiratory Questionnaire Score;High resolution CT for chest;Blood gas analysis;Percutaneous blood oxygen saturation;6 min walking distance;Pulmonary function VCmax;Blood routine;Liver and kidney function;Cytokine analysis;Immunoglobulin;Lymphocyte subsets;Coagulation;Myocardial enzymes;Serum ferritin;Procalcitonin;IL-6;Lactic acid;D-Dimer;CRP;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "case-control study",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031430",
			"start_date": "2020-03-20",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Evaluation of  the safety and efficacy for human umbilical cord mesenchymal stem cells in COVID-19 induced pulmonary fibrosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=49254",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "hiruz.ctu@uzgent.be",
			"corresp_author_email_certainty": "prefilled",
			"country": "Belgium",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e- Patients with known history of serious allergic reactions, including anaphylaxis, to human granulocyte-macrophage colony stimulating factor such as sargramostim, yeast-derived products, or any component of the product.\r\u003cbr\u003e- mechanical ventilation before start of study\r\u003cbr\u003e- patients with peripheral white blood cell count above 25.000 per microliter and/or active myeloid malignancy\r\u003cbr\u003e-patients on high dose systemic steroids (\u003e 20 mg methylprednisolone or equivalent)\r\u003cbr\u003e-patients on lithium carbonate therapy\r\u003cbr\u003e- Patients enrolled in another investigational drug study\r\u003cbr\u003e- Pregnant or breastfeeding females (all female subjects regardless of childbearing potential status must have negative pregnancy test at screening)\r\u003cbr\u003e- Patients with serum ferritin \u003e2000 mcg/ml (which will exclude ongoing HLH)\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003eRecent (=2weeks prior to randomization) PCR-Confirmed (GLIMS) COVID-19 infection\r\u003cbr\u003e- Presence of acute hypoxic respiratory failure defined as (either or both)\r\u003cbr\u003e? saturation below 93% on minimal 2 l/min O2\r\u003cbr\u003e? PaO2/FiO2 below 350\r\u003cbr\u003e- Admitted to specialized COVID-19 ward\r\u003cbr\u003e- Age 18-80\r\u003cbr\u003e- Male or Female\r\u003cbr\u003e- Willing to provide informed consent\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range 40\u003cbr\u003eF.1.3 Elderly (\u003e=65 years) yes\u003cbr\u003eF.1.3.1 Number of subjects for this age range 40\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eTrade Name: Leukine\u003cbr\u003eProduct Name: Leukine\u003cbr\u003ePharmaceutical Form: Powder for nebuliser solution\u003cbr\u003eINN or Proposed INN: SARGRAMOSTIM\u003cbr\u003eCAS Number: 123774-72-1\u003cbr\u003eConcentration unit: µg microgram(s)\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 250-\u003cbr\u003e\u003cbr\u003eTrade Name: Leukine\u003cbr\u003eProduct Name: Leukine\u003cbr\u003ePharmaceutical Form: Powder for solution for infusion\u003cbr\u003eINN or Proposed INN: SARGRAMOSTIM\u003cbr\u003eCAS Number: 123774-72-1\u003cbr\u003eConcentration unit: µg microgram(s)\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 250-\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Timepoint(s) of evaluation of this end point: day 5;Primary end point(s): To measure the effectiveness of sargramostim on restoring lung homeostasis, the primary endpoint of this intervention is measuring oxygenation after 5 DAYS of inhaled (and intravenous) treatment through assessment of pretreatment (day 0) and post-treatment (day 5) ratio of PaO2/FiO2 and through measurement of the P(A-a)O2 gradient, which can easily be performed in the setting of clinical observation of patients admitted to the COVID -19 ward or ICU COVID-19 unit. During the 5 day treatment period, we will perform daily measurements of oxygen saturation (pulse oximetry) in relation to FiO2, and the slope of alterations in this parameters could also be an indicator that our hypothesis is correct.;Secondary Objective: - to study if early intervention with sargramostim is safe (number of AEs/SAEs)\u003cbr\u003e- to study if early intervention with inhaled sargramostim affects clinical outcome defined by\u003cbr\u003eduration of hospital stay, 6-point ordinal scale, clinical sign score, SOFA score, NEWS2 score\u003cbr\u003e- to study if early intervention with sargramostim affects the rate of nosocomial infection\u003cbr\u003e- to study if early intervention with inhaled sargramostim affects progression to mechanical ventilation and/or ARDS\u003cbr\u003e- to study if treatment with sargramostim affects all-cause mortality rate at 4 and 20 weeks post inclusion\u003cbr\u003e-to study if treatment with sargramostim affects features of secondary haemophagocytic lymphohistiocytosis, defined by HS score\u003cbr\u003e- to study if treatment with sargramostim has a favourable effect on long term 10-20 week follow up\u003cbr\u003e;Main Objective: The primary objective is to investigate whether the administration of inhaled sargramostim (Leukine®) at a dose of 250 mcg daily during 5 days improves oxygenation in COVID-19 patients with acute hypoxic respiratory failure .",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: yes\u003cbr\u003erandomised: yes\u003cbr\u003eopen: yes\u003cbr\u003esingle blind: no\u003cbr\u003edouble blind: no\u003cbr\u003eparallel group: yes\u003cbr\u003ecross over: no\u003cbr\u003eother: no\u003cbr\u003eif controlled, specify comparator, other medicinial product: no\u003cbr\u003eplacebo: no\u003cbr\u003eother: yes\u003cbr\u003eother specify the comparator: standard of care\u003cbr\u003enumber of treatment arms in the trial: 2\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001254-22-BE",
			"start_date": "24/03/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "A prospective, randomized, open-label, interventional study to investigate the efficacy of sargramostim (Leukine®) in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure. - SARPAC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001254-22",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "soumelas@uni-pharma.gr",
			"corresp_author_email_certainty": "prefilled",
			"country": "Greece",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e• Under 18 years of age\r\u003cbr\u003e• Denial of written consent\r\u003cbr\u003e• Any patient case where it has been decided not to rejuvenate\r\u003cbr\u003e• Serum AST values greater than 5 times the upper normal range\r\u003cbr\u003e• QTc interval in rest electrocardiogram greater than 500msecs\r\u003cbr\u003e• Pregnancy or lactation. Urgent pregnancy test to exclude pregnancy before inclusion in the study\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e• Age 18 or older\r\u003cbr\u003e• Both genders\r\u003cbr\u003e• For women of childbearing age, they should use or be willing to use a double contraceptive method during the study. A urine pregnancy test to exclude pregnancy will be performed prior to study initiation.\r\u003cbr\u003e• Written consent after information provided by the patient or the legal representative in the event that the patient cannot consent.\r\u003cbr\u003e• Upper respiratory or lower respiratory tract infection, as in Annexes II and III respectively\r\u003cbr\u003e• Positive respiratory secretion test for SARS-CoV-2 virus by molecular techniques or positive blood IgM titers\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range 60\u003cbr\u003eF.1.3 Elderly (\u003e=65 years) yes\u003cbr\u003eF.1.3.1 Number of subjects for this age range 60\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eTrade Name: UNIKINON Tablets 200mg/tab\u003cbr\u003eProduct Name: UNIKINON Tablets 200mg/tab\u003cbr\u003ePharmaceutical Form: Tablet\u003cbr\u003eINN or Proposed INN: CHLOROQUINE PHOSPHATE\u003cbr\u003eOther descriptive name: CHLOROQUINE PHOSPHATE\u003cbr\u003eConcentration unit: mg milligram(s)\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 200-\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Timepoint(s) of evaluation of this end point: Days 1, 2-7, 8;Primary end point(s): • Recording of co-administered drugs, vital signs, absolute blood cell count (if any), biochemical markers (if any), microbiological tests and antibiotics (if any)\u003cbr\u003e• Pneumonia symptoms ratings for patients with lower respiratory infection (Appendix V)\u003cbr\u003e• Recording of adverse reactions (AEs) or serious adverse reactions (SAEs);Secondary Objective: • Comparison of the primary endpoint with respective patients not receiving the treatment\u003cbr\u003e• Serious respiratory failure until day 14. This will be compared with respective patients not receiving the treatment\u003cbr\u003e• Frequency of AEs and SAEs;Main Objective: Achieving one of two goals on day 8 visit from study initiation:\u003cbr\u003e• 50% reduction in symptom score for patients with lower respiratory tract infection\u003cbr\u003e• Lack of progression to lower respiratory tract infection in patients enrolled in the study due to upper respiratory tract infection\u003cbr\u003e\u003cbr\u003ePatients leaving the hospital alive before day 8 visit are considered to have reached the primary endpoint. Patients who die before the day 8 visit are considered to have failed at the primary endpoint.",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: no\u003cbr\u003erandomised: no\u003cbr\u003eopen: yes\u003cbr\u003esingle blind: no\u003cbr\u003edouble blind: no\u003cbr\u003eparallel group: no\u003cbr\u003ecross over: no\u003cbr\u003eother: yes\u003cbr\u003eother trial design description: prospective, multicenter, open, phase 2 study, one arm-non randomized\u003cbr\u003eif controlled, specify comparator, other medicinial product: no\u003cbr\u003eplacebo: no\u003cbr\u003eother: no\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001345-38-GR",
			"start_date": "02/04/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "CHROLOQUINE PHOSPHATE AGAINST INFECTION BY THE NOVEL CORONAVIRUS SARS-CoV-2 (COVID-19): THE HOPE OPEN-LABEL, NON-RANDOMIZED CLINICAL TRIAL - HOPE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001345-38",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "j.aman@amsterdamumc.nl",
			"corresp_author_email_certainty": "prefilled",
			"country": "Netherlands",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e- Pre-existing chronic pulmonary disease\u003cbr\u003e\t- Former diagnosis of Interstitial pulmonary disease\u003cbr\u003e\t- Former diagnosis of COPD 4 or FEV1\u003c30%pred\u003cbr\u003e\t- Previous DLCO \u003c45%\u003cbr\u003e\t- Total lung capacity (TLC) \u003c 60% of predicted\u003cbr\u003e\t- Lung cancer with non-surgical treatment in last year \u003cbr\u003e\t- Home oxygen treatment\u003cbr\u003e\t- Active treatment of hematological or non-hematological cancer with targeted, \timmuno- or chemotherapy in the last year \u003cbr\u003e\t- Chronic or acute renal failure, defined as eGFR \u003c30ml/min\u003cbr\u003e\t- Inability to provide informed consent\u003cbr\u003e\t- Any subject who had received any investigational medication within 1 \tmonth prior \tto the start of this study or who is scheduled to receive another investigational drug \tduring the course of this study\u003cbr\u003e\t- Active liver disease, porphyria or elevations of serums transaminases \u003e3 x \tULN \t(upper limit of normal) or bilirubin \u003e 1.5 x ULN\u003cbr\u003e\t- History or suspicion of inability to cooperate adequately.\u003cbr\u003e\t- White blood count \u003c 4.0^109/l\u003cbr\u003e\t- Hemoglobin \u003c 6.0 mmol/l\u003cbr\u003e\t- Thrombocytes \u003c 100^109/l\u003cbr\u003e\t- Pregnant female subjects\u003cbr\u003e\t- Breastfeeding female subjects\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e- Age \u003e18 years\u003cbr\u003e\t- Hospital admission with proven SARS2-Covid19 infection\u003cbr\u003e\t- Hypoxemic respiratory failure (SaO2 \u003c92%, PaO2 \u003c8kPa)\u003cbr\u003e\t- Ability to give informed consent.\u003cbr\u003e\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range 200\u003cbr\u003eF.1.3 Elderly (\u003e=65 years) yes\u003cbr\u003eF.1.3.1 Number of subjects for this age range 104\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eTrade Name: Imatinib mesilate \u003cbr\u003eProduct Name: Imatinib mesilate\u003cbr\u003eProduct Code: L01XE01\u003cbr\u003ePharmaceutical Form: Tablet\u003cbr\u003ePharmaceutical form of the placebo: Tablet\u003cbr\u003eRoute of administration of the placebo: Oral use\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Timepoint(s) of evaluation of this end point: 28 days;Primary end point(s): Composite outcome of death / need for invasive ventilation / need for ECMO ;Secondary Objective: The secondary objective is to evaluate the pharmacokinetics of a 10-day course of oral imatinib in patients with severe Covid19 pneumonitis.;Main Objective: To test whether treatment with oral imatinib reduce disease burden and consumption of medical resources.",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: yes\u003cbr\u003erandomised: yes\u003cbr\u003eopen: no\u003cbr\u003esingle blind: yes\u003cbr\u003edouble blind: no\u003cbr\u003eparallel group: no\u003cbr\u003ecross over: no\u003cbr\u003eother: no\u003cbr\u003eif controlled, specify comparator, other medicinial product: yes\u003cbr\u003eplacebo: yes\u003cbr\u003eother: no\u003cbr\u003enumber of treatment arms in the trial: 2\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001236-10-NL",
			"start_date": "31/03/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "COUNTER-COVID - Oral imatinib to prevent pulmonary vascular leak in COVID-19 – a randomized, single-blind, placebo controlled, clinical trial in patients with severe COVID-19 disease - CounterCovid Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001236-10",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "jan.erik.berdal@medisin.uio.no",
			"corresp_author_email_certainty": "prefilled",
			"country": "Norway",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e1.\tRequiring ICU admission at screening\r\u003cbr\u003e2.\tHistory of psoriasis\r\u003cbr\u003e3.\tTinnitus, reduced hearing\r\u003cbr\u003e4.\tVisual impairment\r\u003cbr\u003e5.\tKnown adverse reaction to hydroxychloroquine sulphate\r\u003cbr\u003e6.\tPregnancy\r\u003cbr\u003e7.\tProlonged QT interval (\u003e450 ms)\r\u003cbr\u003e\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e1.\tHospitalised\r\u003cbr\u003e2.\tAdults 18 year or older\r\u003cbr\u003e3.\tModerately severe disease (NEWS score = 6)\r\u003cbr\u003e4.\tSARS-CoV-2 positive nasopharyngeal swab \r\u003cbr\u003e5.\tSigned informed consent must be obtained and documented according to ICH GCP, and national/local regulations.\r\u003cbr\u003e\r\u003cbr\u003e\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range 40\u003cbr\u003eF.1.3 Elderly (\u003e=65 years) yes\u003cbr\u003eF.1.3.1 Number of subjects for this age range 160\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eTrade Name: Plaquenil\u003cbr\u003eProduct Name: Plaquenil\u003cbr\u003ePharmaceutical Form: Film-coated tablet\u003cbr\u003eINN or Proposed INN: hydroxychloroquine sulfate\u003cbr\u003eCAS Number: 747-36-4\u003cbr\u003eOther descriptive name: HYDROXYCHLOROQUINE SULFATE\u003cbr\u003eConcentration unit: mg milligram(s)\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 200-\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Timepoint(s) of evaluation of this end point: 96 hours.;Primary end point(s): Rate of decline in SARS-CoV-2 viral load in nasopharyngeal samples as assessed by RT-PCR  in samples collected at baseline, 48 and 96 hours after randomization;Secondary Objective: •\tAssess the impact of early treatment with chloroquine in patients with established COVID-19 on rate of decline in SARS-CoV-2 viral load in nasopharyngeal samples as assessed by RT-PCR from baseline to 96 hours\u003cbr\u003e•\tAssess the impact of early treatment with chloroquine in patients with established COVID-19 on changes in NEWS score\u003cbr\u003e•\tAssess the impact of early treatment with chloroquine in patients with established COVID-19 on admission rate to ICU\u003cbr\u003e•\tAssess the impact of early treatment with chloroquine in patients with established COVID-19 on in hospital mortality\u003cbr\u003e;Main Objective: To assess whether early treatment with chloroquine in patients with established COVID-19 will significantly reduce replication rate of SARS-CoV-2.",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: yes\u003cbr\u003erandomised: yes\u003cbr\u003eopen: yes\u003cbr\u003esingle blind: no\u003cbr\u003edouble blind: no\u003cbr\u003eparallel group: no\u003cbr\u003ecross over: no\u003cbr\u003eother: no\u003cbr\u003eif controlled, specify comparator, other medicinial product: no\u003cbr\u003eplacebo: no\u003cbr\u003eother: yes\u003cbr\u003eother specify the comparator: standard of care\u003cbr\u003enumber of treatment arms in the trial: 2\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001010-38-NO",
			"start_date": "23/03/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "NORWEGIAN CORONAVIRUS DISEASE 2019 (NO COVID-19) STUDY: AN OPEN LABELED RANDOMIZED CONTROLLED PRAGMATIC TRIAL TO EVALUATE THE ANTIVIRAL EFFECT OF CHLOROQUINE IN ADULT PATIENTS WITH SARS-COV-2 INFECTION - NO-COVID-19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001010-38",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "s.borregaard@ctc-north.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "Denmark",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e1. Patients whose clinical condition is deteriorating rapidly or any patient for whom the investigator does not consider there is a reasonable expectation that they will be able to complete the study.\r\u003cbr\u003e2. Known positive Hepatitis B surface antigen, Hepatitis C antibody or HIV antibody\r\u003cbr\u003e3. Current or chronic history of liver disease (Child Pugh score = 10), or known hepatic or biliary abnormalities (with the excep-tion of Gilbert's syndrome or asymptomatic gallstones).\r\u003cbr\u003e4. The patient has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).\r\u003cbr\u003e5. Patients requiring high doses of loop diuretics (i.e. \u003e 240 mg fu-rosemide daily) with significant intravascular volume depletion, as assessed clinically.\r\u003cbr\u003e6. History of sensitivity to any of the study medications, or compo-nents thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation.\r\u003cbr\u003e7. Pregnant females as determined by positive serum or urine hCG test prior to dosing.\r\u003cbr\u003e8. Lactating females.\r\u003cbr\u003e9. Unwillingness or inability to follow the procedures outlined in the protocol.\r\u003cbr\u003e10. History of sensitivity to heparin or heparin-induced thrombocy-topenia.\r\u003cbr\u003e11. Unstable Hemoglobin (Hb \u003c 7) at time of drug infusion (i.e. Hb must be \u003e 7 mg/dL at the time of drug infusion. Transfusion is permitted to increase Hb levels to allow entry into the study.\r\u003cbr\u003e12. Malignancy or other irreversible condition for which 6 month mortality is estimated to be \u003e50%.\r\u003cbr\u003e13. Arterial blood pH less than 7.2 or serum HCO3- \u003c15 (if ABG not available) before infusion is started.\r\u003cbr\u003e14. Known severe chronic pulmonary disease:\r\u003cbr\u003e      - known FEV1/FVC less than 45% predicted, or\r\u003cbr\u003e      - known chronic hypercapnia (PaCO2 \u003e 45 mmHg) or chronic hypoxemia [(PaO2\u003c55 mmHg) on FiO2 =0.21, or supplemental oxygen therapy prior to this admission], or\r\u003cbr\u003e      - known FEV1 \u003c15 ml/kg (e.g. 1L for 70 kg person), or\r\u003cbr\u003e      - known radiographic evidence of chronic interstitial infil-tration, or\r\u003cbr\u003e      - known hospitalization within the past six months for respiratory failure (PaCO2 \u003e 50 mmHg or PaO2 \u003c 55 mmHg, or oxygen saturation \u003c88% on FiO2 = 0.21)\r\u003cbr\u003e      - known chronic restrictive, obstructive, neuromuscular, chest wall, or pulmonary vascular disease resulting in severe exercise restriction (i.e. unable to climb stairs or perform household duties), known secondary polycythemia,  \r\u003cbr\u003e        severe pulmonary hypertension, or ventilator dependency\r\u003cbr\u003e15. Known vasculitis with diffuse alveolar hemorrhage\r\u003cbr\u003e16. Lung transplantation\r\u003cbr\u003e17. Pre-existing renal failure, i.e. requiring renal replacement ther-apy with hemodialysis or peritoneal dialysis\r\u003cbr\u003e18. There are other uncontrolled co-morbidities that increase the risks associated with the study drug administration, that are as-sessed by the medical expert team as unsuitable\r\u003cbr\u003e19. Patient in trials for COVID-19 within 30 days before ICF\r\u003cbr\u003e20. Unstable hemodynamics in the preceding 4 hours (MAP = 65 mmHg, or SAP \u003c 90 mmHg, DAP \u003c 60 mmHg, and vaso-active agents required)\r\u003cbr\u003e21. Immunocompromised patients (chemotherapy, HIV, organ transplants, stem cell transplants),\r\u003cbr\u003e22. Receive any Angiotensin-Converting-Enzyme inhibitor (ACEi) or renin inhibitor treatment within 7 days before ICF\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e1. Hospitalized male or female, = 35 to = 80 years of age\r\u003cbr\u003e2. Diagnosed to be COVID-19 POSITIVE(SARS-CoV-2 nucleic acid – qPCR)\r\u003cbr\u003e3. Oxygenation criterion:\r\u003cbr\u003e    Oxygen saturation =93% (either on Room Air or while the patient is on supplement oxygen)\r\u003cbr\u003e4. Respiratory frequency, RR = 25 breaths/min\r\u003cbr\u003e5. ALT \u003c 5xULN; bilirubin = 1.5xULN\r\u003cbr\u003e6. Presence of at least 1 relevant co-morbid condition (defined as arterial hypertension, diabetes, or coronary artery disease) if age \u003c65 years\r\u003cbr\u003e7. Signed Inform Consent Form\r\u003cbr\u003e8. Body weight = 85kg\r\u003cbr\u003e\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range 80\u003cbr\u003eF.1.3 Elderly (\u003e=65 years) yes\u003cbr\u003eF.1.3.1 Number of subjects for this age range 120\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eProduct Name: Recombinant human angiotensin-converting enzyme 2\u003cbr\u003eProduct Code: APN01\u003cbr\u003ePharmaceutical Form: Solution for infusion\u003cbr\u003eINN or Proposed INN: APN01 / GSK2586881\u003cbr\u003eOther descriptive name: GSK2586881\u003cbr\u003eConcentration unit: mg/ml milligram(s)/millilitre\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 5-\u003cbr\u003ePharmaceutical form of the placebo: Solution for infusion\u003cbr\u003eRoute of administration of the placebo: Intravenous use\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Timepoint(s) of evaluation of this end point: Continioulsy over the duration of the trial;Primary end point(s): The primary endpoint is a composite endpoint of all cause-death or invasive mechanical ventilation up to 28 days or hospital discharge.;Secondary Objective: To assess efficacy of APN01 using log transformed levels of Lactate dehydrogenase (LDH) as a surrogate marker for organ damage.\u003cbr\u003eTo evaluate the safety of APN01 in patients with severe COVID-19\u003cbr\u003eTo monitor other biomarker changes (e.g. IL-6, AngII) in patient with severe COVID-19 treated with APN01\u003cbr\u003e\u003cbr\u003e;Main Objective: To assess clinical efficacy of APN01 using a composite outcome of all cause-death or need of invasive mechanical ventilation up to 28 days",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: yes\u003cbr\u003erandomised: yes\u003cbr\u003eopen: no\u003cbr\u003esingle blind: no\u003cbr\u003edouble blind: yes\u003cbr\u003eparallel group: no\u003cbr\u003ecross over: no\u003cbr\u003eother: no\u003cbr\u003eif controlled, specify comparator, other medicinial product: no\u003cbr\u003eplacebo: yes\u003cbr\u003eother: no\u003cbr\u003enumber of treatment arms in the trial: 2\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001172-15-DK",
			"start_date": "03/04/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-19 - APN01-01-COVID19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001172-15",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "global.rochegenentechtrials@roche.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "Italy",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range \u003cbr\u003eF.1.3 Elderly (\u003e=65 years) yes\u003cbr\u003eF.1.3.1 Number of subjects for this age range \u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eTrade Name: RoActemra 20 mg/mL concentrato per soluzione per infusione – flacone 20 ml (400 mg)\u003cbr\u003eProduct Name: RoActemra 20 mg/mL concentrato per soluzione per infusione – flacone 20 ml (400 mg)\u003cbr\u003ePharmaceutical Form: Concentrate for solution for infusion\u003cbr\u003eINN or Proposed INN: TOCILIZUMAB\u003cbr\u003eCAS Number: 375823-41-9\u003cbr\u003eOther descriptive name: TOCILIZUMAB\u003cbr\u003eConcentration unit: mg/ml milligram(s)/millilitre\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 20-\u003cbr\u003e\u003cbr\u003eTrade Name: RoActemra 20 mg/mL concentrato per soluzione per infusione – flacone 10 ml (200 mg)\u003cbr\u003eProduct Name: RoActemra 20 mg/mL concentrato per soluzione per infusione – flacone 10 ml (200 mg)\u003cbr\u003ePharmaceutical Form: Concentrate for solution for infusion\u003cbr\u003eINN or Proposed INN: TOCILIZUMAB\u003cbr\u003eCAS Number: 375823-41-9\u003cbr\u003eOther descriptive name: TOCILIZUMAB\u003cbr\u003eConcentration unit: mg/ml milligram(s)/millilitre\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 20-\u003cbr\u003e\u003cbr\u003eTrade Name: RoActemra 20 mg/mL concentrato per soluzione per infusione – flacone 4 ml (80 mg)\u003cbr\u003eProduct Name: RoActemra 20 mg/mL concentrato per soluzione per infusione – flacone 4 ml (80 mg)\u003cbr\u003ePharmaceutical Form: Concentrate for solution for infusion\u003cbr\u003eINN or Proposed INN: TOCILIZUMAB\u003cbr\u003eCAS Number: 375823-41-9\u003cbr\u003eOther descriptive name: TOCILIZUMAB\u003cbr\u003eConcentration unit: mg/ml milligram(s)/millilitre\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 20-\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Primary end point(s): ;Secondary Objective: ;Main Objective: ",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: yes\u003cbr\u003erandomised: yes\u003cbr\u003eopen: yes\u003cbr\u003esingle blind: no\u003cbr\u003edouble blind: no\u003cbr\u003eparallel group: no\u003cbr\u003ecross over: no\u003cbr\u003eother: no\u003cbr\u003eif controlled, specify comparator, other medicinial product: no\u003cbr\u003eplacebo: no\u003cbr\u003eother: no\u003cbr\u003enumber of treatment arms in the trial: 2\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001386-37-IT",
			"start_date": "27/03/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "Uno studio randomizzato multicentrico in aperto per valutare l’efficacia della somministrazione precoce del Tocilizumab (TCZ) in pazienti affetti da polmonite da COVID-19. - TOCI-RE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001386-37",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "DRCI-Promotion-Interne@chu-angers.fr",
			"corresp_author_email_certainty": "prefilled",
			"country": "France",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e- RT-PCR SARS-Cov2 négative\r\u003cbr\u003e- Saturation capillaire périphérique en oxygéne inférieure ou égale à 94% (SpO2 =94%) malgré une oxygénothérapie supérieure ou égale à 3L/min (= 3L/min)\r\u003cbr\u003e- Défaillance d’organe nécessitant une admission en réanimation ou unité de soins-continus\r\u003cbr\u003e- Comorbidité engageant le pronostic vital à court terme (espérance de vie \u003c 3 mois)\r\u003cbr\u003e- Toute raison rendant le suivi à J28 impossible\r\u003cbr\u003e- Traitement en cours par hydroxychloroquine\r\u003cbr\u003e- Contre-indication absolue au traitement par hydroxychloroquine (hypersensibilité connue, traitement concomitant à risque de torsades de pointe)\r\u003cbr\u003e- ECG chez les patients à risque mettant en évidence un allongement du QT corrigé supérieure à 440 ms chez l’homme et 460 ms chez la femme.\r\u003cbr\u003e- Femme enceinte, allaitante ou parturiente \r\u003cbr\u003e- Personne privée de liberté par décision judiciaire ou administrative \r\u003cbr\u003e- Personne faisant l’objet de soins psychiatriques sous la contrainte\r\u003cbr\u003e- Personne faisant l’objet d’une mesure de protection légale\r\u003cbr\u003e\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e- Patient majeur\r\u003cbr\u003e- Infection COVID-19 confirmée par RT-PCR SARS-Cov2 ou, à défaut, par scanner thoracique en faveur d’une pneumopathie virale à prédominance périphérique dans un contexte évocateur\r\u003cbr\u003e- Diagnostic porté depuis moins de 48h\r\u003cbr\u003e- Présence d’au moins un des deux facteurs de risque d’évolution compliquée suivant :\r\u003cbr\u003e\t- âge = 75 ans \r\u003cbr\u003e\t- oxygénodépendance avec saturation capillaire périphérique en oxygène (SpO2) = 94% en air ambiant ou un ratio pression partielle en oxygène (PaO2) sur fraction en oxygène dans l’air inspiré (FiO2) = 300 mmHg.\r\u003cbr\u003e- Patient affilié ou bénéficiaire d’un régime de sécurité sociale \r\u003cbr\u003e- Consentement écrit signé du patient ou d’un proche ou, en cas d’impossibilité,  procédure d’inclusion en urgence\r\u003cbr\u003e\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range 750\u003cbr\u003eF.1.3 Elderly (\u003e=65 years) yes\u003cbr\u003eF.1.3.1 Number of subjects for this age range 750\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eTrade Name: Plaquenil®\u003cbr\u003ePharmaceutical Form: Tablet\u003cbr\u003ePharmaceutical form of the placebo: Tablet\u003cbr\u003eRoute of administration of the placebo: Oral use\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Timepoint(s) of evaluation of this end point: Le critère de jugement principal est le décès quelle qu’en soit la cause ou le recours à une intubation et ventilation invasive dans les 14 jours (J14) suivant l’inclusion et le début du traitement (J0).;Primary end point(s): Le critère de jugement principal est le décès quelle qu’en soit la cause ou le recours à une intubation et ventilation invasive dans les 14 jours (J14) suivant l’inclusion et le début du traitement (J0).;Secondary Objective: Les objectifs secondaires sont :\u003cbr\u003e\u003cbr\u003e1) Évaluer l’efficacité de l’hydroxychloroquine versus placebo chez les patients COVID-19 sur : \u003cbr\u003ea- l’évolution clinique via l’échelle OSCI (Ordinal Scale for Clinical Improvement) pour COVID-19 de l’OMS\u003cbr\u003eb- la mortalité toute cause \u003cbr\u003ec- le portage viral \u003cbr\u003ed- l’incidence des accidents thrombo-emboliques veineux \u003cbr\u003e\u003cbr\u003e2) Évaluer l’efficacité de l’hydroxychloroquine versus placebo dans le sous-groupe des personnes âgées de 75 ans ou plus sur :\u003cbr\u003ea- l’évolution clinique via l’échelle OSCI pour COVID-19 de l’OMS \u003cbr\u003eb- la mortalité toute cause\u003cbr\u003e\u003cbr\u003e3) Évaluer la tolérance de l’hydroxychloroquine versus placebo sur la survenue d’évènements indésirables graves\u003cbr\u003e\u003cbr\u003eObjectifs ancillaires \u003cbr\u003eÉvaluer, dans un sous-groupe de patients COVID-19, l’impact de l’hydroxychloroquine versus placebo sur l’évolution des cytokines et des marqueurs biologiques de l’immunité, de l’inflammation et de l’hémostase\u003cbr\u003e;Main Objective: L’objectif principal est d’évaluer l’efficacité de l’hydroxychloroquine versus placebo sur le taux de décès ou de recours à une ventilation invasive chez les patients ayant une infection COVID-19 à haut risque d’aggravation.",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: yes\u003cbr\u003erandomised: yes\u003cbr\u003eopen: no\u003cbr\u003esingle blind: no\u003cbr\u003edouble blind: yes\u003cbr\u003eparallel group: yes\u003cbr\u003ecross over: no\u003cbr\u003eother: no\u003cbr\u003eif controlled, specify comparator, other medicinial product: no\u003cbr\u003eplacebo: yes\u003cbr\u003eother: no\u003cbr\u003enumber of treatment arms in the trial: 2\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001271-33-FR",
			"start_date": "31/03/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "HYCOVID - Hydroxychloroquine versus placebo chez les patients ayant une infection COVID-19 à risque d’aggravation secondaire : étude prospective multicentrique randomisée en double aveugle - HYCOVID                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001271-33",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "carine.labruyere@chu-st-etienne.fr",
			"corresp_author_email_certainty": "prefilled",
			"country": "France",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e- Hypersensitivity to the active substances or to any of the following excipients: lactose monohydrate, povidone, corn starch, magnesium stearate.\u003cbr\u003e- Retinopathies\u003cbr\u003e- Combination with citalopram, escitalopram, hydroxyzine, domperidone and piperazine due to increased risk of ventricular rhythm disturbances, including torsades de pointes. \u003cbr\u003e- Patient with known QT prolongation\u003cbr\u003e- Known deficit in G6PD\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e- Patients hospitalized in the intensive care unit infected with SARS-CoV-2, for whom a diagnosis of respiratory SARS-CoV-2 infection was made by nasopharyngeal swab or deep respiratory sampling.\u003cbr\u003e- Patient receiving Hydroxychloroquine treatment \u003cbr\u003e\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range 50\u003cbr\u003eF.1.3 Elderly (\u003e=65 years) yes\u003cbr\u003eF.1.3.1 Number of subjects for this age range 50\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eTrade Name: Plaquenil\u003cbr\u003eProduct Name: Sulfate d'hydroxychloroquine\u003cbr\u003ePharmaceutical Form: Coated tablet\u003cbr\u003eCAS Number: 747-36-4\u003cbr\u003eOther descriptive name: HYDROXYCHLOROQUINE SULFATE\u003cbr\u003eConcentration unit: mg milligram(s)\u003cbr\u003eConcentration type: range\u003cbr\u003eConcentration number: 400-800\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Timepoint(s) of evaluation of this end point: daily for 10 days;Primary end point(s): determination of the blood concentration of hydroxychloroquine by liquid chromatography coupled with mass spectrometry.;Secondary Objective:  - Describe the relationship between HCQ concentration and cardiac toxicity.\u003cbr\u003e- To describe the pharmacokinetic (concentration) and pharmacodynamic (viral load) relationship of hydroxychloroquine in resuscitation patients infected with SARS-CoV-2.\u003cbr\u003e- To define the best modalities of administration of hydroxychloroquine in resuscitation patients infected with SARS-CoV-2  based on the PK/PD relationship.;Main Objective: to describe the pharmacokinetics of hydroxychloroquine in resuscitation patients infected with SARS-CoV-2.",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: no\u003cbr\u003erandomised: \u003cbr\u003eopen: \u003cbr\u003esingle blind: \u003cbr\u003edouble blind: \u003cbr\u003eparallel group: \u003cbr\u003ecross over: \u003cbr\u003eother: \u003cbr\u003eif controlled, specify comparator, other medicinial product: \u003cbr\u003eplacebo: \u003cbr\u003eother: \u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001281-11-FR",
			"start_date": "30/03/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "Evaluation of the concentration/viral effect relationship of hydroxychloroquine in COVID-19 patients in the intensive care unit.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001281-11",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"country": "Australia;Hong Kong;Taiwan, Province Of China;Indonesia;Korea, Republic Of;Japan;Italy;Singapore;Viet Nam;Thailand;United Kingdom;United States of America",
			"country_certainty": "generated",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1.\tPatients treated with mechanical ventilation for other concomitant causes.\r\u003cbr\u003e2.\tPatients treated with ECMO for other concomitant causes\r\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1.\tLaboratory-confirmed 2019-nCoV infection by real-time RT-PCR and/or next-generation sequencing\r\u003cbr\u003e2.\tAdmission to an intensive care unit\r\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "In patients in patients with 2019-nCoV who require admission to the intensive care unit mechanical ventilation and extracorporeal membrane oxygenation (ECMO). It is expected that this study will not require individual patient consent. This study is in effect a large-scale clinical audit during a global health emergency, as all data is already recorded as part of routine clinical care, therefore justifying participant enrolment using a waiver of consent. Retrospective data will be sourced from all collaborating hospitals across Australia from January 2020 to March 2020. Whereas, international hospitals will provide their retrospective data between January 2019 and march 2020. Prospective data will be collected in Australian and International hospitals until completion of COVID-19 global epidemic, as judged by the World Health Organization. The total duration of observation per participant will be until hospital discharge or 28 days post intensive care unit admission, whichever comes first. The study will combine prospective observation, and retrospective observations sourced from clinical charts. \u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Mortality\u003cbr\u003e[At hospital discharge or 28 days post intensive care unit admission, whichever comes later. ]",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "purpose: natural history;duration: longitudinal;selection: defined population;timing: both;",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ACTRN12620000421932",
			"start_date": "05/03/2020",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "ExtraCorporeal Membrane Oxygenation for 2019 novel Coronavirus Acute Respiratory Disease (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ",
			"title_certainty": "prefilled",
			"url": "https://anzctr.org.au/ACTRN12620000421932.aspx",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"country": "Australia",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: Participants fulfilling any of the following criteria are not eligible for inclusion in this study:\r\u003cbr\u003e1. History of allergy or intolerance to chloroquine, vitamin C or any excipients.\r\u003cbr\u003e2. Contraindication to taking chloroquine as chemoprophylaxis e.g. known epileptic, creatinine clearance \u003c 10 mL/min, known prolonged QT syndrome, diabetes.\r\u003cbr\u003e3. Those having previously received hydroxychloroquine for skin conditions or rheumatological diseases, chloroquine for malaria, tamoxifen, amiodarone or other drugs that may affect the retina within 30 days or 5 half-lives (whichever is longer) of study start.\r\u003cbr\u003e4. Taking a concomitant medication (abiraterone acetate, agalsidase, amodiaquine, conivaptan, dabrafenib, dacomitinib, dapsone (systemic), enzalutamide, fusidic acid (systemic), idealisib, lanthanum, lumefantrine, mefloquine, MiFEPRIStone, Mitotane, Pimozide, QT-prolonging agents, or stiripentol) which cannot be safely stopped.\r\u003cbr\u003e5. Participants who, in the opinion of the Investigator, do not have the ability to complete the study.\r\u003cbr\u003eFor other eligibility criteria considerations, the Investigator is referred to the IB (ADFMIDI IB) for detailed information regarding warnings, precautions, contraindications, AEs, and other significant data pertaining to the use of chloroquine.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: Participants eligible for inclusion in this study must fulfill all of the following criteria:\r\u003cbr\u003e1.\tCompletion of the written informed consent process (signed) with video recording of the verbal consent process;\r\u003cbr\u003e2.\tMale or female age 18 to 64 years inclusive, in general good health equivalent to Army Medical Employment Classification J22 or above. Civilian personnel would need to be in good general health as advised by their General Practitioner (GP);\r\u003cbr\u003e3.\tNot previously diagnosed with COVID-19;\r\u003cbr\u003e4.\tParticipant works in/in association with a healthcare facility or other high-risk environment characterised by high level of contact with persons thought likely to be infected with respiratory viruses;\r\u003cbr\u003e5.\tPossess an internet enabled smart phone capable of receiving and responding to alerts;\r\u003cbr\u003e6.\tWilling and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures;\r\u003cbr\u003e7.\tAgrees not to self-medicate with chloroquine, hydroxychloroquine or other potential antivirals; and\r\u003cbr\u003e8.\tAgree to stay in contact with the study site for the duration of the study and up to 2 weeks following the EOS visit (unless deployed), provide updated contact information as necessary.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Oral 500mg chloroquine phosphate tablets prophylactic weekly regimen against COVID-19 over 10 week trial period followed with plasma chloroquine levels.",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Number of sick days (SDS) during the study period: The number of sick days will be obtained from participants medical records as defined as the number of days deemed 'not fit for duty/work' by their reviewing medical professional, and will be compared between participants randomised to chloroquine and vitamin C.[12 weeks post-commencement of the IMP. Study to commence Apr 2020.]",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "purpose: prevention; allocation: randomised controlled trial; masking: open (masking not used);assignment: parallel;type of endpoint: efficacy;",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ACTRN12620000417987",
			"start_date": "30/03/2020",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Multi-Site, Randomized, Open-Label, Parallel-Group, Placebo-Controlled Study to Assess the Chemoprophylactic Efficacy of Chloroquine Against SARS-CoV-2/COVID-19 in Healthcare Workers at High-Risk of Exposure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ",
			"title_certainty": "prefilled",
			"url": "https://anzctr.org.au/ACTRN12620000417987.aspx",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "contact@vipstudy.org",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Christian Jung, MD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Denmark;France;Germany;Norway;Denmark;France;Germany;Norway",
			"country_certainty": "generated",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          1. Age \u003e 70 years\r\u003cbr\u003e\r\u003cbr\u003e          2. ICU-Admission\r\u003cbr\u003e\r\u003cbr\u003e          3. Infection or suspected infection with SARS-CoV-2\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        1. Age \u003c70 years\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "Survival",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04321265",
			"start_date": "2020-03-19",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Outcomes and Prognostic Factors in Coronavirus Disease (COVID-19) in Very Old Intensive Care Patients",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04321265",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "lars.erik.kristensen@regionh.dk",
			"corresp_author_email_certainty": "prefilled",
			"country": "Denmark",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003eAge \u003c18 years, pregnancy suspected or confirmed, severe heart failure, suspected or confirmed bacterial infection, current solid or haematological malignancy, neutropenia, ALAT elevation more than three times the laboratory upper limit, ASA class 5 (after COVID19 admission) or higher at inclusion (prior admission), severe chronic obstructive pulmonary disease or heart failure (NYHA class II or higher), current treatment with conventional synthetic disease-modifying antirheumatic drugs (DMARDs)/immunosuppressive agents including IL-6 inhibitors, or with Janus kinase inhibitors (JAKi) in the past 30 days or plans to receive during the study period, current use of chronic oral corticosteroids in a dose higher than prednisone 10 mg or equivalent per day, previous or active tuberculosis (TB), HIV infection regardless of immunological status, hepatitis, evidence of recent (30 days) invasive bacterial or fungal infections, patients who have received immunosuppressive antibody therapy within the past 5 months, including intravenous immunoglobulin or plans to receive during the study period, IV drug abuse, history of inflammatory bowel disease, diverticulitis, ulcer, perforated gastrointestinal tract, participation in any clinical research study evaluating an investigational product (IP) or therapy within 3 months and less than five half-lives of IP prior inclusion to the study, any physical examination findings and/or history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the patient by their participation in the study, inability to give informed consent.\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e- SARS-CoV-2 infection confirmed by real time-PCR \u003cbr\u003e- Positive imaging: consolidation, ground glass opacities, or bilateral pulmonary infiltration either by CT-scan or chest x-ray;   \u003cbr\u003e- Need of oxygen therapy to maintain SO2\u003e94% OR FiO2/PaO2 \u003c 22 \u003cbr\u003e- and at least two of the following laboratory parameters:\u003cbr\u003e   * CRP level \u003e70 mg/L or CRP level \u003e= 40 mg/L and doubled within 48 hours (without other confirmed infectious or non-infectious course), \u003cbr\u003e   * Lactatdehydrogenase \u003e 250 U/L, \u003cbr\u003e   * thrombocytopenia \u003c 120 x 10E9/L, \u003cbr\u003e   * lymphocyte count \u003c 0.6 x 10E9/L, \u003cbr\u003e   * D-dimer \u003e 1 ug/mL, \u003cbr\u003e   * serum ferritin \u003e 300 ug/mL  \u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range 100\u003cbr\u003eF.1.3 Elderly (\u003e=65 years) yes\u003cbr\u003eF.1.3.1 Number of subjects for this age range 100\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eTrade Name: RoActemra\u003cbr\u003eProduct Name: Tocilizumab\u003cbr\u003ePharmaceutical Form: Infusion\u003cbr\u003eINN or Proposed INN: Tocilizumab\u003cbr\u003eCAS Number: 375823-41-9\u003cbr\u003eConcentration unit: mg milligram(s)\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 400-\u003cbr\u003e\u003cbr\u003eTrade Name: Roactemra\u003cbr\u003eProduct Name: Tocilizumab\u003cbr\u003ePharmaceutical Form: Solution for injection in pre-filled pen\u003cbr\u003eINN or Proposed INN: Tocilizumab\u003cbr\u003eCAS Number: 375823-41-9\u003cbr\u003eConcentration unit: mg milligram(s)\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 162-\u003cbr\u003e\u003cbr\u003eTrade Name: Kevzara\u003cbr\u003eProduct Name: Sarilumab\u003cbr\u003ePharmaceutical Form: Solution for injection in pre-filled pen\u003cbr\u003eINN or Proposed INN: SARILUMAB\u003cbr\u003eOther descriptive name: Kevzara\u003cbr\u003eConcentration unit: mg milligram(s)\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 200-\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Timepoint(s) of evaluation of this end point: Up to 28 days;Primary end point(s): Time to independence from supplementary oxygen therapy in days ;Secondary Objective: Not applicable;Main Objective: To investigate  the effect of different types of IL-6 inhibition versus no adjuvant treatment compared to standard of care in patients with severe SARS-CoV-2 pneumonia. ",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: yes\u003cbr\u003erandomised: yes\u003cbr\u003eopen: yes\u003cbr\u003esingle blind: no\u003cbr\u003edouble blind: no\u003cbr\u003eparallel group: no\u003cbr\u003ecross over: no\u003cbr\u003eother: no\u003cbr\u003eif controlled, specify comparator, other medicinial product: no\u003cbr\u003eplacebo: no\u003cbr\u003eother: yes\u003cbr\u003eother specify the comparator: usual care\u003cbr\u003enumber of treatment arms in the trial: 4\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001275-32-DK",
			"start_date": "03/04/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "Effectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients with Severe SARS-CoV-2 Pneumonia: An Open-Label Multicenter Sequential Randomized Controlled Trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001275-32",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";philippe.vanhems@chu-lyon.fr",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Philippe VANHEMS, MD, PhD;Philippe VANHEMS, MD, PhD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "France",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        1 ) Any adult or child or member of the nursing staff from the study participant hospital\r\u003cbr\u003e        who presents an infectious syndrome including the following definition :\r\u003cbr\u003e\r\u003cbr\u003e        2) Suspect Case:\r\u003cbr\u003e\r\u003cbr\u003e        Fever above 37.8 ° C if no antipyretics are taken; And or Cough or pharyngeal pain or other\r\u003cbr\u003e        symptom suggestive of respiratory infection. AND at least 1 of the following\r\u003cbr\u003e        characteristics:\r\u003cbr\u003e\r\u003cbr\u003e          -  return from a trip to China, or to a country in which the increase in the incidence of\r\u003cbr\u003e             infections in SARS-CoV-2 has been proven;\r\u003cbr\u003e\r\u003cbr\u003e          -  close contact (sharing the same place of family, professional life, same plane, etc.)\r\u003cbr\u003e             with a person defined as a suspected or confirmed case;\r\u003cbr\u003e\r\u003cbr\u003e          -  Occurring in an establishment having received at least one case of suspected or\r\u003cbr\u003e             confirmed infection at SARS-CoV-2.\r\u003cbr\u003e\r\u003cbr\u003e        Or 3) Confirmed Case: The same clinical definitions, in addition to a positive RT-PCR-type\r\u003cbr\u003e        virological diagnostic result specific to SARS-CoV-2\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Anyone who does not meet the above definition.\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: nosocomial infection/hospital acquired infection",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "nosocomial infection",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04290780",
			"start_date": "2020-03-09",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Multicenter Study on Nosocomial Transmission of SARS-CoV-2 Virus",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04290780",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  COVID-19 pneumonia patients diagnosed by WHO criteria\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients who were younger than 18 years.\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients whose entire stay lasted for less than 48 hours.\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "Rate of Death",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04318301",
			"start_date": "2020-03-21",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Hypertension in Patients Hospitalized With COVID-19 in Wuhan, China: A Single-center Retrospective Observational Study",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04318301",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";neurocovid19study@ictalgroup.org;neurocovid19study@ictalgroup.org",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Stephane LEGRIEL, MD, PhD;Stephane LEGRIEL, MD, PhD;Stephane LEGRIEL, MD, PhD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "France",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Critical/Intensive care or Neurocritical care admission\r\u003cbr\u003e\r\u003cbr\u003e          -  Admission for/with acute encephalopathy defined as a rapidly developing (over less\r\u003cbr\u003e             than 4 weeks, but usually within hours to a few days) pathobiological process in the\r\u003cbr\u003e             brain; including delirium or subsyndromal (DSM V definition) or coma (Glasgow coma\r\u003cbr\u003e             scale score \u003c 9)\r\u003cbr\u003e\r\u003cbr\u003e          -  SARS-COV-2 infection (respiratory or other PCR specimen)\r\u003cbr\u003e\r\u003cbr\u003e          -  Age = 18 years\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        - Opposition to study participation from the patient itself or patient surrogate\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: Follow up",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "prevalence",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04320472",
			"start_date": "2020-03-23",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Outcomes in Patients With Acute Encephalopathy and SARS-Cov-2 Infection",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04320472",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";mark.sendak@duke.edu",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Becky Smith, MD;Mark Sendak, MD, MPP",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "United States",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  flu-like symptoms\r\u003cbr\u003e\r\u003cbr\u003e          -  a viral test order for COVID-19\r\u003cbr\u003e\r\u003cbr\u003e          -  confirmed COVID-19\r\u003cbr\u003e\r\u003cbr\u003e          -  concern for exposure to COVID-19\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        - None\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "Number of participants who experience inpatient admission",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04320862",
			"start_date": "2020-04-03",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Pandemic Response Network: Duke Community Health Watch",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04320862",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";stephen.freedman@ahs.ca;stephen.freedman@ahs.ca",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Stephen Freedman, MD;Stephen Freedman, MDCM, MSc;Stephen Freedman, MDCM, MSc",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Canada",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          1. \u003c 18 years-old, and\r\u003cbr\u003e\r\u003cbr\u003e          2. Present to a participating ED for care, and\r\u003cbr\u003e\r\u003cbr\u003e          3. Undergo SARS-CoV-2 testing.\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        1) Refusal to participate (no informed consent)\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: Exposure (not intervention) - SARS-CoV-2 infection",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Clinical characteristics of children with SARS-CoV-2;Factors associated with severe COVID-19 outcomes",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04330261",
			"start_date": "2020-03-18",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Clinical Characteristics and Outcomes of Children Potentially Infected by Severe Acute Respiratory Distress Syndrome (SARS)-CoV-2 Presenting to Pediatric Emergency Departments",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04330261",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_lastname": "Ethan Berke, MD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "United States",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Able to consent and agree to participate in the project after discussing the project\r\u003cbr\u003e\r\u003cbr\u003e          -  Coming to The Everett Clinic during the operational project duration\r\u003cbr\u003e\r\u003cbr\u003e          -  Evidence of upper respiratory symptoms suggesting higher risk of testing positive for\r\u003cbr\u003e             SARS-CoV-2 virus.\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Not able to demonstrate understanding of the study\r\u003cbr\u003e\r\u003cbr\u003e          -  Not willing to commit to having all four samples collected\r\u003cbr\u003e\r\u003cbr\u003e          -  Medical history evidencing any of the following\r\u003cbr\u003e\r\u003cbr\u003e               -  Active nosebleed in the past 24 hours\r\u003cbr\u003e\r\u003cbr\u003e               -  Nasal surgery in the past two weeks\r\u003cbr\u003e\r\u003cbr\u003e               -  Chemotherapy treatment with low platelet and low white blood cell counts\r\u003cbr\u003e\r\u003cbr\u003e               -  Acute facial trauma\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Diagnostic Test: Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Accuracy of patient administered tests",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04321369",
			"start_date": "2020-03-09",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Impact of Swab Site and Sample Collector on Testing Sensitivity for COVID-19 Virus in Symptomatic Individuals",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04321369",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";g.gritti@asst-pg23.it;arambaldi@asst-pg23.it",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Giuseppe GRITTI, MD;GIUSEPPE GRITTI, MD;Alessandro Rambaldi, MD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Italy",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          1. Clinical and radiological diagnosis of pulmonary infection by COVID-19\r\u003cbr\u003e\r\u003cbr\u003e          2. Positive microbiological evidence of SARS-CoV-2 infection\r\u003cbr\u003e\r\u003cbr\u003e          3. Diagnosis of acute respiratory distress syndrome clinical panel in accordance with\r\u003cbr\u003e             Berlin 2012 criteria\r\u003cbr\u003e\r\u003cbr\u003e          4. For Cohort A only: subjects are eligible if they are enrolled and treated within 48\r\u003cbr\u003e             hours from the beginning of NIV (non invasive ventilation) or CPAP(continous positive\r\u003cbr\u003e             airway pressure)\r\u003cbr\u003e\r\u003cbr\u003e          5. For Cohort B only: subjects are eligible if they are enrolled and treated within 48\r\u003cbr\u003e             hours from the beginning of invasive ventilation\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        1. Active infection of bacterial or viral (non COVID-19) origin\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "Cohort A: reduction of the need of invasive ventilation or 30-day mortality;Cohort B: reduction of mortality",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04322188",
			"start_date": "2020-03-19",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "An Observational Case-control Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04322188",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_lastname": "Rahul Kashya, MBBS",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "United States",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  COVID-19 PCR positive (within 7 days)\r\u003cbr\u003e\r\u003cbr\u003e          -  COVID-19 PCR pending\r\u003cbr\u003e\r\u003cbr\u003e          -  COVID-19 high clinical suspicion\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patient without Prior Research Authorization (applicable to Mayo Clinic sites)\r\u003cbr\u003e\r\u003cbr\u003e          -  Non COVID-19 related admissions\r\u003cbr\u003e\r\u003cbr\u003e          -  Repeated Admission to ICUs/Hospital\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: observational",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "ICU and hospital mortality of COVID-19 patients",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04323787",
			"start_date": "2020-03-30",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry and Validation of C2D2 (Critical Care Data Dictionary)",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04323787",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";;antonia.bendau@charite.de;corona-angst@charite.de",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Andreas Ströhle, Prof.Dr.;Antonia Bendau, M.Sc.Psych.;Antonia Bendau, M.Sc.Psych.;",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Germany",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  informed consent was given\r\u003cbr\u003e\r\u003cbr\u003e          -  age = 18\r\u003cbr\u003e\r\u003cbr\u003e          -  able to complete the questionnaire in German\r\u003cbr\u003e\r\u003cbr\u003e          -  country of residence: Germany\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  if at least one of the inclusion criteria is not met\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Diagnostic Test: Online Questionnaire",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Characteristics of COVID-19-related anxiety;COVID-19-related anxiety symptoms",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04331106",
			"start_date": "2020-03-27",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Online-based Survey of the Anxiety Associated With the COVID-19 Pandemic in the General Population in Germany",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04331106",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";;;;;;;guiaccar@unina.it;",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Guido Iaccarino, MD;Guido Grassi, MD;MariaLorenza Muiesan, MD;Claudio Borghi, MD;Claudio Ferri, MD;MASSIMO VOLPE, MD;Leonardo Sechi;Guido Iaccarino, MD, PhD;Marialorenza Muiesan",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Italy",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        Patients affected by COVID19 referring to italian outpatient clinics or hospitals\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        -\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "Numbers of COVID-19 patients enrolled that use ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents;Numbers of COVID-19 patients enrolled with no symptoms, with moderate symptoms or with severe symptoms of pneumoni based on the WHO specification for ARDS that also used ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04331574",
			"start_date": "2020-03-10",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Phase IV Observational Study to Associate Hypertension and Hypertensinon Treatment to COVID19",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04331574",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "landoni.giovanni@hsr.it",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Giovanni Landoni, Professor",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Italy",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients admitted to hospital with biological samples positive for SARS-CoV-2\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients admitted to hospital with negative test but clinical and radiological\r\u003cbr\u003e             characteristics highly suggestive of SARS-CoV-2 disease\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients discharged from emergency department with biological samples positive for\r\u003cbr\u003e             SARS-CoV-2\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  None\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: Observational Study",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Characterize Patients With SARS-Cov-2 Infection and to Create a Biobank to Identify Predictors of Disease Severity, Mortality and Treatment Response",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04318366",
			"start_date": "2020-03-19",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Study to Characterize Patients With SARS-Cov-2 Infection and to Create a Biobank to Identify Predictors of Disease Severity, Mortality and Treatment Response",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04318366",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "gabriele.saccone@libero.it",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Gabriele Saccone",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Italy",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  pregnant women with laboratory-confirmed 2019-n-CoV\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: pregnant women with laboratory-confirmed 2019-n-CoV",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Maternal and perinatal outcomes",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04319016",
			"start_date": "2020-01-01",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04319016",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";PRIORITYCOVID19@ucsf.edu;PRIORITYCOVID19@ucsf.edu",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Vanessa Vacoby, MD, MAS;Ruth Gebrezghi;Study Coordinator",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "United States",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          1. Pregnant women or women who have been pregnant within the last 6 weeks\r\u003cbr\u003e\r\u003cbr\u003e          2. Able to give informed consent\r\u003cbr\u003e\r\u003cbr\u003e          3. Diagnosed with COVID-19; or being evaluated for COVID-19 (\"patient under\r\u003cbr\u003e             investigation\") since January 1, 2020\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        1. \u003c18 years of age.\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: Pregnant women under investigation for Coronavirus or diagnosed with COVID-19;Other: Postpartum women under investigation for Coronavirus or diagnosed with COVID-19",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Clinical presentation;Disease prognosis outcomes;Pregnancy outcomes;Obstetric outcomes;Neonatal outcomes;Modes of transmission of COVID-19",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04323839",
			"start_date": "2020-03-20",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "PRIORITY (Pregnancy Coronavirus Outcomes Registry)",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04323839",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "isabelle.pellegrin@chu-bordeaux.fr;isabelle.pellegrin@chu-bordeaux.fr",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Isabelle PELLEGRIN;Isabelle PELLEGRIN",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "France",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients / caregivers treated at Bordeaux University Hospital for asymptomatic or\r\u003cbr\u003e             symptomatic infection by SARS -CoV-2\r\u003cbr\u003e\r\u003cbr\u003e          -  men and women, adults and minors as well as pregnant or breastfeeding women\r\u003cbr\u003e\r\u003cbr\u003e          -  patients who died following infection with SARS-CoV-2 (specific criterion for\r\u003cbr\u003e             post-mortem biopsies)\r\u003cbr\u003e\r\u003cbr\u003e          -  Be affiliated with or beneficiary of a social security scheme\r\u003cbr\u003e\r\u003cbr\u003e          -  Free and informed consent obtained and signed by the patient\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Under guardianship or curatorship\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: biological samples collection",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "COVID-19 desease description;COVID-19 desease description",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04332016",
			"start_date": "2020-04-02",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Biological Samples Collection From Patients and Caregivers Treated at Bordeaux University Hospital for Asymptomatic and Symptomatic Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) Infection (COVID-19).",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04332016",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";aliaehussein@aun.edu.eg;aliaehussein@aun.edu.eg",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Aliae Mohamed-Hussein;Aliae Mohamed-Hussein;Aliae Hussein, MD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Egypt",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Medical Physicians in Middle East area\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  none\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: survey",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Number of physicians affected by social media measured by online survey designed to measure the influence of social media on medical practice",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04319315",
			"start_date": "2020-03-11",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Impact of Social Media on Knowledge Dissemination Between Physicians During COVID-19 Virus Outbreak",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04319315",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";joanne.gondert@beaumont.org;joanne.gondert@beaumont.org",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Girish B Nair, MD;Joanne Gondert, RN, BSN;Joanne Gondert, RN, BSN",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "United States",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion criteria:\r\u003cbr\u003e\r\u003cbr\u003e          1. Adults \u003e18 years of age\r\u003cbr\u003e\r\u003cbr\u003e          2. Informed consent\r\u003cbr\u003e\r\u003cbr\u003e          3. A confirmed diagnosis of SARS-CoV-2 with mild to moderate disease defined as oxygen \u003e\r\u003cbr\u003e             90% on room air on or supplemental oxygen not more than 6L\r\u003cbr\u003e\r\u003cbr\u003e          4. Concomitant medications for the treatment are allowed\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion criteria:\r\u003cbr\u003e\r\u003cbr\u003e          1. Patients \u003c18 years\r\u003cbr\u003e\r\u003cbr\u003e          2. Pregnant females\r\u003cbr\u003e\r\u003cbr\u003e          3. Invasive ventilator support or non-invasive ventilator support including high flow\r\u003cbr\u003e             nasal cannula\r\u003cbr\u003e\r\u003cbr\u003e          4. COPD or Congestive Heart Failure patients requiring home oxygen\r\u003cbr\u003e\r\u003cbr\u003e          5. History of lung cancer and radiation to lung or had prior radiation to the chest\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Device: CT-V",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Predictive association between CT-V, PBM score and disease progression",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04320511",
			"start_date": "April 2020",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "COVID CT, Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04320511",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "Arne.Vasli.Lund.Soraas@rr-research.no;Arne.Vasli.Lund.Soraas@rr-research.no",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Arne Søraas, MD, PhD;Arne Søraas, PhD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Norway",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Norwegian adult\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Unable to consent\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Behavioral: Observation of behavior and COVID-19 infection will be conducted.",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Rate of COVID-19 infection",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04320732",
			"start_date": "2020-03-27",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Risk Factors for Community- and Workplace Transmission of COVID-19",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04320732",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "gallelli@unicz.it;gallelli@unicz.it",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "LUCA GALLELLI;LUCA GALLELLI",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Italy",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Aged between 18 and 75 years, extremes included, male or female In conscious patients,\r\u003cbr\u003e             ability to understand and the willingness to sign a written informed consent document;\r\u003cbr\u003e             in unconscious patients informed consent will be signed from parents or legal tutors.\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients that don't sign the informed consent\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Diagnostic Test: Biomarkers expression",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Biomarkers expression;Liver Biomarkers expression",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04322513",
			"start_date": "2020-03-24",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Biomarkers Identification for Diagnosis and Treatment of SARS-COV-2 Infection",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04322513",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";info@beat19.org;info@beat19.org",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Mark Shapiro;BEAT19.org;BEAT19.org",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "United States",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  People who are feeling sick and have tested positive for COVID-19\r\u003cbr\u003e\r\u003cbr\u003e          -  People who are feeling sick but have not tested positive for COVID-19\r\u003cbr\u003e\r\u003cbr\u003e          -  People who are not feeling sick but want to participate\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        • People who are unwilling or unable to provide informed consent\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: Observation of patients with known, suspected, or at risk for COVID-19 infection",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Define Natural Symptom Course",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04321811",
			"start_date": "2020-03-21",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "A PATIENT-CENTRIC OUTCOMES REGISTRY OF PATIENTS WITH KNOWN OR SUSPECTED NOVEL CORONAVIRUS INFECTION SARS-COV-2 (COVID-19)",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04321811",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";richard.skells@addenbrookes.nhs.uk;rkg20@cam.ac.uk",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Ravindra Prof. Gupta, BMBCh;Richard D. Skells, BSc.;Ravi K Gupta, PhD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "United Kingdom",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  16 years or above\r\u003cbr\u003e\r\u003cbr\u003e          -  Patient requiring hospital admission AND AT LEAST ONE OF\r\u003cbr\u003e\r\u003cbr\u003e          -  Clinical or Radiological evidence of pneumonia\r\u003cbr\u003e\r\u003cbr\u003e          -  Acute respiratory distress syndrome\r\u003cbr\u003e\r\u003cbr\u003e          -  Influenza like illness (defined as fever \u003e37.8oC and at least one of the following\r\u003cbr\u003e             respiratory symptoms, which much be of acute onset: persistent cough (with or without\r\u003cbr\u003e             sputum), hoarseness, nasal discharge or congestion, shortness of breath, sore throat,\r\u003cbr\u003e             wheezing, sneezing)\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients who have not had the standard PHE COVID-19 test applied\r\u003cbr\u003e\r\u003cbr\u003e          -  Unwilling or unable to comply with research swab of nose \u0026 throat or tracheal fluid\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Diagnostic Test: SAMBA II (Diagnostic for the Real World);Diagnostic Test: Public Health England Gold Standard;Diagnostic Test: Cambridge Validated Viral Detection Method;Diagnostic Test: Radiological Detection",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "SAMBA COVID-19 POC PCR Test",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04326387",
			"start_date": "2020-04-06",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Evaluation of Novel Diagnostic Tests for 2019-nCOV",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04326387",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "dandachid@health.missouri.edu",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Dima Dandachi, MD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "United States",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  HIV disease\r\u003cbr\u003e\r\u003cbr\u003e          -  Laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction\r\u003cbr\u003e             (PCR) or other commercial or public health assay\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  None\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: No intervention",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Mortality",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04333953",
			"start_date": "2020-04-01",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Prospective Observational Study for Patients With HIV and Confirmed SARS-CoV-2",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04333953",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";Guido.bertolini@marionegri.it",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Guido Bertolini, MD;Guido Bertolini, MD",
			"corresp_author_lastname_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        All the ED patients positive to or suspected of COVID-19 infection with at least one of the\r\u003cbr\u003e        following symptoms:\r\u003cbr\u003e\r\u003cbr\u003e          -  fever\r\u003cbr\u003e\r\u003cbr\u003e          -  cough/dyspnea\r\u003cbr\u003e\r\u003cbr\u003e          -  SpO2 \u003c 95% in ambient air (\u003c 91% if BPCO patient).\r\u003cbr\u003e\r\u003cbr\u003e          -  positive Quick Walk Test\r\u003cbr\u003e\r\u003cbr\u003e          -  respiratory symptoms or admission in ED for respiratory reason\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  age \u003c 18 years\r\u003cbr\u003e\r\u003cbr\u003e          -  intubated patients or patients discharged in ICU in 1 hour from ED arrival\r\u003cbr\u003e\r\u003cbr\u003e          -  denied consent\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "Death or need of intubation",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04323878",
			"start_date": "2020-04-06",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "EC-COVID-PCS - Early CPAP in COVID Patients With Respiratory Failure. A Prospective Cohort Study.",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04323878",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";anna.caprodossi@policlinicogemelli.it;anna.caprodossi@policlinicogemelli.it",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Geltrude Mingrone, MD PhD;Anna Caprodossi;Anna Caprodossi",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Italy",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        diagnosis of pneumonia; Covid-19 test positive; hospitalized subjects; both sexes aged;\r\u003cbr\u003e        given informed consent.\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        age lower than 18 years; pregnancy; breast-feeding.\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "rate of recovery",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04324684",
			"start_date": "2020-03-31",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Time of Recovery and Prognostic Factors of Covid19 Pneumonia",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04324684",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "ohermine@gmail.com",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Olivier HERMINE, MD-PhD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "France",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or\r\u003cbr\u003e             public health assay in any specimen \u003c 72 hours and/or CT Scan prior to randomization\r\u003cbr\u003e             (Following typical radiological findings (ground glass abnormalities, and absence of\r\u003cbr\u003e             lymphadenopathy, pleural effusion, pulmonary nodules, lung cavitation)\r\u003cbr\u003e\r\u003cbr\u003e          -  Hospitalized patients\r\u003cbr\u003e\r\u003cbr\u003e          -  Illness of any duration and severity (mild, moderate, severe, critical, see annexe 1),\r\u003cbr\u003e             with symptoms (fever, cough, respiratory difficulties, shortness of breath), and at\r\u003cbr\u003e             least one of the following:\r\u003cbr\u003e\r\u003cbr\u003e          -  Radiographic infiltrates by imaging (CT scan)\r\u003cbr\u003e\r\u003cbr\u003e          -  Clinical assessment (evidence of rales/crackles on exam or respiratory rate \u003e25/min)\r\u003cbr\u003e             AND SpO2=94% on room air\r\u003cbr\u003e\r\u003cbr\u003e          -  SpO2=97 % with O2 \u003e 5L/min or Respiratory rate\u003e=30/min\r\u003cbr\u003e\r\u003cbr\u003e          -  Requiring mechanical ventilation\r\u003cbr\u003e\r\u003cbr\u003e          -  With any comorbidities (TBD such as acute kidney injury, cardiovascular condition,\r\u003cbr\u003e             pulmonary disease, obesity, high blood pressure, diabetes, chronic kidney diseases,\r\u003cbr\u003e             haematological diseases, sickle cell diseases, autoimmune and auto-inflammatory,\r\u003cbr\u003e             pregnant women, HIV infected, etc)\r\u003cbr\u003e\r\u003cbr\u003e          -  Male or female adult = 18 years of age at time of enrolment\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients must be able and willing to comply with study visits and procedures.\r\u003cbr\u003e\r\u003cbr\u003e          -  Patient agrees to the collection of oropharyngeal and nasal swabs and venous blood per\r\u003cbr\u003e             protocol Written informed consent provided by the patient or alternatively by\r\u003cbr\u003e             next-of-kin prior to any protocol-specific procedures.\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients with any condition that the physician judges could be detrimental to the\r\u003cbr\u003e             patient participating in this study; including any clinically important deviations\r\u003cbr\u003e             from normal clinical laboratory values or concurrent medical conditions (active\r\u003cbr\u003e             infection diseases such as severe bacterial infections, aspergillosis, tuberculosis,\r\u003cbr\u003e             depending on the tested medication).\r\u003cbr\u003e\r\u003cbr\u003e          -  Absence of Health Insurance\r\u003cbr\u003e\r\u003cbr\u003e          -  Subject protected by law under guardianship or curatorship\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "Survival;WHO progression scale COVID 19",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04324047",
			"start_date": "2020-03-27",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04324047",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"country": "Turkey",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  turkish physicians\r\u003cbr\u003e\r\u003cbr\u003e          -  work active in pandemic hospital\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  work in another country\r\u003cbr\u003e\r\u003cbr\u003e          -  retired physicians\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Behavioral: turkish physicians",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Evaluation of covid-19 knowledge level of turkish physicians",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04327531",
			"start_date": "2020-03-26",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Evaluation of Covid 19 Knowledge Anxiety and Expectation Levels of Turkish Physicians, Survey Study",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04327531",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "bruno.hoen@pasteur.fr",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Bruno HOEN, Pr",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "France",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Affiliated with or benefiting from a Social Security system\r\u003cbr\u003e\r\u003cbr\u003e          -  State of health compatible with a blood sample as defined in the protocol\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Person benefiting from a legal protection measure or unable to express informed\r\u003cbr\u003e             consent to participation\r\u003cbr\u003e\r\u003cbr\u003e          -  For women: pregnancy or breastfeeding in progress\r\u003cbr\u003e\r\u003cbr\u003e          -  Have had an infectious episode and/or respiratory signs in the 14 days prior to the\r\u003cbr\u003e             scheduled visit (CORSER 1 and 2a, 2b)\r\u003cbr\u003e\r\u003cbr\u003e          -  Have been in contact with a confirmed case of SARS-CoV-2 infection within 14 days\r\u003cbr\u003e             prior to the date of the visit.(CORSER 1 and 2a, 2b)\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: Human Biological samples",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Presence of specific anti-SARS-CoV-2 antibodies in the different study groups.",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04325646",
			"start_date": "2020-03-13",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Sero-epidemiological Study of the SARS-CoV-2 Virus in France: Constitution of a Collection of Human Biological Samples",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04325646",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";claire-anne.siegrist@unige.ch;",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Claire-Anne Siegrist, MD;Claire-Anne Siegrist, MD;Claire-Anne Siegrist, MD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Switzerland",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        The following persons may be included:\r\u003cbr\u003e\r\u003cbr\u003e          -  A patient of any age meeting the European Centre for Disease Control and Prevention's\r\u003cbr\u003e             confirmed case definition: \"A person with laboratory confirmation of virus causing\r\u003cbr\u003e             COVID-19, irrespective of clinical signs and symptoms\" (and/or high suspicion/actively\r\u003cbr\u003e             being treated as CoVID+ cases pending test confirmation)\r\u003cbr\u003e\r\u003cbr\u003e          -  Household contacts (defined as those sleeping in the same apartment/house as an\r\u003cbr\u003e             infected patient) of a patient with laboratory-confirmed COVID-19 (and/or high\r\u003cbr\u003e             suspicion/actively being treated as CoVID+ cases pending test confirmation), whether\r\u003cbr\u003e             symptomatic or not, and whether testing positive or not during a period of 14 days\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criterion:\r\u003cbr\u003e\r\u003cbr\u003e          -  Long-term incapacity leading to the inability to provide informed consent while not\r\u003cbr\u003e             having a patient representative with the ability to provide informed consent\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: NA (no intervention)",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Immunogenicity primary outcome: Geometric mean antibody concentration of total IgG antibodies to SARS-CoV-2 assessed by ELISA at 28 days;Virologic primary outcome: Peak viral load in the 56 days following diagnosis/suspected diagnosis",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04329546",
			"start_date": "2020-03-27",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "How Immune Responses Shape Virological and Clinical Characteristics of COVID-19: a Prospective Cohort Study",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04329546",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          1. The patients must be 18 years or older.\r\u003cbr\u003e\r\u003cbr\u003e          2. Patients who opt in to complete the survey.\r\u003cbr\u003e\r\u003cbr\u003e          3. Patients must have the capacity to verbally consent for the interview.\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        1.Patients who under the age of 18 years old.\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "Number of participants who fill out the survey and participate in the semi-structured interviews.",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04330521",
			"start_date": "April 2020",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Impact of the Coronavirus (COVID-19) on Patients With Cancer",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04330521",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";;;snamendys@gmail.com",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Silvio A. Ñamendys-Silva, MD, MSc;Guillermo Dominguez-Cherit, MD;Eduardo Rivero-Sigarroa, MD;Silvio A. Ñamendys-Silva, MD, MSc",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Mexico",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Confirmed case: Critically ill patient who meets the operational definition of a\r\u003cbr\u003e             suspected case and who has a confirmed diagnosis by the National Network of Public\r\u003cbr\u003e             Health Laboratories recognized by the Institute of Epidemiological Diagnosis and\r\u003cbr\u003e             Reference (Indre) (Mexico).\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  If a negative for SARS-CoV-2 result is obtained from a critically ill patient with a\r\u003cbr\u003e             high index of suspicion for COVID-19 virus infection.\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients who had participated in another observational study in the last 30 days prior\r\u003cbr\u003e             to inclusion.\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "Hospital mortality",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04336345",
			"start_date": "2020-04-01",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Outcomes of Patients With COVID-19 in the Intensive Care Unit: A National Observational Study (Mexico COVID-19 ICU Study)",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04336345",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";p-amedro@chu-montpellier.fr;p-amedro@chu-montpellier.fr",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Pascal AMEDRO, MD-PhD;Pascal AMEDRO, MD-PhD;Pascal AMEDRO, MD-PHD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "France",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patient with CHD as defined in the international classification ACC-CHD\r\u003cbr\u003e\r\u003cbr\u003e          -  Covid-19 infection over the study period\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion criteria:\r\u003cbr\u003e\r\u003cbr\u003e        - Patient with genetic heart disease (cardiomyopathy, hereditary rhythmic disease).\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "Population characteristics",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04336384",
			"start_date": "2020-03-01",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Impact of Covid-19 in Congenital Heart Disease - COVID-CHD",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04336384",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "ozmenmm@gmail.com;mahir.ozmen@istinye.edu.tr",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Mahir M Ozmen, Professor;Istinye University M ozmen, Prof",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Turkey",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          1. person who are working as health professional with contact to known COVID positive\r\u003cbr\u003e             case\r\u003cbr\u003e\r\u003cbr\u003e          2. Their first degree relatives (child, spouse or parents)\r\u003cbr\u003e\r\u003cbr\u003e          3. must be able to swallow tablets\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          1. Already using plaquenil for other reasons (RA etc)\r\u003cbr\u003e\r\u003cbr\u003e          2. person with the diagnosis of COVID infection\r\u003cbr\u003e\r\u003cbr\u003e          3. Person with the condition may cause complications with this medication (severe CVD, av\r\u003cbr\u003e             block, already has ophtalmological complications, organ failure of any degree etc).\r\u003cbr\u003e\r\u003cbr\u003e          4. Documented allergic history to chloroquine;\r\u003cbr\u003e\r\u003cbr\u003e          5. Documented history of hematological system diseases;\r\u003cbr\u003e\r\u003cbr\u003e          6. Documented history of chronic liver and kidney diseases;\r\u003cbr\u003e\r\u003cbr\u003e          7. Documented history of cardiac arrhythmia or chronic heart diseases;\r\u003cbr\u003e\r\u003cbr\u003e          8. Documented history of retina or hearing dysfunction;\r\u003cbr\u003e\r\u003cbr\u003e          9. Documented history of mental illnesses; 10. Use of digitalis due to the previous\r\u003cbr\u003e             disease.\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Drug: Plaquenil 200Mg Tablet",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Protection against COVID-19",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04326725",
			"start_date": "2020-03-20",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Proflaxis for Healthcare Professionals Using Hydroxychloroquine Plus Vitamin Combining Vitamins C, D and Zinc During COVID-19 Pandemia: An Observational Study",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04326725",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";julien.poissy@chru-lille.fr;",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Julien Poissy, MD,PhD;Julien Poissy, MD,PhD;",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "France",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  All patient admitted in ICU Lille Hospital and hospitalized in the unit \"Emergent\r\u003cbr\u003e             Biological Risk\" (REB) before a suspicion of infection with COVID-19\r\u003cbr\u003e\r\u003cbr\u003e          -  Clinical infectious syndrome: fever (\u003e38°C) or hypothermia ( 36°C), chill, fever at\r\u003cbr\u003e             home\r\u003cbr\u003e\r\u003cbr\u003e          -  a severe respiratory table defined by:\r\u003cbr\u003e\r\u003cbr\u003e          -  Oxygen demand \u003e 3 L/min in the presence of significant comorbidity (pregnancy, chronic\r\u003cbr\u003e             respiratory disease, chronic heart disease, hemopathy, cirrhosis) or \u003e 6 L/min in the\r\u003cbr\u003e             absence of comorbidity\r\u003cbr\u003e\r\u003cbr\u003e          -  or a respiratory rate \u003e 30 cycles per minute\r\u003cbr\u003e\r\u003cbr\u003e          -  the need for mechanical, invasive or non-invasive ventilation\r\u003cbr\u003e\r\u003cbr\u003e          -  the need for humidified high-flow oxygen therapy\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patient already included in study for first stay\r\u003cbr\u003e\r\u003cbr\u003e          -  Cirrhosis CHILD C\r\u003cbr\u003e\r\u003cbr\u003e          -  Major surgery in the last 7 days Minor patient\r\u003cbr\u003e\r\u003cbr\u003e          -  Patient under guardianship or curatorship\r\u003cbr\u003e\r\u003cbr\u003e          -  Refusal to participate\r\u003cbr\u003e\r\u003cbr\u003e          -  No social security coverage.\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "Correlation between nasal and deep PCR positivity for Covid-19 patients performed and all predictors for Covid-19 patients performed within 24 hours of admission to ICU",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04327180",
			"start_date": "2020-03-30",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "PCR-COVID-19 Predictors of Positivity in Patients Admitted to ICU for Respiratory Infection: A Prospective Observational Cohort Study",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04327180",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";soeska@rm.dk",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Søren H Skaarup;Søren H Skaarup",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Denmark",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Clinical suspicion of COVID-19 requiring contact to a hospital.\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Age less than 18 years\r\u003cbr\u003e\r\u003cbr\u003e          -  Previous enrollment in this study.\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "FLUS findings and respiratory failure",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04327674",
			"start_date": "2020-03-14",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "The Use of Focused Lung Ultrasound in Patients Suspected of COVID-19",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04327674",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";f.denis@cjb72.org;",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Fabrice DENIS, MD;Fabrice DENIS, MD;Fabrice DENIS, MD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "France",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  All users of the https://www.maladiecoronavirus.fr/ application over the age of 18\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  not applicable\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Device: Web application users",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "To assess of the evolution of the number of calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/;To assess of the evolution of the proportion of relevant calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04331171",
			"start_date": "2020-03-17",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Epidemiological Observation From a Smartphone Self-monitoring Application for Suspected COVID-19 Patients' Triage",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04331171",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "azengin@istanbul.edu.tr;",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Ayse Zengin Alpözgen, assistant professor;Ayse Zengin Alpözgen, Assistant Professor",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Turkey",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Volunteer to participate in the study\r\u003cbr\u003e\r\u003cbr\u003e          -  Being pregnant\r\u003cbr\u003e\r\u003cbr\u003e          -  Aged between 18 - 45\r\u003cbr\u003e\r\u003cbr\u003e          -  To understand Turkish\r\u003cbr\u003e\r\u003cbr\u003e          -  Spend most of the day at home\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Risky pregnancy status\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: Survey",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "International Physical Activity Questionnaire;Pittsburgh Sleep Quality Index;Perceived Stress Scale;Numerical Pain Rating Scale",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04336787",
			"start_date": "2020-04-12",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Determination Of Physical Activity, Sleep And Stress Level Of Pregnant Women In The Covid-19 Quarantine Period",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04336787",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";f.iqbal@imperial.ac.uk",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Ara Darzi, Prof;Fahad M Iqbal, MBChB (hons)",
			"corresp_author_lastname_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Aged 18 years or over.\r\u003cbr\u003e\r\u003cbr\u003e          -  Able to provide written consent.\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Any participants that withdraw their consent.\r\u003cbr\u003e\r\u003cbr\u003e          -  A skin condition/reaction preventing wearing the wearable sensor.\r\u003cbr\u003e\r\u003cbr\u003e          -  The presence of a permanent pacemaker or cardiac defibrillator.\r\u003cbr\u003e\r\u003cbr\u003e          -  Any form of psychiatric disorder or a condition that, in the opinion of the\r\u003cbr\u003e             investigator, may hinder communication with the research team.\r\u003cbr\u003e\r\u003cbr\u003e          -  Inability to cooperate or communicate with the research team.\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Device: SensiumVitals wearable sensor",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Deterioration resulting in healthcare review",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04337489",
			"start_date": "2020-04-01",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "REmote MOniToring usE in Suspected Cases of COVID-19 (Coronavirus): REMOTE-COVID Trial",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04337489",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "mlid163@163.com",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Ming Li, M.D.",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Adult aged \u003e=18years old; Diagnosed with CONVID19. Diagnostic criteria including:\r\u003cbr\u003e             Laboratory (RT-PCR) confirmed SARS-Cov-2 infection; CT of the lung conformed to the\r\u003cbr\u003e             manifestation of viral pneumonia.\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Near-death state (expected survival time less than 24 hours); Malignant tumor;\r\u003cbr\u003e             Pregnancy or puerperium women; Patients who refused to participant.\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: retrospective analysis",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Time to negative conversion of severe acute respiratory syndrome coronavirus 2",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04328454",
			"start_date": "2020-01-30",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Clinical Characteristics and Prognostic Factors of Patients With COVID-19 in Chibi Hospital of Hubei Province",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04328454",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "esannorberto@hotmail.com;esannorberto@hotmail.com",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Enrique M San Norberto, MD, PhD, MsC;Enrique M San Norberto, MD, PhD, MsC",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Spain",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Adults (age =18 years) undergoing ANY type of vascular surgery in an operating\r\u003cbr\u003e             theatre, this includes obstetrics. AND\r\u003cbr\u003e\r\u003cbr\u003e          -  Either before or after surgery: (i) lab test confirmed COVID-19 infection or (ii)\r\u003cbr\u003e             clinical diagnosis of COVID-19 infection (no test performed).\r\u003cbr\u003e\r\u003cbr\u003e        Therefore this study should capture:\r\u003cbr\u003e\r\u003cbr\u003e          -  emergency surgery patients with clinical diagnosis or lab confirmation of COVID-19\r\u003cbr\u003e             infection before surgery.\r\u003cbr\u003e\r\u003cbr\u003e          -  emergency surgery patients with clinical diagnosis or lab confirmation of COVID-19\r\u003cbr\u003e             infection after surgery.\r\u003cbr\u003e\r\u003cbr\u003e          -  elective surgery patients with clinical diagnosis or lab confirmation of COVID-19\r\u003cbr\u003e             infection after surgery.\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Not informed consent signed.\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Procedure: Vascular surgery",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "30-days mortality",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04333693",
			"start_date": "2020-04-01",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Outcomes of Vascular Surgery in COVID-19 Infection: National Cohort Study (Covid-VAS)",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04333693",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "m.eddleston@ed.ac.uk",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Michael Eddleston",
			"corresp_author_lastname_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  =18 years old with clinical features consistent with pneumonia or chest infection due\r\u003cbr\u003e             to SARS-CoV-2 AND\r\u003cbr\u003e\r\u003cbr\u003e               -  presenting to the Royal Infirmary of Edinburgh where they are swabbed and triaged\r\u003cbr\u003e                  for Covid-19.\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Inability to provide informed consent\r\u003cbr\u003e\r\u003cbr\u003e          -  Age 17 years or less\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Diagnostic Test: Breath test",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "To perform a study in patients with clinical features of pneumonia/chest infection to identify a signature of Covid-19 pneumonia in patients exposed to SARS-CoV-2, compared to unexposed patients or those without.",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04329507",
			"start_date": "2020-03-25",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Non-invasive Detection of Pneumonia in Context of Covid-19 Using Gas Chromatography - Ion Mobility Spectrometry (GC-IMS)",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04329507",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  confirmed COVID-19 patients by high-throughput sequencing or real-time\r\u003cbr\u003e             reverse-transcriptase polymerase-chain-reaction (RT-PCR) assay for nasal and\r\u003cbr\u003e             pharyngeal swab specimens.\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          1. patients with severe illness when admitted;\r\u003cbr\u003e\r\u003cbr\u003e          2. time interval \u003e 2 days between the admission and examinations;\r\u003cbr\u003e\r\u003cbr\u003e          3. absent data or delayed results\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Diagnostic Test: Machine learning model",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Predictive performance",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04337502",
			"start_date": "2019-12-23",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "A Clinical and Radiological Model to Predict the Prognosis for COVID-19 Patients",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04337502",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";srogy@capricor.com;Mitch.Gheorghiu@cshs.org",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Raj Makkar, MD;Siegfried Rogy, PhD;Mitch Gheoghiu, MD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "United States",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          1. Male or female subjects at least 18 years of age at time of consent\r\u003cbr\u003e\r\u003cbr\u003e          2. Confirmed COVID-19 infection by clinical diagnosis and laboratory testing\r\u003cbr\u003e\r\u003cbr\u003e          3. In critical condition as indicated by life support measurements\r\u003cbr\u003e\r\u003cbr\u003e          4. Have one or more of the following laboratory parameters:\r\u003cbr\u003e\r\u003cbr\u003e               -  lymphocytopenia\r\u003cbr\u003e\r\u003cbr\u003e               -  elevated IL-6\r\u003cbr\u003e\r\u003cbr\u003e               -  elevated Troponin I/Troponin T (TnI/T)\r\u003cbr\u003e\r\u003cbr\u003e               -  elevated myoglobin\r\u003cbr\u003e\r\u003cbr\u003e               -  elevated C-Reactive Protein (CRP)\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Biological: CAP-1002 Allogeneic Cardiosphere-Derived Cells",
			"intervention_name_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04338347",
			"start_date": "2019-01-10",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "CAP-1002 Treatment in Patients With Severe COVID-19 and in Critical Condition as Indicated by Life Support Measurements",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04338347",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";USCOVIDplasma@mayo.edu",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Michael Joyner, MD;Michael Joyner, MD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "United States",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Age at least 18 years\r\u003cbr\u003e\r\u003cbr\u003e          -  Laboratory confirmed diagnosis of infection with SARS-CoV-2\r\u003cbr\u003e\r\u003cbr\u003e          -  Admitted to an acute care facility for the treatment of COVID-19 complications\r\u003cbr\u003e\r\u003cbr\u003e          -  Severe or life threatening COVID-19, or judged by the treating provider to be at high\r\u003cbr\u003e             risk of progression to severe or life-threatening disease\r\u003cbr\u003e\r\u003cbr\u003e          -  Informed consent provided by the patient or healthcare proxy\r\u003cbr\u003e\r\u003cbr\u003e        Severe COVID-19 is defined by one or more of the following:\r\u003cbr\u003e\r\u003cbr\u003e          -  dyspnea\r\u003cbr\u003e\r\u003cbr\u003e          -  respiratory frequency = 30/min\r\u003cbr\u003e\r\u003cbr\u003e          -  blood oxygen saturation = 93%\r\u003cbr\u003e\r\u003cbr\u003e          -  partial pressure of arterial oxygen to fraction of inspired oxygen ratio \u003c 300\r\u003cbr\u003e\r\u003cbr\u003e          -  lung infiltrates \u003e 50% within 24 to 48 hours\r\u003cbr\u003e\r\u003cbr\u003e        Life-threatening COVID-19 is defined as one or more of the following:\r\u003cbr\u003e\r\u003cbr\u003e          -  respiratory failure\r\u003cbr\u003e\r\u003cbr\u003e          -  septic shock\r\u003cbr\u003e\r\u003cbr\u003e          -  multiple organ dysfunction or failure\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  None\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Biological: COVID-19 convalescent plasma",
			"intervention_name_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04338360",
			"start_date": "2019-01-10",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04338360",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "janneke.cox@jessazh.be",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Janneke Cox, Dr",
			"corresp_author_lastname_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  All adult patients \u003e 18 years scheduled for a (semi) urgent surgery, hematological or\r\u003cbr\u003e             oncological treatment or elektrophysiciological investigations in the Jessa hospital\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients \u003c 18 years\r\u003cbr\u003e\r\u003cbr\u003e          -  Adult patients who are unable the give informed consent\r\u003cbr\u003e\r\u003cbr\u003e          -  Language barrier\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: Questionnaire",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Prevalence of symptoms;Prevalence of positive Sars CoV-2 PCR;Prevalence of positive radiological findings",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04334252",
			"start_date": "2020-04-17",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Descriptive Study Regarding the Ambulant Screening Protocol for COVID-19 in Times of High SARS CoV-2 Prevalence",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04334252",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";;;;;;;;;;;;;;;;qixiaolong@vip.163.com",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Mingkai Chen, MD;Xiaolong Qi, MD;Fengmei Wang, MD;Ye Gu, MD;Zicheng Jiang, MD;Guo Zhang, MD;Yong Zhang, MD;Dengxiang Liu, MD;Qing He, MD;Hua Yang, MD;Zhengyan Wang, MD;Bin Xiong, MD;Xiaodan Li, MD;Hongguang Zhang, MD;Chuxiao Shao, MD;Hongmei Yue, MD;Xiaolong Qi, MD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  1) Aged 18 or above;\r\u003cbr\u003e\r\u003cbr\u003e          -  2) Laboratory-confirmed COVID-19 infection;\r\u003cbr\u003e\r\u003cbr\u003e          -  3) Pre-existing liver cirrhosis based on liver biopsy or clinical findings.\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  1) Pregnancy or unknown pregnancy status.\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "All-cause mortality of COVID-19 patients with liver cirrhosis",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04329559",
			"start_date": "2020-03-30",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Clinical Characteristics of COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04329559",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";victoria.vazquez@kcl.ac.uk",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Tim D Spector;Victoria Vazquez",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "United States;United Kingdom;United States",
			"country_certainty": "generated",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Adults of 18 years and above, both in the UK and internationally where the app has\r\u003cbr\u003e             been approved for download from the Apple App store and Google Play. The web-based\r\u003cbr\u003e             equivalent to the app will also be made available via a link for those unable to\r\u003cbr\u003e             download.\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Anyone below the age of 18; anyone unable to provide informed consent.\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: No Intervention",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Physical health symptoms;Lack of physical health symptoms",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04331509",
			"start_date": "2020-03-23",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "COVID-19 Symptom Tracker",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04331509",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "a.martineau@qmul.ac.uk",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Adrian Martineau, PhD",
			"corresp_author_lastname_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  UK resident\r\u003cbr\u003e\r\u003cbr\u003e          -  Age =16 years\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria: none\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "Incidence of suspected, probable or confirmed COVID-19",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04330599",
			"start_date": "2020-04-02",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Longitudinal Population-based Observational Study of Coronavirus Disease in the UK Population",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04330599",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "cmoser@targetpharmasolutions.com",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Chuck Moser",
			"corresp_author_lastname_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Adults (age =18 years) who are or have been hospitalized and diagnosed with Severe\r\u003cbr\u003e             Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) infection.\r\u003cbr\u003e\r\u003cbr\u003e          -  SARS-CoV-2 confirmed diagnosis (e.g. polymerase chain reaction [PCR] or other\r\u003cbr\u003e             clinically utilized test).\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        N/A\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "Natural history of COVID-19: Characteristics of COVID-19;Natural history of COVID-19: Participant demographics;Natural history of COVID-19: Treatment use;Time point of clinical response",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04331886",
			"start_date": "April 2020",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "An Observational Study of Patients With Coronavirus Disease 2019",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04331886",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";mehdi.benchoufi@aphp.fr",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Mehdi BENCHOUFI, MD;Mehdi BENCHOUFI, MD",
			"corresp_author_lastname_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion criteria :\r\u003cbr\u003e\r\u003cbr\u003e          -  \u003e 18 years old\r\u003cbr\u003e\r\u003cbr\u003e          -  Suspected of COVID-19 infection or having a systematic COVID-19 screening\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion criteria :\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients on whom the ultrasonographic examination is not feasible for technical\r\u003cbr\u003e             reasons (morbid obesity, thoracic extensive subcutaneous emphysema, absorbent\r\u003cbr\u003e             subcutaneous infiltrations, ...)\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients with comorbidities justifying priority intensive care, not linked to the\r\u003cbr\u003e             COVID-19 condition\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: Pulmonary ultrasound",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Association of pulmonary lesions on ultrasound on D0 classified according to three stages of severity",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04335019",
			"start_date": "April 2020",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Interest of the Use of Pulmonary Ultrasound in the Referral of Patients With or Suspected COVID-19 +",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04335019",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "roberto.giacomelli@univaq.it;roberto.giacomelli@univaq.it",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Roberto Giacomelli, MD, PhD;Roberto Giacomelli, MD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Italy",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  All gender patients aged = 18 years;\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients with SARS-CoV-2 infection confirmed by tests (RT-PCR) and pulmonary\r\u003cbr\u003e             involvement, hospitalized, at the end of the initial phase of high viral load of\r\u003cbr\u003e             COVID-19 (apyretic\u003e 72 hours and / or at least 7 days after onset of symptoms);\r\u003cbr\u003e\r\u003cbr\u003e          -  Worsening of respiratory exchanges such as to require non-invasive or invasive\r\u003cbr\u003e             ventilation support (BCRSS score = 3).\r\u003cbr\u003e\r\u003cbr\u003e          -  High levels of IL-6 (\u003e 40 pg/mL) or alternatively CRP and/or ferritin and/or D-dimer\r\u003cbr\u003e             and/or fibrinogen values higher than the reference values or rapidly increasing;\r\u003cbr\u003e\r\u003cbr\u003e          -  Signature of informed consent.\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Alanine aminotransferase and/or Aspartate aminotransferase (ALT / AST) \u003e 5 times\r\u003cbr\u003e             compared to normal laboratory values.\r\u003cbr\u003e\r\u003cbr\u003e          -  Presence of a chronic renal failure = 4 stage (glomerular filtrate values \u003c30\r\u003cbr\u003e             ml/min/1.73 m2).\r\u003cbr\u003e\r\u003cbr\u003e          -  Presence of neutropenia (neutrophils count \u003c 500 / mm3).\r\u003cbr\u003e\r\u003cbr\u003e          -  Platelet count less than 50 x 103/µL.\r\u003cbr\u003e\r\u003cbr\u003e          -  Documented sepsis from other pathogens other than SARS-CoV-2.\r\u003cbr\u003e\r\u003cbr\u003e          -  Presence of co-morbidities associated, in clinical judgment, with an unfavourable\r\u003cbr\u003e             outcome.\r\u003cbr\u003e\r\u003cbr\u003e          -  Complicated diverticulitis and / or intestinal perforation.\r\u003cbr\u003e\r\u003cbr\u003e          -  Skin infection in progress (e.g. dermohypodermitis not controlled by antibiotic\r\u003cbr\u003e             therapy).\r\u003cbr\u003e\r\u003cbr\u003e          -  Immuno-suppressive anti-rejection therapy.\r\u003cbr\u003e\r\u003cbr\u003e          -  Pregnancy or woman of childbearing age who does not use contraceptive and/or\r\u003cbr\u003e             breastfeeding measures.\r\u003cbr\u003e\r\u003cbr\u003e          -  Previous ischemic attack or myocardial infarction.\r\u003cbr\u003e\r\u003cbr\u003e          -  NYHA class III or IV heart failure.\r\u003cbr\u003e\r\u003cbr\u003e          -  Severe depressive syndrome or other psychiatric disease which, in the opinion of the\r\u003cbr\u003e             doctor, can preclude patient participation in the study.\r\u003cbr\u003e\r\u003cbr\u003e          -  Presence of known malignant neoplasms.\r\u003cbr\u003e\r\u003cbr\u003e          -  Clinically significant history of alcohol abuse or drug addiction which, in the\r\u003cbr\u003e             opinion of the doctor, may preclude the subject's participation in the study.\r\u003cbr\u003e\r\u003cbr\u003e          -  Any condition which, in the opinion of the doctor, precludes the possibility of using\r\u003cbr\u003e             the study drug provided for in the RCP.\r\u003cbr\u003e\r\u003cbr\u003e          -  Any other laboratory condition or parameter that, in the doctor's judgment, precludes\r\u003cbr\u003e             the subject's participation in the study.\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "Percentage of patients with complete recovery defined as fever disappearance and return to normal peripheral oxygen saturation values (SpO2) after 14 days from the end of treatment with tocilizumab.",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04332913",
			"start_date": "2020-04-01",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Efficacy and Safety of Tocilizumab in the Treatment of Patients With Respiratory Distress Syndrome and Cytokine Release Syndrome Secondary to COVID-19: a Proof of Concept Study",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04332913",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";;;robert.koerner@uk-koeln.de;robert.koerner@uk-koeln.de",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Robert W Körner, Dr.;Jan Rybniker, PD Dr. Dr.;Miguel A Alejandre Alcazar, Prof. Dr. Dr.;Robert W Körner, Dr.;Robert W Koerner, Dr.",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Germany",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  patients with COVID-19: detection of SARS-CoV-2 by PCR in naso- or oropharyngeal swab\r\u003cbr\u003e             or sputum, no age limit\r\u003cbr\u003e\r\u003cbr\u003e          -  control group: any respiratory tract infection not caused by SARS-CoV-2, no age limit\r\u003cbr\u003e\r\u003cbr\u003e          -  informed consent\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  no respiratory tract infection and no detection of SARS-CoV-2\r\u003cbr\u003e\r\u003cbr\u003e          -  no informed consent\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: this study is non- interventional",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Clinical course of COVID-19;Analysis of development of antibodies to SARS-CoV-2;Estimation of viral load;Detection of viral coinfections;Measurement of cytokine and chemokine response;Characterisation of virus-host-interaction;Identification of disease patterns in proteome;Analysis of change in lymphocyte subtypes;Analysis of histological changes in severe lung disease;Detection of bacterial coinfections",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04341168",
			"start_date": "April 2020",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Clinical and Immunological Characterisation of COVID-19 in Children, Adolescents and Adults",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04341168",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";;jeffrey.carson@rutgers.edu",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Jeffrey L Carson, MD;Reynold A Panettieri, MD;Jeffrey L Carson, MD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "United States",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  20 years and older\r\u003cbr\u003e\r\u003cbr\u003e          -  Hospital and RBHS healthcare workers who have regular direct patient contact (=3\r\u003cbr\u003e             patients/shift) in emergency rooms or inpatient settings that is expected to continue\r\u003cbr\u003e             regularly over the next =3 months and who work =20 hours in the hospital weekly\r\u003cbr\u003e             (residents, clinical fellows, attending physicians, nurse practitioners, physician\r\u003cbr\u003e             assistants, registered nurses, license practice nurses, medical technicians,\r\u003cbr\u003e             respiratory therapists, physical therapists, clinical pharmacists, dentists, dental\r\u003cbr\u003e             hygienists, or dental assistants)\r\u003cbr\u003e\r\u003cbr\u003e          -  Hospital workers who do not have patient contact and non-healthcare from the Rutgers\r\u003cbr\u003e             faculty, postdoctoral students, administrators, and staff.\r\u003cbr\u003e\r\u003cbr\u003e          -  Household members in a subset of the participants who test positive and negative for\r\u003cbr\u003e             SARS-CoV-2\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Previous diagnosis with COVID-19\r\u003cbr\u003e\r\u003cbr\u003e          -  Pregnant or have been diagnosed with a new medical condition in the past 30 days or\r\u003cbr\u003e             have had a change in medications in the past 30 days\r\u003cbr\u003e\r\u003cbr\u003e          -  Participants who have been hospitalized in the past 30 days, had and had an emergency\r\u003cbr\u003e             room, urgent care visit, or have had surgery.\r\u003cbr\u003e\r\u003cbr\u003e          -  Participants who have a fever on the day of their first visit to the study site (for\r\u003cbr\u003e             consent, biospecimen collection, etc.).\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: Non-Interventional",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Prevalence;Incidence",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04336215",
			"start_date": "2020-03-28",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Cohort Study of SARS-CoV-2 Incidence, Transmission, and Disease Severity in Healthcare Workers",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04336215",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "aliaehussein@aun.edu.eg;aliaehussein@gmail.com",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Aliae Mohamed-Hussein;Aliae AR Mohamed-Hussein",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Egypt",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  All subject except excluded group\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  subject diagnosed as COVID-19 positive and their contacts\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: Questionnaire;Diagnostic Test: IgG",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Measure frequency of people suffered from unusual flu-like symptoms before December 2019",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04336657",
			"start_date": "April 2020",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "COVID-19-Like Illness: Did we Have Unusual Severe Respiratory Tract Infections October-December 2019 Before WHO Announcement ?",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04336657",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "corinne.levy@activ-france.fr",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Corinne Levy, MD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "France",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Children \u003c 18 years old\r\u003cbr\u003e\r\u003cbr\u003e          -  Admitted in French pediatric wards\r\u003cbr\u003e\r\u003cbr\u003e          -  With a confirmed COVID-19 infection. ( on Nasal and pharyngeal swab specimens or blood\r\u003cbr\u003e             samples tested positive for 2019-nCoV nucleic acid using real-time\r\u003cbr\u003e             reverse-transcriptase polymerase-chain-reaction (RT- PCR) assay; or on typical chest\r\u003cbr\u003e             CT signs\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Expressed refusal to participate\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: hospitalized children with Covid19",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Percentage of children with severe or critical form.",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04336956",
			"start_date": "2020-04-07",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Covid-19 Pediatric Observatory",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04336956",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"country": "France",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Age \u003e 18 years old\r\u003cbr\u003e\r\u003cbr\u003e               -  Collection of the subject's non-opposition\r\u003cbr\u003e\r\u003cbr\u003e               -  Patient registration on Vik breast, Vik asthma, Vik migraine, Vik depression\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patient unable to formulate non-opposition\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: questionnaire assesment",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "quantify and qualify distress over a large population in times of pandemic crisis.",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04337047",
			"start_date": "2020-03-31",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Assessment of Distress in Crisis Situations During COVID-19",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04337047",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";piasfar@chu-angers.fr;julien.demiselle@chu-angers.fr",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Pierre Asfar, MD, PhD;Pierre Asfar, MD, PhD;Julien Demiselle, M.D.",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "France",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  admission to the intensive care unit,\r\u003cbr\u003e\r\u003cbr\u003e          -  with a proven COVID infection, responsible for acute respiratory failure\r\u003cbr\u003e\r\u003cbr\u003e          -  agree with participation to the study.\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  aged under 18\r\u003cbr\u003e\r\u003cbr\u003e          -  under legal protection\r\u003cbr\u003e\r\u003cbr\u003e          -  pregnant or breastfeeding\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Biological: blood sampling",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "ACE2 level change over time",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04337190",
			"start_date": "2020-04-03",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Impact of Previous Treatment With Angiotensin II Receptor Blockers in Patients With SARS-Cov2 Infection Admitted to the Intensive Care Unit on Survival and Severity of the Disease (COVID-ARA2)",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04337190",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";rachel.e.olson@duke.edu",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Adrian Hernandez, MD;Rachel Olson, RN",
			"corresp_author_lastname_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Completed Informed Consent\r\u003cbr\u003e\r\u003cbr\u003e          -  Age = 18 years old\r\u003cbr\u003e\r\u003cbr\u003e          -  Individual is currently working with a trial participating site where individuals\r\u003cbr\u003e             receive healthcare (\"healthcare worker\") or is associated with the site through\r\u003cbr\u003e             emergency services\r\u003cbr\u003e\r\u003cbr\u003e          -  Able to speak and read English or Spanish\r\u003cbr\u003e\r\u003cbr\u003e          -  At risk for COVID-19 infection through one or more of the following work exposures:\r\u003cbr\u003e\r\u003cbr\u003e               -  in the Intensive care unit, or\r\u003cbr\u003e\r\u003cbr\u003e               -  in the Emergency department, or\r\u003cbr\u003e\r\u003cbr\u003e               -  in Emergency Services, or\r\u003cbr\u003e\r\u003cbr\u003e               -  in a COVID-19 hospital unit/ward, or\r\u003cbr\u003e\r\u003cbr\u003e               -  in respiratory services\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Prior diagnosis of COVID-19 infection\r\u003cbr\u003e\r\u003cbr\u003e          -  Participation in another COVID-19 prophylaxis trial within 30 days of consent\r\u003cbr\u003e\r\u003cbr\u003e          -  Respiratory illness with new-onset fever (Temperature \u003e 100°F) or ongoing cough or\r\u003cbr\u003e             dyspnea within 14 days\r\u003cbr\u003e\r\u003cbr\u003e          -  Known allergy to HCQ or chloroquine\r\u003cbr\u003e\r\u003cbr\u003e          -  Congenital prolonged QT syndrome\r\u003cbr\u003e\r\u003cbr\u003e          -  Current or planned use of QT prolonging drugs (e.g. procainamide, disopyramide,\r\u003cbr\u003e             mexilitine, flecainide, propafenone, amiodarone, sotalol, cimetidine, dronedarone,\r\u003cbr\u003e             dofetilide, levofloxacin, ciprofloxacin, moxifloxacin)\r\u003cbr\u003e\r\u003cbr\u003e          -  End stage renal disease\r\u003cbr\u003e\r\u003cbr\u003e          -  Pre-existing retinopathy\r\u003cbr\u003e\r\u003cbr\u003e          -  Current or planned use of the following for treatment or prevention of COVID-19\r\u003cbr\u003e             infection:\r\u003cbr\u003e\r\u003cbr\u003e               -  Hydroxychloroquine (study drug) or chloroquine\r\u003cbr\u003e\r\u003cbr\u003e               -  azithromycin\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Drug: Hydroxychloroquine;Drug: Placebo oral tablet",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Number of participants testing positive for COVID-19 infection",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "allocation: randomized. intervention model: parallel assignment. primary purpose: prevention. masking: triple (participant, care provider, investigator). ",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04334148",
			"start_date": "April 2020",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine Trial (HERO-HCQ Trial)",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04334148",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  All patients with laboratory-confirmed COVID-19 in Wenzhou\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Suspected cases of COVID-19\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "days to cure;Days of turning negative on RT-PCR test",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04342702",
			"start_date": "2020-03-16",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "A Study on the Prospective Cohort Library of Novel Coronavirus Pneumonia in Southeran",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04342702",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"country": "Italy",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        - Residents in the following surgical specialities: cardiothoracic surgery, colon and\r\u003cbr\u003e        rectal surgery, general surgery, gynecology and obstetrics, gynecologic oncology,\r\u003cbr\u003e        neurological surgery, ophthalmic surgery, oral and maxillofacial surgery, orthopaedic\r\u003cbr\u003e        surgery, otorhinolaryngology, pediatric surgery, plastic and maxillofacial surgery,\r\u003cbr\u003e        urology, and vascular surgery\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Undergratuated and postgraduated students\r\u003cbr\u003e\r\u003cbr\u003e          -  Consultants in surgical areas\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Behavioral: COVID-surgRES questionaire",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Measure of the impact of COVID Emergency on surgical specialist training programs",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04338945",
			"start_date": "2020-03-15",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Impact of Pandemic COVID-19 on Surgical Specialities Residents in Italy: an Italian Polispecialistic Society of Young Surgeons (S.P.I.G.C.) Survey",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04338945",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "dmlevine@bwh.harvard.edu;dmlevine@bwh.harvard.edu",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "David Levine, MD;David M Levine, MD MPH MA",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "United States",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Positive reverse transcription polymerase chain reaction for severe acute respiratory\r\u003cbr\u003e             syndrome coronavirus 2\r\u003cbr\u003e\r\u003cbr\u003e          -  Age 18 and older\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  None\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "Suitable for discharge",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04339387",
			"start_date": "2020-03-01",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "COVID-19 Risk Stratification",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04339387",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";sujeet.jha@maxhealthcare.com;samreensiddiqui@maxhealthcare.com",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Sujeet Jha, MRCP (U.K);Sujeet Jha, MRCP (U.K);Samreen Siddiqui, PhD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "India",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Indian males and females currently living in India, OR\r\u003cbr\u003e\r\u003cbr\u003e          -  All the employees of Max Super Speciality Hospital, New Delhi, India\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Anyone who has filled the questionnaire once per household\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "COVID-19 positive case",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04339608",
			"start_date": "2020-04-02",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "A Prospective, Longitudinal, Observational Study of Healthcare Workers and the General Population to Watch for Flu-like Symptoms in Suspicion of COVID 19",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04339608",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";gitta@klilu.de;gitta@klilu.de",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Anselm Gitt, MD;Anselm Gitt, MD;Anselm Gitt, MD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Germany",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  In-patients fulfilling the following criteria:\r\u003cbr\u003e\r\u003cbr\u003e        SARS-CoV-2 infection In-patient treatment Written informed consent for participation in\r\u003cbr\u003e        observational study\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  No explicit medical exclusion criteria are stated to avoid selection bias.\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: Prospective oberservational registry",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Chest x-ray;Chest CT;Supportive care - ICU;Supportive care - oxygen therapy;Supportive care - ventilation;Medication;Therapeutic strategies;Lab parameters;Intra-hospital complications;Vital status at discharge",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04335188",
			"start_date": "2020-04-06",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "COVID-19 Registry Rhineland-Palatinate (Germany) - COVID-19 Disease Registry a National, Multicentre, Non-interventional, Prospective Observational Study",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04335188",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_lastname": "Cédric Annweiler, M.D., Ph.D.",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "France",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  confirmed COVID-19 defined by a positive RT-PCR to SARS-CoV-2\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  none\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: observation",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "symptoms of COVID-19 in older patients",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04343781",
			"start_date": "2020-03-22",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "National Survey of Symptoms of People Aged 70 and Overs Diagnosed With COVID-19",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04343781",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"country": "Australia",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: Exclusion Criteria:\r\u003cbr\u003e•\tCurrent psychosis\r\u003cbr\u003e•\tImminent suicidal risk\r\u003cbr\u003e•\tCurrent substance dependence (but not abuse) \r\u003cbr\u003eNo access to internet-based access to teleconferencing facility\r\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: Inclusion Criteria:\r\u003cbr\u003e•\tScore of greater than or equal to 3 on the General Health Questionnaire\r\u003cbr\u003e•\tAged at least 18 years\r\u003cbr\u003e•\tSufficient English language comprehension \r\u003cbr\u003e•\tAccess to teleconferencing platform\r\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "There are two arms to this trial. Arm 1: Problem Management Plus. Arm 2: Enhanced Treatment as Usual. Therapy is administered once-weekly 60 minute sessions by clinical psychologists over 6 weeks delivered via teleconferencing to groups of 4 people at a time. Problem Management Plus is a program developed by the World Health Organization. Across sessions the clinical psychologist will teach the following stress coping strategies: anxiety reduction, problem solving, behavioral activation, and accessing social support. This will occur will via educational sessions, group discussions via teleconference, and handouts. The duration of the study for any participant will conclude after a 2-month follow-up assessment, resulting in participation duration of 15 weeks.",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Anxiety and depression represent a composite primary outcome, as measured by the Hospital Anxiety and Depression scale.[Pretreatment (week 1), posttreatment (week 7), primary follow-up (week 15). ]",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "purpose: treatment; allocation: randomised controlled trial; masking: blinded (masking used);assignment: parallel;type of endpoint: efficacy;",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ACTRN12620000468921",
			"start_date": "20/04/2020",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Randomised Controlled Trial of Problem Management Plus versus Enhanced Treatment as Usual on Anxiety and Depression in People Distressed by Covid 19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ",
			"title_certainty": "prefilled",
			"url": "https://anzctr.org.au/ACTRN12620000468921.aspx",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "ceannweiler@chu-angers.fr",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Cedric ANNWEILER, MD, PhD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "France",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Hospitalisation in the acute care geriatric unit (Angers UH) or institutionalization\r\u003cbr\u003e             in St Nicolas during the isolation measures linked to the SARS-CoV-2 epidemic.\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Refusal to participate.\r\u003cbr\u003e\r\u003cbr\u003e          -  Contraindication posed by the medical team to proposing dematerialized communication.\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "Preferred means of communication for elderly people in isolation, hospitalized in the acute care geriatric unit or residing at St Nicolas nursing home (Angers UH).",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04333849",
			"start_date": "2020-03-27",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Telephony Or Videophony for Isolated elDerly in Maine-Et-Loire 49 During COVID-19",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04333849",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"country": "Australia",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: Prospective participants are excluded from the study if they decline the offer to participate in the study experimental arm. ",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: Any person aged 18 or older, confirmed with COVID-19 referred to home rehabilitation services delivered at Flinders medical Centre through the division of rehabilitation, aged and palliative care. ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "The primary aim of this study is to evaluate the efficacy and efficiency of two telerehabilitation interventions. The intervention consists of a rehabilitation intervention which focuses more on participation in usual activities and is offered via a coaching model to a virtual group of people. The intervention components are: identifying patient goals with therapist (1:1); and participation in virtual groups (up to 4 participants per session) with physiotherapist and occupational therapists which focus on increasing participation in life roles and usual activities. \u003cbr\u003eThe 1:1 session will last for approximately 45 minutes and will be followed by commencement of group sessions within 5 days.\u003cbr\u003eGroups adopt a coaching model where the therapist talks about common challenges, facilitates discussion and sharing of experiences and ideas and the group brainstorm and plan next steps together. The group sessions will last approximately 45 minutes and will be delivered 3 times per week for up to 4 weeks. \u003cbr\u003eAdherence will be measured using attendance logs. \u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Integration to community as measured on the Reintegration to Normal Living Index (RNLI) -  A 11-item questionnaire-based instrument that measures the degree to which individuals achieve reintegration into normal social activities (such as recreation, movement in the community, and interaction in family or other relationships). [Baseline, \u003cbr\u003eThree (3) months following baseline assessment. ]",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "purpose: treatment; allocation: randomised controlled trial; masking: blinded (masking used);assignment: parallel;type of endpoint: efficacy;",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ACTRN12620000443998",
			"start_date": "01/05/2020",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Home telerehabilitation for people with COVID-19: Implementing telehealth approaches to care and its effect on reintegration into the community                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ",
			"title_certainty": "prefilled",
			"url": "https://anzctr.org.au/ACTRN12620000443998.aspx",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"country": "Germany",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. Pregnant",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e                1. Aged 18 or older\u003cbr\u003e                2. Critically ill\u003cbr\u003e                3. COVID-19 and acute respiratory distress syndrome (ARDS) according to Berlin-Definition\u003cbr\u003e                4. No contra-indication to PiCCO-monitoring\u003cbr\u003e            ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "According to the standard of the ICU for COVID-19 and non-COVID-19 patients, routine data of patients with COVID-19 and ARDS including PiCCO-monitoring will be documented from the day of intubation until extubation. All measurements were repeated at least once per day.",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Extravascular lung water index EVLWI measured using TPTD (PiCCO; Pulsion Medical Systems; Feldkirechen Germany) daily from intubation until extubation",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "observational single-centre cohort study; comparison to a recent cohort of non-covid-19 patients with ards (see isrctn32938630) (diagnostic)",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ISRCTN10077335",
			"start_date": "19/03/2020",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "EVALUATION: Extravascular lung water index in patients with COVID-19: A prospective comparison to a recent cohort with non-COVID-19 ARDS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ",
			"title_certainty": "prefilled",
			"url": "http://isrctn.com/ISRCTN10077335",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";;;",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Veronique Michaud, PhD;Malavika Deodhar, PhD;Sweilem B Al Rihani, PharmD, PhD;Jacques Turgeon, PhD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "United States",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patient enrolled in a PACE organization during the implementation period;\r\u003cbr\u003e\r\u003cbr\u003e          -  PACE organization contractually receiving pharmacy services from CareKinesis;\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  No drug claims data available for the period of 2019-2020\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: Simulation of Repurposed Drugs for COVID-19",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "To determine the Medication Risk Score of de-identified PACE's participants using their current drug regimen.;To simulate the Medication Risk Score following the addition of different repurposed drugs against COVID-19 to their current drug regimen.;To compare the impact on Medication Risk Score before and after the addition of repurposed drugs for COVID-19.;To assess and compare the effects of various repurposed drugs for COVID-19 on each of the 5 factors computed by algorithms to derive the Medication Risk Score.",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04339634",
			"start_date": "2020-04-07",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04339634",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";claire.roger@chu-nimes.fr;claire.roger@chu-nimes.fr",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "CLAIRE ROGER;CLAIRE ROGER, MD, PhD;Claire Roger, MD, PhD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "France",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients admitted to ICU for suspected or proven SARS-Cov-2 infection, defined by\r\u003cbr\u003e             positive SARS-Cov-2 PCR or CT scan images\r\u003cbr\u003e\r\u003cbr\u003e          -  Patient \u003e or= 18 years\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patient study refusal\r\u003cbr\u003e\r\u003cbr\u003e          -  Patient already enrolled in the present study\r\u003cbr\u003e\r\u003cbr\u003e          -  Patient with respiratory illness with negative COVID-19 CT scan images and negative\r\u003cbr\u003e             COVID_19 PCR\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: No intervention",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Mortality at day 28",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04340466",
			"start_date": "2020-04-03",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management: the FRENCH CORONA Study",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04340466",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "Efstratios.Koutroumpakis@uth.tmc.edu;Efstratios.Koutroumpakis@uth.tmc.edu",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Efstratios Koutroumpakis, MD;Efstratios Koutroumpakis, MD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "United States",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients admitted to the hospital with symptoms of fever, sore throat, cough, nasal\r\u003cbr\u003e             congestion and/or dyspnea who were tested positive for SARS-CoV-2 by PCR\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients of high clinical suspicion for COVID-19 with only one negative PRC test for\r\u003cbr\u003e             SARS-CoV-2\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients with COVID-19 who do not require hospitalization\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Diagnostic Test: Electrocardiogram, telemetry, echocardiogram, laboratory values",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Prevalence of cardiomyopathy, myocardial infarction, heart failure, clinically significant arrhythmias, cardiogenic shock or cardiac arrest.",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04335630",
			"start_date": "2020-03-30",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Cardiovascular Manifestations of Hospitalized Patients With Coronavirus Disease 2019",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04335630",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";l.uhrenholt@rn.dk;l.uhrenholt@rn.dk",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Salome Kristensen, MD, PhD;Line Uhrenholt, MD;Line Uhrenholt, MD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Denmark",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        Group 1:\r\u003cbr\u003e\r\u003cbr\u003e          -  Diagnosed with RA, PsA, axSpA, SLE or AT and currently treated with either\r\u003cbr\u003e             conventional synthetic disease modifying antirheumatic drugs (csDMARDs), biologic\r\u003cbr\u003e             disease modifying antirheumatic drugs (bDMARDs), targeted synthetic disease modifying\r\u003cbr\u003e             antirheumatic drugs (tsDMARDs) or prednisolone.\r\u003cbr\u003e\r\u003cbr\u003e          -  Diagnosed with COVID-19 verified by Polymerase Chain Reaction (PCR) or other accepted\r\u003cbr\u003e             methods and hospitalized.\r\u003cbr\u003e\r\u003cbr\u003e          -  NOT diagnosed with disease known to cause either immunodeficiency or modification\r\u003cbr\u003e             (Human Immunodeficiency Virus [HIV], lymphoproliferative disease etc.).\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients (=18 years).\r\u003cbr\u003e\r\u003cbr\u003e          -  Ability and willingness to give written informed consent.\r\u003cbr\u003e\r\u003cbr\u003e          -  Ability to cooperate with research staff.\r\u003cbr\u003e\r\u003cbr\u003e        Group 2:\r\u003cbr\u003e\r\u003cbr\u003e          -  NOT diagnosed with an inflammatory disease\r\u003cbr\u003e\r\u003cbr\u003e          -  NOT treated with either csDMARDs, bDMARDs, tsDMARDs during the past 6 months or\r\u003cbr\u003e             current oral prednisolone treatment.\r\u003cbr\u003e\r\u003cbr\u003e          -  Diagnosed with COVID-19 verified by PCR or other accepted methods and hospitalized.\r\u003cbr\u003e\r\u003cbr\u003e          -  NOT diagnosed with disease known to cause either immunodeficiency or modification\r\u003cbr\u003e             (HIV, lymphoproliferative disease etc.).\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients (=18 years).\r\u003cbr\u003e\r\u003cbr\u003e          -  Ability and willingness to give written informed consent.\r\u003cbr\u003e\r\u003cbr\u003e          -  Ability to cooperate with research staff.\r\u003cbr\u003e\r\u003cbr\u003e        Group 3:\r\u003cbr\u003e\r\u003cbr\u003e          -  Diagnosed with RA, PsA, axSpA, SLE or AT and currently treated with either csDMARDs,\r\u003cbr\u003e             bDMARDs, tsDMARDs or prednisolone.\r\u003cbr\u003e\r\u003cbr\u003e          -  NOT hospitalised due to a COVID-19 infection.\r\u003cbr\u003e\r\u003cbr\u003e          -  NOT diagnosed with disease known to cause either immunodeficiency or modification\r\u003cbr\u003e             (HIV, lymphoproliferative disease etc.).\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients (=18 years).\r\u003cbr\u003e\r\u003cbr\u003e          -  Ability and willingness to give written informed consent.\r\u003cbr\u003e\r\u003cbr\u003e          -  Ability to cooperate with research staff.\r\u003cbr\u003e\r\u003cbr\u003e        Group 4:\r\u003cbr\u003e\r\u003cbr\u003e          -  Healthy subjects from the Danish Blood Donors.\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients (=18 years).\r\u003cbr\u003e\r\u003cbr\u003e          -  NOT diagnosed with an inflammatory disease.\r\u003cbr\u003e\r\u003cbr\u003e          -  NOT treated with either csDMARDs, bDMARDs, tsDMARDs during the past 6 months or\r\u003cbr\u003e             current oral prednisolone treatment.\r\u003cbr\u003e\r\u003cbr\u003e          -  NOT hospitalised due to a COVID-19 infection.\r\u003cbr\u003e\r\u003cbr\u003e          -  Ability and willingness to give written informed consent.\r\u003cbr\u003e\r\u003cbr\u003e          -  Ability to cooperate with research staff.\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: COVID-19 infection",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Disease activity",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04335747",
			"start_date": "2020-04-08",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04335747",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "chris.inchley@gmail.com",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Christopher Inchley, Phd",
			"corresp_author_lastname_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        Suspected covid-19 infection and age 0-18 years\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        Age \u003e18 years\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "Risk Factors;Immunulogical mechanisms;Long term outcome",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04335773",
			"start_date": "2020-04-01",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "COVID-19 in Hospitalised Norwegian Children - Risk Factors, Outcomes and Immunology",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04335773",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"country": "United Kingdom",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e                1. Prior receipt of any vaccines (licensed or investigational) \u003c = 30 days before enrolment\u003cbr\u003e                2. Planned receipt of any vaccine other than the study intervention within 30 days before and after each study vaccination\u003cbr\u003e                3. Prior receipt of an investigational or licensed vaccine likely to impact on interpretation of the trial data\u003cbr\u003e                4. Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate\u003cbr\u003e                5. Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent severe infections and chronic use of (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed)\u003cbr\u003e                6. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine\u003cbr\u003e                7. Any history of hereditary angioedema or idiopathic angioedema\u003cbr\u003e                8. Any history of anaphylaxis in relation to vaccination\u003cbr\u003e                9. Pregnancy, lactation or willingness/intention to become pregnant during the study\u003cbr\u003e                10. History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)\u003cbr\u003e                11. History of serious psychiatric condition likely to affect participation in the study\u003cbr\u003e                12. Bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture\u003cbr\u003e                13. Any other serious chronic illness requiring hospital specialist supervision\u003cbr\u003e                14. Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week\u003cbr\u003e                15. Suspected or known injecting drug abuse in the 5 years preceding enrolment\u003cbr\u003e                16. Any clinically significant abnormal finding on screening biochemistry, haematology blood tests or urinalysis\u003cbr\u003e                17. Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data\u003cbr\u003e                18. History of laboratory confirmed COVID-19\u003cbr\u003e                19. New onset of fever and a cough or shortness of breath in the 30 days preceding screening and/or enrolment\u003cbr\u003e            ",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e                1. Healthy adults aged 18 - 55 years\u003cbr\u003e                2. Able and willing (in the Investigator’s opinion) to comply with all study requirements\u003cbr\u003e                3. Willing to allow the investigators to discuss the volunteer’s medical history with their General Practitioner and access all medical records when relevant to study procedures\u003cbr\u003e                4. For females only, willingness to practice continuous effective contraception (see below) during the study and a negative pregnancy test on the day(s) of screening and vaccination\u003cbr\u003e                5. Agreement to refrain from blood donation during the course of the study\u003cbr\u003e                6. Provide written informed consent\u003cbr\u003e            ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003e                Volunteers will initially be required to complete an online screening. This is an initial confirmation of eligibility. Volunteers will initially be invited for a screening visit. Prior to attending they will have received written information about the study and had time to consider it. At the screening visit a doctor will explain about the study and answer any questions they may have. If the volunteer decides to take part, they will be asked to sign a consent form. The doctor will then check whether the volunteer is eligible to take part. This will involve taking a medical history, performing a physical examination, taking blood tests, urine tests, and measuring blood pressure and temperature.\u003cbr\u003e                The doctor will then write to the volunteers own GP to enquire about their medical health. If all the inclusion criteria are met and none of the exclusion criteria are present then the volunteer is invited to return for vaccination. Due to the need for rapid delivery of this study, there will be minimal flexibility around appointment dates.\u003cbr\u003e\u003cbr\u003e                Before vaccination, volunteers will be asked about their recent health to ensure that they are still medically fit. They will have blood tests taken and participants in groups 1 and 2 will be randomised (1:1) to receive either ChAdOx1 nCoV-19 or saline placebo. Group 3 participants will not be randomised and therefore not blinded.\u003cbr\u003e\u003cbr\u003e                Participants from group 1 or 3 will be vaccinated first. The first volunteer to receive the IMP will be vaccinated ahead of any other participants. The investigators and/or chair of DSMB will assess there are no safety concerns within 48 hours (±24h) post vaccination. The next 3 volunteers will be vaccinated with the IMP at least 1 hour apart. The inve",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "\u003cbr\u003e                1. Efficacy of candidate vaccine measured by virologically confirmed (PCR positive) symptomatic cases of COVID-19 over the course of 6 months\u003cbr\u003e                2. Safety of candidate vaccine measured by the occurrence of serious adverse events (SAEs) over the course of 6 months\u003cbr\u003e            ",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "interventional randomized controlled trial (prevention)",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ISRCTN15281137",
			"start_date": "26/03/2020",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "A phase I/II study to determine efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      ",
			"title_certainty": "prefilled",
			"url": "http://isrctn.com/ISRCTN15281137",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"country": "United Kingdom",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. Any woman not meeting the criteria.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e                1. Any pregnant woman hospitalised who has tested positive for COVID-19 will be included.\u003cbr\u003e                2. Aged 16-45 years.\u003cbr\u003e            ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003e                Research design:\u003cbr\u003e                This cohort study will use the UK Obstetric Surveillance System (UKOSS) to identify women hospitalized with pandemic novel coronavirus infection in pregnancy throughout a 6-month period. Participants will receive their usual management and information will be collected subsequently, detailing their treatment and outcomes. Research participants will not be contacted directly and no personally identifiable information (names, addresses or dates of birth will be collected.\u003cbr\u003e\u003cbr\u003e                Cohort identification:\u003cbr\u003e                Infected women will be identified through the UKOSS network of nominated reporting clinicians in each consultant-led maternity unit in the UK. Nominated reporting clinicians will be asked to report all pregnant women with confirmed pandemic novel coronavirus infection admitted to their unit. In view of the need for rapid and ongoing data analysis and production of guidance, we will use a specific web-based rapid reporting and data collection system for this study to enable UKOSS nominated clinicians to report cases as they occur. In addition, nominated clinicians will be sent a standard UKOSS reporting card each month to further enhance case ascertainment.\u003cbr\u003e\u003cbr\u003e                Comparison group identification:\u003cbr\u003e                Information about comparison women will be obtained from previously conducted UKOSS studies. Previous UKOSS studies have collected detailed demographic, pregnancy and delivery information about a cohort of over 1200 women giving birth in the UK identified from the same hospitals as infected women. This pragmatic approach has been adopted to allow risk factors for severe outcomes of pandemic influenza or novel coronavirus to be identified while minimizing the data collection burden on",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Incidence of pandemic COVID-19 in pregnancy assessed as proportion of pregnant women hospitalised with confirmed COVID-19 disease per 100,000 maternities during the study period",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "observational cohort study (other)",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ISRCTN40092247",
			"start_date": "20/03/2020",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Maternal and perinatal outcomes of pandemic COVID-19 in pregnancy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ",
			"title_certainty": "prefilled",
			"url": "http://isrctn.com/ISRCTN40092247",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";francois.dubos@chru-lille.fr",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "François Dubos, MD,PhD;François DUBOS, MD,PhD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "France",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  1st Line Consultation in Pediatric Emergencies\r\u003cbr\u003e\r\u003cbr\u003e          -  All reasons for consultation during working hours\r\u003cbr\u003e\r\u003cbr\u003e          -  Informed and written consent of a parent holder (only 1 authorized companion) and a\r\u003cbr\u003e             child of understanding age\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Refusal of participation by parents/child of decision age\r\u003cbr\u003e\r\u003cbr\u003e          -  No membership of a social security scheme (beneficiary or entitled)\r\u003cbr\u003e\r\u003cbr\u003e          -  No understanding of French\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Diagnostic Test: nasopharyngeal swab",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Prevalence of positivity of COVID-19 virus measured by rt-PCR",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04336761",
			"start_date": "April 2020",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Prevalence of Covid-19 in Children Admitted to Paediatric Emergency Departments During the Pandemic Period in France",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04336761",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "harry.hothi@nhs.net",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Harry Hothi, PhD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "United Kingdom",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients that have been treated with, and still have, a MAGEC rod.\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients that do not have a MAGEC rod implant.\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Device: MAGEC Spine Rod;Diagnostic Test: Titanium blood test",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Titanium level",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04337151",
			"start_date": "April 2020",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Blood Titanium Analysis of Patients With MAGEC Spine Rods in the COVID-19 Environment",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04337151",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"country": "Turkey",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  from covid 19 positive mothers\r\u003cbr\u003e\r\u003cbr\u003e          -  newborn mothers had not other condition or illness\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  from covid 19 negative mothers\r\u003cbr\u003e\r\u003cbr\u003e          -  childs\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: newborns from covid 19 positive mothers",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Evaluation of apgar status of newborns from covid 19 positive mothers",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04337320",
			"start_date": "2020-04-01",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Postnatal Outcomes of Covid 19 Positive Mothers Newborns",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04337320",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";Guido.Beldi@insel.ch;Guido.Beldi@insel.ch",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Guido Beldi, Prof. Dr.;Guido Beldi;Guido Beldi",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Switzerland",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Healthcare workers of the Department for Visceral Surgery and Medicine\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients of the Department for Visceral Surgery and Medicine\r\u003cbr\u003e\r\u003cbr\u003e          -  Written informed consent\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  No informed consent\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients with known COVID-19 infection before hospitalization in the investigators'\r\u003cbr\u003e             department\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "Fraction of healthcare workers infected with SARS-CoV-2",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04333862",
			"start_date": "2020-03-19",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Assessment of Covid-19 Infection Rates in Healthcare Workers Using a Desynchronization Strategy",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04333862",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "ibnsky@yahoo.es;ibnsky@yahoo.es",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "IVAN J NUNEZ GIL, MD, PhD, MSc;IVAN J NUÑEZ J NUÑEZ GIL, MD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Spain",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients discharged (deceased or alive) from any hospital center with a confirmed\r\u003cbr\u003e             diagnosis or a COVID-19 high suspicion.\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  There are no exclusion criteria, except for the patient's explicit refusal to\r\u003cbr\u003e             participate.\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Combination Product: Observational (registry)",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Death",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04334291",
			"start_date": "2020-03-23",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "International COVID19 Clinical Evaluation Registry: HOPECOVID19. (Health Outcome Predictive Evaluation for COVID19)",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04334291",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "lgh19870628@126.com",
			"corresp_author_email_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. The child was combined with other acute and chronic somatic diseases, hereditary diseases, and hearing and hearing impairment; 2. The parents of the child refused to cooperate after the investigator explained; 3. The child could not participate in the full study; 4. The child was participating or was participated in related experimental research projects in the last 8 months. ",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. A diagnosis of an ASD according to the fifth edition of Diagnostic and Statistical Manual(DSM-5); 2. Preschool Children (3-7 years);DQ (Development Quotient) \u003e 75; 3. Mothers were conscious and gave informed consent. ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Experimental group:WeChat-based parenting education;Control groop:Electronic Manual + Teaching Plan;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Psycho Educational Profile,PEP;Self-Rated Anxiety Scale,SAS;Self-Rated Depression Scale,SDS;Parenting Stress Index-Short Form,PSI-SF;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "non randomized control",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031772",
			"start_date": "2020-01-10",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Impact of WeChat-based parenting education for children with autism spectrum disorder and their mothers during the epidemic of Coronavirus disease 2019 (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=52165",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "liuliu9027@163.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: Exclusion criteria: incomplete case data. ",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. suspicion of COVID-19 based on the Novel Coronavirus Pneumonia Prevention and Control Program 7th edition (National Health Commission of China, 2020b);\r\u003cbr\u003e2. aged \u003e16 years.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Case series:Nursing care;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Fever;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031770",
			"start_date": "2020-01-22",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Public health emergencies of hospital emergency nursing human resource database to development and construction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=52148",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "rjager@beatcovidtrial.com",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Rama Jager, M.D.",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "United States",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          1. Adults residing in the United States aged 18 years or older proficient in\r\u003cbr\u003e             understanding and reading the English language who wish to participate in the fight\r\u003cbr\u003e             against COVID-19 by providing self-reported health information.\r\u003cbr\u003e\r\u003cbr\u003e          2. Ability to complete electronic informed consent process.\r\u003cbr\u003e\r\u003cbr\u003e          3. Ability to use the internet and check email regularly.\r\u003cbr\u003e\r\u003cbr\u003e          4. Consent to provide a HIPAA waiver of health information to share protected health\r\u003cbr\u003e             information.\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        1. Inability to provide regular updates to their health status when contacted by the BEAT\r\u003cbr\u003e        COVID study personnel via email or SMS.\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "Health Outcomes",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04337762",
			"start_date": "2020-04-06",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "A Virtual Observational Protocol to Gain Longitudinal Data in Participants to Help Understand COVID-19 Spread and Disease Progression",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04337762",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "xavier.monnet@aphp.fr",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Xavier Monnet, MD.PhD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "France",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Confirmed or suspected SARS-Cov2 cases\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients admitted to ICU, defined as a unit in which patients can receive\r\u003cbr\u003e             vasopressors.\r\u003cbr\u003e\r\u003cbr\u003e          -  Monitored by a transpulmonary thermodilution system (PiCCO2 (Pulsion Medical Systems,\r\u003cbr\u003e             Feldkirchen, Germany) or EV1000 (Edwards Lifesciences, Irvine, United States of\r\u003cbr\u003e             America).\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  SARS Cov-2 Negative\r\u003cbr\u003e\r\u003cbr\u003e          -  Refusal to participate in the study\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Device: Transpulmonary thermodilution;Device: Echocardiography",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Body temperature;Blood pressure;Pulse (heart rate);Respiratory rate;Data provided by transpulmonary thermodilution-CI;Data provided by transpulmonary thermodilution-GEDV;Data provided by transpulmonary thermodilution-EVLW;Data provided by transpulmonary thermodilution-PVPI;Incidence of abnormal laboratory test results",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04337983",
			"start_date": "2020-04-15",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Hemodynamic Characteristics of Patients With SARS-CoV-2: PiCCOVID Study",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04337983",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";;;;;;;;;Francois.Morin@chu-angers.fr",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Philippe LE CONTE, Pr;Thomas FLAMENT, Dr;Louis SOULAT, Pr;Nicolas MARJANOVIC, Dr;Francis COUTURAUD, Dr;Laure BAUDIN, Dr;Karim TAZAROURTE, Pr;Thomas DELOMAS, Dr;Luc-Marie JOLY, Pr;François MORIN, Dr",
			"corresp_author_lastname_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patient with COVID-19 confirmed by positive RT-PCR or considered as probable by the\r\u003cbr\u003e             in-charge physician,\r\u003cbr\u003e\r\u003cbr\u003e          -  =18 years old,\r\u003cbr\u003e\r\u003cbr\u003e          -  Not requiring respiratory assistance and/or other intensive care\r\u003cbr\u003e\r\u003cbr\u003e          -  Not subject to a limitation of active therapeutics\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  History of pneumonectomy\r\u003cbr\u003e\r\u003cbr\u003e          -  Any reason making chest ultrasonography impossible\r\u003cbr\u003e\r\u003cbr\u003e          -  Any reason making 14-day follow-up impossible\r\u003cbr\u003e\r\u003cbr\u003e          -  Patient opposition to research participation.\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Procedure: Follow-up at 14 days",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Risk of unfavourable outcome at D14",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04338100",
			"start_date": "2020-04-06",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Point Of Care UltraSonography to Perform Risk-stratification of Patients With Suspected or Confirmed COVID-19 - POCUSCO Study",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04338100",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";doyen.d@chu-nice.fr",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Denis DOYEN;Denis DOYEN",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "France",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        - All consecutive patients with COVID-19 infection admitted to the ICU or hospitalized\r\u003cbr\u003e        because of severe form (eg: hypoxia, orthopnea, pneumonitis, kidney insufficiency) will be\r\u003cbr\u003e        included\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        - Patients under 18 years\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "Determine the incidence of cardiomyopathies and venous thromboembolism",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04335162",
			"start_date": "2020-02-28",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Screening of Cardiovascular Complications in Patients With COVID-19",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04335162",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "yanggang201301@163.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. Patients who have received treatment in the ICU due to death or transfer out within 24 hours;\r\u003cbr\u003e2. The medical record information is seriously missing, according to the case report form, the data is missing more than 50% of patients.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. Patients with Corona Virus Disease 2019 admitted to Wuhan First Hospital and Wuhan Jinyintan Hospital ICU from January 1, 2020 to March 31, 2020;\r\u003cbr\u003e2. Patients diagnosed with Corona Virus Disease 2019 according to WHO diagnostic criteria (including nucleic acid examination and chest CT examination);\r\u003cbr\u003e3. Patients whose mechanical ventilation is required, FIO2 is greater than or equal to 60%, and intravenous vasoactive drugs are required to maintain blood pressure.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "survival group:none;death group:none;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "survival;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "factorial",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031752",
			"start_date": "2020-01-01",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Observational study for myocardial injury and cardiac function in critically ill patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=52135",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "happyzhupengfei@163.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. Participated in other clinical trials 4 weeks before the start of this study;\r\u003cbr\u003e2. Patients with hypertension, diabetes or other chronic diseases;\r\u003cbr\u003e3. People with other system basic diseases;\r\u003cbr\u003e4. Patients with other pathogens before or at the time of admission;\r\u003cbr\u003e5. Patients who recur after discharge;\r\u003cbr\u003e6. Pregnant or lactating women;\r\u003cbr\u003e7. Those who do not sign the informed consent.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. Aged 18-45 years old men and women;\r\u003cbr\u003e2. Inpatients;\r\u003cbr\u003e3. According to the novel coronavirus diagnosis and treatment plan (Seventh Edition), it meets the diagnostic criteria of light and general type and achieves discharge standard after treatment;\r\u003cbr\u003e4. Signing informed consent.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Case group:N/A;control group:N/A;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Colour Sonography;electrocardiogram;Pulmonary function(TLC, FVC, FEV1, DLCO);",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "factorial",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031751",
			"start_date": "2020-04-01",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Novel coronavirus pneumonia (COVID-2019) patients' prognosis and their influence on heart and lung function                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=52130",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "gilles.mangiapan@chicreteil.fr",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Gilles MANGIAPAN, MD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "France",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients admitted to hospital with proven COVID-19 infection with respiratory signs\r\u003cbr\u003e             warranting a chest CT scan\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patient not agreeing to have his or her data collected for the study\r\u003cbr\u003e\r\u003cbr\u003e          -  Unconscious patient\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: No special intervention",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Characteristics of pulmonary ultrasound for Covid-19 patients",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04341766",
			"start_date": "2020-03-31",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Prospective Descriptive Study on the Evolution of Pulmonary Ultrasound in Patients Hospitalized for Covid19",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04341766",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";Delphine.garrigue@chru-lille.fr",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Delphine Garrigue, MD;Delphine Garrigue, MD",
			"corresp_author_lastname_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Clinical criteria for suspicion of Covid-19 in an epidemic period: Signs of acute\r\u003cbr\u003e             respiratory infection (rhinorrhea, odynophagia, cough, dyspnea, polypnea, signs of\r\u003cbr\u003e             struggle, pathological auscultation) or syndrome influenza or acute respiratory\r\u003cbr\u003e             distress (hypoxia, polypnoea, signs of respiratory distress).\r\u003cbr\u003e\r\u003cbr\u003e          -  Consultation in the emergency departement\r\u003cbr\u003e\r\u003cbr\u003e          -  Non-opposition agree\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Respiratory impairment related to another identified cause than Covid-19, in\r\u003cbr\u003e             particular a rapid diagnostic test flu-positive\r\u003cbr\u003e\r\u003cbr\u003e          -  Severe patient from the outset with transfer to intensive care within 12 hours of\r\u003cbr\u003e             admission to the Emergency Department\r\u003cbr\u003e\r\u003cbr\u003e          -  No social security coverage (beneficiary or entitled person)\r\u003cbr\u003e\r\u003cbr\u003e          -  Poor understanding of French\r\u003cbr\u003e\r\u003cbr\u003e          -  Refusal to participate\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "Rate of secondary aggravation",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04341792",
			"start_date": "April 2020",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Predictive Biomarkers of Secondary Aggravation in Covid-19 Suspect Patient Admitted to Emergency Departments During an Epidemic",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04341792",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "bjorn.stessel@jessazh.be",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Bjorn Stessel, Dr",
			"corresp_author_lastname_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  12 intubated and mechanically ventilated COVID-19 patients admitted to the ICU at a\r\u003cbr\u003e             single time point (29/03/2020).\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  None\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "to investigate the prevalence and identify possible risk factors of the occurrence of a DVT in these patients at the ICU.",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04338932",
			"start_date": "2020-04-17",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "COVID-19 and Deep Venous Thrombosis: a Cross-sectional Study",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04338932",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";jose.diaz-miron@childrenscolorado.org;jose.diaz-miron@childrenscolorado.org",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Jose L Diaz-Miron, MD;Jose L Diaz-Miron, MD;Jose L Diaz-Miron, MD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "United States",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusions:\r\u003cbr\u003e\r\u003cbr\u003e          1. Trauma patients presenting to our institution as trauma activation\r\u003cbr\u003e\r\u003cbr\u003e          2. Trauma patients presenting to our institution as trauma alerts\r\u003cbr\u003e\r\u003cbr\u003e        Exclusions:\r\u003cbr\u003e\r\u003cbr\u003e          1. Patients who require prompt surgical exploration based on physical exam findings\r\u003cbr\u003e             (minimize delays in transport to the operating room)\r\u003cbr\u003e\r\u003cbr\u003e          2. Patients with an open chest injury\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Diagnostic Test: Ultrasound lung imaging as part of FAST+ evaluation",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Correlation of FAST+ pulmonary findings with active COVID infection",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04340479",
			"start_date": "2020-05-01",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "The Use of Ultrasound in Establishing COVID-19 Infection as Part of a Trauma Evaluation",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04340479",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";;d.harding@qmul.ac.uk",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Sam (Saidi) Mohiddin, MD;Federica Marelli-Berg, PhD;Daniel E Harding, BM BCh",
			"corresp_author_lastname_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Patient groups\r\u003cbr\u003e\r\u003cbr\u003e          1. COVID-19+ (n=140) All patients =18 years old admitted to Barts NHS Trust will be\r\u003cbr\u003e             eligible for this group.\r\u003cbr\u003e\r\u003cbr\u003e          2. COVID-19+ Myocardial injury+ (n=20) All patients =18 years old admitted to Barts NHS\r\u003cbr\u003e             Trust who have a diagnosis of COVID-19 and evidence of myocardial injury (troponin\r\u003cbr\u003e             \u003e99th centile). We will exclude patients from this cohort who have significant chronic\r\u003cbr\u003e             kidney disease (eGFR =30 or on dialysis) or septic shock. We will also exclude\r\u003cbr\u003e             patients with a diagnosis of chronic heart failure and obstructive coronary artery\r\u003cbr\u003e             disease (treated or untreated).\r\u003cbr\u003e\r\u003cbr\u003e          3. COVID-19+ Complication+ (n=20) All patients =18 years old admitted to the Barts NHS\r\u003cbr\u003e             Trust who have a diagnosis of COVID-19 and who develop a complication directly related\r\u003cbr\u003e             to the viral infection. Specifically, we will recruit patients who require admission\r\u003cbr\u003e             to ICU, develop acute respiratory distress syndrome (ARDS) or secondary hemophagocytic\r\u003cbr\u003e             lymphohistiocytosis (as defined in the referenced paper13).\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Biological: COVID-19 exposure",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "T-cell immunophenotype",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04340921",
			"start_date": "2020-04-10",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "The Role of Adaptive Immunity in COVID-19 Associated Myocardial Injury",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04340921",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "chris.kclai@cuhk.edu.hk",
			"corresp_author_email_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: Refusal to consent",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. Adult \u003e= 18 years old;\r\u003cbr\u003e2. Laboratory confirmed COVID-19 infection (i.e. detection of SARS-CoV-2 virus by RT-PCR in one or more clinical specimens);\r\u003cbr\u003e3. Provide direct clinical care to confirmed COVID-19 patients.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Patient:Surface swab and air sample collection;Healthcare providers:Surface swab from personal protective equipment;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Environment viral load;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031712",
			"start_date": "2020-04-01",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "A cross-sectional observation study to delineate the degree of environmental contamination by SARS-CoV-2 in the clinical environment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51650",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "leetangbaba@163.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: N/A",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: All medical team members who completed the sleep therapy questionnaire survey;\r\u003cbr\u003eThe subject who signed an informed consent form;",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "For the mild new coronary pneumonia: General Ward Group:Nil;For the severe new coronary pneumonia: ICU Group:Nil;Support staff: Logistics group:Nil;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "PSQI;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "cross-sectional",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031707",
			"start_date": "2020-03-01",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Study for sleep quality of medical teams members moved to Hubei for the fighting of novel coronavirus pneumonia (COVID-19) pandemic                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=52079",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";brannock.robert@mayo.edu;brannock.robert@mayo.edu",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Tushar Patel;Robert Brannock;Robert Brannock",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "United States",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Able to provide informed consent\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  None\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Diagnostic Test: Collection of breath sample",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Breath volatile organic compound profiles;Utility of breath profiles for disease diagnosis or prognosis",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04341012",
			"start_date": "2019-09-10",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Development of a Breath Analysis Test for Disease Diagnosis and Prognosis",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04341012",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "qingleigao@hotmail.com;qingleigao@hotmail.com",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Qinglei Gao, Dr.;Qinglei Gao, Dr.",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patient is 18 to 80 years old female.\r\u003cbr\u003e\r\u003cbr\u003e          -  Patient must have histologically confirmed either type of gynecological malignancies.\r\u003cbr\u003e\r\u003cbr\u003e          -  Chemotherapy must be essential for the patient.\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Diagnosed or suspected patients with covid-19 pneumonia, according to the symptom,\r\u003cbr\u003e             nucleic acid tests, antibody tests for SARS-CoV-2, or CT scan of the lungs.\r\u003cbr\u003e\r\u003cbr\u003e          -  Patient has a prior SARS-CoV-2 infection without clinical cure for 28 days.\r\u003cbr\u003e\r\u003cbr\u003e          -  Patient has close contact with diagnosed or suspected SARS-CoV-2 infected person\r\u003cbr\u003e             within 14 days.\r\u003cbr\u003e\r\u003cbr\u003e          -  Patient has inadequate general condition, severe complication or organ dysfunction not\r\u003cbr\u003e             fit for chemotherapy (based on the judgment of researchers).\r\u003cbr\u003e\r\u003cbr\u003e          -  Patient or the family refuses to sign the informed consent.\r\u003cbr\u003e\r\u003cbr\u003e          -  Patient does not cooperate in following up.\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Drug: Chemotherapy",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "SARS-CoV-2 infection",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04341480",
			"start_date": "2020-04-10",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "The Safety of Chemotherapy for Patients With Gynecological Malignancy in High-risk Region of COVID-19, a Prospective Cohort Study",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04341480",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "liyingshuai2013@163.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. Patients with primary and secondary cardiovascular, cerebrovascular, renal, endocrine, neurological and blood system diseases, tumors and tuberculosis;\r\u003cbr\u003e2. Patients who have participated in or are participating in other clinical trials within one month;\r\u003cbr\u003e3. Patients with mental disorders who can not express their feelings;\r\u003cbr\u003e4. There are other situations that are not suitable to be included in the study.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. Meet the history of COVID-19 confirmed in accordance with the diagnosis and treatment plan of COVID-19(trial seventh edition);\r\u003cbr\u003e2. Meet the discharge standards of COVID-19(trial seventh edition);\r\u003cbr\u003e3. Meet the diagnosis standard of qi deficiency and phlegm stasis syndrome;\r\u003cbr\u003e4. Patients aged 18-70 years old, 28 days after discharge, still have abnormal manifestations on lung CT;\r\u003cbr\u003e5. Patients willing to sign informed consent.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Experimental Group:Xiaotan Sanjiefang granule;Control Group:placebo (contain 5% test drug);",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Lung CT Score;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "parallel",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031672",
			"start_date": "2020-04-01",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Development and application of TCM body regulating protection scheme for the convalescent population of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51940",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"country": "Turkey",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  endometriosis patients\r\u003cbr\u003e\r\u003cbr\u003e          -  no psychiatric illness\r\u003cbr\u003e\r\u003cbr\u003e          -  no antidepressant use\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  women who had not endometriosis\r\u003cbr\u003e\r\u003cbr\u003e          -  no extra health conditions\r\u003cbr\u003e\r\u003cbr\u003e          -  women younger than 18 and older than 45\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "Covid 19 Anxiety levels in Endometriosis Patients",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04337346",
			"start_date": "2020-04-05",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Endometriosis Patients Covid 19 Anxiety",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04337346",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";novartis.email@novartis.com",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Novartis Pharmaceuticals;Novartis Pharmaceuticals",
			"corresp_author_lastname_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        Patients eligible for inclusion in this Treatment Plan have to meet all of the following\r\u003cbr\u003e        criteria:\r\u003cbr\u003e\r\u003cbr\u003e        Written patient informed consent or assent must be obtained prior to start of treatment.\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients aged = 6 years\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients clinically diagnosed with SARS-CoV-2 infection, either through positive serum\r\u003cbr\u003e             antibodies (IgM or IgG); or by PCR; or by other approved diagnostic methodology.\r\u003cbr\u003e             Patients with presumptive diagnosis of COVID-19 (other respiratory causes ruled out\r\u003cbr\u003e             and SARS-CoV-2 test pending) may be included.\r\u003cbr\u003e\r\u003cbr\u003e          -  Adult and adolescent patients (=12years), who meet one of the below criteria\r\u003cbr\u003e\r\u003cbr\u003e               -  Respiratory frequency = 30/min\r\u003cbr\u003e\r\u003cbr\u003e               -  Oxygen saturation = 93% on room air (FiO2=0.21)\r\u003cbr\u003e\r\u003cbr\u003e               -  Arterial oxygen partial pressure (PaO2)/ fraction of inspired oxygen (FiO2)\r\u003cbr\u003e                  \u003c300mmHg(1mmHg=0.133kPa) (corrective formulation should be used for higher\r\u003cbr\u003e                  altitude regions (over 1000m).\r\u003cbr\u003e\r\u003cbr\u003e        AND\r\u003cbr\u003e\r\u003cbr\u003e        -- Patients with lung imaging showing pulmonary infiltrates (chest X-ray or CT scan)\r\u003cbr\u003e\r\u003cbr\u003e        Pediatric patients (=6-\u003c12 years) who meet one of the below criteria (where appropriate):\r\u003cbr\u003e\r\u003cbr\u003e          -  Shortness of breath\r\u003cbr\u003e\r\u003cbr\u003e          -  Oxygen saturation \u003c92% on room air (Fi)2=0.21)\r\u003cbr\u003e\r\u003cbr\u003e          -  Labored breathing (e.g. wheezing, flaring of nostrils, three concave sign), cyanosis,\r\u003cbr\u003e             intermittent apnea.\r\u003cbr\u003e\r\u003cbr\u003e          -  Lethargy or convulsions\r\u003cbr\u003e\r\u003cbr\u003e          -  Refusal to eat or difficulty with feeding; signs of dehydration\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients eligible for this Treatment Plan must not meet any of the following criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  History of hypersensitivity to any drugs or metabolites of similar chemical classes as\r\u003cbr\u003e             ruxolitinib\r\u003cbr\u003e\r\u003cbr\u003e          -  Presence of severely impaired renal function defined by serum creatinine \u003e 2 mg/dL\r\u003cbr\u003e             (\u003e176.8 µmol/L), or have estimated creatinine clearance \u003c 30 ml/min measured or\r\u003cbr\u003e             calculated by Cockroft Gault equation or calculated by the updated bedside Schwartz\r\u003cbr\u003e             equation.\r\u003cbr\u003e\r\u003cbr\u003e          -  Pregnant or nursing (lactating) women.\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients who are NOT able to understand and to comply with treatment instructions and\r\u003cbr\u003e             requirements unless health care proxy is able to provide consent.\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Drug: Ruxolitinib",
			"intervention_name_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04337359",
			"start_date": "2020-04-05",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04337359",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";;miguelguia7@gmail.com;antmesquinas@gmail.com",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Miguel Guia;Antonio Esquinas;Miguel Guia;Antonio Esquinas",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Spain",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients with acute respiratory failure due to COVID-19 who have initiated NIV or CPAP\r\u003cbr\u003e             based on assistant clinician decision\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients with imediate indication to invasive mechanical ventilation\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients with any formal contraindication to noninvasive respiratory support\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: Monitoring for aggravation;Other: Evaluate HACOR score effectivity in this patients",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "HACOR score efficacy;HACOR score addaptation",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04342104",
			"start_date": "2020-04-01",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "NIV and CPAP Failure Predictors in COVID-19 Associated Respiratory Failure",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04342104",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "alboraie@azhar.edu.eg",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Mohamed Alboraie, MD, MRCP(UK)",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "United States;Egypt;Iran, Islamic Republic of;Egypt;Iran, Islamic Republic of;United States",
			"country_certainty": "generated",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  physicians working in endoscopy units worldwide\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  physicians not working in endoscopy units worldwide\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: Practice details",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Effect of GI societies recommendations on prevention of SARS-CoV-2 infection;To measure the percentage change in performed endoscopic procedure in response to COVID-19",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04342637",
			"start_date": "2020-04-10",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Gastrointestinal Endoscopy in the Era of COVID-19: a Multinational Survey",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04342637",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "azengin@istanbul.edu.tr",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Ayse Zengin Alpözgen",
			"corresp_author_lastname_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  between the ages of 18-65\r\u003cbr\u003e\r\u003cbr\u003e          -  works from home\r\u003cbr\u003e\r\u003cbr\u003e          -  works in the office before isolation\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  have any systemic disease that may affect on musculoskeletal system such as\r\u003cbr\u003e             fibromyalgia, myofacial pain syndrome, etc.\r\u003cbr\u003e\r\u003cbr\u003e          -  have any vision problem\r\u003cbr\u003e\r\u003cbr\u003e          -  have difficulty of understanding and following online survey\r\u003cbr\u003e\r\u003cbr\u003e          -  have any physical disability\r\u003cbr\u003e\r\u003cbr\u003e          -  have self-reported computer use for less than four hours on a typical workday\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "The Rapid Office Strain Assessment (ROSA)",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04342208",
			"start_date": "2020-04-10",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Evaluate the Working Environments of Individuals Working From Home During Covid-19 Outbreak",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04342208",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";jwsander@wakehealth.edu",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "John W Sanders, MD, MPH\u0026TM;Wake Forest Baptist Medical Center",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "United States",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  All clients and health care worker of WFBH are eligible for enrollment.\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Health care workers who do not receive medical services through WFBH will not be\r\u003cbr\u003e             enrolled.\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "Seroprevalence of SARS-CoV-2 infection in the general population of North Carolina;Seroprevalence of SARS-CoV-2 infection among health care workers of North Carolina",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04342884",
			"start_date": "April 2020",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "A Multicenter, Prospective Study of COVID-19 Using Real-Time Syndromic Surveillance, Scheduled At-home Serologic Testing, and Electronic Health Records",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04342884",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "j.m.weehuizen-2@umcutrecht.nl",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Weehuizen",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "The Netherlands",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: -\tSevere Covid-19 defined as NEWS-2 score \u003e5 or admission to the ICU needing ventilation or pressure support. \u003cbr\u003e-\tContra-indications for hydroxychloroquine or chloroquine\u003cbr\u003e-\tKnown pregnancy, not using adequate contraception and having a chance of being pregnant (unless a negative pregnancy test is documented) or breast-feeding\u003cbr\u003e-\tUnable to take oral medication (chloroquine and hydroxychloroquine can be administered through tube feeding and is considered oral administration)\u003cbr\u003e-\tIdentified allergies to 4-aminoquinoline\u003cbr\u003e-\tSevere diseases of the blood system \u003cbr\u003e-\t6-phosphate dehydrogenase deficiency \u003cbr\u003e-\tHistory of acute myocardial infarction, unstable angina pectoris, severe arrhythmia (frequent ventricular, ventricular tachycardia, ventricular fibrillation) in recent 6 months; New York Heart Association (NYHA) level III-IV\u003cbr\u003e-\tCorrected QT interval (QTc) = 480ms on baseline electrocardiogram. (The treatment guideline states: An electrocardiogram is made before start chloroquine and hydroxychloroquine)\u003cbr\u003e-\tUncorrected severe hypokalaemia (\u003c 2,5 mmol/l) or uncorrected severe hypomagnesemia (\u003c 0.6 mmol/l) \u003cbr\u003e-\tPancreatitis\u003cbr\u003e-\tConcomitant medication that affect drug absorption, metabolism and excretion, that can induce QT interval prolongation: \u003cbr\u003eo\tAmiodarone, disopyramide, flecainide, ibutailide, kinidine, sotalol, \u003cbr\u003eo\tchlorpromazine, citolapram, escitalopram, haloperidol, pimozide, \u003cbr\u003eo\tazitromycine, claritromycine, erytromycine, moxifloxacine, trimethoprim/sulfamethoxazole, \u003cbr\u003eo\tDimperidon, ondansetron,\u003cbr\u003eo\tMethadon, \u003cbr\u003eo\tAnagrelide, arseentrioxide, droperidol, pentamidine, sevofluraan, vandetanib. \u003cbr\u003e-\tRefusal to participate expressed by patient or legally authorized representative if they are present \u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: -\tPatients (=18 years of age) admitted to the hospital with confirmed COVID-19 and not needing admission to MC or ICU\u003cbr\u003e-\tPatient has moderate to severe COVID-19. This will be defined as patients with NEWS-2 score = 5. \u003cbr\u003e-\tWilling and able to give written informed consent",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "All treatment arms contain standard supportive care during hospital and:\u003cbr\u003e1.\tChloroquine arm: loading dose 600mg as chloroquine base followed by 300mg 12 hours later followed by 300mg twice a day; total treatment duration 5 days (same dose as LCI guideline) \u003cbr\u003e2.\tHydroxychloroquine arm: loading dose 400mg bid followed by 200mg twice a day; total treatment duration 5 days (same dose as LCI guideline)\u003cbr\u003e3.\tNo antiviral treatment arm",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "-\tComposite endpoint with disease progression defined as a NEWS2score = 7 within 14 days or resulting in admission to Intensive/Medium Care unit or resulting in death within 14 days.",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "\u003cbr\u003e                        randomized: no, \u003cbr\u003e                        masking: none, \u003cbr\u003e                        control: not applicable, \u003cbr\u003e                        group: undefined, \u003cbr\u003e                        type: 2 or more arms, randomized\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NL8490",
			"start_date": "12/04/2020",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "An open label randomized controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID-19\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ",
			"title_certainty": "prefilled",
			"url": "https://trialregister.nl/trial/8490",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "thomas@interactivestudios.nl",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Timmers",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "The Netherlands",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: No possession of smartphone or tablet, no understanding of Dutch language.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: Patients need to have a smartphone and install the app that is provided to them through their own hospital. ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "NA",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Number of people that download the app and choose to check their health, perform the self-assessment and use the 7 day self-reported symptoms diary for one or more days.",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "\u003cbr\u003e                        randomized: no, \u003cbr\u003e                        masking: unknown, \u003cbr\u003e                        control: not applicable, \u003cbr\u003e                        group: undefined, \u003cbr\u003e                        type: not applicable\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NL8501",
			"start_date": "23/03/2020",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Using eHealth to support COVID-19 self-assessment and collection of self-reported health data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ",
			"title_certainty": "prefilled",
			"url": "https://trialregister.nl/trial/8501",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "roi.anteby@sheba.health.gov.il;roi.anteby@sheba.health.gov.il",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Roi Anteby, MD;Roi Anteby, MD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Israel",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  All patients visiting the ER of Sheba Medical Center between January 1 - March 31 in\r\u003cbr\u003e             the following years: 2017, 2018, 2019, 2020\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients less than 18 years of age\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: COVID-19 Pandemic",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Rates of emergency visits needing surgical consult;The ratio of severe presentations to non-severe presentations",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04338672",
			"start_date": "2020-04-05",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "The Impact of the Coronavirus Disease 2019 (Covid-19) Outbreak on Emergency Room Attendances of Surgical Patients at a Tertiary Medical Center",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04338672",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";h-donnadieu_rigole@chu-montpellier.fr;h-donnadieu_rigole@chu-montpellier.fr",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Hélène Donnadieu-Rigole, MD PhD;Hélène Donnadieu-Rigole, MD PhD;hélène Donnadieu-Rigole, doctor",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "France",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  \u003e18 years\r\u003cbr\u003e\r\u003cbr\u003e          -  Accept study\r\u003cbr\u003e\r\u003cbr\u003e          -  live with an addiction\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion criteria:\r\u003cbr\u003e\r\u003cbr\u003e        - not being able to answer the questionnaire\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "Evolution of consumption;Evolution of consumption",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04343339",
			"start_date": "2020-04-08",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Evolution of Psychoactive Substances Consumption in Connection With COVID-19 Containement - EPILOGUE",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04343339",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";pierre-emmanuel.falcoz@chru-strasbourg.fr;pierre-emmanuel.falcoz@chru-strasbourg.fr",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Pierre-Emmanuel FALCOZ, MD, PhD;Pierre-Emmanuel FALCOZ, MD, PhD;Pierre-Emmanuel FALCOZ, MD, PhD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "France",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patient over the age of 18;\r\u003cbr\u003e\r\u003cbr\u003e          -  Diagnostic COVID-19 by RT-PCR;\r\u003cbr\u003e\r\u003cbr\u003e          -  Hospitalisation in resuscitation for the management of complications related to\r\u003cbr\u003e             COVID-19\r\u003cbr\u003e\r\u003cbr\u003e          -  Implanted ECMO-VV during hospitalisation;\r\u003cbr\u003e\r\u003cbr\u003e          -  Patient agreeing to participate in the study\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Sujet under guardianship or trusteeship\r\u003cbr\u003e\r\u003cbr\u003e          -  Sujet under safeguard of justice\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "Retrospective description of COVID-19 patients receiving respiratory ECMO-VV supplementation and what happens to them",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04343404",
			"start_date": "2020-04-01",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "STUDY ECMO-COVID-19 : PLACE OF VENOVENOUS ECMO IN THE MANAGEMENT OF SEVERE REFRACTORY ARDS ASSOCIATED WITH SARS-COV-2",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04343404",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";;twiga00@yahoo.com",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Tjhin Wiguna, PhD;Tjhin Wiguna, PhD;Tjhin Wiguna, PhD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Indonesia",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Willing to participate on this study by signing the informed consent\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  No\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "Depression;Anxiety symptoms;Stress related problems;Behavior and emotional problem among children and adolescents",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04343664",
			"start_date": "2020-04-12",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Mental Health Assessment Among Community Member During the Covid-19 Pandemic in Indonesia",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04343664",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"country": "France",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e•\tPatients with known allergy to hydroxychloroquine or chloroquine,  \r\u003cbr\u003e•\tPatients with known allergy to azithromycine, erythromycine, or all antibiotics belonging to the macrolide family. \r\u003cbr\u003e•\tPatients currently treated with Tamoxifen\r\u003cbr\u003e•\tPatients with known contra-indication to treatment with the study drug, including retinopathy, G6PD deficiency, QT prolongation and severe hepato-cellular insufficiency. \r\u003cbr\u003e•\tPregnant or breastfeeding women. Women of childbearing potential (WOCBP, as defined in appendix 2) should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication.  If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\r\u003cbr\u003e\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e•\tAll types of locally advanced and metastatic malignancy\r\u003cbr\u003e•\tMale/female participants\r\u003cbr\u003e•\tAge\u003e18 y.o. \r\u003cbr\u003e•\tSigned informed consent for participation in the study \r\u003cbr\u003e•\tNo restriction on Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) Performance Status \r\u003cbr\u003e•\tSubject should not have received a prior systemic anti-viral treatment for Covid19 disease. \r\u003cbr\u003e\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range 800\u003cbr\u003eF.1.3 Elderly (\u003e=65 years) yes\u003cbr\u003eF.1.3.1 Number of subjects for this age range 200\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eTrade Name: Plaquenil 200mg\u003cbr\u003eProduct Name: hydroxychloroquine\u003cbr\u003ePharmaceutical Form: Coated tablet\u003cbr\u003e\u003cbr\u003eTrade Name: Azithromycine\u003cbr\u003ePharmaceutical Form: Coated tablet\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Main Objective: To determine the prevalence and the 3-months incidence of SARS-CoV-2 in cancer patients (Part A).\u003cbr\u003eTo evaluate the Covid-19 disease mortality rate in cancer patients treated by hydroxychloroquine and azithromycin (Part B).\u003cbr\u003e;Secondary Objective: To evaluate the safety, Covid-19 disease severity, response to cancer treatment, Progression-free survival (PFS), cancer mortality, and Overall Survival (OS) of cancer patients infected by SARS-Cov2.\u003cbr\u003eTo follow the evolution of SARS-CoV-2 infection and viral load in different compartments (nasal epithelia, blood and urine) during the course of therapy.\u003cbr\u003eTo evaluate the impact of mutation shifts in SARS-CoV-2 genotype (in sever cases only).\u003cbr\u003eTo follow the humoral and cellular immune responses to the virus, to cancer and control antigens during infection with SARS-CoV-2.\u003cbr\u003eTo deconvolute SARS-CoV-2-specific MHC class I and II binding epitopes to follow T cell responses with tetramers and Elispot assays, as well as cancer antigens (NY-ESO-1, MAGEn, preprocalcitonin, actinin...)-specific responses.\u003cbr\u003e;Primary end point(s): The primary endpoints of the study are for the: \u003cbr\u003eo\tPart A: prevalence at first visit and 12 weeks cumulative incidence (in a competing risk model with mortality) of SARS-CoV-2 positive subjects (RT-PCR)\u003cbr\u003eo\tPart B: Covid-19 disease specific mortality;Timepoint(s) of evaluation of this end point: 12 weeks and 12 month (mortality)",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: yes\u003cbr\u003erandomised: no\u003cbr\u003eopen: yes\u003cbr\u003esingle blind: no\u003cbr\u003edouble blind: no\u003cbr\u003eparallel group: yes\u003cbr\u003ecross over: no\u003cbr\u003eother: no\u003cbr\u003eif controlled, specify comparator, other medicinial product: no\u003cbr\u003eplacebo: no\u003cbr\u003eother: yes\u003cbr\u003eother specify the comparator: standard treatment\u003cbr\u003enumber of treatment arms in the trial: 2\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001250-21-FR",
			"start_date": "03/04/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "COVID-19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease upon Hydroxychloroquine and Azithromycin Therapy in French Cancer patients - ONCOVID                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001250-21",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "hiruz.ctu@uzgent.be",
			"corresp_author_email_certainty": "prefilled",
			"country": "Belgium",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e-Patients with known history of serious allergic reactions, including anaphylaxis, to any of the study medications, or any component of the product.\r\u003cbr\u003e-mechanical ventilation \u003e 24 h at randomization\r\u003cbr\u003e-clinical frailty scale above 3\r\u003cbr\u003e-active bacterial or fungal infection\r\u003cbr\u003e-unlikely to survive beyond 48h\r\u003cbr\u003e-neutrophil count below 1500 cells/microliter\r\u003cbr\u003e-platelets below 50.000/microliter\r\u003cbr\u003e-Patients enrolled in another investigational drug study\r\u003cbr\u003e-patients on high dose systemic steroids (\u003e 8 mg methylprednisolone or equivalent for more than 1 month) for COVID-19 unrelated disorder\r\u003cbr\u003e-patients on immunosuppressant or immunomodulatory drugs\r\u003cbr\u003e-patients on current anti-IL1 or anti-IL6 treatment\r\u003cbr\u003e-signs of active tuberculosis\r\u003cbr\u003e-serum transaminase levels \u003e5 times upper limit of normal, unless there are clear signs of cytokine release syndrome defined by LDH \u003e300 IU/L and ferritin \u003e700 ng/ml\r\u003cbr\u003e-history of (non-iatrogenic) bowel perforation or diverticulitis\r\u003cbr\u003e- Pregnant or breastfeeding females (all female subjects deemed of childbearing potential by the investigator must have negative pregnancy test at screening)\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e-Recent (=6 days of flu-like symptoms or malaise yet =16 days of flu-like symptoms or malaise prior to randomization) infection with COVID-19.\r\u003cbr\u003e-COVID-19 diagnosis confirmed by antigen detection test and/or PCR and/or positive serology, or any emerging and validated diagnostic laboratory test for COVID-19 within this period.\r\u003cbr\u003e-In some patients, it may be impossible to get a confident laboratory confirmation of COVID-19 diagnosis after 24h of hospital admission because viral load is low and/or problems with diagnostic sensitivity. In those cases, in absence of an alternative diagnosis, and with highly suspect bilateral ground glass opacities on recent (\u003c24h) chest-CT scan (confirmed by a radiologist and pulmonary physician as probable COVID-19), and a typical clinical and chemical diagnosis with signs of cytokine release syndrome, a patient can be enrolled as probable COVID-19 infected. In all cases, this needs confirmation by later seroconversion.\r\u003cbr\u003e-Presence of hypoxia defined as\r\u003cbr\u003ePaO2/FiO2 below 350 while breathing room air in upright position or PaO2/FiO2 below 280 on supplemental oxygen and immediately requiring high flow oxygen device or mechanical ventilation\r\u003cbr\u003e-signs of cytokine release syndrome defined as\r\u003cbr\u003eANY of the following\r\u003cbr\u003e-serum ferritin concentration \u003e1000 mcg/L and rising since last 24h\r\u003cbr\u003e-single ferritin above 2000 mcg/L in patients requiring immediate high flow oxygen device or mechanical ventilation\r\u003cbr\u003e-lymphopenia defined as \u003c800 lymphocytes/microliter and two of the following extra criteria\r\u003cbr\u003eFerritin \u003e 700 mcg/L and rising since last 24h\r\u003cbr\u003e-increased LDH (above 300 IU/L) and rising since last 24h\r\u003cbr\u003e-D-Dimers \u003e 1000 ng/mL and rising since last 24h\r\u003cbr\u003e-CRP above 70 mg/L and rising since last 24h and absence of bacterial infection\r\u003cbr\u003e-if three of the above are present at admission, no need to document 24h rise\r\u003cbr\u003e-Chest X-ray and/or CT scan showing bilateral infiltrates within last 2 days\r\u003cbr\u003e-Admitted to specialized COVID-19 ward or an ICU ward taking care of COVID-19 patients\r\u003cbr\u003e-Age = 18 years\r\u003cbr\u003e-Male or Female\r\u003cbr\u003e-Willing and able to provide informed consent or legal representative willing to provide informed consent\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range 171\u003cbr\u003eF.1.3 Elderly (\u003e=65 years) yes\u003cbr\u003eF.1.3.1 Number of subjects for this age range 171\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eTrade Name: Kineret\u003cbr\u003eProduct Name: Kineret\u003cbr\u003ePharmaceutical Form: Solution for injection in pre-filled syringe\u003cbr\u003eINN or Proposed INN: ANAKINRA\u003cbr\u003eCAS Number: 143090-92-0\u003cbr\u003eConcentration unit: mg milligram(s)\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 100-\u003cbr\u003e\u003cbr\u003eTrade Name: RoActemra\u003cbr\u003eProduct Name: RoActemra\u003cbr\u003ePharmaceutical Form: Concentrate for solution for infusion\u003cbr\u003eINN or Proposed INN: TOCILIZUMAB\u003cbr\u003eCAS Number: 375823-41-9\u003cbr\u003eOther descriptive name: TOCILIZUMAB\u003cbr\u003eConcentration unit: mg/ml milligram(s)/millilitre\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 20-\u003cbr\u003e\u003cbr\u003eTrade Name: RoActemra\u003cbr\u003eProduct Name: RoActemra\u003cbr\u003ePharmaceutical Form: Solution for injection in pre-filled syringe\u003cbr\u003eINN or Proposed INN: TOCILIZUMAB\u003cbr\u003eCAS Number: 375823-41-9\u003cbr\u003eOther descriptive name: TOCILIZUMAB\u003cbr\u003eConcentration unit: mg milligram(s)\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 162-\u003cbr\u003e\u003cbr\u003eTrade Name: SYLVANT\u003cbr\u003eProduct Name: SYLVANT\u003cbr\u003ePharmaceutical Form: Powder for concentrate for solution for infusion\u003cbr\u003eINN or Proposed INN: Siltuximab\u003cbr\u003eCAS Number: 541502-14-1\u003cbr\u003eConcentration unit: mg milligram(s)\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 400-\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Main Objective: Study if blockade of IL-6 +/- IL-1 to block the cytokine storm and acute lung injury in comparison with usual care reduces time to clinical improvement as defined by an increase of more than 2 on the 6 point ordinal scale or discharge from the hospital;Secondary Objective: -to investigate whether treatment with either tocilizumab, siltuximab, anakinra or combinations thereof\u003cbr\u003e-improves oxygenation\u003cbr\u003e-causes defervescence, measured as time to first fever-free 48h period\u003cbr\u003e-improves features of secondary haemophagocytic lymphohistiocytosis\u003cbr\u003e-improves features of secondary haemophagocytic lymphohistiocytosis in relation to serum IL-6 and IL-1\u003cbr\u003e-affects clinical outcome in relation to IL-6 and IL-1 levels\u003cbr\u003e-affects the rate of nosocomial infection\u003cbr\u003e-affects progression to mechanical ventilation, high oxygen delivery device, and/or ARDS in non-ventilated patients\u003cbr\u003e-affects length of dependency of ventilation in ventilated patients\u003cbr\u003e-affects all-cause mortality rate at 4 and 20 weeks post inclusion\u003cbr\u003e-affects long term 10-20 week follow up clinical status and lung function\u003cbr\u003e-is safe (number of AEs/SAEs)\u003cbr\u003e-When there is a significant association between IL-6 blockade and time to clinical improvement, tocilizumab and siltuximab will be compared versus usual care ;Primary end point(s): Time to clinical improvement (defined as the time from randomization to either an improvement of two points on a six-category ordinal scale measured daily till day 28 or discharge from the hospital or death)\u003cbr\u003e1. Death\u003cbr\u003e2. Hospitalized, on invasive mechanical ventilation or ECMO;\u003cbr\u003e3. Hospitalized, on non-invasive ventilation or high flow oxygen devices;\u003cbr\u003e4. Hospitalized, requiring supplemental oxygen\u003cbr\u003e5. Hospitalized, not requiring supplemental oxygen\u003cbr\u003e6. Not hospitalized;Timepoint(s) of evaluation of this end point: 28 days",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: yes\u003cbr\u003erandomised: yes\u003cbr\u003eopen: yes\u003cbr\u003esingle blind: no\u003cbr\u003edouble blind: no\u003cbr\u003eparallel group: yes\u003cbr\u003ecross over: no\u003cbr\u003eother: no\u003cbr\u003eif controlled, specify comparator, other medicinial product: no\u003cbr\u003eplacebo: no\u003cbr\u003eother: yes\u003cbr\u003eother specify the comparator: standard of care\u003cbr\u003enumber of treatment arms in the trial: 6\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001500-41-BE",
			"start_date": "03/04/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome. - COV-AID                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001500-41",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"country": "Australia",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: Confirmed diagnosis of a pathogen unrelated to the objectives of this study and no indication or likelihood of co-infection with a relevant pathogen\r\u003cbr\u003e\r\u003cbr\u003eRefusal by participant, parent, or appropriate representative.\r\u003cbr\u003e\r\u003cbr\u003eAny other reason, as determined by the Lead Investigator or treating clinician, that the patient should not be included in the study, in-line with ICH GCP (E6 R2) requirements and the Australian Code for Responsible Conduct of Research (2018).\r\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: Suspected or proven novel Coronavirus (nCoV) infection as main reason for admission or presentation to hospital or clinic.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Exposure to COVID-19.\u003cbr\u003e\u003cbr\u003eParticipant involvement is required, including but not limited to extra nasopharyngeal swabs, blood draws, as well as possible surveys (local site intervention is bound to ISARIC protocol).\u003cbr\u003eThere may be follow-up after discharge, at 3 and 6 month timepoints (protocol is evolving).",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Describe the clinical features of COVID-19.\u003cbr\u003e\u003cbr\u003e(This is verbatim from submitted protocol)[Due to the nature of the evolving pandemic, there is no timeline for the assessment of primary timepoints. ];Describe the response to treatment, including supportive care and novel therapeutics, based on data linkage to medical records. (composite primary outcome)\u003cbr\u003e\u003cbr\u003e(This is verbatim from submitted protocol)\u003cbr\u003e[Due to the nature of the evolving pandemic, there is no timeline for the assessment of primary timepoints.]",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "purpose: natural history;duration: longitudinal;selection: defined population;timing: prospective;",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ACTRN12620000444987",
			"start_date": "07/04/2020",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections COVID-19 Research Response Trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ",
			"title_certainty": "prefilled",
			"url": "https://anzctr.org.au/ACTRN12620000444987.aspx",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";;eduardoinsignarescarrione@gmail.com;yohanny.andrade2@gmail.com",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "yohanny andrade, researcher;oswaldo leyva, researcher;EDUARDO INSIGNARES-CARRIONE, Research Direc.;YOHANNY ANDRADE, INVESTIGATOR",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Colombia",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        - to. Covid 19 positives b. Some of the characteristic symptoms of covid 19: fever,\r\u003cbr\u003e        odynophagia, respiratory distress.\r\u003cbr\u003e\r\u003cbr\u003e        c. Age between 18 years and 80 years\r\u003cbr\u003e\r\u003cbr\u003e        Criteria Exclusion:\r\u003cbr\u003e\r\u003cbr\u003e          -  to. Covid 19 negatives b. Kidney failure IV / VI. c. Congestive heart failure. d.\r\u003cbr\u003e             Patients taking anticoagulants, particularly warfarin sodium\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Drug: chlorine dioxide 3000 ppm",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "negative testing of covid19",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04343742",
			"start_date": "2020-04-01",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID 19",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04343742",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients with diagnosis of Covid-19 .\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients refuse to participate in the study\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: Follow up",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Demographics of Coronavirus Disease 2019 (COVID-19) in the cohort group;Clinical manifestations of Coronavirus Disease 2019 (COVID-19);Laboratory data of included Coronavirus Disease 2019 (COVID-19) cohort;Radiological features of Coronavirus Disease 2019 (COVID-19) cohort",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04339322",
			"start_date": "2020-05-01",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Characteristics and Outcome of COVID-19 Among Egyptian Patients",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04339322",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";alison.gibbons@nih.gov;alison.gibbons@nih.gov",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Joyce Y Chung, M.D.;Alison Gibbons;Alison Gibbons",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "United States",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        -  INCLUSION CRITERIA:\r\u003cbr\u003e\r\u003cbr\u003e        In order to be eligible to participate in this study, an individual must meet all of the\r\u003cbr\u003e        following criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  18 years of age and older.\r\u003cbr\u003e\r\u003cbr\u003e          -  Able to read and write English.\r\u003cbr\u003e\r\u003cbr\u003e          -  Able to provide informed consent online using study website.\r\u003cbr\u003e\r\u003cbr\u003e        EXCLUSION CRITERIA:\r\u003cbr\u003e\r\u003cbr\u003e        There are no exclusion criteria for this study.\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "NIMH COVID Study survey - adult responses",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04339790",
			"start_date": "2020-04-16",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Mental Health Impact of COVID-19 Pandemic on NIMH Research Participants and Volunteers",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04339790",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";yocum007@umn.edu",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Matthew Yocum, MD;Matthew Yocum, MD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "United States",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  patients under investigation for COVID-19\r\u003cbr\u003e\r\u003cbr\u003e          -  patients that are positive for COVID-19 at UMMC and Bethesda\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        - ultrasound contraindication such as overlying skin wound\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Diagnostic Test: Point-of-Care Ultrasonography (POCUS)",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "POCUS Score - Lungs;POCUS Score - Heart",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04339998",
			"start_date": "2020-04-15",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS)",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04339998",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";heini.kanervo@uzgent.be;",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Hannelore Denys, MD, PhD;Heini Kanervo, RN;Hannelore Denys",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Belgium",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  = 18 years of age\r\u003cbr\u003e\r\u003cbr\u003e          -  Histologically confirmed cancer\r\u003cbr\u003e\r\u003cbr\u003e          -  Receive systemic therapy (including chemotherapy, targeted small-molecule therapy,\r\u003cbr\u003e             anticancer monoclonal antibody, immunotherapy, endocrine therapy, or investigational\r\u003cbr\u003e             agent) (either exclusively or in combination with other anticancer therapy) between\r\u003cbr\u003e             February 14, 2020 and March 31, 2020 (Note: Patients whose systemic treatment\r\u003cbr\u003e             administration was initially planned for this period but was modified, delayed,\r\u003cbr\u003e             stopped, or withheld due to COVID-19 measures are also eligible for inclusion)\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Insufficient understanding of the Dutch language\r\u003cbr\u003e\r\u003cbr\u003e          -  Severe cognitive impairment\r\u003cbr\u003e\r\u003cbr\u003e          -  Acute psychiatric crisis\r\u003cbr\u003e\r\u003cbr\u003e          -  Not able to give informed consent\r\u003cbr\u003e\r\u003cbr\u003e          -  Confirmed or clinically suspected COVID-19\r\u003cbr\u003e\r\u003cbr\u003e          -  Endocrine therapy in (neo)adjuvant setting (Note: Patients whose (neo)adjuvant\r\u003cbr\u003e             systemic treatment was initially planned as chemotherapy, targeted small-molecule\r\u003cbr\u003e             therapy, anticancer monoclonal antibody, immunotherapy, or investigational agent\r\u003cbr\u003e             (either exclusively or in combination in combination with other anticancer therapy)\r\u003cbr\u003e             but was modified to endocrine therapy due to COVID-19 measures are also eligible for\r\u003cbr\u003e             inclusion)\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: Survey administration",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Distress at baseline measured by the COVID-19 Peritraumatic Distress Index (CPDI); in terms of proportions (0-28 vs = 29).;Depression at baseline measured by the 7-item depression subscale of the 21-item Depression, Anxiety, and Stress Scale (DASS-21) (DASS-21—Depression); in terms of proportions (0-4 vs = 5).;Anxiety at baseline measured by the 7-item anxiety subscale of the DASS-21 (DASS-21—Anxiety); in terms of proportions (0-3 vs = 4).;Stress at baseline measured by the 7-item stress subscale of the DASS-21 (DASS-21—Stress); in terms of proportions (0-7 vs = 8).",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04340219",
			"start_date": "2020-03-30",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "A Prospective Cohort Study Investigating Oncology-patient-reported Anxiety, Mood, and Quality of Life During the COVID-19 Pandemic (ONCOVID Trial)",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04340219",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "insepsis@otenet.gr",
			"corresp_author_email_certainty": "prefilled",
			"country": "Greece",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e• Age below 18 years\u003cbr\u003e• Denial for written informed consent\u003cbr\u003e• Any stage IV malignancy\u003cbr\u003e• Any do not resuscitate decision\u003cbr\u003e• Active tuberculosis (TB) as defined by the co-administration of drugs for the treatment of TB\u003cbr\u003e• Infection by the human immunodeficiency virus (HIV)\u003cbr\u003e• Any primary immunodeficiency\u003cbr\u003e• Oral or IV intake of corticosteroids at a daily dose equal or greater than 0.4 mg prednisone or greater the last 15 days.\u003cbr\u003e• Any anti-cytokine biological treatment the last one month\u003cbr\u003e• Medical history of systemic lupus erythematosus\u003cbr\u003e• Medical history of multiple sclerosis or any other demyelinating disorder.\u003cbr\u003e• Pregnancy or lactation. Women of child-bearing potential will be screened by a urine pregnancy test before inclusion in the study\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e• Age equal to or above 18 years\u003cbr\u003e• Male or female gender\u003cbr\u003e• In case of women, unwillingness to remain pregnant during the study period.\u003cbr\u003e• Written informed consent provided by the patient or by one first-degree relative/spouse in case of patients unable to consent\u003cbr\u003e• Confirmed infection by SARS-CoV-2 virus using molecular techniques as defined by the World Health Organization11\u003cbr\u003e• Organ dysfunction defined as the presence of at least one of the following conditions: \u003cbr\u003e - Total SOFA score greater than or equal to 2; \u003cbr\u003e - Involvement of the lower respiratory tract\u003cbr\u003e• Laboratory documentation of MAS or immune dysregulation. MAS is documented by the findings of any serum ferritin greater than 4,420ng/ml. immune dysregulation is documented by the combination of two findings: a) serum ferritin equal to or lower than 4,420ng/ml; and b) less than 5,000 receptors of the membrane molecule of HLA-DR on the cell membrane of blood CD14-monocytes or less than 30 MFI of HLA-DR on the cell membrane of blood CD14-monocytes as counted by flow cytometry.\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range 20\u003cbr\u003eF.1.3 Elderly (\u003e=65 years) yes\u003cbr\u003eF.1.3.1 Number of subjects for this age range 20\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eTrade Name: Kineret\u003cbr\u003eProduct Name: Anakinra\u003cbr\u003ePharmaceutical Form: \u003cbr\u003e\u003cbr\u003eTrade Name: RoActemra\u003cbr\u003eProduct Name: Tocilizumab\u003cbr\u003ePharmaceutical Form: Concentrate for solution for infusion\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Main Objective: Our aim is to conduct one trial of personalized immunotherapy in patients with SARS-CoV-2 associated with organ dysfunction and with laboratory findings of macrophage activation syndrome or immune dysregulation. These patients will be selected by the use of a panel of biomarkers and laboratory findings and they will be allocated to immunotherapy treatment according to their needs.  ;Secondary Objective: Not applicable;Primary end point(s): The study primary endpoint is composite and contains the achievement of at least one of the following goals or both goals after 7 days (study visit of day 8):\u003cbr\u003e• At least 25% decrease of baseline total SOFA score or increase of the pO2/FiO2 ratio by at least 50%\u003cbr\u003e• Clinical improvement of lung involvement\u003cbr\u003ePatients discharged from hospital alive before study visit of day 8 are considered achieving the primary endpoint. Patients dying before study visit of day 8 are considered non-achieving the primary endpoint.;Timepoint(s) of evaluation of this end point: Visit study day 8",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: no\u003cbr\u003erandomised: no\u003cbr\u003eopen: yes\u003cbr\u003esingle blind: no\u003cbr\u003edouble blind: no\u003cbr\u003eparallel group: no\u003cbr\u003ecross over: no\u003cbr\u003eother: no\u003cbr\u003eif controlled, specify comparator, other medicinial product: \u003cbr\u003eplacebo: \u003cbr\u003eother: \u003cbr\u003enumber of treatment arms in the trial: 2\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001039-29-GR",
			"start_date": "01/04/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "EFFICIENCY IN MANAGEMENT OF ORGAN DYSFUNCTION ASSOCIATED WITH INFECTION BY THE NOVEL SARS-CoV-2 VIRUS (COVID-19) THROUGH A PERSONALIZED IMMUNOTHERAPY APPROACH: THE ESCAPE CLINICAL TRIAL - PERSONALIZED IMMUNOTHERAPY FOR SARS-CoV-2 ASSOCIATED ORGAN DYSFUCTION                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001039-29",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"country": "Australia",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: Individuals aged \u003c18 years old.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: Patients admitted to ICU at the Royal Brisbane \u0026 Women's Hospital with suspected or proven severe COVID-19 infection, prescribed hydroxychloroquine as part of their routine management.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Based on preclinical and non-randomised studies, the Royal Brisbane and Women’s Hospital Intensive Care Unit clinical Consultant Medical Staff, in agreement with the Infectious Diseases Department and the Pharmacy Department, have decided that all patients admitted to the ICU with COVID-19 infection should receive hydroxychloroquine as standard care. Therefore, hydroxychloroquine is NOT considered a trial intervention for the purpose of this study.\u003cbr\u003e\u003cbr\u003eThe dose of hydroxychloroquine used for COVID-19 infection is extrapolated from that in common use for malaria and other approved indications. However, the organ dysfuction that accompanies critical illness suggests dosing is likely to require adjustment. This study will adjust the dose of hydroxychloroquine using therapeutic drug monitoring (TDM) to a goal concentration known to be safe. The observation period for TDM will be a total of up to 10 days or until the time of ICU discharge, which ever is sooner.\u003cbr\u003e\u003cbr\u003eAs is routine practice at the RBWH ICU, TDM will be led by the senior ICU pharmacist after initiation of therapy. Trough venous blood samples (3 ml) will be taken via an indwelling arterial cannula. The first TDM should ideally occur before the administration of the FIRST MAINTENANCE DOSE, provided the appropriate loading dose schedule has been completed. Sampling thereafter can occur every 24-48 hours to confirm the appropriateness of ongoing dosing as guided by the Pharmacy and Medical Team. Blood samples will be transported to Queensland Pathology on the Herston Campus for drug analysis. Prescribing of initial and ongoing/revised dosing will remain the responsibility of medical officers, whilst fidelity of the intervention will be maintained through pharmacy dosing adjustment notes which are subjected to ",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Dose adjustment required to attain a steady-state target trough hydroxychloroquine concentration of 0.24mg/L using TDM (proportion of patients / magnitude of adjustments)\u003cbr\u003e\u003cbr\u003eDose adjustment data will be collected and maintained by the senior ICU clinical pharmacist.[Up to the point of ICU discharge, in the first 10 days after commencement of initial HCQ dose, ]",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "purpose: treatment; allocation: non-randomised trial; masking: open (masking not used);assignment: single group;type of endpoint: pharmacokinetics;",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ACTRN12620000447954",
			"start_date": "31/03/2020",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Use of therapeutic drug monitoring (TDM) to optimise oral/enteral hydroxychloroquine dosing in critically ill patients with COVID-19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ",
			"title_certainty": "prefilled",
			"url": "https://anzctr.org.au/ACTRN12620000447954.aspx",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "recoverytrial@ndph.ox.ac.uk",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Nunn",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "United Kingdom",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e                1. Patients will be excluded if they have a medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he/she were to participate in the trial\u003cbr\u003e                2. In addition, if the attending clinician believes that there is a specific contra-indication to one of the active drug treatment arms, then the patient will be excluded from randomisation to that arm\u003cbr\u003e            ",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e                1. Aged at least 18 years\u003cbr\u003e                2. Hospitalised\u003cbr\u003e                3. SARS-CoV-2 infection\u003cbr\u003e            ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003e                RECOVERY is a randomised trial among adults hospitalised for COVID-19. Eligible patients are randomly allocated between several treatment arms, each to be given in addition to the usual standard of care in the participating hospital: No additional treatment vs lopinavir + ritonavir vs interferon 1ß vs low-dose corticosteroids vs hydroxychloroquine. For patients for whom not all the trial arms are appropriate or at locations where not all are available, randomisation will be between fewer arms.\u003cbr\u003e\u003cbr\u003e                RECOVERY has an adaptive trial design. The interim trial results will be monitored by an independent Data Monitoring Committee (DMC). The DMC will assess whether the randomised comparisons in the study have provided evidence on mortality that is strong enough (with a range of uncertainty around the results that is narrow enough) to affect national and global treatment strategies. In such a circumstance, the DMC will inform the Trial Steering Committee who will make the results available to the public and amend the trial arms accordingly. New trial arms can be added as evidence emerges that other candidate therapeutics should be evaluated.\u003cbr\u003e\u003cbr\u003e                Eligible patients are randomly allocated between several treatment arms, each to be given in addition to the usual standard of care in the participating hospital: No additional treatment vs Lopinavir-Ritonavir vs Interferon 1ß vs Low-dose Corticosteroids vs Hydroxychloroquine.\u003cbr\u003e                For patients for whom not all the trial arms are appropriate or at locations where not all are available, randomisation will be between fewer arms.\u003cbr\u003e\u003cbr\u003e                Drug dosage and duration:\u003cbr\u003e                Lopinavir 400 mg + ritonavir 100 mg: by mouth (or nasogastric tube) every 12 hours for 10 days or unti",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Number of hospitalised patients who died within 28 days of randomisation, data collected via a secure web-based case report form",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "randomised adaptive trial (treatment)",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ISRCTN50189673",
			"start_date": "19/03/2020",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Randomized evaluation of COVID-19 therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ",
			"title_certainty": "prefilled",
			"url": "http://isrctn.com/ISRCTN50189673",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"country": "Australia",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: Severe distress based on K10 (scores 30-50 very high distress) as these participants would require a more intensive therapeutic approach.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: Diagnosis of IBD: Crohn’s disease, ulcerative colitis or indeterminate colitis established using standard criteria (we will ask for the details of patient's gastroenterologist, and these will be verified by our team); \r\u003cbr\u003eDistress: at least mild distress on K10 (scores 20-29); \r\u003cbr\u003eAge: 18 years and older; \r\u003cbr\u003eOther: Australians, able to read and write in English, with access to internet to participate in online intervention, able to download Zoom and available to participate for approx. 30 minutes for 4 consecutive days (likely in the evening).",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Expressive/gratitude writing intervention – This group will participate in the adapted evidenced-based 4-day writing program (Pennebaker 1997). Participants will meet with the facilitator (a researcher with a Psychology degree) using Zoom in a group format four times in one week for approx. 30 minutes (25 minutes of writing time). Daily e-mail reminders will be sent during the 4 days of writing. Session structure – 1 min to complete the distress VAS measure (before), 5 minutes write any reflection from last session, 15 minutes spent writing about your thoughts and feelings, 5 minutes writing about the things you are grateful for, 1 min to complete the distress VAS measure (after). The instruction each day will be (adapted from Pennebaker): \u003cbr\u003e“Please write about your thoughts and feelings about your IBD and the recent situation with COVID-19. Try to select something that you had a strong reaction to – perhaps this was a thought that was challenging or unpleasant. Feel free to really let go and explore your very deepest emotions and thoughts. You might tie your topic to your relationships with others, including parents, lovers, friends or relatives, to your past, your present, your future, or to who you have been, who you would like to be, or who you are now. All of your writing will be completely confidential. Please don’t worry about spelling, sentence structure, or grammar. Feel free to type or write by hand.” \u003cbr\u003eParticipants will not be asked to share their writing with the study investigators, to ensure free expression.\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Distress measured on Kessler Psychological Distress Scale (K10)[Baseline, post-intervention (within one week since the completion of the intervention, primary endpoint), 3 months post-intervention]",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "purpose: treatment; allocation: randomised controlled trial; masking: blinded (masking used);assignment: parallel;type of endpoint: efficacy;",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ACTRN12620000448943",
			"start_date": "01/06/2020",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Expressive Writing To Combat Distress Associated With The COVID-19 Pandemic In People With Inflammatory Bowel Disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ",
			"title_certainty": "prefilled",
			"url": "https://anzctr.org.au/ACTRN12620000448943.aspx",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"country": "Australia;Austria;Belgium;Brazil;Bulgaria;Croatia;Cyprus;Czech Republic;Denmark;Finland;France;French Southern Territories;Germany;Greece;Ireland;Isle of Man;Israel;Italy;Lebanon;Liechtenstein;Lithuania;Luxembourg;Malta;Netherlands;New Zealand;Norway;Portugal;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States of America",
			"country_certainty": "generated",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: Does not meet inclusion criteria",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e                1. Healthcare professionals\u003cbr\u003e                2. \u003e18 years of age\u003cbr\u003e                3. Willing to participate\u003cbr\u003e            ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003e                Matched longitudinal internet-based survey with pre-existing, validated self-questionnaires (Work-SoC, PHQ-9, IES-6, PVD, SFI, CD-RISC 10), at 3 time periods of 2 weeks over 6 months, with the option to prolong depending on the development of the pandemic.\u003cbr\u003e\u003cbr\u003e                Semi-structured interviews with focus groups after the last period of the survey.\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "COVID-19 Anxiety (adapted SARS-Anxiety-Scale) at 3 time periods of 2 weeks over 6 months",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "mixed-methods observational (other)",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ISRCTN13694948",
			"start_date": "02/04/2020",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Distress And Resilience of healthcare professionals during the COVID-19 pandemic                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ",
			"title_certainty": "prefilled",
			"url": "http://isrctn.com/ISRCTN13694948",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"country": "United Kingdom",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e                1. Respiratory failure not the primary reason for ICU admission\u003cbr\u003e                2. History of proven/ probable invasive pulmonary aspergillosis\u003cbr\u003e            ",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e                Current inclusion criteria as of 26/03/2020:\u003cbr\u003e                1. Adults \u003e 18 years\u003cbr\u003e                2. Admitted to ICU for respiratory support requiring intubation and ventilation for \u003e24 hours\u003cbr\u003e                AND EITHER:\u003cbr\u003e                3. Positive influenza or SARS-CoV-2 PCR from nasal, throat swab, BAL or other respiratory specimen taken either \u003c 7 days pre, or \u003c 3 days post, admission to ICU\u003cbr\u003e                OR\u003cbr\u003e                4. Influenza or SARS-CoV-2 suspected but PCR results awaited – under these circumstances the patient can be provisionally enrolled, but later excluded if no specimens taken within either \u003c 7 days pre, or \u003c 3 days post admission to ICU positive as above\u003cbr\u003e\u003cbr\u003e                Previous inclusion criteria:\u003cbr\u003e                1. Adults \u003e  18 years\u003cbr\u003e                2. Admitted to intensive care for respiratory support requiring intubation and ventilation for \u003e 24 hours\u003cbr\u003e                AND EITHER:\u003cbr\u003e                3. Positive influenza PCR from nasal, throat swab, BAL or other respiratory specimen taken within 48 hours (of admission to ICU – pre or post\u003cbr\u003e                OR\u003cbr\u003e                4. Influenza suspected but influenza PCR results awaited – under these circumstances the patient can be provisionally enrolled, but later excluded if no specimens taken within 48 hours pre/post admission to ICU is positive as above\u003cbr\u003e            ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003e                After consent and enrolment patients in the influenza cohort will undergo a single-draw set of baseline blood tests. This will include peripheral blood mononuclear cells and Paxgene DNA. Approximately 30-40 ml of blood will be taken. BAL will only be performed at the discretion of the treating team as per standard clinical care. Surplus BAL samples from participants will be stored for analysis after the influenza season. Leftover serum will also be stored.\u003cbr\u003e\u003cbr\u003e                Data Collection\u003cbr\u003e                Clinical data will be collected from the electronic hospital records at baseline, during the patient’s ICU stay, and after ICU discharge - up to 90 days or hospital discharge (whichever is longer).\u003cbr\u003e\u003cbr\u003e                Data Analysis\u003cbr\u003e                The researchers will use the collected clinical and microbiological data and BAL/blood galactomannan results to determine the primary and secondary outcome measures, with input from the study statistician for the multivariable analyses.\u003cbr\u003e\u003cbr\u003e                Retrospective Diagnostic Evaluation\u003cbr\u003e                Once the prospective study is complete, stored BAL/blood samples will be tested retrospectively in parallel by two tests: galactomannan EIA (the current ‘gold standard’ biomarker test for IA) and by the AspLFD (the new test we wish to validate). This will be done after the influenza season so results will have no implications for participants. The BAL/blood AspLFD results will be compared against the IA status of the patient to evaluate test performance against the AspICU definition.\u003cbr\u003e\u003cbr\u003e                Planned Sub-studies\u003cbr\u003e                These will be subject to further funding and are laboratory studies to help us understand why certain patients with influenza might be at greater risk of developing IA. This will i",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "\u003cbr\u003e                1. Incidence and risk factors for invasive aspergillosis (IA) in the study cohort (as per modified AspICU criteria):\u003cbr\u003e                1.1. Diagnostic classification of Influenza-associated aspergillosis (IAA) during ICU admission as per modified AspICU criteria, determined at the end of ICU stay\u003cbr\u003e                1.2. Risk factors to be elicited from baseline clinical data points collected at enrolment (within three days of ICU admission) and ICU therapeutics/interventions collected at the end of ICU stay\u003cbr\u003e            ",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "observational; design type: cohort study (other)",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ISRCTN51287266",
			"start_date": "13/12/2019",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Incidence and pathogenesis of invasive aspergillosis in intensive care patients with severe influenza or COVID-19 (AspiFlu)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ",
			"title_certainty": "prefilled",
			"url": "http://isrctn.com/ISRCTN51287266",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "aburns@caredx.com",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Alana Burns",
			"corresp_author_lastname_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Liver, Heart, Lung or Kidney organ transplant recipient with a suspected or confirmed\r\u003cbr\u003e             diagnosis of COVID-19\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "Assessing the utility of AlloSure dd-cfDNA to guide clinical immune-optimization for transplant patients with COVID-19",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04341103",
			"start_date": "2020-04-01",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "AlloSure Guided Immuno-Optimization for COVID-19: An Early Experience",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04341103",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"country": "Australia;New Zealand",
			"country_certainty": "generated",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. Currently admitted to an Intensive Care Unit (ICU)\r\u003cbr\u003e2. Currently receiving intensive respiratory support (invasive or non-invasive ventilation or humidified high flow nasal oxygen)\r\u003cbr\u003e3. Currently taking LPV/r OR hydroxychloroquine\r\u003cbr\u003e4. Known allergy or hypersensitivity to LPV/r OR hydroxychloroquine\r\u003cbr\u003e5. Use of medications that are contraindicated with LPV/r OR hydroxychloroquine that cannot be replaced or stopped during the study period. https://www.covid19-druginteractions.org/.\r\u003cbr\u003e6. Currently on other investigational agents with targeted antiviral effects\r\u003cbr\u003e7. Known cirrhosis or ALT or AST greater than 5x upper limit of normal\r\u003cbr\u003e8. Previous participation in the trial\r\u003cbr\u003e9. Known pregnancy\r\u003cbr\u003e10. Known HIV infection not on antiretroviral therapy \r\u003cbr\u003e11. QTc greater than or equal to 470 for males, QTc greater than or equal to 480 for females\r\u003cbr\u003e12. Treating team deems enrolment in the study is not in the best interests of the patient\r\u003cbr\u003e13. Unable to provide consent\r\u003cbr\u003e14. Death is deemed to be imminent and inevitable within the next 24 hours",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. Age 18 years and over\r\u003cbr\u003e2. Confirmed SARS-CoV-2 by nucleic acid testing in the past 12 days\r\u003cbr\u003e3. Able to be randomised within 12 days of symptom onset\r\u003cbr\u003e4. Expected to be remain an inpatient for at least 48 hours from the time of randomisation\r\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Intervention 1\u003cbr\u003eIntervention Type: Drug\u003cbr\u003eIntervention Administration: Oral\u003cbr\u003eIntervention Name: Lopinavir/ritonavir\u003cbr\u003eIntervention Description: Lopinavir (400mg)/ritonavir (100mg) twice daily for 10 days\u003cbr\u003eIntervention Adherence: direct supervision while in hospital. Once home, adherence will be monitored through daily phone calls\u003cbr\u003e\u003cbr\u003eIntervention 2\u003cbr\u003eIntervention Type: Drug\u003cbr\u003eIntervention Administration: Oral\u003cbr\u003eIntervention Name: Hydroxychloroquine\u003cbr\u003eIntervention Description: 800mg twice a day (4x200mg administered 12 hours apart) on Day 1, followed by 400mg twice a day for 6 days\u003cbr\u003eIntervention Adherence: direct supervision while in hospital. Once home, adherence will be monitored through daily phone calls\u003cbr\u003e\u003cbr\u003eIntervention 3\u003cbr\u003eIntervention Type: Drug\u003cbr\u003eIntervention Administration: Oral\u003cbr\u003eIntervention Name: Lopinavir / ritonavir plus hydroxychloroquine\u003cbr\u003eIntervention Description: Lopinavir (400mg)/ritonavir (100mg) twice daily for 10 days plus hydroxychloroquine 800mg twice a day (4x200mg administered 12 hours apart) on Day 1, followed by 400mg twice a day for 6 days\u003cbr\u003eIntervention Adherence: direct supervision while in hospital. Once home, adherence will be monitored through daily phone calls\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Proportion of participants alive and not having required intensive respiratory support (invasive or non-invasive ventilation or humidified high flow nasal oxygen flow) at 15 days after enrolment.\u003cbr\u003e\u003cbr\u003eThis outcome is assessed by the number of patients who are not admitted into the intensive care unit (ICU)\u003cbr\u003e\u003cbr\u003e[15 days after enrolment]",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "purpose: treatment; allocation: randomised controlled trial; masking: open (masking not used);assignment: factorial;type of endpoint: efficacy;",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ACTRN12620000445976",
			"start_date": "10/04/2020",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Australasian COVID-19 Trial (ASCOT). A multi-centre randomised clinical trial to assess clinical, virological and immunological outcomes in patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ",
			"title_certainty": "prefilled",
			"url": "https://anzctr.org.au/ACTRN12620000445976.aspx",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"country": "Australia",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: •\tKnown iodine sensitivity \r\u003cbr\u003e•\tPreviously diagnosed thyroid disease\r\u003cbr\u003e•\tPreviously diagnosed kidney disease\r\u003cbr\u003e•\tKnown to be pregnant or currently breastfeeding \r\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: Adult (18+ years old) patients with \r\u003cbr\u003e(a) confirmed COVID-19 symptoms and\r\u003cbr\u003e(b) symptom onset within the past five days. ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Intervention is an aqueous buffered solution of 0.5% povidone-iodine (PVP-I) contained in a 30 mL bottle closed with a traditional nasal spray pump.\u003cbr\u003eSubjects will receive a single dose to their nasal passages, administered by the investigator. \u003cbr\u003eThe amount a subject receives consists of 6 x 140µL pump actuations (3 into each nostril), being 0.84 mL total volume.",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Impact of Nasodine on the reduction in virus in the nasal passages of subjects who are shedding the virus.  Virus concentration is  measured by PCR analysis of cell culture medium 96 hours after inoculation with a post-treatment nasal swab and compared to an equivalent culture inoculated with swab collected prior to treatment.[Endpoint is swab taken 5 minutes after dosing and compared against a swab taken 5 minutes prior to dosing.]",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "purpose: prevention; allocation: non-randomised trial;",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ACTRN12620000470998",
			"start_date": "20/04/2020",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Virucidal pilot study of Nasodine® Antiseptic Nasal Spray (povidone-iodine 0.5%) in people with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      ",
			"title_certainty": "prefilled",
			"url": "https://anzctr.org.au/ACTRN12620000470998.aspx",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "k.couper@warwick.ac.uk",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Couper",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "United Kingdom",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e                1. Planned intubation and mechanical ventilation imminent within 1 hour\u003cbr\u003e                2. Known or clinically apparent pregnancy\u003cbr\u003e                3. Any absolute contraindication to CPAP or HFNO\u003cbr\u003e                4. Decision not to intubate due to ceiling of treatment or withdrawal of care anticipated\u003cbr\u003e                5. Equipment for both CPAP and HFNO not available\u003cbr\u003e            ",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e                1. Adults = 18 years\u003cbr\u003e                2. Admitted to hospital with suspected or proven COVID-19\u003cbr\u003e                3. On 40% oxygen (or greater) with SpO2 \u003c94%\u003cbr\u003e                4. Plan for escalation to intubation if needed\u003cbr\u003e            ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003e                Patients will be randomised in a 1:1:1 ratio to:\u003cbr\u003e                Arm 1: Continuous positive airway pressure (CPAP), administered according to local protocol/guidelines. Administration will be left to clinical discretion.\u003cbr\u003e                Arm 2: High flow nasal oxygen (HFNO) will be administered according to local protocol/guidelines. Administration will be left to clinical discretion.\u003cbr\u003e                Arm 3: Standard care. Standard oxygen therapy according to local protocol/guidelines.\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Composite outcome comprising tracheal intubation or mortality within 30 days. Mortality will be reported from hospital records up until discharge and tracked after discharge. Intubation will be obtained from hospital data.",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "adaptive (group-sequential), pragmatic, randomised controlled, open-label, multi-centre, effectiveness trial (treatment)",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ISRCTN16912075",
			"start_date": "06/04/2020",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "In adult patients with known or suspected COVID-19, does the use of Continuous Positive Airway Pressure (CPAP) or high-flow nasal oxygen (HFNO), compared with standard care reduce mortality or need for tracheal intubation?                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ",
			"title_certainty": "prefilled",
			"url": "http://isrctn.com/ISRCTN16912075",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"country": "Indonesia;Iran;Norway;Peru;Qatar;South Africa;Spain;Switzerland;Thailand;Argentina;Brazil;Canada;Germany",
			"country_certainty": "generated",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e                1. Any of the available study drugs are contra-indicated (e.g. because of patient characteristics, chronic liver or heart disease, or some concurrent medication)\u003cbr\u003e                2. Pregnant\u003cbr\u003e                3. Declined to participate in the study\u003cbr\u003e            ",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e                1. Adults (aged =18 years) hospitalized with definite COVID-19\u003cbr\u003e                2. Not already receiving any of the study drugs\u003cbr\u003e                3. Without known allergy or contraindications to any of them (in the view of the physician responsible for their care)\u003cbr\u003e                4. Without anticipated transfer within 72 h to a non-study hospital\u003cbr\u003e\u003cbr\u003e                Patients invited to join the study will be those who are admitted to a collaborating hospital; no wider recruitment efforts are expected\u003cbr\u003e            ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003e                Adults (aged =18 years) recently hospitalized, or already in the hospital, with definite COVID-19 and, in the view of the responsible doctor, no contra-indication to any of the study drugs will be randomly allocated between five groups:\u003cbr\u003e                1. Local standard of care alone\u003cbr\u003e                OR local standard of care plus one of\u003cbr\u003e                2. Remdesivir (daily infusion for 10 days)\u003cbr\u003e                3. Chloroquine or hydroxychloroquine (two oral loading doses, then orally twice daily for 10 days)\u003cbr\u003e                4. Lopinavir + ritonavir (orally twice daily for 14 days)\u003cbr\u003e                5. Lopinavir + ritonavir ((orally twice daily for 14 days) plus interferon-beta (daily injection for 6 days)\u003cbr\u003e\u003cbr\u003e                Follow-up is until death or discharge from hospital.\u003cbr\u003e                Randomization is performed at one central global location through an online portal.\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "All-cause mortality, subdivided by the severity of disease at the time of randomization, measured using patient records throughout the study",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "open-label randomized multicountry clinical trial  (treatment)",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ISRCTN83971151",
			"start_date": "26/03/2020",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "\n                An international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ",
			"title_certainty": "prefilled",
			"url": "http://isrctn.com/ISRCTN83971151",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "andrew.gostine@nm.org",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Andrew Gostine, MD",
			"corresp_author_lastname_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Any employee of Lake Forrest Memorial Hospital presenting to work\r\u003cbr\u003e\r\u003cbr\u003e          -  Age greater than 18 years-old\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Age less than 18 years-old\r\u003cbr\u003e\r\u003cbr\u003e          -  Non-employee\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Device: Non-contact ECG",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "ECG changes associated with COVID-19",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04341506",
			"start_date": "2020-04-15",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Evaluating Non-contact ECG Sensor System for Early Detection of COVID19",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04341506",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";nancy.kentish@aphp.fr;nancy.kentish@aphp.fr",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Elie AZOULAY, MD PhD;Nancy KENTISH-BARNES, PhD;Nancy KENTISH-BARNES, MD PHD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "France",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients:\r\u003cbr\u003e\r\u003cbr\u003e               -  Age\u003e18y\r\u003cbr\u003e\r\u003cbr\u003e               -  Admission to the participating ICUs for any cause of acute respiratory failure\r\u003cbr\u003e                  during the COVID-19 pandemic\r\u003cbr\u003e\r\u003cbr\u003e               -  Having received invasive or noninvasive mechanical ventilation\r\u003cbr\u003e\r\u003cbr\u003e               -  Non-opposition to participate to the telephone interviews.\r\u003cbr\u003e\r\u003cbr\u003e        Family members:\r\u003cbr\u003e\r\u003cbr\u003e          -  Age\u003e18y\r\u003cbr\u003e\r\u003cbr\u003e          -  Non-opposition to participate to the telephone interviews\r\u003cbr\u003e\r\u003cbr\u003e          -  One family member per patient: the family member the most implicated in the patient's\r\u003cbr\u003e             care\r\u003cbr\u003e\r\u003cbr\u003e        Healthcare providers:\r\u003cbr\u003e\r\u003cbr\u003e          -  All nurses and physicians (including those in training) in the participating ICUs\r\u003cbr\u003e             during the COVID-19 pandemic\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Patients:\r\u003cbr\u003e\r\u003cbr\u003e               -  Language barrier to be able to respond to the telephone interview\r\u003cbr\u003e\r\u003cbr\u003e               -  Cognitive disorders disabling patients to respond to the telephone interview\r\u003cbr\u003e\r\u003cbr\u003e               -  Person under legal protection (1121-8 of CSP, Public Health Code) Failure to\r\u003cbr\u003e                  obtain the non-opposition\r\u003cbr\u003e\r\u003cbr\u003e        Family members:\r\u003cbr\u003e\r\u003cbr\u003e          -  Language barrier to be able to respond to the telephone interview\r\u003cbr\u003e\r\u003cbr\u003e          -  Person under legal protection (1121-8 of CSP, Public Health Code)\r\u003cbr\u003e\r\u003cbr\u003e          -  Failure to obtain the non-opposition\r\u003cbr\u003e\r\u003cbr\u003e        Healthcare providers:\r\u003cbr\u003e\r\u003cbr\u003e        Failure to obtain the non-opposition\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Behavioral: PTSD;Behavioral: Burnout",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "PTSD Family members sup 22",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04341519",
			"start_date": "2020-04-09",
			"start_date_certainty": "generated",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "\"Psychological Burden in ICU Survivors of Severe COVID-19 Pneumonia, Their Relatives and Their Healthcare Providers\" \"Impact Psychologique de l'épidémie COVID-19 Chez Les Patients, Familles et Soignants de Reanimation\" \"BURDENCOV\"",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04341519",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";greengrc01@gmail.com;greengrc01@gmail.com",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Gérard Amarenco, PhD;Camille Chesnel, MD;Camille Chesnel, MD",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "France",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Age = 18 years old\r\u003cbr\u003e\r\u003cbr\u003e          -  Telephone consultation\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  New patient in the department\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: Satisfaction evaluation",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Efficiency of the telephone consultation",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04341714",
			"start_date": "2020-03-16",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Efficiency and Satisfaction With Telephone Consultation in Neuro-urology: Experience of the COVID-19 Pandemic",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04341714",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "ydkfedu@163.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: (1) body temperature\u003e38 degree C\r\u003cbr\u003e(2) heart rate at rest\u003e120 cpm or \u003c40 cpm,SBP\u003c90mmHg or \u003e180mmHg,respiratory rate\u003c25 cpm. Or the above vital signs change significantly;\r\u003cbr\u003e(3) continuous oxygen therapy is required;\r\u003cbr\u003e(4) patients with myocarditis, pulmonary hypertension, congestive heart failure, acute renal failure, fresh venous thromboembolic disease, unstable fractures, who are not suitable for exercise;\r\u003cbr\u003e(5) Patients with disturbance of consciousness, cognitive impairment, mental disorder, severe balance disorder, severe osteoarticular diseases, who cannot cooperate with treatment and evaluation;\r\u003cbr\u003e(6) Other conditions that do not cooperate with rehabilitation treatment.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: (1) patients diagnosed with COVID-19;\r\u003cbr\u003e(2) patients after discharge;\r\u003cbr\u003e(3) patients aged 18 to 80 years old;\r\u003cbr\u003e(4) patients voluntarily agree to join the cohort and cooperate with treatment and evaluation.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "intervention group:exercise;Control group:Blank;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "cardiopulmonary function;motor function;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "non randomized control",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031860",
			"start_date": "2020-04-27",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Study for the exercise rehabilitation therapy for the dysfunction of cured discharged novel coronavirus pneumonia (COVID-19) patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=52198",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "lijianan@njmu.edu.cn",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. Dyspnea scale mMRC 0~1 or 4;\r\u003cbr\u003e2. Resting heart rate\u003e100bpm;\r\u003cbr\u003e3. Adjusting dosage of drugs which affect cardiopulmonary function or heart rate (such as: trimetazidine, salbutamol, beta-blocker);\r\u003cbr\u003e4. Combined uncontrolled chronic disease, such as uncontrolled hypertension (resting BP=160100mmHg), uncontrolled diabetes (random blood glucose\u003e16.7 mmol/l, HbA1C\u003e7.0%);\r\u003cbr\u003e5. Combined severe organic disease, such as unstable hemodynamic heart disease, heart failure with limited movement (previous diagnosis, or have clinical symptoms of heart failure, after consultation by cardiologist);\r\u003cbr\u003e6. Cerebrovascular disease occurred within the past 6 months;\r\u003cbr\u003e7. Active stage of digestive ulcer, thyroid dysfunction, or active tuberculosis;\r\u003cbr\u003e8. Chronic kidney disease \u003e=stage 3 (eGFR\u003c60ml/min);\r\u003cbr\u003e9. Have received intra-articular drug injection or surgical treatment in the lower extremity within the past 6 months;\r\u003cbr\u003e10. Poor compliance, unable to cooperate with assessment or training;\r\u003cbr\u003e11. Unable to walk independently with auxiliary;\r\u003cbr\u003e12. Combined mental disease that prevents patients from living independently or receiving treatment;\r\u003cbr\u003e13. Alcohol abuse or illegal drug use history;\r\u003cbr\u003e14. Pregnancy, nursing or preparing for pregnancy (including male subjects);\r\u003cbr\u003e15. Have participated in other clinical trials within the past 3 months.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. Discharged patients with COVID-19 pneumonia;\r\u003cbr\u003e2. With dyspnea symptom (mMRC 2~3);\r\u003cbr\u003e3. Aged 18~75 years old;\r\u003cbr\u003e4. Have and can use smart phone (study subjects or family members);\r\u003cbr\u003e5. Obtain the consent of the subjects or legal representative and sign the informed consent. ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Experimental group:exercise rehabilitation under remote monitoring;Control group:patient education;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Total distances of 6 minutes walk test;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "parallel",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031834",
			"start_date": "2020-04-20",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "A clinical study for the effect of remote monitoring exercise rehabilitation on the discharged patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=52216",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "41025513@qq.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: Patients not suitable for study judged by researchers ",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: Patients diagnosed with severe new coronavirus pneumonia from January to March 2020",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Case series:Nil;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "clinical characteristics and risk factors of death;inflammatory factors;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031794",
			"start_date": "2020-04-08",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Clinical features and outcomes of critically ill adult patients with COVID-19 admitted to ICUs of non-Wuhan city, China: a medical records based retrospective study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=52193",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "dicespedes2@hotmail.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "Bolivia",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. Staff who are not pursuing a career at Medical school at UMSA \r\u003cbr\u003e2. Incomplete information in the questionnaire.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. Students cursing through the first year to internship (sixth year).\r\u003cbr\u003e2. Students currently registered in medical school system of University Mayor de San Andres (UMSA)",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Case series:None;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "attitudes toward COVID-19;Consciousness awareness toward COVID-19;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031783",
			"start_date": "2020-03-24",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "The impact of Information Sources over behaviors and preventive measures against COVID-19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51832",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "kjkceh@126.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1) left heart failure pulmonary edema;\r\u003cbr\u003e2) pregnancy and lactation or perinatal period;\r\u003cbr\u003e3) liver failure MELD score \u003e40;\r\u003cbr\u003e4) a history of deep vein thrombosis or pulmonary embolism in the past 3 months;\r\u003cbr\u003e5) cases that the researcher judged to be unsuitable for the group.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. Aged 18 years old;\r\u003cbr\u003e2. diagnosed with viral pneumonia such as new coronavirus;\r\u003cbr\u003e3. voluntary informed consent",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "NK cell group:NK cells were injected by intravenous drip once a day for 2 to 3 times in total, each dose was 4 10^7 pieces /kg body weight,100ml normal saline suspension;Control group:100ml normal saline intravenous drip;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Monitoring of adverse events within 24 hours after infusion (including infusion related events and severe adverse reactions associated with non-primary disease);",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "parallel",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031735",
			"start_date": "2020-03-01",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Clinical study for natural killer (NK) cells from umbilical cord blood in the treatment of viral pneumonia include novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=50613",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "baixiaoxia@zju.edu.cn",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: incomplete case date",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: Cases of cesarean section in Women's Hospital Medical School of Zhejiang University from January 24, 2020 to March 31, 2020",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Case series:cesarean section;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Perioperative fever;Perioperative cough;Outcome of lung CT;Operative time;Volume of Postpartum hemorrhage;postoperative hospitalization;Stay in isolation ward;Apgar score of newborn;Neonatal admission to NICU;Medical observation of personnel involved in the operation;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031675",
			"start_date": "2020-04-06",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Retrospective analysis of maternal and infant outcomes in Cesarean delivery in Hangzhou non pneumonia Hospital during pandemic of Novel coronovirus pneumonia(COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=52037",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";yl4459@cumc.columbia.edu;",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "David Ho, M.D,;Yang Luo, PhD;Brett Gray",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "United States",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Age 18 to 65 (inclusive)\r\u003cbr\u003e\r\u003cbr\u003e          -  Confirmed COVID-19 infection by a FDA-approved molecular based assay (including those\r\u003cbr\u003e             under emergency use authorization) of respiratory or blood specimens;\r\u003cbr\u003e\r\u003cbr\u003e          -  If symptomatic with COVID-19, must have evidence of improvement of symptoms and a\r\u003cbr\u003e             duration of at least 4 weeks from the onset of symptoms to day of enrollment;\r\u003cbr\u003e\r\u003cbr\u003e          -  If asymptomatic, must have a duration of at least 4 weeks from first positive\r\u003cbr\u003e             molecular based COVID-19 assay to day of enrollment\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  \u003c18 years or \u003e65 years old\r\u003cbr\u003e\r\u003cbr\u003e          -  No confirmed diagnosis of COVID-19\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Procedure: Blood draw",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Number of antibodies against coronaviruses isolated and identified from patient samples",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04342195",
			"start_date": "2020-03-25",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Acquiring Convalescent Specimens to Isolate and Identify Potent Monoclonal Antibodies Against COVID-19",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04342195",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "docd1@sina.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. The pneumonia patients with severe new coronavirus infection met one of the following conditions: respiratory distress, RR\u003e=30 times / min; or SaO2 / SpO2 \u003c93% in resting state; or arterial partial pressure of oxygen (PaO2) / concentration of oxygen (FiO2) \u003c300MMHG (1mmhg = 0.133kpa);\r\u003cbr\u003e2. Pneumonia patients with severe new coronavirus infection meet one of the following conditions: respiratory failure and need mechanical ventilation; or shock; or other organ failure combined with ICU monitoring treatment;\r\u003cbr\u003e3. Severe liver disease (such as child Pugh score \u003e=C, AST \u003e 5 times upper limit);\r\u003cbr\u003e4. Patients with contraindications specified in the instructions of danoprevir and ritonavir tablets;\r\u003cbr\u003e5. Patients who plan to take protease inhibitors other than danoprevir and ritonavir simultaneously during the trial.\r\u003cbr\u003e6. The pregnancy test of female subjects in the screening period was positive;\r\u003cbr\u003e7. The researchers judged that it was not suitable to participate in this clinical trial (for example, patients who may be transferred to another hospital during the study period; patients with multiple basic diseases, etc.). ",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. Aged 18-75 years old;\r\u003cbr\u003e2. Pneumonia patients with new coronavirus infection were confirmed to be positive by RT-PCR and clinical manifestations. The diagnosis standard refers to the diagnosis and treatment plan for pneumonia with new coronavirus infection (Current Trial Version);\r\u003cbr\u003e3. Women and their partners who have no planned pregnancy for nearly half a year and are willing to take effective contraceptive measures within 30 days from the first administration of the study drug to the last administration;\r\u003cbr\u003e4. Agree not to participate in other clinical research within 30 days from the first administration of the study drug to the last administration;\r\u003cbr\u003e5. Patients who voluntarily sign informed consent. ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Case series:Danorevir sodium tablets,/ritonavir oral;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Rate of composite advers outcomes: SpO2, PaO2/FiO2, respiratory rate;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "single arm",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031734",
			"start_date": "2020-03-19",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Evaluation Danorevir sodium tablets combined with ritonavir in the treatment of novel Coronavirus Pneumonia (COVID-19): a randomized, open-label, controlled trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=52103",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "fanyingsh@126.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. Pregnant women;\r\u003cbr\u003e2. Previous history of drug and alcohol abuse;\r\u003cbr\u003e3. Inability to communicate or comply with research requirements;\r\u003cbr\u003e4. Patients with acquired immune deficiency syndrome;\r\u003cbr\u003e5. Patients with malignant tumors.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. Patients aged 14-75 years;\r\u003cbr\u003e2. Real-time fluorescence rt-pcr detection of novel coronavirus nucleic acid positive in respiratory or blood specimens;\r\u003cbr\u003e3. The respiratory tract specimen or blood specimen virus gene sequencing, and novel coronavirus highly homologous patients.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Case series:no intervention;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "NGAL;MAU;cystatin C;Beta 2-MG;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "factorial",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031705",
			"start_date": "2020-03-10",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Study for early biological warning signals in patients with acute renal injury caused by novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51793",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "DF.van.Wijk@nwz.nl",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "van Wijk",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "The Netherlands",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: None",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: Clinical diagnosis of COVID-19\u003cbr\u003eIntubation for mechanical respiratory support (including\u003cbr\u003eECMO) \u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "mortality and end of mechanical respiratory support. ",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "\u003cbr\u003e                        randomized: no, \u003cbr\u003e                        masking: none, \u003cbr\u003e                        control: not applicable, \u003cbr\u003e                        group: undefined, \u003cbr\u003e                        type: not applicable\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NL8512",
			"start_date": "18/03/2020",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "The use of ACE2 receptor increasing medication at hospital admission and\nmortality rates in COVID-19 patiënts \n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ",
			"title_certainty": "prefilled",
			"url": "https://trialregister.nl/trial/8512",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";laura.webb@duke.edu;laura.webb@duke.edu",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Emily O'Brien, PhD;Laura Webb;Laura Webb",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "United States",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e          -  Individual currently works in a setting where individuals receive healthcare\r\u003cbr\u003e             (\"healthcare worker\") in the United States (including emergency medical services)\r\u003cbr\u003e\r\u003cbr\u003e          -  Age = 18\r\u003cbr\u003e\r\u003cbr\u003e          -  Able to speak and read English or Spanish\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        * There are no specific exclusion criteria for this study. Participants must meet inclusion\r\u003cbr\u003e        criteria.\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "Number and percent of participants who enroll in the HERO Registry Study by geographic region, age, COVID-19 risk factors, and past COVID-19 diagnosis;Distribution of COVID-19 risk factors by participant characteristics;Proportion of participants undergoing changes in health status (e.g. new diagnosis of COVID-19, ER visits, hospitalization);Proportion of all participants enrolled in the HERO Registry who participate in an ancillary research study;Proportion of participants who continue to supple information about their health to the HERO Registry at various time points after their enrollment",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04342806",
			"start_date": "2020-04-10",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Healthcare Worker Exposure Response and Outcomes (HERO) Registry Study",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04342806",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "f.hooijberg@reade.nl",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Hooijberg",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "The Netherlands",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: Patients who meet the following criteria will be excluded from the study:\u003cbr\u003e- Language problems precluding the completion of the questionnaire;\u003cbr\u003e- Likelihood of absence in the next 6 months;\u003cbr\u003e- Lack of informed consent.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria:\u003cbr\u003e- Age = 18 years.\u003cbr\u003e\u003cbr\u003eFor patients:\u003cbr\u003e- Diagnosed by their treating physician with RA, PsA, or AS.\u003cbr\u003e\u003cbr\u003eFor controls:\u003cbr\u003e- Belonging to family or close friend of patient (of the same gender). \u003cbr\u003e\u003cbr\u003eFor the sub-study:\u003cbr\u003e- A confirmed infection with SARS-CoV-2 by the GGD or typical COVID-19 complaints and contact with someone who is also suspected for an infection with SARS-CoV-2. ",
			"inclusion_criteria_certainty": "prefilled",
			"out_primary_measure": "Our primary study parameter is the percentage of participants with a positive IgM or IgG response admitted to the hospital.",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "\u003cbr\u003e                        randomized: no, \u003cbr\u003e                        masking: none, \u003cbr\u003e                        control: not applicable, \u003cbr\u003e                        group: undefined, \u003cbr\u003e                        type: not applicable\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NL8513",
			"start_date": "13/04/2020",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "COVID-19 in rheumatic patients: a prospective cohort study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      ",
			"title_certainty": "prefilled",
			"url": "https://trialregister.nl/trial/8513",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "frank.bosch@radboudumc.nl",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Bosch",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "The Netherlands",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: -Pre-existing pulmonary disease or heart failure\u003cbr\u003e-Absence of COVID infection",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: Age (=18 years)\u003cbr\u003eProven(PCR) or suspected (based on clinical signs and imaging) COVID-19 infection-\u003cbr\u003eReferral or admission for internal, emergency or respiratory medicine-\u003cbr\u003eCertified sonographerpresent ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Lung Ultrasound",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Patients will receive regular care as indicated by the treating physician. LUS is performed immediately in  the  Emergency  Department  or after  admissionto  the hospital. SARS-CoV-2  PCR testing  will  be performed along with standard laboratory testing and other microbiological tests to detect pathogens that cause respiratory tract infection.CT-scan during admission is only performed if this is clinically indicated or protocol during COVID outbreak.",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "\u003cbr\u003e                        randomized: no, \u003cbr\u003e                        masking: none, \u003cbr\u003e                        control: not applicable, \u003cbr\u003e                        group: undefined, \u003cbr\u003e                        type: not applicable\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NL8498",
			"start_date": "15/03/2020",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Lung ultrasound (LUS) as a tool to determine the clinical course in COVID-19 patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ",
			"title_certainty": "prefilled",
			"url": "https://trialregister.nl/trial/8498",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "hamza@hamzayousuf.nl",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Yousuf",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "The Netherlands",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: Younger than 8 years old",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: Able to fill in the questionnaire in Dutch",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Infotainment intervention with (social) media and influencers.",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Elevation of proper hygiene behaviour (behavioural change)",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "\u003cbr\u003e                        randomized: no, \u003cbr\u003e                        masking: none, \u003cbr\u003e                        control: active, \u003cbr\u003e                        group: undefined, \u003cbr\u003e                        type: 2 or more arms, non-randomized\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NL8483",
			"start_date": "16/03/2020",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "The use of (social) media                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ",
			"title_certainty": "prefilled",
			"url": "https://trialregister.nl/trial/8483",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": ";deleaf@bwh.harvard.edu",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "David E Leaf, MD, MMSc;David E Leaf, MD, MMSc",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "United States",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"inclusion_criteria": "\r\u003cbr\u003e        Inclusion Criteria (each of the following):\r\u003cbr\u003e\r\u003cbr\u003e          1. Adults (aged =18 years)\r\u003cbr\u003e\r\u003cbr\u003e          2. Confirmed diagnosis of COVID-19\r\u003cbr\u003e\r\u003cbr\u003e          3. Hospitalized in the ICU for illness related to COVID-19\r\u003cbr\u003e\r\u003cbr\u003e          4. Died or discharged from the hospital, or at least 14 days of survival data available\r\u003cbr\u003e             from the time of ICU admission\r\u003cbr\u003e\r\u003cbr\u003e        Exclusion Criteria:\r\u003cbr\u003e\r\u003cbr\u003e        -None\r\u003cbr\u003e      ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Other: No intervention",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "14-Day Mortality",
			"out_primary_measure_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NCT04343898",
			"start_date": "2020-04-01",
			"start_date_certainty": "generated",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19",
			"title_certainty": "prefilled",
			"url": "https://clinicaltrials.gov/show/NCT04343898",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"country": "Australia",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: Moribund or for palliative care",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: Positive for COVID 19 with pulmonary involvement - severe\r\u003cbr\u003eAdmission or being considered for admission to intensive care unit",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Patients with pulmonary infection and COVID 19 will have their respiratory management during ICU admission decided in one of two ways\u003cbr\u003eMethod 1. Lung ultrasound will be used to make management decisions - this is a non-invasive way of ultrasounding the lungs \u003cbr\u003eOne hospital site will use method 1\u003cbr\u003eThree hospitals will use method 2\u003cbr\u003eBoth methods are currently standard at the respective hospitals\u003cbr\u003eThe comparator treatment will be decided by the attending intensivist. The treatment will be different in every patient. Depending on the results of the auscultation and waveform analysis, a different method of mechanical ventilation or respiratory physiotherapy may be chosen. \u003cbr\u003e\u003cbr\u003eRespiratory physiotherapy may be different in each case but will consist of either ventilator hyperinflation, positioning or manual techniques. The senior respiratory physiotherapist will decide the type of physiotherapy treatment delivered based on COVI 19 guidelines. \u003cbr\u003eThis will be from admission to ICU to 28 days post hospital discharge",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Mortality[During Intensive care unit stay \u003c 14 days];Mortality[28 day post discharge from ICU];Length of stay intensive care unit from patient medical record[Discharge from intensive care]",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "purpose: natural history;duration: longitudinal;selection: defined population;timing: prospective;",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ACTRN12620000438954",
			"start_date": "20/04/2020",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Utilizing lung ultrasound in COVID-19 patients in ICU – comparison of management strategies on survival and time on ventilation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ",
			"title_certainty": "prefilled",
			"url": "https://anzctr.org.au/ACTRN12620000438954.aspx",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "carla.vandenabele@aphp.fr",
			"corresp_author_email_certainty": "prefilled",
			"country": "France",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003eSubjects presenting with any of the following will not be included in the study:\r\u003cbr\u003e1.\tShock requiring vasoactive agents \r\u003cbr\u003e2.\tAcute respiratory distress syndrome requiring invasive mechanical ventilation\r\u003cbr\u003e3.\tCirculatory assistance\r\u003cbr\u003e4.\tHistory of malignant hypertension according to the definition of the 2018 ESC/ESH guidelines on hypertension\r\u003cbr\u003e5.\tUncontrolled blood pressure despite the use of five antihypertensive drugs \r\u003cbr\u003e6.\tHistory of nephrotic syndrome\r\u003cbr\u003e7.\tHistory of hospitalization for hemorrhagic stroke in the past 3 months\r\u003cbr\u003e8.\tRAS blockers therapy previously stopped \u003e 48h\r\u003cbr\u003e9.\tNo affiliation to the French Health Care System “Sécurité Sociale”\r\u003cbr\u003e10.\tInability to obtain informed consent\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003eSubjects meeting all of the following criteria will be considered for enrolment into the study:\r\u003cbr\u003e1.\tAge = 18 year/old \r\u003cbr\u003e2.\tChronically treated with RAS blockers (ACE inhibitors or ARBs on the last prescription prior to admission with a treatment duration = 1 month))\r\u003cbr\u003e3.\tDiagnosis of COVID-19 confirmed by the presence of SARS-CoV-2 on any biological sample with any detection method\r\u003cbr\u003e4.\tPatients hospitalized in a non-ICU\r\u003cbr\u003e5.\tPregnancy test at inclusion visit for women of childbearing potential\r\u003cbr\u003e6.\tWomen of childbearing potential must agree to use adequate contraception according to Recommendations related to contraception and pregnancy testing in clinical trials, by Clinical Trial Facilitation Group (CTFG)\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range 277\u003cbr\u003eF.1.3 Elderly (\u003e=65 years) yes\u003cbr\u003eF.1.3.1 Number of subjects for this age range 277\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003ePharmaceutical Form: Tablet\u003cbr\u003e\u003cbr\u003ePharmaceutical Form: Tablet\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Main Objective: To compare the effect of discontinuation versus continuation of RAS blockers on the clinical course of patients with confirmed COVID-19 infection leading to hospitalization;Secondary Objective: 1.\tEvaluate the cardiovascular safety of RAS blockers discontinuation in patients hospitalized for COVID-19 by a composite endpoint of MACE.\u003cbr\u003e2.\tEvaluate the efficacy of RAS blockers discontinuation in patients hospitalized for COVID-19 by the secondary efficacy endpoints.\u003cbr\u003e;Primary end point(s): Primary endpoint: \u003cbr\u003eTime to clinical improvement from day 0 to day 28.\u003cbr\u003eClinical improvement is defined as an improvement of two points  on a seven-category ordinal scale, or live discharge from the hospital, whichever comes first,  as recommended by the WHO R\u0026D Blueprint expert group (3).\u003cbr\u003e\u003cbr\u003eThe seven-category ordinal scale consisted of the following categories: \u003cbr\u003e1.\tnot hospitalized with resumption of normal activities \u003cbr\u003e2.\tnot hospitalized, but unable to resume normal activities\u003cbr\u003e3.\thospitalized, not requiring supplemental oxygen \u003cbr\u003e4.\thospitalized, requiring supplemental oxygen\u003cbr\u003e5.\thospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both\u003cbr\u003e6.\thospitalized, requiring ECMO, invasive mechanical ventilation, or both\u003cbr\u003e7. death. ;Timepoint(s) of evaluation of this end point: 28 days",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: yes\u003cbr\u003erandomised: yes\u003cbr\u003eopen: yes\u003cbr\u003esingle blind: no\u003cbr\u003edouble blind: no\u003cbr\u003eparallel group: no\u003cbr\u003ecross over: no\u003cbr\u003eother: no\u003cbr\u003eif controlled, specify comparator, other medicinial product: no\u003cbr\u003eplacebo: no\u003cbr\u003eother: yes\u003cbr\u003eother specify the comparator: discontinuation\u003cbr\u003enumber of treatment arms in the trial: 2\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001381-11-FR",
			"start_date": "08/04/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "COVID-19 - ACE inhibitors or ARBs discontinuation for Clinical Outcome Risk reduction in patients hospitalized for the Endemic Severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection: the randomized ACORES-2 study - ACORES-2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001381-11",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"country": "Australia",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: Suspected COVID-19 not subsequently confirmed on PCR, serology or imaging",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: All pregnant women admitted to a participating hospital with COVID-19 during pregnancy",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "All women infected with SARS-CoV 2 (novel coronavirus) infection or who were diagnosed with COVID-19 during pregnancy. Observation will continue throughout pregnancy up until 6 weeks postpartum. In addition to standard care, women will be asked to complete a questionnaire after discharge to include postpartum and neonatal outcomes.",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Maternal mortality from COVID-19[During pregnancy until 6 weeks postpartum];Perinatal mortality (stillbirth, neonatal death)[During pregnancy and until day 28 in the neonate]",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "purpose: natural history;duration: longitudinal;selection: defined population;timing: prospective;",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ACTRN12620000449932",
			"start_date": "10/04/2020",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Prospective registry of maternal, perinatal and neonatal outcomes from pregnancies infected with SARS-COV2 (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ",
			"title_certainty": "prefilled",
			"url": "https://anzctr.org.au/ACTRN12620000449932.aspx",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"country": "New Zealand",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: •\tKnown pregnancy or planning to become pregnant during the study period\r\u003cbr\u003e•\tCurrently breastfeeding\r\u003cbr\u003e•\tKnown maculopathy or retinal disorder.\r\u003cbr\u003e•\tKnown cardiac disease/dysrhythmia or prolonged QTc\r\u003cbr\u003e•\tKnow renal disease\r\u003cbr\u003e•\tKnown hepatic disease\r\u003cbr\u003e•\tKnown hypomagnesaemia or hypokalaemia. \r\u003cbr\u003e•\tCurrently using hydroxychloroquine or any 4-aminoquinoline.\r\u003cbr\u003e•\tUse of medications prolonging QTc including: Class IA (quinidine, procainamide, disopyramide) and III (amiodarone, sotalol, ibutilide, dofetilide) antiarrythmics, macrolides, methadone, fluoroquinolones, domperidone, fluconazole, ondansetron, tacrolimus, tramadol, anti-retrovirals.\r\u003cbr\u003e•\tCurrent use of tamoxifen, digoxin, tricyclics, SSRIs, antipsychotics, halfantrine, cyclosporin and anti-epileptic medications\r\u003cbr\u003e•\tCurrent use of oral hypoglycaemics including glipizide, glyburide, gliclazide, glimepiride, repaglinide, nateglinide, metformin, rosiglitazone, pioglitazone, acarbose, miglitol, voglibose, sitagliptin, saxagliptin, vildagliptin, linagliptin, alogliptin, dapagliflozin, canagliflozin, bromocriptine. \r\u003cbr\u003e•\tSensitivity or allergy to 4-aminoquinilone compounds or any excipients used in the study\r\u003cbr\u003e•\tUnable to access digital consent forms or maintain remote contact with the study team\r\u003cbr\u003e•\tHave any other condition which, at the investigator’s discretion, is believed may present a safety risk or impact the feasibility of the study or the study results.\r\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: •\tAged 18 to 75 years.\r\u003cbr\u003e•\tLaboratory confirmed SARS-CoV2 infection. \r\u003cbr\u003e•\tAdvised to self-manage COVID-19 in the community by the regional public health team. \r\u003cbr\u003e•\tIn the Investigator’s opinion, is able and willing to comply with all trial requirements.\r\u003cbr\u003e•\tBaseline Flu PRO score \u003e1.3\r\u003cbr\u003e•\tAble to receive and commence randomised treatment via courier the day after consent was obtained. \r\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Oral administration of Hydroxychloroquine capsules for five days. \u003cbr\u003eDay 1: 800mg (4 capsules) Hydroxychloroquine stat\u003cbr\u003eDays 2 - 5: 400mg (2 capsules) Hydroxychloroquine once daily\u003cbr\u003eAdherence to trial treatment will be assessed through the study diaries which will require the participant to complete the time of administration and number of tablets taken each day. Participants will not be required to return used study treatments to the research office but encouraged to dispose of any unused medication via their community pharmacy or general practice.",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Efficacy of Hydroxychloroquine in the community-based management of COVID-19 assessed by the mean daily InFLUenza Patient-Reported Outcome (FLU-PRO) illness severity score[Day 5 of treatment administration]",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "purpose: treatment; allocation: randomised controlled trial; masking: blinded (masking used);assignment: parallel;type of endpoint: efficacy;",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ACTRN12620000457943",
			"start_date": "14/04/2020",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "A Randomised, Double Blind, Placebo-Controlled Trial of the Efficacy of Hydroxychloroquine for the Community-Based Treatment of Adults With Diagnosed COVID-19\r\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ",
			"title_certainty": "prefilled",
			"url": "https://anzctr.org.au/ACTRN12620000457943.aspx",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "hj.bogaard@amsterdamumc.nl",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Bogaard",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "The Netherlands",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. Pre-existing chronic pulmonary disease, including:\u003cbr\u003e? Known diagnosis of Interstitial Lung disease\u003cbr\u003e? Former diagnosis of COPD 4 or FEV1\u003c30%pred\u003cbr\u003e? DLCO \u003c45%\u003cbr\u003e? Total lung capacity (TLC) \u003c 60% of predicted\u003cbr\u003e? Lung cancer with non-surgical treatment in last year\u003cbr\u003e2. Home oxygen treatment\u003cbr\u003e3. Pre-existing heart failure with a known left ventricular ejection fraction \u003c40%\u003cbr\u003e4. Active treatment of hematological or non-hematological cancer with targeted, immuno- or chemotherapy in the last year\u003cbr\u003e4. Inability to provide informed consent\u003cbr\u003e5. Any subject who had received any investigational medication within 1 month prior to the start of this study or who is scheduled to receive another investigational drug during the course of this study\u003cbr\u003e6. Active liver disease, porphyria or elevations of serums transaminases \u003e3 x ULN (upper limit of normal) or bilirubin \u003e 1.5 x ULN\u003cbr\u003e7. History or suspicion of inability to cooperate adequately.\u003cbr\u003e8. White blood count \u003c 4.0^109/l\u003cbr\u003e9. Hemoglobin \u003c 6.0 mmol/l\u003cbr\u003e10. Thrombocytes \u003c 100^109/l\u003cbr\u003e11. Pregnant female subjects\u003cbr\u003e12. Breastfeeding female subjects",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: - Age \u003e18 years\u003cbr\u003e- Hospital admission with proven SARS2-Covid19 infection\u003cbr\u003e- Hypoxemic respiratory failure (SaO2 \u003c92%, PaO2 \u003c8kPa)\u003cbr\u003e- Ability to give informed consent",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Imatinib or placebo",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "time to liberation from ventilation and supplemental oxygen and alive during a 28day period after randomization",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "\u003cbr\u003e                        randomized: no, \u003cbr\u003e                        masking: double, \u003cbr\u003e                        control: placebo, \u003cbr\u003e                        group: undefined, \u003cbr\u003e                        type: 2 or more arms, randomized\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NL8491",
			"start_date": "31/03/2020",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Countering Lung Damage in COVID-19 infection (CounterCovid) study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ",
			"title_certainty": "prefilled",
			"url": "https://trialregister.nl/trial/8491",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "s.koerper@blutspende.de",
			"corresp_author_email_certainty": "prefilled",
			"country": "Germany",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e1.\tAccompanying diseases other than COVID-19 with an expected survival time of \r\u003cbr\u003e                    less than 12 months\r\u003cbr\u003e2.\tIn the opinion of the clinical team, progression to death is imminent and \r\u003cbr\u003e                    inevitable within the next 48 hours, irrespective of the provision of treatment\r\u003cbr\u003e3.\tInterval \u003e 72 hours since start of ventilation support\r\u003cbr\u003e4.\tNot considered eligible for extracorporeal oxygenation support  (even in case of \r\u003cbr\u003e                     severe ARDS according to Berlin classification with Horovitz-Index \u003c 100 mg Hg) \r\u003cbr\u003e5.\tChronic obstructive lung disease (COPD), stage 4\r\u003cbr\u003e6.\tLung fibrosis with UIP pattern in CT and severe emphysema\r\u003cbr\u003e7.\tChronic heart failure NYHA = 3 and/or pre-existing reduction of left ventricular \r\u003cbr\u003e                    ejection fraction to = 30%\r\u003cbr\u003e8.\tCardiovascular failure requiring = 0.5 µg/kg/min noradrenaline (or equivalent) or \r\u003cbr\u003e                     requiring more than two types of vasopressor medication\r\u003cbr\u003e9.\tLiver cirrhosis Child C\r\u003cbr\u003e10.\tLiver failure: Bilirubin \u003e 5 x ULN and elevation of ALT or AST (\u003e 10 x ULN)\r\u003cbr\u003e11.\tAny history of adverse reactions to plasma proteins\r\u003cbr\u003e12.\tKnown deficiency of immunoglobulin A\r\u003cbr\u003e13.\tPregnancy\r\u003cbr\u003e14.\tBreastfeeding women\r\u003cbr\u003e15.\tVolume overload until sufficiently treated\r\u003cbr\u003e16.\tPulmonary edema\r\u003cbr\u003e17.\tParticipation in another clinical trial for treatment of COVID-19\r\u003cbr\u003e\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003ePatients with SARS-CoV-2 infection and:\r\u003cbr\u003e1.\tage = 18 years and = 75 years\r\u003cbr\u003e2.\tSARS-CoV-2 infection confirmed by PCR (BAL, sputum, nasal and/or pharyngeal \r\u003cbr\u003e                    swap)\r\u003cbr\u003e3.\tsevere disease defined by at least one of the following:\r\u003cbr\u003e  a.\trespiratory rate = 30 breaths / minute under ambient air\r\u003cbr\u003e  b.\trequirement of any type of ventilation support\r\u003cbr\u003e  c.\tneeds ICU Treatment\r\u003cbr\u003e4.                 Written informed consent by patient or legally authorized representative\r\u003cbr\u003e\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range 77\u003cbr\u003eF.1.3 Elderly (\u003e=65 years) yes\u003cbr\u003eF.1.3.1 Number of subjects for this age range 29\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eTrade Name: Fresh frozen plasma (FFP) with marketing authorisation in Germany issued by PEI\u003cbr\u003e\u003cbr\u003eProduct Name: For example \"Gefrorenes Frischplasma / Apherese DRK Blutspendedienst\"\u003cbr\u003ePharmaceutical Form: Solution for infusion\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Main Objective: To improve survival \u003cbr\u003e\u003cbr\u003eAND\u003cbr\u003e\u003cbr\u003eremove criteria of severe COVID-19 (CoV-2 infection) within 21 days after randomization;Secondary Objective: - Time to clinical improvement on WHO R\u0026D Blueprint seven-category ordinal scale by 2 \u003cbr\u003e- Adverse events \u003cbr\u003e- Case fatality rate on days 21, 35 and 60\u003cbr\u003e- Length of hospital stay\u003cbr\u003e- Length of ICU stay \u003cbr\u003e- Duration of ventilation Support / ECMO\u003cbr\u003e- Time until negative SARS-CoV-2 PCR\u003cbr\u003e- Predictive value of comorbidities and inflammation markers \u003cbr\u003e- Feasibility of collection of plasma units \u003cbr\u003e- Kinetics of anti-SARS-CoV-2 antibodies in plasma of patients = plasma donors who recovered \u003cbr\u003e   from a SARS-CoV-2 infection\u003cbr\u003e- Titer of anti-SARS-CoV-2 in transfused plasma units\u003cbr\u003e- Impact of donor characteristics on anti-SARS-CoV-2 humoral response\u003cbr\u003e- Course of anti-SARS-CoV-2 titer in patients \u003cbr\u003e- Effect of timing of plasma transfusions on outcome\u003cbr\u003e;Primary end point(s): Composite endpoint of:\u003cbr\u003e\u003cbr\u003e- Survival \u003cbr\u003e\u003cbr\u003eAND\u003cbr\u003e\u003cbr\u003e- no longer fulfilling criteria of severe COVID-19 within 21 days after randomization\u003cbr\u003e\u003cbr\u003eAll criteria must be met in order to fulfill the primary endpoint.\u003cbr\u003e;Timepoint(s) of evaluation of this end point: Treatment group: Day 21\u003cbr\u003e\u003cbr\u003eControl group: Days 14 and 21",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: yes\u003cbr\u003erandomised: yes\u003cbr\u003eopen: yes\u003cbr\u003esingle blind: no\u003cbr\u003edouble blind: no\u003cbr\u003eparallel group: no\u003cbr\u003ecross over: no\u003cbr\u003eother: yes\u003cbr\u003eother trial design description: cross-over allowed for patients with progressive covid-19\u003cbr\u003eif controlled, specify comparator, other medicinial product: no\u003cbr\u003eplacebo: no\u003cbr\u003eother: yes\u003cbr\u003eother specify the comparator: best supportive care\u003cbr\u003enumber of treatment arms in the trial: 2\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001310-38-DE",
			"start_date": "06/04/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "A randomized, prospective, open label clinical trial on the use of convalescent plasma compared to best supportive care in patients with severe COVID-19 - Convalescent Plasma against COVID-19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001310-38",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "patrick.cassai@chu-bordeaux.fr",
			"corresp_author_email_certainty": "prefilled",
			"country": "France",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e- Inability to make a decision to participate (dementia, guardianship)\u003cbr\u003e- Long QT syndrome, or QTc space \u003e 500 ms \u003cbr\u003e- Presence of a pace maker\u003cbr\u003e- Hyperkalemia \u003e 5.5 mmol/L or hypokalemia \u003c 3.5 mmol/L \u003cbr\u003e- Treatment with piperazine, halofantrine, dasatinib, nilotinib.citalopram, escitalopram, hydroxyzine, domperidone, potent inhibitors of cytochrome P450 CYP3A4 isoenzyme, potent inducers of cytochrome P450 CYP3A4 isoenzyme. \u003cbr\u003e- Hypersensitivity to any of the test drugs or chloroquine and other 4-aminoquinolines, amodiaquine, mefloquine, glafenine, floctafenine, antrafenine, ARB2 or sartan.\u003cbr\u003e- Hepatic porphyria, known obstructive hepato-biliary disease, liver failure (stage = Child-Pugh B), stage 4 or 5 chronic kidney disease (DFG \u003c30 mL/min/1.73 m²) or person on dialysis, retinopathy, lactose hypersensitivity, abnormalities in galactose metabolism, lactase deficiency, malabsorption syndrome, known glucose-6-phosphate dehydrogenase deficiency, symptomatic gout/hyperuricemia.\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e- Positive CoV-2 SARS test on nasopharyngeal swab\u003cbr\u003e- Onset of symptoms \u003c 72 hours prior to nasopharyngeal swabbing\u003cbr\u003e- Age = 65 years old\u003cbr\u003e- Valid, ambulatory person, fully capable of understanding the challenges of the tria\u003cbr\u003e- No hospitalization criteria according to current recommendations\u003cbr\u003e- Signed informed consent\u003cbr\u003e\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) no\u003cbr\u003eF.1.2.1 Number of subjects for this age range \u003cbr\u003eF.1.3 Elderly (\u003e=65 years) yes\u003cbr\u003eF.1.3.1 Number of subjects for this age range 1057\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eTrade Name: PLAQUENIL 200 mg\u003cbr\u003ePharmaceutical Form: Tablet\u003cbr\u003eINN or Proposed INN: Hydroxychloroquine\u003cbr\u003eCAS Number: 118-42-3\u003cbr\u003eConcentration unit: mg milligram(s)\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 200-\u003cbr\u003e\u003cbr\u003eTrade Name: Imatinib Teva 400 mg\u003cbr\u003ePharmaceutical Form: Tablet\u003cbr\u003eINN or Proposed INN: IMATINIB\u003cbr\u003eCAS Number: 152459-95-5\u003cbr\u003eOther descriptive name: IMATINIB\u003cbr\u003eConcentration unit: mg milligram(s)\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 400-\u003cbr\u003e\u003cbr\u003eTrade Name: AVIGAN 200mg\u003cbr\u003ePharmaceutical Form: Tablet\u003cbr\u003eINN or Proposed INN: FAVIPIRAVIR\u003cbr\u003eOther descriptive name: FAVIPIRAVIR\u003cbr\u003eConcentration unit: mg milligram(s)\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 200-\u003cbr\u003e\u003cbr\u003eTrade Name: MICARDIS 20mg\u003cbr\u003ePharmaceutical Form: Tablet\u003cbr\u003eINN or Proposed INN: TELMISARTAN\u003cbr\u003eCAS Number: 144701-48-4\u003cbr\u003eConcentration unit: mg milligram(s)\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 20-\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Main Objective: The main objective of this trial is To estimate the efficacy of several specific experimental treatments, compared to standard care, to prevent hospitalization or death at D14 in adults over 65 years of age, with documented SARS-CoV-2 infection, with symptoms lasting less than 72 hours and not meeting any hospitalization criteria.;Secondary Objective: To estimate :\u003cbr\u003e- the effectiveness of experimental treatments against SARS-CoV-2, to prevent death on D28\u003cbr\u003e- the effectiveness of experimental treatments against SARS-CoV-2, to prevent hospitalization on D28\u003cbr\u003e- the effectiveness of experimental treatments against SARS-CoV-2, compared to standard care, to prevent hospitalization in intensive care on D28\u003cbr\u003e- the effectiveness of experimental treatments against SARS-CoV-2 to suppress nasopharyngeal viral carriage, compared to standard care\u003cbr\u003e- the effectiveness of experimental treatments against SARS-CoV-2, compared to standard care, to prevent a loss of autonomy on D14 and D28\u003cbr\u003e- the tolerance of experimental treatments against SARS-CoV-2\u003cbr\u003e- Study the factors associated with the worsening of the disease\u003cbr\u003e- Evaluate the feasibility and acceptability of the trial and the care model implemented\u003cbr\u003e- Assess the relationship between the concentration of each drug and the effectiveness of each treatment;Primary end point(s): Proportion of participants with an occurrence of hospitalization and/or death between D0 and D14 in each arm;Timepoint(s) of evaluation of this end point: day 14 after inclusion",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: yes\u003cbr\u003erandomised: yes\u003cbr\u003eopen: yes\u003cbr\u003esingle blind: no\u003cbr\u003edouble blind: no\u003cbr\u003eparallel group: yes\u003cbr\u003ecross over: no\u003cbr\u003eother: no\u003cbr\u003eif controlled, specify comparator, other medicinial product: no\u003cbr\u003eplacebo: no\u003cbr\u003eother: yes\u003cbr\u003eother specify the comparator: azinc forme et vitalite (vitamins supplements)\u003cbr\u003enumber of treatment arms in the trial: 5\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001435-27-FR",
			"start_date": "10/04/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "Home treatment of elderly patients with symptomatic SARS-CoV-2 infection (COVID-19) : a multiarm, multi-stage (MAMS) randomized trial to assess the efficacy and safety\nof several experimental treatments to reduce the risk of hospitalization or death\n(COVERAGE trial) - COVERAGE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001435-27",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "l.lamrani@hml.fr",
			"corresp_author_email_certainty": "prefilled",
			"country": "France",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e1. Patient under guardianship or curatorship\u003cbr\u003e2. Patient with plausible alternate diagnosis\u003cbr\u003e3. ARDS evolving for more than 4 days\u003cbr\u003e4. Contraindication to the HCQ\u003cbr\u003e5. Contraindication to DXM\u003cbr\u003e6. Uncontrolled septic shock\u003cbr\u003e7. Untreated active infection or treated less than 24 hours\u003cbr\u003e8. Long-term patient treated with corticosteroids (\u003e 20 mg / day) or HCQ\u003cbr\u003e9. Immunocompromised patients: AIDS, bone marrow or solid organ transplant recipients\u003cbr\u003e10. Pregnant women\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e1. Patient aged \u003e 18\u003cbr\u003e2. Patient affiliated to a health insurance plan\u003cbr\u003e3. Patient who has given their free, informed and written consent or patient for whom an independent doctor has given their signed consent as part of an emergency procedure\u003cbr\u003e4. Serum Potassium\u003e 3,5 mmol / L\u003cbr\u003e5. Patient diagnosed COVID positive by RT-PCR and / or scanner\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range 80\u003cbr\u003eF.1.3 Elderly (\u003e=65 years) yes\u003cbr\u003eF.1.3.1 Number of subjects for this age range 42\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eTrade Name: DEXAMETHASONE MYLAN 20mg/5mL \u003cbr\u003eProduct Name: DEXAMETHASONE\u003cbr\u003ePharmaceutical Form: Injection\u003cbr\u003e\u003cbr\u003eTrade Name: PLAQUENIL 200MG\u003cbr\u003eProduct Name: HYDROXYCHLOROQUINE\u003cbr\u003ePharmaceutical Form: Tablet\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Main Objective: Assess, in patients with ARDS caused by COVID-19, the efficacy of dexamethasone (DXM) associated with hydroxychloroquine (HCQ) compared to HCQ alone on mortality at 28 days;Secondary Objective: Assess, in patients with ARDS causedd by COVID-19, the efficacy of DXM associated with HCQ compared to HCQ alone on :\u003cbr\u003e- the ventilator-free days\u003cbr\u003e- mortality in intensive care unit\u003cbr\u003e- mortality on D60\u003cbr\u003e- the occurrence of infectious complications ;Primary end point(s): Mortality on D28\u003cbr\u003e;Timepoint(s) of evaluation of this end point: the 28th day after the start of treatment\u003cbr\u003e",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: yes\u003cbr\u003erandomised: yes\u003cbr\u003eopen: yes\u003cbr\u003esingle blind: no\u003cbr\u003edouble blind: no\u003cbr\u003eparallel group: yes\u003cbr\u003ecross over: no\u003cbr\u003eother: no\u003cbr\u003eif controlled, specify comparator, other medicinial product: no\u003cbr\u003eplacebo: no\u003cbr\u003eother: yes\u003cbr\u003eother specify the comparator: dexamethasone associated with hydroxychloroquine will be compared to hydroxychloroquine alone\u003cbr\u003enumber of treatment arms in the trial: 2\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001333-13-FR",
			"start_date": "09/04/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "Dexamethasone associated with hydroxychloroquine vs. hydroxychloroquine alone for the early treatment of severe ARDS caused by COVID-19 : a randomized controlled trial - DHYSCO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001333-13",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"country": "Australia",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: •\tAge less than 18yo or pregnant or lactating female\r\u003cbr\u003e•\tAllergy to Zn\r\u003cbr\u003e•\tSevere hepatic impairment defined as Child C liver disease. \r\u003cbr\u003e•\teGFR equal to or less than 30 mL/min/1.73 m2 (defined using CKD-EPI SCr formula)\r\u003cbr\u003e•\tHistory of any organ transplant which requires active immunosuppressive treatment which can interfere with kidney function\r\u003cbr\u003e•\tIf a patient required cardiopulmonary resuscitation (CPR) within 14 days \r\u003cbr\u003e•\tDNR (do not resuscitate) DNI (do not intubate) orders \r\u003cbr\u003e•\tDeath is deemed imminent or inevitable during this admission, and either the attending physician, patient or substitute decision-maker is not committed to active treatment \r\u003cbr\u003e•\tAlready receiving dialysis (either acute or chronic) or imminent need of dialysis at the time of enrolment \r\u003cbr\u003e•\tPatients with known HIV infection\r\u003cbr\u003e•\tPatients with a known or suspected history of oxalate nephropathy or hyperoxaluria, scurvy, chronic iron overload, G-6PD deficiency \r\u003cbr\u003e•\tClinician expects to prescribe Zinc for another indication\r\u003cbr\u003e•\tPatients with known haemochromatosis.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: •\tConsenting adult patients adult male or female, age 18 years or older. Laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction (PCR) or another commercial or public health assay\r\u003cbr\u003e•\tHospitalized with a SARS-CoV-2 infection of any duration\r\u003cbr\u003e•\tAbility to provide informed consent signed by study patient or legally acceptable representative\r\u003cbr\u003e•\tWillingness and ability to comply with study-related procedures/assessments\r\u003cbr\u003e•\tHave an oxygen saturation (SaO2) of 94% or less while they were breathing ambient air or a ratio of the partial pressure of oxygen (PaO2) to the fraction of inspired oxygen (FiO2) (Pao2: Fio2) at or below 300 mg Hg. \r\u003cbr\u003e•\tNo chronic kidney disease (CKD) defined by stage II or higher using the Kidney Disease Improving Global Outcomes (KDIGO) classification\r\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "COVID-19 symptomatic confirmed hospitalized adult patients will be enrolled as soon as possible after fulfilling the criteria for randomisation. Patients will be allocated in a 1:1 ratio to either the treatment group receiving intravenous zinc chloride (0.5mg/kg/d) or to control group, receiving saline placebo alone. \u003cbr\u003ePharmaceutical grade Zinc Chloride stock solution obtained from an Australian company (Phebra Pty Ltd) will be diluted in 250ml of normal saline and infused, resulting in a final dosage of 0.5mg/kg/d. Patients will be administered zinc for seven days. To standardise administration time, zinc infusions will commence around 9am but anywhere between 8am to 12pm in the morning is adequate. Zinc chloride will be administered via central venous or peripheral access over 3-6 hrs.\u003cbr\u003eWe will monitor fidelity to the intervention by review of nursing documentation in the intravenous fluid given section of the electronic fluid balance chart. Note will be made of what was given, time commenced, volume given, time completed.\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "In non-ventilated patients- Mean change in the worst (highest) level of oxygenation (oxygen flow in litres/min). This will be assessed by the nursing documentation in the participant's electronic record of the flow rate of oxygen delivered and the delivery method (ie nasal prongs, Hudson mask, or non-breather mask). \u003cbr\u003eIn ventilated patients- Mean change in the worst (lowest) PaO2 /FiO2 ratio (in mmHg). This will be assessed by nursing documented PaO2 and FiO2 levels in the patient chart.[Worst recorded level of oxygenation during the 7 days of intervention.];Feasibility will be assesses by the following measures:\u003cbr\u003e• The primary assessment of our ability to blind treatment of the HDIVZn in a 250-ml saline preparation\u003cbr\u003e• Drug availability from supplier, storage and timely delivery to a patient\u003cbr\u003e• Good clinical practice documentation of drug prescription on Cerner (an electronic medical record), delivery to ICU by project research officer, double signing by nursing staff\u003cbr\u003e• Appropriate preparation of drug- onsite refrigeration storage, preparation with SOPs, maintenance of sterile conditions, protocol compliance, breaches, and variation, documentation processes including patient retention and follow-up rates\u003cbr\u003e• Determine the per-patient cost to estimate subsequent pivotal trial costs\u003cbr\u003e• Assess the process for efficient and effective data entry and analysis\u003cbr\u003eThese will be assessed by our research investigators on a regular basis and data collected in the case report forms.[During 7 days of intervention]",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "purpose: treatment; allocation: randomised controlled trial; masking: blinded (masking used);assignment: parallel;type of endpoint: safety/efficacy;",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ACTRN12620000454976",
			"start_date": "09/04/2020",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "High-dose intravenous zinc (HDIVZn) as adjunctive therapy in COVID-19 positive critically ill patients: A pilot randomized controlled trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ",
			"title_certainty": "prefilled",
			"url": "https://anzctr.org.au/ACTRN12620000454976.aspx",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "g.elder@northumbria.ac.uk",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Elder",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "United Kingdom",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e                Poor sleepers:\u003cbr\u003e                1. Long-term (i.e. chronic) sleep problems (\u003e 3 months)\u003cbr\u003e            ",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e                All participants must:\u003cbr\u003e                1. Be aged 18 years and above\u003cbr\u003e                2. Have a sufficient level of English comprehension to understand and complete questionnaires\u003cbr\u003e\u003cbr\u003e                Poor sleepers:\u003cbr\u003e                1. Must have difficulties in falling asleep, staying asleep, or awakening too early at least three nights per week, for a time period of between two weeks and three months\u003cbr\u003e                2. Must have distress or impairment caused by sleep loss\u003cbr\u003e                3. Both 1. and 2. must occur despite the individual having an adequate opportunity for sleep\u003cbr\u003e\u003cbr\u003e                Good sleepers:\u003cbr\u003e                1. No current sleep problems\u003cbr\u003e            ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003e                This is an interventional study where good sleepers will be recruited as a wait-list control, where they will receive the treatment after a delay of one week. An additional group of good sleeper participants will be recruited who will not receive the intervention. An equal number of participants will be recruited to each group and healthy good sleepers and individuals with sleep problems will be recruited at a 2:1 ratio (estimated n = 40:20 participants).\u003cbr\u003e\u003cbr\u003e                The study is single-centre and the study will be run entirely online.\u003cbr\u003e\u003cbr\u003e                Participants who are in the two intervention groups (poor sleep and wait-list control good sleepers) will be provided with an online version of a self-help leaflet. A printed version of this leaflet has been used in previous treatment studies conducted by our research group. Briefly, this self-help leaflet aims to improve sleep by identifying and addressing sleep-related dysfunctional thinking by providing education about sleep, providing techniques to distract from intrusive worrisome thoughts at night, and providing guidelines for sleep-related stimulus control.\u003cbr\u003e\u003cbr\u003e                The duration of treatment will be one week and the follow-up period is at the end of the treatment period. Participants will be randomised using online software (where good sleepers will be randomised to treatment or no treatment).\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Insomnia severity measured using the Insomnia Severity Index at one week post-intervention",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "interventional cluster randomized trial (treatment)",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ISRCTN43900695",
			"start_date": "06/04/2020",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Testing an early online intervention for the treatment of disturbed sleep during the COVID-19 pandemic (Sleep COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         ",
			"title_certainty": "prefilled",
			"url": "http://isrctn.com/ISRCTN43900695",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "fibucicec.hcsc@salud.madrid.org",
			"corresp_author_email_certainty": "prefilled",
			"country": "Spain",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003eknown allergy or contra-indications to investigational products\u003cbr\u003eanticipated transfer within 72 hours to a non-study hospital.\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003econsenting adults (age =18) hospitalised with definite COVID-19, not already receiving any of the study drugs\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range 500\u003cbr\u003eF.1.3 Elderly (\u003e=65 years) yes\u003cbr\u003eF.1.3.1 Number of subjects for this age range 2000\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eProduct Name: Remdesivir\u003cbr\u003ePharmaceutical Form: Lyophilisate for solution for infusion\u003cbr\u003eINN or Proposed INN: REMDESIVIR\u003cbr\u003eCurrent Sponsor code: REMDESIVIR\u003cbr\u003eOther descriptive name: REMDESIVIR\u003cbr\u003eConcentration unit: mg milligram(s)\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 100-\u003cbr\u003e\u003cbr\u003eTrade Name: Chloroquine\u003cbr\u003ePharmaceutical Form: Tablet\u003cbr\u003eINN or Proposed INN: Chloroquine\u003cbr\u003eCAS Number: 54-05-7\u003cbr\u003eConcentration unit: mg milligram(s)\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 250-\u003cbr\u003e\u003cbr\u003eTrade Name: HYDROXYCHLOROQUINE SULFATE\u003cbr\u003ePharmaceutical Form: \u003cbr\u003eINN or Proposed INN: HYDROXYCHLOROQUINE SULFATE\u003cbr\u003eCAS Number: 747-36-4\u003cbr\u003eCurrent Sponsor code: HYDROXYCHLOROQUINE SULFATE\u003cbr\u003eOther descriptive name: HYDROXYCHLOROQUINE SULFATE\u003cbr\u003eConcentration unit: mg milligram(s)\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 200-\u003cbr\u003e\u003cbr\u003eTrade Name: Lopinavir/Ritonavir\u003cbr\u003ePharmaceutical Form: \u003cbr\u003eINN or Proposed INN: LOPINAVIR\u003cbr\u003eCAS Number: 192725-17-0\u003cbr\u003eConcentration unit: mg milligram(s)\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 200-\u003cbr\u003e\u003cbr\u003eTrade Name: Interferón b 1A\u003cbr\u003ePharmaceutical Form: \u003cbr\u003eINN or Proposed INN: Interferon beta-1a\u003cbr\u003eCAS Number: 220581-49-7\u003cbr\u003eCurrent Sponsor code: Interferon beta-1a\u003cbr\u003eOther descriptive name: Interferon beta-1a\u003cbr\u003eConcentration unit: g gram(s)\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 152-\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Main Objective: The aim of this core protocol is to compare the effects on major outcomes in hospital of the local standard of care alone versus the local standard of care plus one of four alternative anti-viral agents. \u003cbr\u003e\u003cbr\u003eThe primary objective of this large international randomised trial is to provide reliable estimates on any effects of these anti-viral treatments on in-hospital mortality in moderate and in severe COVID;Secondary Objective: The secondary objectives are to assess any effects of these anti-viral treatments on hospital duration and receipt of ventilation or intensive care, and to identify any serious adverse reactions.;Primary end point(s): The primary outcome is all-cause mortality, subdivided by severity of disease at the time of randomisation.;Timepoint(s) of evaluation of this end point: At discharge or death.",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: yes\u003cbr\u003erandomised: yes\u003cbr\u003eopen: yes\u003cbr\u003esingle blind: no\u003cbr\u003edouble blind: no\u003cbr\u003eparallel group: no\u003cbr\u003ecross over: no\u003cbr\u003eother: no\u003cbr\u003eif controlled, specify comparator, other medicinial product: no\u003cbr\u003eplacebo: no\u003cbr\u003eother: yes\u003cbr\u003eother specify the comparator: local standard of care\u003cbr\u003enumber of treatment arms in the trial: 5\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001366-11-ES",
			"start_date": "27/03/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001366-11",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "lola.serna@carm.es",
			"corresp_author_email_certainty": "prefilled",
			"country": "Spain",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e? Patients with acute bleeding.\u003cbr\u003e? Patients with thrombolytic treatment and anticoagulant treatment at therapeutic doses.\u003cbr\u003e? Patients with an active malignant tumor.\u003cbr\u003e? Patients with severe systemic or neuropsychiatric diseases.\u003cbr\u003e? Patients with hypersensitivity to the active substance or to any of the excipients of the study drug.\u003cbr\u003e? Patients who are participating in other clinical trials.\u003cbr\u003e? Patients with an inability to understand informed consent.\u003cbr\u003e? Pregnant patientsb, in the postpartum period or in the period of active lactation.\u003cbr\u003ePhysically fertile patients, UNLESS they are using a highly effective contraceptive method\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e? Patients of both sexes with an age greater than or equal to 18 years.\u003cbr\u003e? Patients with a diagnosis of SARS-CoV-2 infection confirmed by RT-PCR.\u003cbr\u003e? Patients with grade 4, 5 or 6 clinical status according to the WHO classification.\u003cbr\u003e- Grade 4: Hospitalized patients requiring oxygen therapy.\u003cbr\u003e- Grade 5: Hospitalized patients requiring high-flow oxygen therapy, non-invasive mechanical ventilation, or both.\u003cbr\u003e- Grade 6: Hospitalized patients requiring extracorporeal membrane oxygenation or invasive mechanical ventilation.\u003cbr\u003e? Patients with IL-6 levels equal to or greater than 3 times the value of normality\u003cbr\u003e? Potentially fertile patients should have a negative pregnancy test in serum (beta-HCG) or urine (evaluated between 2 and 1 days prior to administration of the study medication).\u003cbr\u003e? Patients who offer sufficient guarantees of adherence to the protocol.\u003cbr\u003e? Patients who give their written informed consent to participate in the study\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range 60\u003cbr\u003eF.1.3 Elderly (\u003e=65 years) yes\u003cbr\u003eF.1.3.1 Number of subjects for this age range 60\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eTrade Name: DEFITELIO\u003cbr\u003eProduct Name: DEFITELIO\u003cbr\u003ePharmaceutical Form: Solution for infusion\u003cbr\u003eINN or Proposed INN: DEFIBROTIDE\u003cbr\u003eCAS Number: 83712-60-1\u003cbr\u003eConcentration unit: mg/kg milligram(s)/kilogram\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 25-\u003cbr\u003ePharmaceutical form of the placebo: Solution for infusion\u003cbr\u003eRoute of administration of the placebo: Intravenous use\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Main Objective: To determine the efficacy of the intravenous infusion of Defibrotide (Defitelio) to reduce mortality in patients with SARS-CoV-2 infection with clinical status grade 4, 5 or 6 according to the WHO classification.;Secondary Objective: To assess the safety of intravenous Defibrotide (Defitelio) infusion in patients with SARS-CoV-2 infection with clinical status grade 4, 5 or 6 according to the WHO classification.\u003cbr\u003e? To analyze the effects of the intravenous infusion of Defibrotide (Defitelio) on the clinical state of patients with SARS-CoV-2 infection with clinical status grade 4, 5 or 6 according to the WHO classification.\u003cbr\u003e? Assess the capacity of intravenous infusion of Defibrotide (Defitelio) to improve the radiological response of patients with SARS-CoV-2 infection with clinical status grade 4, 5 or 6 according to the WHO classification.\u003cbr\u003e? Study the action of Defibrotide (Defitelio) on risk biomarkers in patients with SARS-CoV-2 infection with grade 4, 5 or 6 clinical status according to the WHO classification.;Primary end point(s): Mortality rate 30 days after starting treatment.;Timepoint(s) of evaluation of this end point: 15, 30 ,60 days",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: yes\u003cbr\u003erandomised: yes\u003cbr\u003eopen: no\u003cbr\u003esingle blind: no\u003cbr\u003edouble blind: yes\u003cbr\u003eparallel group: yes\u003cbr\u003ecross over: no\u003cbr\u003eother: no\u003cbr\u003eif controlled, specify comparator, other medicinial product: no\u003cbr\u003eplacebo: yes\u003cbr\u003eother: yes\u003cbr\u003eother specify the comparator: conventional treatment\u003cbr\u003enumber of treatment arms in the trial: 2\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001409-21-ES",
			"start_date": "01/04/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "A prospective, multicenter, randomized, parallel, double-blind, placebo-controlled phase IIb clinical trial to evaluate intravenous infusion of Defibrotide in the prevention and treatment of respiratory distress and cytokine release syndrome in patients with COVID-19. - DEFACOVID                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001409-21",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "jan.fehr@uzh.ch",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Fehr",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "Switzerland",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e                1. Unable to follow study procedures\u003cbr\u003e                2. Insufficient knowledge of the German, English, French, or Italian language\u003cbr\u003e                3. Aged \u003c16 years\u003cbr\u003e            ",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e                1. Present to the UZH COVID-19 Testing Center for SARS-CoV-2 testing following a phone-based triage assessing their eligibility for SARS-CoV-2 testing\u003cbr\u003e                2. Provide consent for study participation\u003cbr\u003e            ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003e                Patients presenting to the UZH COVID-19 Testing Center for SARS-CoV-2 testing will be enrolled in the cohort study. All patients will undergo routine testing at the testing center. The cohort study-specific follow-up and prospective data collection will depend on the test result.\u003cbr\u003e\u003cbr\u003e                Patients tested positive for SARS-CoV-2 will receive three calls at 7, 14 and 60 days after their visit to the testing center. Information will be collected about the disease course and current health status, as well as further health care contacts. Further information about the disease course, hospitalization and patient outcomes will be collected from patient records obtained from general practitioners and treating physicians in hospitals.\u003cbr\u003e\u003cbr\u003e                Patients tested negative for SARS-CoV-2 will receive one call at 14 days after their visit to the testing center. Information will be collected about the disease course and current health status, as well as further health care contacts and retesting. If retested, further information about the second test result will be collected from general practitioners and treating physicians in hospitals. Biological samples obtained for viral testing will additionally be analyzed for further respiratory pathogens.\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Hospital admission for any reason among patients who tested positive for SARS-CoV-2 within 30 days following initial consultation for SARS-CoV-2 testing. Information will be collected from participants via follow-up phone calls at days 7, 14, and 60 after consultation, as well as via patient records from general practitioners and/or treating physicians in hospitals after 60 days.",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "single-center, prospective cohort study (diagnostic)",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ISRCTN77353041",
			"start_date": "08/04/2020",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Predicting hospitalization and poor clinical outcomes in patients presenting for SARS-CoV-2 testing in an outpatient testing center in Switzerland - a prospective cohort study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ",
			"title_certainty": "prefilled",
			"url": "http://isrctn.com/ISRCTN77353041",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "secretaria@delosclinical.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "Spain",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e1. Health care workers previously treated with hydroxycloroquine in the 60 days before.\u003cbr\u003e\u003cbr\u003e2. Health care workers participating  in another clinical study where they received an investigational drug in the 24 weeks before to signing the informed consent.\u003cbr\u003e\u003cbr\u003e3. Pregnant or lactating women.\u003cbr\u003e\u003cbr\u003e4. Postmenopausal women \u003cbr\u003e\u003cbr\u003e5. Psoriasis.\u003cbr\u003e\u003cbr\u003e6. Retinopathy, maculopathy or changes in the visual field, regardless of its origin.\u003cbr\u003e\u003cbr\u003e7. Neurogenic hearing impairment.\u003cbr\u003e\u003cbr\u003e8. Myasthenia gravis.\u003cbr\u003e\u003cbr\u003e9. Disease of the hematopoietic system.\u003cbr\u003e\u003cbr\u003e10. Glucose-6-phosphate dehydrogenase deficiency (eg hemolytic anemia or favism).\u003cbr\u003e\u003cbr\u003e11. Hypersensitivity to hydroxychloroquine or 4-aminoquinoline derivatives.\u003cbr\u003e\u003cbr\u003e12. Inability to take oral medication.\u003cbr\u003e\u003cbr\u003e13. Diagnosis of any other pathology that, in the investigator's opinion, may increase the subject's risk or reduce the possibilities of obtaining satisfactory data to achieve the objectives of the study.\u003cbr\u003e\u003cbr\u003e14. Consumption of alcohol or any other drug that could disable him in the judgment of the investigator to participate in the study.\u003cbr\u003e\u003cbr\u003e15. Other circumstances or difficulties that, in the investigator's opinion, may increase the subject's risk or reduce the possibilities of obtaining satisfactory data to achieve the study's objectives.\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e1. Absence of SARS-CoV-2 infection (COVID-19) due to the absence of a symptoms of acute respiratory infection or a diagnostic test with a negative result.\u003cbr\u003e\u003cbr\u003e2. Men or women 18 years of age or older at the time of signing the informed consent.\u003cbr\u003e\u003cbr\u003e3. For fertile women, negative pregnancy test and written commitment to use a reliable contraceptive method for the duration of the study and for 3 months after the end of treatment.\u003cbr\u003e\u003cbr\u003e4. Health care workers active at the center.\u003cbr\u003e\u003cbr\u003e5. Informed consent signed\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range 2163\u003cbr\u003eF.1.3 Elderly (\u003e=65 years) no\u003cbr\u003eF.1.3.1 Number of subjects for this age range \u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eTrade Name: Hidroxicloroquina Aristo\u003cbr\u003eProduct Name: Hidroxicloroquina sulfato\u003cbr\u003ePharmaceutical Form: Coated tablet\u003cbr\u003eINN or Proposed INN: HYDROXYCHLOROQUINE SULFATE\u003cbr\u003eCAS Number: 747-36-4\u003cbr\u003eCurrent Sponsor code: 81939\u003cbr\u003eOther descriptive name: HYDROXYCHLOROQUINE SULFATE\u003cbr\u003eConcentration unit: mg milligram(s)\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 200-\u003cbr\u003e\u003cbr\u003eTrade Name: Hidroxicloroquina Aristo\u003cbr\u003eProduct Name: Hidroxicloroquina sulfato\u003cbr\u003ePharmaceutical Form: Coated tablet\u003cbr\u003eINN or Proposed INN: HYDROXYCHLOROQUINE SULFATE\u003cbr\u003eCAS Number: 747-36-4\u003cbr\u003eCurrent Sponsor code: 81939\u003cbr\u003eOther descriptive name: HYDROXYCHLOROQUINE SULFATE\u003cbr\u003eConcentration unit: mg milligram(s)\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 200-\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Main Objective: To assess the efficacy of hydroxychloroquine as chemoprophylaxis against SARS-CoV-2 (COVID-19) infection in healthcare professionals by negative PCR.;Secondary Objective: To assess the safety of hydroxychloroquine as chemoprophylaxis against SARS-CoV-2 (COVID-19) infection in healthcare professionals.\u003cbr\u003e\u003cbr\u003eTo assess the efficacy of personal protective equipment against SARS-CoV-2 (COVID-19) infection in healthcare professionals;Primary end point(s): Diagnosis of SARS-CoV-2 COVID-19 infection;Timepoint(s) of evaluation of this end point: - At the end of prophylaxis treatment\u003cbr\u003e- Fourteen days after the last dose of treatment",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: yes\u003cbr\u003erandomised: yes\u003cbr\u003eopen: yes\u003cbr\u003esingle blind: no\u003cbr\u003edouble blind: no\u003cbr\u003eparallel group: yes\u003cbr\u003ecross over: no\u003cbr\u003eother: no\u003cbr\u003eif controlled, specify comparator, other medicinial product: no\u003cbr\u003eplacebo: no\u003cbr\u003eother: yes\u003cbr\u003eother specify the comparator: other doses regimen\u003cbr\u003enumber of treatment arms in the trial: 3\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001421-31-ES",
			"start_date": "06/04/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "Clinical trial randomized, unblinded and controled for evaluation of efficacy and safety of hydroxychloroquine chemoprophylaxis against SARS-CoV-2 (COVID-19) infection in healthcare professionals.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001421-31",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "eunate.aranaarri@osakidetza.eus",
			"corresp_author_email_certainty": "prefilled",
			"country": "Spain",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e- Participation in any other clinical trial with an experimental treatment for COVID-19\u003cbr\u003e- Hypersensitivity to the active substance, to 4-aminoquinoline compounds or to any of the excipients included in section 6.1 of the hydroxychloroquine data sheet\u003cbr\u003e- Hypersensitivity to azithromycin, erythromycin, any other macrolide or ketolide antibiotic or to any of the excipients listed in section 6.1 of the azithromycin SmPC\u003cbr\u003e- psoriasis\u003cbr\u003e- Patients with glucose-6-phosphate dehydrogenase deficiency\u003cbr\u003e- Any contraindication according to the Technical Data Sheet of Hydroxychloroquine and Azithromycin\u003cbr\u003e- pneumonia\u003cbr\u003e- Myasthenia gravis\u003cbr\u003e- Pre-existing maculopathy of the eye\u003cbr\u003e- Presence of changes in acuity or visual field\u003cbr\u003e- QT +/- 450 extension\u003cbr\u003e- ALT or AST\u003e 5 x ULN\u003cbr\u003e- Creatinine clearance \u003c50 ml / min\u003cbr\u003e- Positive pregnancy test\u003cbr\u003e- Woman with breastfeeding\u003cbr\u003e- Active treatment with: artemeter / lumefantrine, mefloquine, natilizumab, live attenuated virus vaccines, pimecrolimus, tacrolimus (topical), mosifloxacin, and agalsidase alpha and beta\u003cbr\u003e- Refusal by the patient to accept the commitment to comply with the procedures indicated during the research process\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e- Patients of both sexes\u003cbr\u003e- Patients = 18 years with COVID and comorbidities (COPD, asthma, heart disease, HT, diabetes, neoplasia, chronic liver disease or with immunosuppressive treatment), without pneumonia or over 60 with COVID\u003cbr\u003e- SARS-CoV-2 infection confirmed by PCR test\u003cbr\u003e- Radiographic evidence of not presenting pneumonia\u003cbr\u003e- O2 saturation\u003e 92%\u003cbr\u003e- Respiratory Rate \u003c20 rpm\u003cbr\u003e- Willing and able to sign the written informed consent before carrying out the study procedures. Exceptionally, oral consent is admitted, preferably before independent witnesses, documenting it in the medical record and provided that it can later be ratified.\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range 62\u003cbr\u003eF.1.3 Elderly (\u003e=65 years) yes\u003cbr\u003eF.1.3.1 Number of subjects for this age range 62\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eTrade Name: Ibuprofen\u003cbr\u003ePharmaceutical Form: Tablet\u003cbr\u003eINN or Proposed INN: IBUPROFEN\u003cbr\u003eCAS Number: 15687-27-1\u003cbr\u003eConcentration unit: mg milligram(s)\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 600-\u003cbr\u003e\u003cbr\u003eTrade Name: Hidroxicloroquina\u003cbr\u003ePharmaceutical Form: Tablet\u003cbr\u003eINN or Proposed INN: Hydroxychloroquine\u003cbr\u003eCAS Number: 118-42-3\u003cbr\u003eConcentration unit: mg milligram(s)\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 200-\u003cbr\u003e\u003cbr\u003eTrade Name: Azitromicina\u003cbr\u003ePharmaceutical Form: Tablet\u003cbr\u003eINN or Proposed INN: Azithromycin\u003cbr\u003eCAS Number: 83905-01-5\u003cbr\u003eOther descriptive name: AZITHROMYCIN\u003cbr\u003eConcentration unit: mg milligram(s)\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 500-\u003cbr\u003e\u003cbr\u003eTrade Name: Paracetamol\u003cbr\u003ePharmaceutical Form: \u003cbr\u003eINN or Proposed INN: Paracetamol\u003cbr\u003eCAS Number: 103-90-2\u003cbr\u003eOther descriptive name: PARACETAMOL\u003cbr\u003eConcentration unit: mg milligram(s)\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 500-\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Main Objective: Demonstrate the therapeutic effectiveness of Hydroxychloroquine associated with Azithromycin treatment for symptom control and negative viral load, in patients with comorbidities without pneumonia and COVID-19 infection.;Secondary Objective: - Evaluate the safety of the treatment\u003cbr\u003e- Assess tolerance of treatment;Primary end point(s): Proportion of patients with negative viral load by CODV-19 [SARS-CoV-2 (PCR)] at 6 days after the start of treatment;Timepoint(s) of evaluation of this end point: 30 DAYS",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: yes\u003cbr\u003erandomised: yes\u003cbr\u003eopen: yes\u003cbr\u003esingle blind: no\u003cbr\u003edouble blind: no\u003cbr\u003eparallel group: no\u003cbr\u003ecross over: no\u003cbr\u003eother: no\u003cbr\u003eif controlled, specify comparator, other medicinial product: no\u003cbr\u003eplacebo: no\u003cbr\u003eother: yes\u003cbr\u003eother specify the comparator: ibuprofen, paracetamol\u003cbr\u003enumber of treatment arms in the trial: 3\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001606-33-ES",
			"start_date": "07/04/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "Randomized clinical trial to evaluate the efficacy of hydroxychloroquine associated or not with azithromycin as a treatment for COVID-19 infection. - Randomized clinical trial to evaluate the efficacy of a treatment for COVID-19 infection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001606-33",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "pvachey@for.paris",
			"corresp_author_email_certainty": "prefilled",
			"country": "France",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e- Known hypersensitivity to Dornase alfa or any of the excipients;\u003cbr\u003e- Pregnant or nursing woman;\u003cbr\u003e- Patient with legal pro\u003cbr\u003e\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e- Major patient (age = 18 years old);\u003cbr\u003e- Hospitalized in intensive care;\u003cbr\u003e- Severe pneumonia COVID-19 with Berlin criteria for ARDS (PaO2/FiO2\u003c300 and PEP\u003e5).\u003cbr\u003e- Intubated for less than 8 days ;\u003cbr\u003e- Expected duration of mechanical ventilation is \u003e48 hours;\u003cbr\u003e- Carrying an arterial catheter;\u003cbr\u003e- Affiliated with or beneficiary of a health insurance social protection scheme\u003cbr\u003e\u003cbr\u003e\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range 50\u003cbr\u003eF.1.3 Elderly (\u003e=65 years) yes\u003cbr\u003eF.1.3.1 Number of subjects for this age range 50\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eTrade Name: Pulmozyme 2500 U/2,5ml, solution pour inhalation par nébuliseur\u003cbr\u003ePharmaceutical Form: Inhalation solution\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Main Objective: To evaluate the efficacy of intratracheal administration of dornase alfa (Pulmozyme) on the evolution of ventilatory parameters at D7;Secondary Objective: 1) all-cause mortality at D28\u003cbr\u003e2) the clinical evolution at D28 ;\u003cbr\u003e3) the duration of mechanical ventilation;\u003cbr\u003e4) the number of days without mechanical ventilation at D28;\u003cbr\u003e5) the length of stay in intensive care ;\u003cbr\u003e6) the concentrations of blood markers of inflammation over time;\u003cbr\u003e7) NET concentrations in bronchial secretions over time\u003cbr\u003e8) the occurrence of adverse events;Primary end point(s): Comparison between the two treatment arms of the evolution of the PaO2/FiO2 ratio between D0 (inclusion) and D7;Timepoint(s) of evaluation of this end point: D7",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: yes\u003cbr\u003erandomised: yes\u003cbr\u003eopen: yes\u003cbr\u003esingle blind: no\u003cbr\u003edouble blind: no\u003cbr\u003eparallel group: no\u003cbr\u003ecross over: no\u003cbr\u003eother: no\u003cbr\u003eif controlled, specify comparator, other medicinial product: no\u003cbr\u003eplacebo: no\u003cbr\u003eother: yes\u003cbr\u003eother specify the comparator: usual treatment\u003cbr\u003enumber of treatment arms in the trial: 2\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001492-33-FR",
			"start_date": "10/04/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "Interest in the administration of Dornase alpha aerosol in ARDS secondary to respiratory infection by the coronavirus SRASCoV-2 / COVID-19 - COVID19-COVIDornase                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001492-33",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "gutierrez_fel@gva.es",
			"corresp_author_email_certainty": "prefilled",
			"country": "Spain",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e-Patients \u003c18 years.\u003cbr\u003e-Patients with symptoms suggestive of SARS-CoV-2 infection.\u003cbr\u003e-Women who are pregnant or who intend to become pregnant for the next three months after taking the drug.\u003cbr\u003e-Patients allergic to mefloquine or other quinine or quinidine-type medications.\u003cbr\u003e-Patients with a neurological history (seizures, epilepsy, etc.).\u003cbr\u003e-Patients with a previous history of psychiatric illnesses (depression, anxiety, suicide attempt).\u003cbr\u003e-Patients with cardiac pathologies or relevant chronic diseases that in the judgment of the clinician recommend the non-inclusion of the patient in the study.\u003cbr\u003e-Patients in treatment with other medications such as valproic acid, antiarrhythmics, antihistamines H1, beta-blockers, calcium channel blockers, chloroquine, halofantrine, phenothiazines, quinidine and quinine.\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003ePeople in close contact with adults diagnosed with COVID-19 who sign the informed consent. Close contact is defined as those who live at home with an infected person, who have had intimate relationships or whose job is less than two meters from the infected person.\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range 100\u003cbr\u003eF.1.3 Elderly (\u003e=65 years) yes\u003cbr\u003eF.1.3.1 Number of subjects for this age range 100\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eTrade Name: Lariam\u003cbr\u003ePharmaceutical Form: Capsule, hard\u003cbr\u003eINN or Proposed INN: MEFLOQUINE\u003cbr\u003eCAS Number: 53230-10-7\u003cbr\u003eConcentration unit: mg milligram(s)\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 250-\u003cbr\u003ePharmaceutical form of the placebo: Capsule, hard\u003cbr\u003eRoute of administration of the placebo: Oral use\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Main Objective: To determine the protective efficacy of mefloquine prophylaxis against placebo in close contacts of people with COVID-19.;Secondary Objective: -Establish if the preventive administration of mefloquine attenuates the clinical manifestations of COVID-19 in people who become infected.\u003cbr\u003e-Evaluate the safety of prophylactic mefloquine in this setting.;Primary end point(s): COVID-19 infection.;Timepoint(s) of evaluation of this end point: The patient will be evaluated weekly for 30 days from enrollment in the study to rule out / confirm COVID-19 infection.",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: yes\u003cbr\u003erandomised: yes\u003cbr\u003eopen: no\u003cbr\u003esingle blind: no\u003cbr\u003edouble blind: yes\u003cbr\u003eparallel group: yes\u003cbr\u003ecross over: no\u003cbr\u003eother: no\u003cbr\u003eif controlled, specify comparator, other medicinial product: no\u003cbr\u003eplacebo: yes\u003cbr\u003eother: no\u003cbr\u003enumber of treatment arms in the trial: 2\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001194-69-ES",
			"start_date": "30/03/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "Pilot study to evaluate the efficacy and safety of mefloquine as prophylaxis in people exposed to the disease caused by the SARS-CoV-2 coronavirus (COVID-19) - MEFLOCOVID-19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001194-69",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "jinzhilu2015@163.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: Cases were excluded as they sustained a pulse oxygen saturation (SpO2) more than 95%. Additionally, patients with pulse oxygen saturation (SpO2) of more than 95% after oxygen therapy ( at a flow rate of 3 liters per minute) were excluded from the study. Patients with oxygenation index higher than 300 mmHg were also excluded from the study. ",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: Laboratory confirmation of COVID-19 was performed at The First Affiliated Hospital of Yangtze University according to WHO interim guidelines,10 while ARDS diagnosis was performed according to the Berlin definitions. \r\u003cbr\u003eall COVID-19 patients who developed ARDS and who received mechanical ventilation. Included cases were confirmed ARDS patients according to their medical charts, had two consecutive arterial blood gas analysis (ABGA) with oxygenation index (OI), partial pressure of arterial oxygen (PaO2)/fraction of inspired oxygen (FiO2) \u003c 300 mmHg (with positive end-expiratory pressure, PEEP \u003e=5 cm H2O), had bilateral radiographic opacities on computed tomography (CT) that could not be explained by effusions, pulmonary collapse, or nodules, and had respiratory failure that could not be explained by cardiogenic pulmonary edema. ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "mild, moderate, severe ARDS:Nil;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "partial pressure of arterial oxygen;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031836",
			"start_date": "2020-01-23",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Clinical Characteristics Of 45 Hospitalized Novel Coronavirus Pneumonia (COVID-19) Patients With Acute Respiratory Distress Syndrome: A Single-Centered, Retrospective, Observational Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=52213",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "qianlu5860@gmail.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: The patient himself/herself cannot finish the survey, while no caregiver who is familiar with patients condition is available.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. Patients with clinically confirmed rosacea and certain  autoimmune?diseases (such as LE, dermatomyositis, RA, Sjogren syndrome or UCTD);\r\u003cbr\u003e2. Have exposure to people with SARS-CoV-2 infection or diagnosed as COVID-19; Or, living in the epidemic regions of SARS-CoV-2; Or, have ever gone to the epidemic regions; Or, have ever contacted with people from the epidemic regions.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Patients with LE and are taking hydroxychloroquine:N/A;Patients with LE and are not taking hydroxychloroquine:N/A;Patients with dermatomyositis and are taking hydroxychloroquine:N/A;Patients with dermatomyositis and are not taking hydroxychloroquine:N/A;Patients with RA and are taking hydroxychloroquine:N/A;Patients with RA and are not taking hydroxychloroquine:N/A;Patients with rosacea and are taking hydroxychloroquine:N/A;Patients with rosacea and are not taking hydroxychloroquine:N/A;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Incidence of SARS-CoV-2 infection (including confirmed SARS-CoV-2 detection, but might asymptomatic);Incidence of COVID-19 pneumonia;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "factorial",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031782",
			"start_date": "2020-04-13",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "A questionnaire investigation of hydroxychloroquine for its potential protective effect against Severe Acute Respiratory Syndromes-coronavirus-2 infection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51934",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "jose.munoz@isglobal.org",
			"corresp_author_email_certainty": "prefilled",
			"country": "Spain",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e- Age \u003c18 years\u003cbr\u003e- Pregnancy or breastfeeding\u003cbr\u003e- Ongoing antiviral or antiretroviral treatment or HIV positive\u003cbr\u003e- Ongoing anti inflammatory treatment (NSAID, corticosteroids)\u003cbr\u003e- Ongoing chloroquine or hydroxychloroquine treatment\u003cbr\u003e- Confirmed case of SARS-CoV-2 infection (positive PCR) at day 0\u003cbr\u003e- Positive serology for SARS-CoV-1 infection at day 0\u003cbr\u003e- Impossibility of signing the informed consent form\u003cbr\u003e- Rejection of participation\u003cbr\u003e- Working less than 5 days a week in the Hospital Clinic of Barcelona.\u003cbr\u003e- Any contraindication for hydroxychloroquine treatment (9):\u003cbr\u003eo Hydroxychloroquine hypersensitivity or 4-aminoquinoline hypersensitivity\u003cbr\u003eo Retinopathy, visual field or visual acuity disturbances\u003cbr\u003eo QT prolongation, bradycardia (\u003c50bpm), ventricular tachycardia, other arrhythmia, as determined on day 0 ECG or medical history\u003cbr\u003eo Potassium \u003c 3 mEq/L or AST or ALT \u003e 5 upper normal limit, as determined on day 0 blood test\u003cbr\u003eo Previous myocardial infarction\u003cbr\u003eo Myasthenia gravis\u003cbr\u003eo Psoriasis or porphyria\u003cbr\u003eo Glomerular clearance \u003c 10ml/min\u003cbr\u003eo Previous history of severe hypoglycaemia\u003cbr\u003eo Ongoing treatment with: antimalarials, antiarrhythmic, tricyclic antidepressants, natalizumab, quinolones, macrolides, agalsidase alfa and beta.\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e- Age = 18 years\u003cbr\u003e- Negative PCR and negative serology at day 0\u003cbr\u003e- Healthcare worker at Hospital Clinic of Barcelona\u003cbr\u003e- Female participants: negative for pregnancy test\u003cbr\u003e- Willing to participate in the study\u003cbr\u003e- Able to sign the informed consent form\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range 435\u003cbr\u003eF.1.3 Elderly (\u003e=65 years) yes\u003cbr\u003eF.1.3.1 Number of subjects for this age range 5\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eTrade Name: Dolquine\u003cbr\u003ePharmaceutical Form: Tablet\u003cbr\u003eINN or Proposed INN: Hydroxychloroquine Sulfate\u003cbr\u003eCAS Number: 747-36-4\u003cbr\u003eOther descriptive name: HYDROXYCHLOROQUINE SULFATE\u003cbr\u003eConcentration unit: mg milligram(s)\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 200-\u003cbr\u003ePharmaceutical form of the placebo: Tablet\u003cbr\u003eRoute of administration of the placebo: Oral use\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Main Objective: To compare the efficacy of the use of PrEP with hydroxychloroquine against placebo in healthcare workers with high risk of SARS-CoV-2 infection in reducing their risk of COVID-19 disease during an epidemic period.;Secondary Objective: 1) To assess the efficacy of the use of PrEP with hydroxychloroquine against placebo in healthcare workers with high risk of SARS-CoV-2 infection in reducing their risk of exposure to SARS-CoV-2 (defined by seroconversion) during an epidemic period.\u003cbr\u003e\u003cbr\u003e2) To evaluate the safety of PrEP with hydroxychloroquine in adults.\u003cbr\u003e\u003cbr\u003e3) To describe the incidence of SARS-CoV-2 infection among healthcare workers at high risk of SARS-CoV-2 infection.\u003cbr\u003e\u003cbr\u003e4) To identify clinical, analytical and microbiological predictors of COVID-19 among healthcare workers at high risk of SARS-CoV-2 infection.\u003cbr\u003e\u003cbr\u003e5) To set up a repository (biobank) of serum samples obtained from healthcare workers at high risk of SARS-CoV-2 infection for future research on blood markers to predict SARS-CoV-2 infection.;Primary end point(s): Confirmed cases of a COVID-19 (defined by symptoms compatible with COVID-19 and/or a positive PCR for SARS-CoV-2) in the PrEP group compared to the placebo group at any time during the 6 months of the follow-up in healthcare workers with negative PCR for SARS-CoV-2 at day 0.;Timepoint(s) of evaluation of this end point: 6 months",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: yes\u003cbr\u003erandomised: yes\u003cbr\u003eopen: no\u003cbr\u003esingle blind: no\u003cbr\u003edouble blind: yes\u003cbr\u003eparallel group: yes\u003cbr\u003ecross over: no\u003cbr\u003eother: no\u003cbr\u003eif controlled, specify comparator, other medicinial product: no\u003cbr\u003eplacebo: yes\u003cbr\u003eother: no\u003cbr\u003enumber of treatment arms in the trial: 2\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001565-37-ES",
			"start_date": "03/04/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "PRE-EXPOSURE PROPHYLAXIS WITH HYDROXYCHLOROQUINE FOR HIGH-RISK HEALTHCARE WORKERS DURING THE COVID-19 PANDEMIC (PrEP_COVID): A UNICENTRIC, DOUBLE-BLINDED RANDOMIZED CONTROLLED TRIAL. - PrEP_COVID                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001565-37",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "jszfc@sina.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: 1. Family history of seizure, epilepsy, brain or mental disease;\r\u003cbr\u003e2. Subject allergic to any component of the investigational vaccine, or a more severe allergic reaction and history of allergies in the past;\r\u003cbr\u003e3. Woman who is pregnant, breast-feeding or positive in ß-HCG (human chorionic gonadotropin) pregnancy test (urine) on day of enrollment, or become pregnant during the next 6 months;\r\u003cbr\u003e4. Any acute fever disease or infections;\r\u003cbr\u003e5. History of SARS;\r\u003cbr\u003e6. Major congenital defects or not well-controlled chronic illness, such as asthma, diabetes, or thyroid disease;\r\u003cbr\u003e7. Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension without controllable drugs, etc.;\r\u003cbr\u003e8. Hereditary angioneurotic edema or acquired angioneurotic edema;\r\u003cbr\u003e9. Urticaria in last one year;\r\u003cbr\u003e10. No spleen or functional spleen;\r\u003cbr\u003e11. Platelet disorder or other bleeding disorder may cause injection contraindication;\r\u003cbr\u003e12. Faint at the sight of needles;\r\u003cbr\u003e13. Prior administration of immunodepressant or corticosteroids,antianaphylaxis treatment, cytotoxic treatment in last 6 months;\r\u003cbr\u003e14. Prior administration of blood products in last 4 months;\r\u003cbr\u003e15. Prior administration of other research medicines in last 1 month;\r\u003cbr\u003e16. Prior administration of attenuated vaccine in last 1 month;\r\u003cbr\u003e17. Prior administration of inactivated vaccine in last 14 days;\r\u003cbr\u003e18. Current anti-tuberculosis prophylaxis or therapy;\r\u003cbr\u003e19. According to the judgement of investigator,various medical, psychological,social or other conditions, those could affect the subjects to sign informed consent.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: 1. Aged above 18 years;\r\u003cbr\u003e2. Able to understand the content of informed consent and willing to sign the informed consent;\r\u003cbr\u003e3. Able and willing to complete all the secluded study process during the whole follow-up period of 6 months.\r\u003cbr\u003e4. Negative in HIV diagnostic test;\r\u003cbr\u003e5. Axillary temperature \u003c=37.0 degree C;\r\u003cbr\u003e6. Negative in serum antibodies (IgG and IgM) screening of COVID-19.\r\u003cbr\u003e7. The BMI index 18.5-30.0;\r\u003cbr\u003e8. General good health as established by medical history and physical examination.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "1:Middle dose (1E11vp);2:Low dose (5E10vp);3:placebo;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Adverse reactions 0-14 days post vaccination;Anti-S antibody IgG titer on day 28 post vaccination;Anti-SARS-CoV-2 neutralizing antibody titer on day 28 post vaccination;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "parallel",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031781",
			"start_date": "2020-04-09",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "A randomized, double-blinded, placebo-controlled phase II clinical trial for Recombinant Novel Coronavirus (2019-nCOV) Vaccine (Adenovirus Vector) in healthy adults aged above 18 years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=52006",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "398139849@qq.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "??",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: (1) Suspected patients with COVID-19; (2) Close contacts with COVID-19; (3) General physical conditions are not allowed to participate in this clinical study. (4) The participants can not understand and sign informed consent.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: (1) RT-PCR or / and NGS method can be used to detect novel coronavirus nucleic acid in nasopharyngeal swabs, sputum and other lower respiratory tract secretions, blood, feces and other specimens; (2) novel coronavirus specific IgM Positive antibody; (3) New coronavirus-specific IgG antibody positive; (4) The body generally allows participation in this clinical study (5) The participants can understand and sign the informed consent.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "1:none;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "semen;feces;blood;urine;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031779",
			"start_date": "2020-01-01",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Effect of novel coronavirus pneumonia (COVID-19) upon male reproductive system                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=52051",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "rebrcca@126.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: (1)Unclear sample collection time or information\r\u003cbr\u003e(2)Insufficient sample size due to mistakes in the test operation\r\u003cbr\u003e(3)Contaminated sample.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: (1)Complete sample information, including sample number, gender, age, sampling time, and clinical diagnosis background information\r\u003cbr\u003e(2)New coronavirus-infected pneumonia confirmed cases (including partial recovery cases), excluded cases, etc. (Confirmed cases should include patients with different disease processes (such as early, middle, late treatment / recovery patients, etc.)\r\u003cbr\u003e(3)Consecutive samples collected at different times from some patients with pneumonitis infected by the new coronavirus were included, including samples from each stage of the new coronavirus nucleic acid and antigen / antibody from negative to positive\r\u003cbr\u003e(4)The samples were selected as inpatients and outpatient patients for clinical needs.The remaining samples can be tested by clinical units or stored as frozen samples.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Gold Standard:clinical outcome; nucleic acid test;Index test:antigen reagent;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "new coronavirus nucleocapsid (N) antigen;SEN, SPE, ACC, AUC of ROC;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031700",
			"start_date": "2020-04-21",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Development and clinical application of novel coronavirus pneumonia (COVID-19) antigen reagent                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=52052",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "tsh006@163.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "China",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: COVID-19 test negative in patients",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: We collected 33 cases of COVID-19 from wenzhou central hospital.After interferon treatment, serum, fece and sputum samples of patients were collected of patients at different time. The nucleic acid virus clearance for 4 weeks or more was divided into one group, and another group was less than 4 weeks. The samples of these patients at different time periods were inactivated, and then multi-group analysis was performed",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Gold Standard:Clinical outcome, novel coronavirus nucleic acid test, clinical symptoms, lung CT;Index test:Proteomics,\u0026#32;metabolomics\u0026#32;and\u0026#32;other\u0026#32;markers,\u0026#32;mass\u0026#32;spectrometer;",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "proteomics;metabonomics;S antibody IgG;S antibody IgM;S-RBD antibody IgG;S-RBD antibody IgM;N antibody IgG;N antibody IgM;SEN, SPE, ACC, AUC of ROC;",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "sequential",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "ChiCTR2000031699",
			"start_date": "2020-02-01",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Serum, faeces and sputum proteins and metabolomic markers in patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ",
			"title_certainty": "prefilled",
			"url": "http://www.chictr.org.cn/showproj.aspx?proj=51924",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "alienke.wijmenga@rivm.nl",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Wijmenga-Monsuur",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "The Netherlands",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: There are no exclusion criteria.",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: Subject previously participated in the PIENTER 3 study (2016/17) and had indicated that they could be approached for a follow-up study.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Not applicable",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "To assess achieved immunity against COVID-19 across the different age groups in The Netherlands by testing a representative part of\u003cbr\u003ethe Dutch population for the presence of SARS-Cov-2 specific antibodies in serum",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "\u003cbr\u003e                        randomized: no, \u003cbr\u003e                        masking: none, \u003cbr\u003e                        control: not applicable, \u003cbr\u003e                        group: undefined, \u003cbr\u003e                        type: single arm\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NL8473",
			"start_date": "23/03/2020",
			"start_date_certainty": "prefilled",
			"status": "not recruiting",
			"status_certainty": "prefilled",
			"title": "Third population-based immune surveillance study used for the evaluation of immunity against SARS-CoV-2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         ",
			"title_certainty": "prefilled",
			"url": "https://trialregister.nl/trial/8473",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "marion.frenken@mmc.nl",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Frenken",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "The Netherlands",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: Women \u003c18 years old",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: Pregnant women who tested positive on SARS-CoV-2, regardless of the presence or absence of any clinical symptoms",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "None",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "-To describe the clinical presentation (symptoms) of pregnant women who tested positive on SARS-CoV-2\u003cbr\u003e-To describe the clinical course of COVID-19 infection during pregnancy",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "\u003cbr\u003e                        randomized: no, \u003cbr\u003e                        masking: none, \u003cbr\u003e                        control: not applicable, \u003cbr\u003e                        group: undefined, \u003cbr\u003e                        type: single arm\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NL8485",
			"start_date": "27/03/2020",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "COVID-19 during pregnancy: a prospective observational cohort                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ",
			"title_certainty": "prefilled",
			"url": "https://trialregister.nl/trial/8485",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "frank.bosch@radboudumc.nl",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Bosch",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "The Netherlands",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: -Other Pre-existing pulmonary disease or heart failure-\u003cbr\u003eAbsence of COVID infection",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: -Age (=18 years)-\u003cbr\u003eProven(PCR) or suspected (based on clinical signs) COVID-19 infection-\u003cbr\u003eReferralor admission for internal, emergency or respiratory medicine-\u003cbr\u003eCertified sonographerpresent ",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Lung Ultrasound and CT-scan",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Diagnostic accuracyof LUSand CT in COVID-19 patients",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "\u003cbr\u003e                        randomized: no, \u003cbr\u003e                        masking: none, \u003cbr\u003e                        control: not applicable, \u003cbr\u003e                        group: undefined, \u003cbr\u003e                        type: not applicable\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NL8497",
			"start_date": "15/03/2020",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "A prospective observational multi-center trial assessingthe diagnostic value of lungultrasound (LUS) vs CT-scan in patientswith COVID-19Infection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               ",
			"title_certainty": "prefilled",
			"url": "https://trialregister.nl/trial/8497",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "m.j.dijkstra-tiekstra@umcg.nl",
			"corresp_author_email_certainty": "prefilled",
			"corresp_author_lastname": "Dijkstra",
			"corresp_author_lastname_certainty": "prefilled",
			"country": "The Netherlands",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: ? Pregnancy\u003cbr\u003e? allergy to tocilizumab",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: ? Patients 18 years and older\u003cbr\u003e? Patients with a diagnosis of COVID-19 based on a compatible clinical presentation AND a positive SARS-CoV-2 PCR on a respiratory sample such as a nasopharyngeal swab, sputum, or BAL fluid\u003cbr\u003e? Clinical features compatible with hyperinflammation:\u003cbr\u003e- Hypoxia, without other explanation for hypoxia than COVID-19 OR\u003cbr\u003e- ferritin \u003e2000 µg/L or doubling of serum ferritin in 20-48 hours\u003cbr\u003eHypoxia is defined according to ASTCT CRS Consensus grading: grade II. [Lee DW, et al. BBMT 2019;25(4):625-638] Inclusion of patients already requiring oxygen administration prior to COVID-19 should be discussed with the study team.\u003cbr\u003e? Written informed consent.\u003cbr\u003e? Patient is capable of giving informed consent.",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "Patients in this study are treated with intravenous tociluzumab: 8 mg/kg (maximum dose 800 mg), which can be repeated at the same dose after 8 hours if the hypoxia has not improved. This is the approved dose for cytokine release syndrome.",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "30-day mortality (from randomization)",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "\u003cbr\u003e                        randomized: no, \u003cbr\u003e                        masking: none, \u003cbr\u003e                        control: active, \u003cbr\u003e                        group: undefined, \u003cbr\u003e                        type: 2 or more arms, randomized\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "NL8504",
			"start_date": "06/04/2020",
			"start_date_certainty": "prefilled",
			"status": "recruiting",
			"status_certainty": "prefilled",
			"title": "Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ",
			"title_certainty": "prefilled",
			"url": "https://trialregister.nl/trial/8504",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "elodie.soler@aphp.fr",
			"corresp_author_email_certainty": "prefilled",
			"country": "France",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e• Presence of do-not-resuscitate order \r\u003cbr\u003e• Pregnancy\r\u003cbr\u003e • Prisoners\r\u003cbr\u003e • Naproxen allergy or intolerance \r\u003cbr\u003e• Severe renal failure\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e• COVID-19 infected patient \r\u003cbr\u003e• Age 18 years or older \r\u003cbr\u003e• Presence of pneumonia \r\u003cbr\u003e• PaO2/FiO2 \u003c 300 mm Hg or SpO2 \u003c 93% in air ambient or need to supplementary oxygen administration in order to maintain SpO2 range in [94-98%] or lung infiltrates \u003e 50% \r\u003cbr\u003e• Medical insurance\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range 292\u003cbr\u003eF.1.3 Elderly (\u003e=65 years) yes\u003cbr\u003eF.1.3.1 Number of subjects for this age range 292\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003ePharmaceutical Form: Tablet\u003cbr\u003eINN or Proposed INN: NAPROXEN\u003cbr\u003eOther descriptive name: NAPROXEN\u003cbr\u003eConcentration unit: mg milligram(s)\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 250-\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Main Objective: To demonstrate the superiority of naproxen treatment addition to standard of care compared to standard of care in term of 30-day mortality;Secondary Objective: To demonstrate the effect of naproxen treatment to in-hospital mortality, morbidity, virus concentration;Primary end point(s): 30-day mortality all causes;Timepoint(s) of evaluation of this end point: 30 days",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: yes\u003cbr\u003erandomised: yes\u003cbr\u003eopen: yes\u003cbr\u003esingle blind: no\u003cbr\u003edouble blind: no\u003cbr\u003eparallel group: yes\u003cbr\u003ecross over: no\u003cbr\u003eother: no\u003cbr\u003eif controlled, specify comparator, other medicinial product: no\u003cbr\u003eplacebo: no\u003cbr\u003eother: yes\u003cbr\u003eother specify the comparator: standard of care\u003cbr\u003enumber of treatment arms in the trial: 2\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001301-23-FR",
			"start_date": "10/04/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "Efficacy of Addition of Naproxen in the Treatment of critically ill Patients Hospitalized for COVID-19 Infection / Enacovid Study - ENACOVID                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001301-23",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "korinna.pilz@inflarx.de",
			"corresp_author_email_certainty": "prefilled",
			"country": "Netherlands",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e1. Oxygenation Index at time of enrollment (PaO2 / FiO2) \u003c 100 or \u003e 250 in supine position\r\u003cbr\u003e2. Intubated \u003e 48h at time point of enrollment\r\u003cbr\u003e3. Patients who demonstrate an improvement in past 24h prior to enrollment in oxygenation and ventilation / support parameters which indicate an expected resolution of lung dysfunction in the next 24h without additional intervention according to judgment of the investigator with one or more of the following parameters present:\r\u003cbr\u003e• Improvement in oxygenation index of \u003e 30% relative to previous measure (last 24h in supine position)\r\u003cbr\u003e• Extubation if intubated before\r\u003cbr\u003e4. Known history of COPD\r\u003cbr\u003e5. Known history of chronic dialysis OR received renal replacement therapy in past 14 days\r\u003cbr\u003e6. Received new other biologic treatment attempt for COVID-19 in the past 14 days\r\u003cbr\u003e7. Received treatment with a viral replication inhibitor in past 3 days\r\u003cbr\u003e8. Known hypersensitivity to IFX-1 or any other ingredient of the study medication\r\u003cbr\u003e9. Known pregnancy\r\u003cbr\u003e10. Received organ or bone marrow transplantation in past 3 months\r\u003cbr\u003e11. Known mechanically resuscitation in past 14 days\r\u003cbr\u003e12. Patient moribund or expected to die in next 12h according to the judgment of the investigator\r\u003cbr\u003e13. Patients otherwise considered restricted from receiving full supportive care (including ICU support)\r\u003cbr\u003e14. Existing diagnosis of progressed cancer or other life-limiting disease with life expectancy \u003c 6 months\r\u003cbr\u003e15. Known to have received anti-cancer therapy for oncological disease in past 4 weeks\r\u003cbr\u003e16. Known severe congestive heart failure (NYHA-Class III - IV)\r\u003cbr\u003e\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e1. At least 18 years of age or older\r\u003cbr\u003e2. Clinically evident or otherwise confirmed severe pneumonia as evidenced by at least one of the following criteria:\r\u003cbr\u003e• Chest X-ray or CT-scan or MRI with pulmonary infiltrates consistent with pneumonia\r\u003cbr\u003e• Clinical history in past 14 days of newly developed severe shortness of breath (\u003e 29 BR / minute) in the absence of oxygen supply or spontaneous peripheral oxygenation = 92 with need for oxygen supply, or need for non-invasive or invasive ventilation (in conjunction with a positive test for SARS-CoV-2 infection)\r\u003cbr\u003e3. Oxygenation Index at time of enrollment (PaO2 / FiO2) = 250 and = 100 in supine position\r\u003cbr\u003e4. SARS-CoV-2 infection confirmation (tested positive in last 14 days or test results to be obtained within 24h after enrollment, both with locally available test system).\r\u003cbr\u003e5. No use OR stop of any corticosteroid treatment at time point of enrollment (topical treatment and systemic dose of = 10mg prednisone / day equivalent allowed)\r\u003cbr\u003e\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range 65\u003cbr\u003eF.1.3 Elderly (\u003e=65 years) yes\u003cbr\u003eF.1.3.1 Number of subjects for this age range 65\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eProduct Name: IFX-1\u003cbr\u003ePharmaceutical Form: Concentrate for solution for infusion\u003cbr\u003eINN or Proposed INN: -\u003cbr\u003eCAS Number: -\u003cbr\u003eCurrent Sponsor code: IFX-1\u003cbr\u003eOther descriptive name: -\u003cbr\u003eConcentration unit: mg/ml milligram(s)/millilitre\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 10-\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Main Objective: The primary objective of Phase II is:\u003cbr\u003e• To explore the effect of IFX-1 on COVID-19 related severe pneumonia (hypothesis generating)\u003cbr\u003e\u003cbr\u003eThe primary objective of Phase III is\u003cbr\u003e• To demonstrate the efficacy of IFX-1 to improve of symptoms and outcome of severe COVID-19 pneumonia (confirmative)\u003cbr\u003e;Secondary Objective: The secondary objectives of Phase II and Phase III are:\u003cbr\u003e• To assess and define other parameters of efficacy\u003cbr\u003e• To assess the safety of IFX-1\u003cbr\u003e;Primary end point(s): Phase II: \u003cbr\u003eThe primary endpoint in Phase II is the relative change (%) from baseline (day 1 prior to study drug administration at ± 1h of randomization) in Oxygenation Index (PaO2 / FiO2) in supine position at day 3, 5, 9, and 15.\u003cbr\u003e\u003cbr\u003ePhase III: \u003cbr\u003eThe primary, secondary, and other endpoints for Phase III are the same as those for Phase II if not adjusted according to recommendations of the expert committee.\u003cbr\u003e;Timepoint(s) of evaluation of this end point: Day 3, 5, 9 and 15",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: yes\u003cbr\u003erandomised: yes\u003cbr\u003eopen: yes\u003cbr\u003esingle blind: no\u003cbr\u003edouble blind: no\u003cbr\u003eparallel group: yes\u003cbr\u003ecross over: no\u003cbr\u003eother: no\u003cbr\u003eif controlled, specify comparator, other medicinial product: no\u003cbr\u003eplacebo: no\u003cbr\u003eother: yes\u003cbr\u003eother specify the comparator: best supportive care\u003cbr\u003enumber of treatment arms in the trial: 2\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001335-28-NL",
			"start_date": "29/03/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "A pragmatic adaptive open label, randomized Phase II/III multicenter study of IFX-1 in Patients with severe COVID-19 Pneumonia - \"PANAMO\" - Panamo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001335-28",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "arnauld.garcin@chu-st-etienne.fr",
			"corresp_author_email_certainty": "prefilled",
			"country": "France",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e-\tHCWs with positive SARS-CoV-2 RT-PCR of nasopharyngeal swab at the inclusion visit.\u003cbr\u003e-\tHCW with past history of confirmed SARS-CoV-2 infection \u003cbr\u003e-\tHCW with positive SARS-CoV-2 serology at the inclusion visit (if the serology is available at inclusion time, if SARS-CoV-2 serology is not available, it will be a secondary exclusion criteria) \u003cbr\u003e-\tHCW with comorbidities such as chronic HCV infection treated by direct antiviral drugs or with hypothyroidism that need hormonal substitution, or retinopathy or known to have hypercholesterolemia hypertriglyceridemia\u003cbr\u003e-\tPregnant HCW\u003cbr\u003e-\tBreastfeeding HCW\u003cbr\u003e-\tHCW taking comedications known to have interactions with LPV/r according to the official characteristics of the product\u003cbr\u003eSee sessions 4.3 Contraindications and 4.5 Interaction with other medicinal products and other forms of interaction\u003cbr\u003eLopinavir and ritonavir are both inhibitors of the P450 isoform CYP3A in vitro. Co-administration of LPV/r and medicinal products primarily metabolised by CYP3A may result in increased plasma concentrations of the other medicinal product, which could increase or prolong its therapeutic and adverse reactions. LPV/r does not inhibit CYP2D6, CYP2C9, CYP2C19, CYP2E1, CYP2B6 or CYP1A2 at clinically relevant concentrations (see section 4.3).\u003cbr\u003eLPV/r has been shown in vivo to induce its own metabolism and to increase the biotransformation of some medicinal products metabolised by cytochrome P450 enzymes (including CYP2C9 and CYP2C19) and by glucuronidation. This may result in lowered plasma concentrations and potential decrease of efficacy of co-administered medicinal products\u003cbr\u003e-\tHCW taking comedications known to have interactions with hydroxychloroquine according to the official characteristics of the product\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e-\tAdult Healthcare workers (HCWs) (physicians, nurses, assistant nurses, dentists, physiotherapists, and midwives)\u003cbr\u003e-\tHCWs involved at the time of enrolment in the care of patients with confirmed or suspected SARS-CoV-2 infection in hospital settings in outpatient care settings or in geriatric long-term care facilities\u003cbr\u003e-\tHCWs tested negative for HIV\u003cbr\u003e-\tHCW affiliated to the French health insurance system\u003cbr\u003e-\tHCW women of childbearing age with an effective contraception (ethinylestradiol-containing contraceptive pills are not regarded as effective in the context of LPV/r treatment) \u003cbr\u003e-\tWilling to comply to study design and the follow-up\u003cbr\u003e\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range 1200\u003cbr\u003eF.1.3 Elderly (\u003e=65 years) no\u003cbr\u003eF.1.3.1 Number of subjects for this age range \u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eTrade Name: Lopinavir/Ritonavir\u003cbr\u003eProduct Name: Lopinavir/Ritonavir\u003cbr\u003ePharmaceutical Form: Coated tablet\u003cbr\u003ePharmaceutical form of the placebo: Coated tablet\u003cbr\u003eRoute of administration of the placebo: Oral use\u003cbr\u003e\u003cbr\u003eTrade Name: Plaquenil\u003cbr\u003eProduct Name: hydroxychloroquine\u003cbr\u003ePharmaceutical Form: Coated tablet\u003cbr\u003ePharmaceutical form of the placebo: Coated tablet\u003cbr\u003eRoute of administration of the placebo: Oral use\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Secondary Objective: 1. To evaluate the occurrence of adverse events in each arm,\u003cbr\u003e2. To evaluate the discontinuation rates of the investigational drug in each arm,\u003cbr\u003e3. To evaluate the adherence of participants to study drug,\u003cbr\u003e4. To evaluate the incidence of symptomatic cases of SARS-CoV-2 infection in each arm,\u003cbr\u003e5. To evaluate the incidence of asymptomatic cases of SARS-CoV-2 infection in each arm, at to 2,5 months after randomization,\u003cbr\u003e6. To evaluate the incidence of severe cases of SARS-CoV-2 infection in each arm. ;Primary end point(s): The primary endpoint is the occurrence of an symptomatic or asymptomatic SARS-CoV-2 infection among healthcare workers (HCWs) \u003cbr\u003eAn infection by SARS-CoV-2 is defined by either:\u003cbr\u003e• a positive specific RT-PCR on periodic systematic nasopharyngeal swab during follow-up\u003cbr\u003eOR\u003cbr\u003e• a positive specific RT-PCR on a respiratory sample in case of onset of symptoms consistent with COVID-19 during follow-up\u003cbr\u003eOR\u003cbr\u003e• a seroconversion to SARS-CoV-2 after randomization.;Timepoint(s) of evaluation of this end point: Day: 7, 14, 21, 28, 35, 42, 49, 57, 71 after the start of the drug;Main Objective: To explore whether a 2-month treatment with either LPV/r or hydroxychloroquine may reduce the incidence of symptomatic or asymptomatic infection by SARS-CoV-2, as compared to their placebo in healthcare workers exposed to SARS-CoV-2.",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: yes\u003cbr\u003erandomised: yes\u003cbr\u003eopen: no\u003cbr\u003esingle blind: no\u003cbr\u003edouble blind: yes\u003cbr\u003eparallel group: yes\u003cbr\u003ecross over: no\u003cbr\u003eother: no\u003cbr\u003eif controlled, specify comparator, other medicinial product: no\u003cbr\u003eplacebo: yes\u003cbr\u003eother: no\u003cbr\u003enumber of treatment arms in the trial: 4\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001188-96-FR",
			"start_date": "07/04/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "Chemoprophylaxis of SARS-CoV-2 infection (COVID-19) in exposed healthcare workers: a randomized double-blind placebo-controlled clinical trial - COVIDAXIS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001188-96",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "julien.gautier@lyon.unicancer.fr",
			"corresp_author_email_certainty": "prefilled",
			"country": "France",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003eE1. For cohort 1 only : Patient currently receiving therapy with an anti- PD-1, anti- PD-L1, or anti-CTLA4.\r\u003cbr\u003eE2. For cohort 2 only: Patient currently receiving therapy with an anti- IL-6 or anti-IL-6R. \r\u003cbr\u003eE3. Contraindication to treatment with nivolumab (cohort 1 only) or to tocilizumab (cohort 2 only) as per respective SPC, including known hypersensitivity to one of these study drugs or severe hypersensitivity reaction to any monoclonal antibody.\r\u003cbr\u003eE4. Patient known to have intolerance or hypersensitivity to chloroquine or any quinoline derivates (e.g., quinine, chloroquine, mefloquine).\r\u003cbr\u003e...See the protocol\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003eI1. Age 18 or older at the time of enrolment.\r\u003cbr\u003eI2. Histologically or cytologically confirmed diagnosis of advanced or metastatic hematological or solid tumor (hematological or solid tumor, any type and any localization).\r\u003cbr\u003eI3. Documented diagnosis of COVID-19 (diagnostic test performed in a certified laboratory) or symptoms of COVID-19 associated with radiological signs of pneumonia as described by Shi et al.;\r\u003cbr\u003eI4. Cohort 2: patients with pneumonia confirmed by chest imaging, and an oxygen saturation (Sao2) of 94% or less while they are breathing ambient air or a ratio of the partial pressure of oxygen (Pao2) to the fraction of inspired oxygen (Fio2) (Pao2:Fio2) at or below 300 mg Hg. \r\u003cbr\u003e...See the protocol\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range 147\u003cbr\u003eF.1.3 Elderly (\u003e=65 years) no\u003cbr\u003eF.1.3.1 Number of subjects for this age range 126\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eProduct Name: GNS561\u003cbr\u003ePharmaceutical Form: Capsule, hard\u003cbr\u003eINN or Proposed INN: Not available\u003cbr\u003eCAS Number: 1914148-72-3\u003cbr\u003eCurrent Sponsor code: GNS561\u003cbr\u003eConcentration unit: mg milligram(s)\u003cbr\u003eConcentration type: range\u003cbr\u003eConcentration number: 50 - 200-\u003cbr\u003e\u003cbr\u003eTrade Name: Opdivo\u003cbr\u003eProduct Name: Nivolumab\u003cbr\u003ePharmaceutical Form: Solution for injection\u003cbr\u003eINN or Proposed INN: NIVOLUMAB\u003cbr\u003eCAS Number: NIVOLUMAB\u003cbr\u003eCurrent Sponsor code: ET17-093\u003cbr\u003eOther descriptive name: NIVOLUMAB\u003cbr\u003eConcentration unit: mg milligram(s)\u003cbr\u003e\u003cbr\u003eProduct Name: Tocilizumab\u003cbr\u003ePharmaceutical Form: Solution for injection\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Main Objective: The main objective is to compare versus standard of care short-term mortality rates in advanced or metastatic cancer patients who are positive for COVID-19 treated with a chloroquine analog (GNS561), an anti-PD1 (nivolumab) or an anti-IL-6R antibody (tocilizumab).;Secondary Objective: The secondary objectives will be to describe in each arm of the study:\u003cbr\u003e• Time to clinical improvement\u003cbr\u003e• Clinical status at days 7, 14 and 28\u003cbr\u003e• Mean change in clinical status from baseline to days 7, 14 and 28 \u003cbr\u003e• Overall survival \u003cbr\u003e• Length of stay in Intensive Care Unit and in Resuscitation Unit\u003cbr\u003e• Duration of mechanical ventilation or high flow oxygen devices\u003cbr\u003e• Duration of hospitalization\u003cbr\u003e• Rate of throat swab negativation at days 7, 14 and 28\u003cbr\u003e• Quantitative SARS-CoV-2 virus in throat swab at days 7, 14 and 28\u003cbr\u003e• Quantitative SARS-CoV-2 virus in blood at days 7, 14 and 28\u003cbr\u003e• Rate of secondary infection by other documented pathogens (bacteria, fungi)\u003cbr\u003e• Biological parameters (hematological parameters and markers of inflammation)\u003cbr\u003e• Safety of experimental treatments.\u003cbr\u003eAnd to perform Cost-Effectiveness Analyses (CEA) with Incremental Cost-Effectiveness Ratios (ICERs) expressed in cost per Life Year Gained.\u003cbr\u003e;Primary end point(s): The primary endpoint will be the 28-day survival rate, defined by the proportion of patients still alive 28 days after randomization. \u003cbr\u003e;Timepoint(s) of evaluation of this end point: 28-day",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: yes\u003cbr\u003erandomised: yes\u003cbr\u003eopen: no\u003cbr\u003esingle blind: no\u003cbr\u003edouble blind: no\u003cbr\u003eparallel group: no\u003cbr\u003ecross over: no\u003cbr\u003eother: no\u003cbr\u003eif controlled, specify comparator, other medicinial product: no\u003cbr\u003eplacebo: no\u003cbr\u003eother: no\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001373-70-FR",
			"start_date": "01/04/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "IMMUNONCOVID-20 : A prospective, controlled, randomized, multicenter study to compare the efficacy of a chloroquine analog (GNS561), anti PD-1 (nivolumab) and anti-interleukine-6 receptor (tocilizumab) versus standard of care in advanced or metastatic cancer patients with SARS-CoV-2 (COVID-19) infection\r\n\r\n - IMMUNONCOVID-20                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001373-70",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "fadila.amerali@aphp.fr",
			"corresp_author_email_certainty": "prefilled",
			"country": "France",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e1. Patient moribond\r\u003cbr\u003e2. Grossesse ou allaitement\r\u003cbr\u003e3. Corticothérapie à long terme à une dose de 0,5 mg / kg / j ou plus\r\u003cbr\u003e4. Infection bactérienne, fongique ou parasitaire active et non traitée\r\u003cbr\u003e5. Absence de consentement éclairé écrit du patient ou d'un représentant légal, le cas échéant\r\u003cbr\u003e6. Hypersensibilité à la Dexamethasone ou l’un de ces excipients \r\u003cbr\u003e\r\u003cbr\u003ePour les patients non ventilés mécaniquement, les critères de non-inclusion supplémentaires sont:\r\u003cbr\u003e7. Facteurs anatomiques empêchant l'utilisation d'une canule nasale\r\u003cbr\u003e8. Hypercapnie indiquant une VNI (paCO2 = 50 mmHg)\r\u003cbr\u003e\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e1.Age = 18 years \r\u003cbr\u003e2.Admitted to ICU within 48 hours\r\u003cbr\u003e3.Confirmed or highly suspected COVID-19 infection \r\u003cbr\u003e4.Acute hypoxemic respiratory failure (PaO2 \u003c70 mmHg or SpO2\u003c90% on room air or tachypnea\u003e30/min or labored breathing or respiratory distress; need for oxygen flow \u003e=6L/min) \r\u003cbr\u003e5.\tAny treatment intended to treat the SARS-CoV-2 infection (either as a compassionate use or in the context of a clinical trial, i.e remdesivir, lopinavir/ritonavir, favipiravir, hydroxychloroquine and any other new drug with potential activity). \r\u003cbr\u003e\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range 400\u003cbr\u003eF.1.3 Elderly (\u003e=65 years) yes\u003cbr\u003eF.1.3.1 Number of subjects for this age range 150\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eTrade Name: Dexamethasone 20 mg/5mL\u003cbr\u003ePharmaceutical Form: Solution for injection\u003cbr\u003eINN or Proposed INN: DEXAMETHASONE\u003cbr\u003eCAS Number: 50-02-2\u003cbr\u003eConcentration unit: mg/ml milligram(s)/millilitre\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 4-\u003cbr\u003ePharmaceutical form of the placebo: Solution for injection\u003cbr\u003eRoute of administration of the placebo: Intravenous use\u003cbr\u003e\u003cbr\u003eTrade Name: Medicinal Oxygen\u003cbr\u003eProduct Name: Medicinal Oxygen\u003cbr\u003ePharmaceutical Form: Medicinal gas, liquefied\u003cbr\u003eINN or Proposed INN: Medicinal Oxygen\u003cbr\u003eOther descriptive name: Medicinal Oxygen\u003cbr\u003eConcentration unit: % (V/V) percent volume/volume\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 100-\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Main Objective: The main objective is to assess the impact of dexamethasone on overall mortality at day-60 after randomization in patients admitted in ICU for severe COVID-19 infection.\u003cbr\u003eIn non mechanical ventilation (MV) patients, the additional objective is to assess whether oxygen support based on either HFNO or CPAP modality in COVID-19 related AHRF reduces the need for mechanical ventilation at day-28.\u003cbr\u003e;Secondary Objective: For the study of the effect of corticosteroids, secondary objectives include: \u003cbr\u003e1.To compare the evolution of the viral load in the respiratory tract \u003cbr\u003e2.To compare the occurrence of healthcare-associated infections \u003cbr\u003e3.To compare the exposition to mechanical ventilation \u003cbr\u003e4.To compare the evolution of SOFA score \u003cbr\u003e5.To compare the exposition to renal replacement therapy \u003cbr\u003e6.To compare the lengths of ICU and hospital-stay\u003cbr\u003e\u003cbr\u003eFor the study of the effect of oxygen support modalities, secondary objectives are, to compare each of oxygen support group to the control group in terms of: \u003cbr\u003e1.overall survival\u003cbr\u003e2.occurrence of healthcare-associated infections \u003cbr\u003e3.length of ICU and hospital-stay\u003cbr\u003e;Primary end point(s): , the primary endpoint is the time-to-death from all causes within the first 60 days after randomization.and the  time to need for mechanical ventilation (MV);Timepoint(s) of evaluation of this end point: october 2020",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: yes\u003cbr\u003erandomised: yes\u003cbr\u003eopen: no\u003cbr\u003esingle blind: no\u003cbr\u003edouble blind: yes\u003cbr\u003eparallel group: yes\u003cbr\u003ecross over: no\u003cbr\u003eother: no\u003cbr\u003eif controlled, specify comparator, other medicinial product: no\u003cbr\u003eplacebo: yes\u003cbr\u003eother: no\u003cbr\u003enumber of treatment arms in the trial: 8\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001457-43-FR",
			"start_date": "10/04/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "Dexamethasone and oxygen support strategies in ICU patients with Covid-19 pneumonia - COVIDICUS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001457-43",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "xsolanich@bellvitgehospital.cat",
			"corresp_author_email_certainty": "prefilled",
			"country": "Spain",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003eExclusion criteria: \u003cbr\u003e1. Imminent death (life expectancy = 24h). \u003cbr\u003e2. Contraindication for the use of tacrolimus according to the summary of product charactheristics . \u003cbr\u003e3. Known adverse reactions to treatment \u003cbr\u003e4. Have participated in a clinical trial in the last 3 months.\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003eInclusion criteria: \u003cbr\u003e\u003cbr\u003ePatients admitted to the HUB with COVID-19 infection confirmed by fluorescent RT-PCR who meet all of the following criteria: \u003cbr\u003e1 New-onset radiological infiltrates (either by plain chest radiography, computed tomography or chest ultrasound) attributed to COVID-19, \u003cbr\u003e2. Respiratory failure (PaO2/FiO2 \u003c 300 or satO2/FiO2 \u003c 220) attributed to 1, \u003cbr\u003e3.PCR \u003e 100 mg/L and/or D-Dimer \u003e 1000 µg/L and/or Ferritin \u003e 1000 ug/L attributed to 1, \u003cbr\u003e4. Age = 18 years. \u003cbr\u003e5. The subject, his legal representative or closest relative (in case of the subject's incapacity due to the seriousness of the clinical situation) that gives informed consent\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range 44\u003cbr\u003eF.1.3 Elderly (\u003e=65 years) yes\u003cbr\u003eF.1.3.1 Number of subjects for this age range 40\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eProduct Name: Metilprednisolona\u003cbr\u003ePharmaceutical Form: Tablet\u003cbr\u003eINN or Proposed INN: METHYLPREDNISOLONE\u003cbr\u003eOther descriptive name: METHYLPREDNISOLONE\u003cbr\u003eConcentration unit: mg milligram(s)\u003cbr\u003eConcentration type: range\u003cbr\u003eConcentration number: 20-125\u003cbr\u003e\u003cbr\u003eTrade Name: Modigraf\u003cbr\u003ePharmaceutical Form: Powder for oral suspension\u003cbr\u003eINN or Proposed INN: TACROLIMUS\u003cbr\u003eCAS Number: 104987-11-3\u003cbr\u003eConcentration unit: mg/kg milligram(s)/kilogram\u003cbr\u003eConcentration type: range\u003cbr\u003eConcentration number: 0.1-0.2\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Main Objective: Main objective: \u003cbr\u003e- To study the time (days) to reach clinical stability after randomization in hospitalized patients with severe pneumonia secondary  to COVID-19, and elevated inflammatory parameters.;Secondary Objective: Clinical \u003cbr\u003e-time to reach an afebrile state during 48 hours. \u003cbr\u003e-time to reach PaO2/FiO2 \u003e400 and/or SatO2/FiO2 \u003e400 \u003cbr\u003e-time until you reach a FR = 24 rpm for 48 hours \u003cbr\u003e-time to D-dimer normalization (\u003c250 ug/L) \u003cbr\u003e-time until PCR is normalized (\u003c5mg/L). \u003cbr\u003e-time to normalisation of ferritin (\u003c400ug/L). \u003cbr\u003e-impact of immunosuppressive treatment on viral dynamics using quantitative PCR. \u003cbr\u003e-duration of treatment with tacrolimus. \u003cbr\u003e-duration of the inpatient stay. \u003cbr\u003e-Percentage of patients requiring artificial respiratory support\u003cbr\u003e-duration of artificial respiratory support needs to be maintained. \u003cbr\u003e-mortality Incidence COVID at 28 and 56 days\u003cbr\u003e-mortality incidence all-cause at 28 and 56 days \u003cbr\u003e-relapses of COVID-19 pneumonia at 28 and 56 days\u003cbr\u003e-Analysis of expanded cytokine profile (day 0 and every 7 days)\u003cbr\u003eSafety\u003cbr\u003e-side effects according to the severity attributed to tacrolimus during its administration. \u003cbr\u003e-side effects according to the severity attributed to other treatments administered;Primary end point(s): Primary endpoint  (for the main objective of effectiveness): \u003cbr\u003e- Time (days) to clinical stability after initiation of trial treatment in hospitalised patients with severe pneumonia secondary to COVID-19 and elevated inflammatory parameters;Timepoint(s) of evaluation of this end point: Throughout the study until clinical stability",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: yes\u003cbr\u003erandomised: yes\u003cbr\u003eopen: yes\u003cbr\u003esingle blind: no\u003cbr\u003edouble blind: no\u003cbr\u003eparallel group: yes\u003cbr\u003ecross over: no\u003cbr\u003eother: no\u003cbr\u003eif controlled, specify comparator, other medicinial product: no\u003cbr\u003eplacebo: no\u003cbr\u003eother: yes\u003cbr\u003eother specify the comparator: antiviral standard treatment\u003cbr\u003enumber of treatment arms in the trial: 2\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001445-39-ES",
			"start_date": "31/03/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "PRAGMATIC, CONTROLLED, OPEN, SINGLE CENTER, RANDOMIZED, PHASE II CLINICAL TRIAL TO EVALUATE METHYLPREDNISOLONE PULSES AND TACROLIMUS IN HOSPITALIZED PATIENTS WITH SEVERE PNEUMONIA SECONDARY TO COVID-19 (TACROVID)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001445-39",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "epenag@santpau.cat",
			"corresp_author_email_certainty": "prefilled",
			"country": "Spain",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e1. ALT / AST\u003e 5 times the normal limit\u003cbr\u003e2. Stage 4 chronic kidney disease (GFR \u003c30) or requiring dialysis.\u003cbr\u003e3. Presence of comorbidities that imply a poor prognosis (according to clinical judgment).\u003cbr\u003e4. Advanced dementia.\u003cbr\u003e5. Pregnancy or breastfeeding.\u003cbr\u003e6. Forecast of transfer to another center in the 12 hours at the beginning of the study.\u003cbr\u003e7. Allergy to study medication.\u003cbr\u003e8. Serious or active bacterial infections or documented sepsis by pathogens other than SARS-CoV-2.\u003cbr\u003e9. Streptococcus pneumoniae antigenuria positive before study start.\u003cbr\u003e10. Neutropenia \u003c500 / mm3.\u003cbr\u003e11. Plateletpenia \u003c100,000 / mm3.\u003cbr\u003e12. History of diverticulosis.\u003cbr\u003e13. Ongoing skin infection (eg, pyodermitis).\u003cbr\u003e14. Transplanted patient under immunosuppressive treatment.\u003cbr\u003e15. Previous evidence of latent untreated tuberculosis.\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e1. Subject (or authorized legal representative) who can provide written informed consent before beginning any study procedure.\u003cbr\u003e2. Understand and agree to abide by the study procedures.\u003cbr\u003e3. Adult =18 years of age at the time of inclusion in the study.\u003cbr\u003e4. Confirmation of SARS-CoV-2 infection by a microbiological test performed before randomization, no longer than 72 hours.\u003cbr\u003e5. Gravity 3-4 according to the WHO 7-point ordinal scale:\u003cbr\u003e- Severity 3. Hospitalized, which does not require supplemental oxygen\u003cbr\u003e- Severity 4. Hospitalized, requiring supplemental oxygen\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range 276\u003cbr\u003eF.1.3 Elderly (\u003e=65 years) no\u003cbr\u003eF.1.3.1 Number of subjects for this age range \u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eTrade Name: RoActemra\u003cbr\u003ePharmaceutical Form: Solution for injection in pre-filled syringe\u003cbr\u003eINN or Proposed INN: TOCILIZUMAB\u003cbr\u003eCAS Number: 375823-41-9\u003cbr\u003eOther descriptive name: TOCILIZUMAB\u003cbr\u003eConcentration unit: mg milligram(s)\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 648-\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Main Objective: To evaluate in-hospital mortality or mechanical ventilation in the Intensive Care Unit (ICU), or need for a rescue dose of tocilizumab in patients with confirmed infection by COVID-19 in treatment with hydroxychloroquine and azithromycin combined or non-tocilizumab.;Secondary Objective: To assess the clinical efficacy of tocilizumab in COVID-19 infection compared to the control arm by:\u003cbr\u003e\u003cbr\u003eClinical severity:\u003cbr\u003ePatient score according to the WHO 7-point ordinal scale\u003cbr\u003eNational Early Warning Score (NEWS)\u003cbr\u003eOxygen therapy\u003cbr\u003eMechanic ventilation\u003cbr\u003eHospitalization\u003cbr\u003eMortality at 15, 30 and 90 days\u003cbr\u003e\u003cbr\u003eTo assess the safety of the intervention 30 days after treatment compared to the control arm.\u003cbr\u003e\u003cbr\u003eTo assess the safety of the intervention at 90 days of treatment compared to the control arm.\u003cbr\u003e- Cumulative incidence of serious adverse effects (SAEs).\u003cbr\u003e- Cumulative incidence of grade 3 and 4 adverse effects (AEs).\u003cbr\u003e- Discontinuation or suspension of treatment for any reason.\u003cbr\u003e- Changes in the white blood cell count, hemoglobin, platelets, creatinine, glucose, total bilirubin, AST, ALT, GGT, LDH, C-reactive protein, D-dimer, troponin, ferritin, fibrinogen, KL-6 during follow-up.;Primary end point(s): In-hospital mortality or need for mechanical ventilation in the Intensive Care Unit.;Timepoint(s) of evaluation of this end point: During hospitalization",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: yes\u003cbr\u003erandomised: yes\u003cbr\u003eopen: yes\u003cbr\u003esingle blind: no\u003cbr\u003edouble blind: no\u003cbr\u003eparallel group: yes\u003cbr\u003ecross over: no\u003cbr\u003eother: no\u003cbr\u003eif controlled, specify comparator, other medicinial product: yes\u003cbr\u003eplacebo: no\u003cbr\u003eother: no\u003cbr\u003enumber of treatment arms in the trial: 2\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001442-19-ES",
			"start_date": "02/04/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "Pilot, randomized, multicenter, open-label clinical trial of combined use of hydroxychloroquine, azithromycin, and tocilizumab for the treatment of SARS-CoV-2 infection (COVID-19) - TCOVID                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001442-19",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"country": "Spain",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e•\tHIV infection\u003cbr\u003e•\tActive hepatitis B infection. Infección activa por virus de la hepatitis  B \u003cbr\u003e•\tRenal failure with estimated glomerular filtration rate (GFR) \u003c 60 ml/min) and patients on Hemodialysis. \u003cbr\u003e•\tOsteoporosis\u003cbr\u003e•\tMyasthenia gravis\u003cbr\u003e•\tPre-existent maculopathy. \u003cbr\u003e•\tRetinitis pigmentosa\u003cbr\u003e•\tBradycardia \u003c 50bpm \u003cbr\u003e•\tWeight \u003c 40kg \u003cbr\u003e•\tParticipant with any immunosuppressive condition or haematological disease\u003cbr\u003e•\tTreatment with drugs that may prolong QT in the last month before randomization for more than 7 days including: azithromycin, chlorpromazine, cisapride, clarithromycin, domperidone, droperidol, erythromycin, halofantrine, haloperidol, lumefantrine, mefloquine, methadone, pentamidine, procainamide, quinidine, quinine, sotalol, sparfloxacin, thioridazine, amiodarone.\u003cbr\u003e•\tPregnancy or fertility desire during the estudy periodo r the following 6 months. \u003cbr\u003e•\tBreastfeeding  \u003cbr\u003e•\tKnown allergy to any of the medication used in this trial \u003cbr\u003e•\tSelf-medication practice to prevent SARS-2-CoV infection\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e•\tParticipants that after receiving appropriate information on the study design, objectives, possible risks and acknowledging that they have the right to withdraw from the study consent at any time sing the informed consent for participation in the study. \u003cbr\u003e•\tMale or female aged 18-65 years. \u003cbr\u003e•\tHealth care workers in public or private hospitals in Spain in an areas of risk of SARS-CoV-2 transmission. \u003cbr\u003e•\tNot previous diagnosis of SARS-CoV-2 (COVID-19) infection plus no symptoms of SARS-CoV-2 (COVID-19) since 1st of March 2020 until the date of enrolment in the study. \u003cbr\u003e•\tUnderstand the aim of the study and have not been on any previous active pre exposure prophylaxis treatment against SARS-CoV-2 (COVID-19) since 1st of March 2020 until the date of enrolment in the study.  This include PrEP for HIV.\u003cbr\u003e•\tNegative PCR rapid test for SARS-CoV-2 (COVID-19) at enrolment.  \u003cbr\u003e•\tParticipant willing and able to give informed consent for participation in the study\u003cbr\u003e•\tNegative pregnancy test during the previous 7 days to start treatments or more than 2 years after menopause. \u003cbr\u003e•\tWomen of reproductive age and their partners should commit to use and highly effective contraceptive method (such sterilisation, double barrier, hormonal  contraception), during the study period and until 6 months after the last dose of treatment.\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range 4000\u003cbr\u003eF.1.3 Elderly (\u003e=65 years) no\u003cbr\u003eF.1.3.1 Number of subjects for this age range \u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eTrade Name: Truvada\u003cbr\u003eProduct Name: Truvada\u003cbr\u003ePharmaceutical Form: Tablet\u003cbr\u003eINN or Proposed INN: TENOFOVIR DISOPROXIL FUMARATE\u003cbr\u003eCAS Number: 202138-50-9\u003cbr\u003eConcentration unit: mg milligram(s)\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 200-\u003cbr\u003eINN or Proposed INN: EMTRICITABINE\u003cbr\u003eCAS Number: 143491-57-0\u003cbr\u003eConcentration unit: mg milligram(s)\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 245-\u003cbr\u003ePharmaceutical form of the placebo: Tablet\u003cbr\u003eRoute of administration of the placebo: Oral use\u003cbr\u003e\u003cbr\u003eTrade Name: Hydroxychloroquine\u003cbr\u003eProduct Name: Hydroxychloroquine\u003cbr\u003ePharmaceutical Form: Tablet\u003cbr\u003eINN or Proposed INN: Hydroxychloroquine\u003cbr\u003eCAS Number: 118-42-3\u003cbr\u003eConcentration unit: mg milligram(s)\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 200-\u003cbr\u003ePharmaceutical form of the placebo: Tablet\u003cbr\u003eRoute of administration of the placebo: Oral use\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Main Objective: To assess the efficacy of a daily single dose of TDF (300 mg)/FTC (200 mg), a daily single dose of HC (200 mg), daily single dose of TDF (300 mg)/FTC (200 mg) plus HC (200 mg) or placebo, during 12 weeks in: (1) reducing the incidence of symptomatic disease and (2) reducing the clinical severity of the coronavirus infection (COVID-19) among hospital healthcare workers aged 18 to 65 years who are exposed to coronavirus infection (COVID-19) in Spain.;Secondary Objective: not applicable;Primary end point(s): number of symptomatic confirmed infections by SARS-CoV-2 (COVID-19);Timepoint(s) of evaluation of this end point: 12 weeks treatment + 4 weeks F/U",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: yes\u003cbr\u003erandomised: yes\u003cbr\u003eopen: no\u003cbr\u003esingle blind: no\u003cbr\u003edouble blind: yes\u003cbr\u003eparallel group: yes\u003cbr\u003ecross over: no\u003cbr\u003eother: no\u003cbr\u003eif controlled, specify comparator, other medicinial product: yes\u003cbr\u003eplacebo: yes\u003cbr\u003eother: no\u003cbr\u003enumber of treatment arms in the trial: 4\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001385-11-ES",
			"start_date": "28/03/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "Prevention of SARS-CoV-2 (COVID-19) through Pre-Exposure Prophylaxis with Tenofovir disoproxil/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial controlled with placebo - EPICOS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001385-11",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "uk-medicalinformation@sanofi.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "France;Hungary;Czech Republic;Denmark;Germany;United Kingdom",
			"country_certainty": "generated",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003eUnlikely to survive for \u003e48 hours from screening\r\u003cbr\u003eParticipants  with critical disease or multi-organ failure \r\u003cbr\u003eAny contraindication to HCQ or intolerance to HCQ \r\u003cbr\u003eAny medical condition or concomitant therapy that may put the particpants at risk if they are treated with HCQ\r\u003cbr\u003ePregnant or breastfeeding women\r\u003cbr\u003eUse of antiarrhythmic medications and medications known to prolong\r\u003cbr\u003eQT interval or cause Torsades de Pointes (TdPs)\r\u003cbr\u003eParticipants with history of congenital or acquired long QT, arrhythmia,\r\u003cbr\u003efamily history of long QT or sudden cardiac death, or any other cardiac\r\u003cbr\u003econdition that, by the judgement of the Investigator, would put the\r\u003cbr\u003epatient at higher risk for QTc prolongation or sudden cardiac death\r\u003cbr\u003eParticipants with the following ECG findings at screening: QTcF \u003e470\r\u003cbr\u003emsec for women or \u003e450 msec for men or heart rate \u003c50 beats/minute\r\u003cbr\u003eParticipants with known glucose-6-phosphate dehydrogenase (G6PD)\r\u003cbr\u003edeficiency\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003eParticipants must be hospitalized with illness consistent with COVID-19 pneumonia by chest imaging and/or clinical examination and with moderate to severe disease\r\u003cbr\u003eLaboratory-confirmed SARS-CoV-2 infection\r\u003cbr\u003eOnset of COVID-19 symptoms  =5 days before randomization \r\u003cbr\u003eWomen of childbearing potential must have a negative highly sensitive\r\u003cbr\u003epregnancy test at screening and should agree to use an acceptable\r\u003cbr\u003econtraceptive method\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range 175\u003cbr\u003eF.1.3 Elderly (\u003e=65 years) yes\u003cbr\u003eF.1.3.1 Number of subjects for this age range 175\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eTrade Name: PLAQUENIL 200 mg, comprimé pelliculé\u003cbr\u003eProduct Code: SAR390530\u003cbr\u003ePharmaceutical Form: Tablet\u003cbr\u003eCAS Number: 747-36-4\u003cbr\u003eCurrent Sponsor code: SAR321068\u003cbr\u003eOther descriptive name: HYDROXYCHLOROQUINE SULFATE\u003cbr\u003eConcentration unit: mg milligram(s)\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 200-\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Main Objective: Evaluate the effect of hydroxychloroquine (HCQ) + standard of care as compared to standard of care only on oxygen saturation/fraction of inspired oxygen (SpO2/FiO2) ratio  in adult patients hospitalized with moderate to severe Coronavirus Disease 2019 (COVID-19) ;Secondary Objective: Evaluate the clinical efficacy of HCQ + standard of care as compared to standard of care only in adult patients hospitalized with moderate to severe COVID-19\u003cbr\u003eEvaluate the effect of HCQ + standard of care as compared to standard of care only on the virologic load in nasopharynx as assessed by quantitative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) counts in adult patients hospitalized with moderate to severe COVID-19  \u003cbr\u003eEvaluate the safety of HCQ + standard of care as compared to standard of care ;Primary end point(s): 1. Phase 2: Change in SpO2/FiO2 ratio from baseline  to  Day 15.\u003cbr\u003e2. Phase 3 (may be reassessed after review of phase 2): Change in SpO2/FiO2 ratio from baseline to Day 15;Timepoint(s) of evaluation of this end point: 1, 2. Baseline to Day 15",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: yes\u003cbr\u003erandomised: yes\u003cbr\u003eopen: yes\u003cbr\u003esingle blind: no\u003cbr\u003edouble blind: no\u003cbr\u003eparallel group: yes\u003cbr\u003ecross over: no\u003cbr\u003eother: no\u003cbr\u003eif controlled, specify comparator, other medicinial product: no\u003cbr\u003eplacebo: no\u003cbr\u003eother: yes\u003cbr\u003eother specify the comparator: standard of care\u003cbr\u003enumber of treatment arms in the trial: 2\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001270-29-GB",
			"start_date": "02/04/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "An adaptive Phase 2/3, randomized, open-label study assessing efficacy and safety of hydroxychloroquine for hospitalized patients with moderate to severe COVID-19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001270-29",
			"url_certainty": "prefilled"
		}
	},
	{
		"fields": {
			"corresp_author_email": "anabelsanchez.hrc@gmail.com",
			"corresp_author_email_certainty": "prefilled",
			"country": "Spain",
			"country_certainty": "prefilled",
			"entry_type": "registration",
			"entry_type_certainty": "prefilled",
			"exclusion_criteria": "Exclusion criteria: \u003cbr\u003e1. Age \u003c18 years;\u003cbr\u003e2. Less than 5 days from the onset of symptoms to randomization;\u003cbr\u003e3. Pregnancy;\u003cbr\u003e4. Hypersensitivity or known allergy to methylprednisolone;\u003cbr\u003e5. Bacterial infection: not drained abscess, intravascular infection, bacterial pneumonia, septic shock, disseminated fungal infection;\u003cbr\u003e6. Participation in another trial in the previous 30 days;\u003cbr\u003e7. Acquired immunodeficiency syndrome;\u003cbr\u003e8. Previous use of corticosteroids (cumulative dose of prednisone [or equivalent] of more than 300 mg in the last 21 days; or more than 15 mg/day in the last 7 days before randomization);\u003cbr\u003e9. Cytotoxic treatment in the last 3 weeks;\u003cbr\u003e10. Known or suspected adrenal insufficiency;\u003cbr\u003e11. Lung or bone marrow transplant;\u003cbr\u003e12. Severe liver disease.\u003cbr\u003e",
			"exclusion_criteria_certainty": "prefilled",
			"inclusion_criteria": "Inclusion criteria: \u003cbr\u003e1. Diagnosis of SARS-CoV-2 by testing the polymerase chain reaction performed on a respiratory sample;\u003cbr\u003e2. Pneumonia confirmed by radiological imaging test;\u003cbr\u003e3. ARDS Criteria:\u003cbr\u003e    (i) bilateral infiltrates;\u003cbr\u003e    (ii) PO2/FiO2 \u003c300 mmHg; And\u003cbr\u003e    (iii) reasonable clinical exclusion of heart cause (requires all).\u003cbr\u003e4. Verbal consent of the patient.\u003cbr\u003eAre the trial subjects under 18? no\u003cbr\u003eNumber of subjects for this age range: \u003cbr\u003eF.1.2 Adults (18-64 years) yes\u003cbr\u003eF.1.2.1 Number of subjects for this age range 39\u003cbr\u003eF.1.3 Elderly (\u003e=65 years) yes\u003cbr\u003eF.1.3.1 Number of subjects for this age range 65\u003cbr\u003e",
			"inclusion_criteria_certainty": "prefilled",
			"intervention_name": "\u003cbr\u003eTrade Name: Solu-Moderín 1 g polvo y disolvente para solución inyectable\u003cbr\u003ePharmaceutical Form: Powder and solvent for solution for injection/infusion\u003cbr\u003eINN or Proposed INN: Metilprednisolona (como succinato de sodio)\u003cbr\u003eCAS Number: 2375-03-3\u003cbr\u003eCurrent Sponsor code: Pfizer, SL\u003cbr\u003eOther descriptive name: METHYLPREDNISOLONE SODIUM HEMISUCCINATE\u003cbr\u003eConcentration unit: g gram(s)\u003cbr\u003eConcentration type: equal\u003cbr\u003eConcentration number: 1-\u003cbr\u003e\u003cbr\u003e",
			"intervention_name_certainty": "prefilled",
			"out_primary_measure": "Main Objective: To evaluate the efficacy of methylprednisolone treatment, added to the standard treatment, in patients with ARDS secondary tp SARS-CoV-2 .;Secondary Objective: To evaluate the safety of methylprednisolone treatment, added to the standard treatment, in patients with ARDS secondary to SARS-CoV-2.;Primary end point(s): The primary end point of efficacy will be death for any cause in the first 28 days after randomization.;Timepoint(s) of evaluation of this end point: The first 28 days after randomization.",
			"out_primary_measure_certainty": "prefilled",
			"randomized": "controlled: yes\u003cbr\u003erandomised: yes\u003cbr\u003eopen: yes\u003cbr\u003esingle blind: no\u003cbr\u003edouble blind: no\u003cbr\u003eparallel group: no\u003cbr\u003ecross over: no\u003cbr\u003eother: no\u003cbr\u003eif controlled, specify comparator, other medicinial product: yes\u003cbr\u003eplacebo: no\u003cbr\u003eother: no\u003cbr\u003enumber of treatment arms in the trial: 2\u003cbr\u003e",
			"randomized_certainty": "prefilled",
			"results_available": "no",
			"results_available_certainty": "generated",
			"review_status": "prefilled automatically",
			"source": "ICTRP",
			"source_id": "EUCTR2020-001307-16-ES",
			"start_date": "01/04/2020",
			"start_date_certainty": "prefilled",
			"status": "authorised",
			"status_certainty": "prefilled",
			"title": "Efficacy and Safety of corticoids in patients with adult respiratory distress syndrome (ARDS) secondary to COVID-19. - Steroids In Coronavirus (SIC)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ",
			"title_certainty": "prefilled",
			"url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001307-16",
			"url_certainty": "prefilled"
		}
	}
]